source,identifier,doi,pmid,nct,title,url,authors_text,citation,abstract,raw,added_at
pubmed,41015259,,41015259,,Engineering unnatural amino acids in peptide linkers enables cathepsin-selective antibody-drug conjugates for HER2-positive breast cancer.,https://pubmed.ncbi.nlm.nih.gov/41015259/,"Gorzeń Oliwia, Łęcka Maria, Ćwilichowska-Puślecka Natalia, Majchrzak Martyna, Horbach Natalia, Wiśniewski Jerzy, Jakimowicz Piotr, Szpot Paweł, Zawadzki Marcin, Dołęga-Kozierowski Bartosz, Kasprzak Piotr, Turk Boris, Drąg Marcin, Groborz Katarzyna M, Matkowski Rafał, Poręba Marcin",,"Antibody-drug conjugates (ADCs) are a rapidly evolving class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads. Their clinical success has led to significant advances in oncology, positioning ADCs as a transformative modality in cancer treatment. Most clinically approved ADCs utilize a protease-cleavable valine-citrulline (Val-Cit) dipeptide linker designed to facilitate intracellular payload release upon proteolytic activation by the lysosomal cathepsins. However, the Val-Cit linker is susceptible to off-target cleavage by proteases expressed in non-malignant tissues, resulting in premature payload release and systemic toxicity. To address this limitation, we established a high-throughput peptide linker discovery platform using Hybrid Combinatorial Substrate Library (HyCoSuL) screening to comprehensively profile protease substrate preferences. By incorporating unnatural amino acids, we identified peptide sequences with high selectivity toward cancer-associated proteases, thereby overcoming the constraints of conventional linker design. As proof of concept, we engineered trastuzumab-based ADCs selectively activated by cathepsin B or cathepsin L and evaluated their cytotoxic efficacy in HER2-positive breast cancer models. Our HyCoSuL-guided linkers display higher selectivity toward cathepsins than Val-Cit and enable faster, protease-dependent activation of peptide prodrugs and ADCs in vitro, while also exhibiting enhanced stability in human plasma to minimize premature payload release. Furthermore, recognizing that efficient protease-activated ADC function requires co-expression of both the target antigen and the activating protease, we performed single-cell mass cytometry analysis of patient-derived breast cancer samples to assess the correlation between HER2 and cathepsin expression. This analysis revealed heterogeneous cathepsin expression, underscoring that pairing the antibody target with the appropriate protease-selective linker might critical for robust, tumor-confined payload release. Our findings highlight the importance of patient stratification based on antigen and protease expression profiles, providing a foundation for developing ADCs with greater protease selectivity and minimized off-target activation. SIGNIFICANCE: This work presents a rational chemistry-driven strategy using unnatural amino acids to engineer peptide linkers with high cysteine cathepsins specificity and enhanced stability in human plasma. By combining comprehensive enzymatic profiling with single-cell CyTOF analysis of patient tumors, we outline a framework for precision-guided ADC design and protease-informed patient stratification in HER2-positive breast cancer.","<PubmedArticle><MedlineCitation Status=""Publisher"" Owner=""NLM""><PMID Version=""1"">41015259</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel=""Print-Electronic""><Journal><ISSN IssnType=""Electronic"">1873-4995</ISSN><JournalIssue CitedMedium=""Internet""><PubDate><Year>2025</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of controlled release : official journal of the Controlled Release Society</Title><ISOAbbreviation>J Control Release</ISOAbbreviation></Journal><ArticleTitle>Engineering unnatural amino acids in peptide linkers enables cathepsin-selective antibody-drug conjugates for HER2-positive breast cancer.</ArticleTitle><Pagination><StartPage>114269</StartPage><MedlinePgn>114269</MedlinePgn></Pagination><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1016/j.jconrel.2025.114269</ELocationID><ELocationID EIdType=""pii"" ValidYN=""Y"">S0168-3659(25)00881-8</ELocationID><Abstract><AbstractText>Antibody-drug conjugates (ADCs) are a rapidly evolving class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads. Their clinical success has led to significant advances in oncology, positioning ADCs as a transformative modality in cancer treatment. Most clinically approved ADCs utilize a protease-cleavable valine-citrulline (Val-Cit) dipeptide linker designed to facilitate intracellular payload release upon proteolytic activation by the lysosomal cathepsins. However, the Val-Cit linker is susceptible to off-target cleavage by proteases expressed in non-malignant tissues, resulting in premature payload release and systemic toxicity. To address this limitation, we established a high-throughput peptide linker discovery platform using Hybrid Combinatorial Substrate Library (HyCoSuL) screening to comprehensively profile protease substrate preferences. By incorporating unnatural amino acids, we identified peptide sequences with high selectivity toward cancer-associated proteases, thereby overcoming the constraints of conventional linker design. As proof of concept, we engineered trastuzumab-based ADCs selectively activated by cathepsin B or cathepsin L and evaluated their cytotoxic efficacy in HER2-positive breast cancer models. Our HyCoSuL-guided linkers display higher selectivity toward cathepsins than Val-Cit and enable faster, protease-dependent activation of peptide prodrugs and ADCs in vitro, while also exhibiting enhanced stability in human plasma to minimize premature payload release. Furthermore, recognizing that efficient protease-activated ADC function requires co-expression of both the target antigen and the activating protease, we performed single-cell mass cytometry analysis of patient-derived breast cancer samples to assess the correlation between HER2 and cathepsin expression. This analysis revealed heterogeneous cathepsin expression, underscoring that pairing the antibody target with the appropriate protease-selective linker might critical for robust, tumor-confined payload release. Our findings highlight the importance of patient stratification based on antigen and protease expression profiles, providing a foundation for developing ADCs with greater protease selectivity and minimized off-target activation. SIGNIFICANCE: This work presents a rational chemistry-driven strategy using unnatural amino acids to engineer peptide linkers with high cysteine cathepsins specificity and enhanced stability in human plasma. By combining comprehensive enzymatic profiling with single-cell CyTOF analysis of patient tumors, we outline a framework for precision-guided ADC design and protease-informed patient stratification in HER2-positive breast cancer.</AbstractText><CopyrightInformation>Copyright © 2025. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Gorzeń</LastName><ForeName>Oliwia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Łęcka</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Ćwilichowska-Puślecka</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Majchrzak</LastName><ForeName>Martyna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Horbach</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wiśniewski</LastName><ForeName>Jerzy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Jakimowicz</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Szpot</LastName><ForeName>Paweł</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Forensic Medicine, Faculty of Medicine, Wroclaw Medical University, 50-345 Wroclaw, Poland; Institute of Toxicology Research, 50-369 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Zawadzki</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Toxicology Research, 50-369 Wroclaw, Poland; Faculty of Medicine, Wroclaw University of Science and Technology, 51-377 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Dołęga-Kozierowski</LastName><ForeName>Bartosz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Kasprzak</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Turk</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Jozef Stefan Institute, Ljubljana 1000, Slovenia; Faculty of Chemistry and Chemical Engineering, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Drąg</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland; Centre for Chemical Biology, Institute of Physical Chemistry, Polish Academy of Sciences, 01-224 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Groborz</LastName><ForeName>Katarzyna M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland; SBP Medical Discovery Institute, La Jolla 92037, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Matkowski</LastName><ForeName>Rafał</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland; Department of Oncology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Poręba</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland; Faculty of Medicine, Wroclaw University of Science and Technology, 51-377 Wroclaw, Poland. Electronic address: marcin.poreba@pwr.edu.pl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Control Release</MedlineTA><NlmUniqueID>8607908</NlmUniqueID><ISSNLinking>0168-3659</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">Antibody-drug conjugates</Keyword><Keyword MajorTopicYN=""N"">Breast cancer</Keyword><Keyword MajorTopicYN=""N"">Cathepsin B</Keyword><Keyword MajorTopicYN=""N"">Cathepsin L</Keyword><Keyword MajorTopicYN=""N"">CyTOF</Keyword><Keyword MajorTopicYN=""N"">HER-2</Keyword><Keyword MajorTopicYN=""N"">Mass cytometry</Keyword><Keyword MajorTopicYN=""N"">Monomethyl auristatin E</Keyword><Keyword MajorTopicYN=""N"">Protease-activated prodrugs</Keyword><Keyword MajorTopicYN=""N"">Trastuzumab</Keyword><Keyword MajorTopicYN=""N"">Unnatural amino acids</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=""revised""><Year>2025</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">41015259</ArticleId><ArticleId IdType=""doi"">10.1016/j.jconrel.2025.114269</ArticleId><ArticleId IdType=""pii"">S0168-3659(25)00881-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.100228
pubmed,41014745,,41014745,,Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study.,https://pubmed.ncbi.nlm.nih.gov/41014745/,"Ding Nan, Visserman Renee, Geurts Sandra M E, Tol Jolien, Vriens Birgit E P J, Aaldering Kirsten N A, Boon Eline, Dercksen Marcus W, van den Berkmortel Franchette, Pepels Manon J A E, Peters Natascha A J B, Heijns Joan B, van de Winkel Linda, de Fallois Aude J O, Tjan-Heijnen Vivianne C G, de Boer Maaike",,"We aimed to describe real-world complete response (CR) rates, predictors of CR, and survival outcomes in patients treated with first-line pertuzumab, trastuzumab, and chemotherapy for HER2-positive (HER2+) metastatic breast cancer (MBC).","<PubmedArticle><MedlineCitation Status=""Publisher"" Owner=""NLM""><PMID Version=""1"">41014745</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel=""Print-Electronic""><Journal><ISSN IssnType=""Electronic"">1532-3080</ISSN><JournalIssue CitedMedium=""Internet""><Volume>84</Volume><PubDate><Year>2025</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Breast (Edinburgh, Scotland)</Title><ISOAbbreviation>Breast</ISOAbbreviation></Journal><ArticleTitle>Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study.</ArticleTitle><Pagination><StartPage>104583</StartPage><MedlinePgn>104583</MedlinePgn></Pagination><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1016/j.breast.2025.104583</ELocationID><ELocationID EIdType=""pii"" ValidYN=""Y"">S0960-9776(25)00600-9</ELocationID><Abstract><AbstractText Label=""BACKGROUND"" NlmCategory=""BACKGROUND"">We aimed to describe real-world complete response (CR) rates, predictors of CR, and survival outcomes in patients treated with first-line pertuzumab, trastuzumab, and chemotherapy for HER2-positive (HER2+) metastatic breast cancer (MBC).</AbstractText><AbstractText Label=""METHODS"" NlmCategory=""METHODS"">Patients with HER2+ MBC who started first-line pertuzumab, trastuzumab, and chemotherapy in 2013-2021 were selected from the SONABRE Registry (NCT-03577197), involving eleven Dutch hospitals. CR was defined as no evidence of disease on imaging during first-line systemic therapy with or without local therapy (surgery and/or radiotherapy). Multivariable logistic regression was used to identify predictors for CR. Progression-free survival (PFS) and overall survival (OS) from the start of first-line pertuzumab, trastuzumab, and chemotherapy were computed with the Kaplan-Meier method.</AbstractText><AbstractText Label=""RESULTS"" NlmCategory=""RESULTS"">We included 244 patients treated with first-line pertuzumab, trastuzumab, and chemotherapy, with a median follow-up duration of 71 months (interquartile range: 60-82 months). A CR during first-line systemic therapy was reached in 63 patients (26 %). Patients younger than 65 years (odds ratio (OR) = 5.24, 95 %CI:1.49-18.44, p = 0.01), those with de Novo MBC (OR = 2.48, 95 %CI:1.24-4.93, p = 0.01), or those with a single metastatic site (OR = 3.81, 95 %CI:1.83-7.96, p &lt; 0.001) were more likely to reach CR than their counterparts. The 5-year PFS and OS rates were, respectively, 63 % (95 %CI:48 %-75 %) and 85 % (95 %CI:72 %-92 %) in patients with a CR and 10 % (95 %CI:6 %-16 %) and 36 % (95 %CI:28 %-44 %) in patients without a CR.</AbstractText><AbstractText Label=""CONCLUSIONS"" NlmCategory=""CONCLUSIONS"">In the real world, one in four patients treated with first-line pertuzumab, trastuzumab, chemotherapy, with or without local therapy, reached CR. Two third of patients with a CR were still free of progression after five years.</AbstractText><CopyrightInformation>Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Ding</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Visserman</LastName><ForeName>Renee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Geurts</LastName><ForeName>Sandra M E</ForeName><Initials>SME</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Tol</LastName><ForeName>Jolien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Vriens</LastName><ForeName>Birgit E P J</ForeName><Initials>BEPJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Aaldering</LastName><ForeName>Kirsten N A</ForeName><Initials>KNA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Boon</LastName><ForeName>Eline</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Viecuri Medical Centre, Venlo, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Dercksen</LastName><ForeName>Marcus W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Máxima Medical Centre, Veldhoven, Eindhoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>van den Berkmortel</LastName><ForeName>Franchette</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Zuyderland Medical Centre, Sittard, Heerlen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Pepels</LastName><ForeName>Manon J A E</ForeName><Initials>MJAE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Elkerliek Hospital, Helmond, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Peters</LastName><ForeName>Natascha A J B</ForeName><Initials>NAJB</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Sint Jans Gasthuis Hospital, Weert, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Heijns</LastName><ForeName>Joan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Amphia, Breda, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>van de Winkel</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, St Anna Hospital, Geldrop, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>de Fallois</LastName><ForeName>Aude J O</ForeName><Initials>AJO</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Tjan-Heijnen</LastName><ForeName>Vivianne C G</ForeName><Initials>VCG</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>de Boer</LastName><ForeName>Maaike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands. Electronic address: maaike.de.boer@mumc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Breast</MedlineTA><NlmUniqueID>9213011</NlmUniqueID><ISSNLinking>0960-9776</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">Breast Neoplasms</Keyword><Keyword MajorTopicYN=""N"">Disease progression</Keyword><Keyword MajorTopicYN=""N"">HER-2 Gene</Keyword><Keyword MajorTopicYN=""N"">Pertuzumab</Keyword><Keyword MajorTopicYN=""N"">Survival</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:DN reports grants scholarship from the China Scholarship Council. SG reports institutional grants from Astra-Zeneca, Daiichi-Sankyo, Eli Lilly, Menarini Stemline, MSD, Novartis, Pfizer, Seagan, and Gilead. JT reports honoraria from Medtalks and CongressCars, and leadership in Medical Ethics Board Brabant, and Board of Dutch Society for Medical Oncology. KH reports institutional grants from Astra-Zeneca, Novartis, and Gilead. AF reports institutional grants and personal fees from Roche, Novartis, Pfizer, and Eli Lilly, institutional grants from Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca, Daiichi Sankyo and Gilead. VTH reports institutional grants and personal fees from Roche, Novartis, Pfizer, and Eli Lilly, institutional grants from Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca, Daiichi Sankyo and Gilead. MB reports institutional grants from Astra-Zeneca, Daiichi-Sankyo, Eli Lilly, Novartis, Roche, Pfizer, and Gilead, and personal consulting fees from Novartis and Pfizer. All remaining authors have declared no conflicts of interest. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus=""revised""><Year>2025</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">41014745</ArticleId><ArticleId IdType=""doi"">10.1016/j.breast.2025.104583</ArticleId><ArticleId IdType=""pii"">S0960-9776(25)00600-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.194063
pubmed,41010995,,41010995,,Is Body Mass Index a Prognostic Factor in Metastatic HER2-Positive Breast Cancer? A Real-World Multicenter Study.,https://pubmed.ncbi.nlm.nih.gov/41010995/,"Birsin Zeliha, Odabaşı Bükün Hülya, Nazlı İsmail, Alkan Onur, Günaltılı Murat, Çerme Emir, Aliyev Vali, Cebeci Selin, Jeral Seda, Abbasov Hamza, Evrensel Türkkan, Papila Çiğdem, Demirci Nebi Serkan, Alan Özkan",,,"<PubmedArticle><MedlineCitation Status=""MEDLINE"" Owner=""NLM"" IndexingMethod=""Automated""><PMID Version=""1"">41010995</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel=""Electronic""><Journal><ISSN IssnType=""Electronic"">1648-9144</ISSN><JournalIssue CitedMedium=""Internet""><Volume>61</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Is Body Mass Index a Prognostic Factor in Metastatic HER2-Positive Breast Cancer? A Real-World Multicenter Study.</ArticleTitle><ELocationID EIdType=""pii"" ValidYN=""Y"">1604</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.3390/medicina61091604</ELocationID><Abstract><AbstractText><i>Background and Objectives:</i> The prognostic significance of body mass index (BMI) in metastatic HER2-positive breast cancer (BC) remains unclear, with previous studies yielding conflicting results. This multicenter real-world study aimed to investigate the prognostic role of BMI in this patient population. <i>Materials and Methods</i>: A total of 169 female patients with metastatic HER2-positive BC who received trastuzumab-based treatment between 2010 and 2024 were included. Patients were categorized by BMI (&lt;30 kg/m<sup>2</sup> vs. ≥30 kg/m<sup>2</sup>). The primary endpoints were overall survival (OS) and progression-free survival (PFS). Kaplan-Meier and Cox regression analyses were performed overall and in subgroups stratified by hormone receptor (HR) status. <i>Results</i>: In the overall cohort, a BMI ≥ 30 was not significantly associated with OS or PFS. However, in the HR-positive/HER2-positive subgroup, BMI ≥ 30 kg/m<sup>2</sup> was linked to significantly shorter OS (<i>p</i> = 0.024) and PFS (<i>p</i> = 0.047) by Kaplan-Meier analysis. However, these associations did not remain statistically significant in multivariate analyses. No significant BMI-related differences were observed in the HR-negative subgroup. Other independent negative prognostic factors included recurrent disease, the presence of brain metastases, and a high Ki-67 index. <i>Conclusions</i>: BMI was not identified as an independent prognostic factor in the overall population. However, among HR-positive/HER2-positive patients, obesity was associated with poorer survival in univariate analysis, but this was not confirmed in multivariate analysis. These findings underscore the need for prospective studies to clarify the prognostic role of adiposity, considering biological subtypes.</AbstractText></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Birsin</LastName><ForeName>Zeliha</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Odabaşı Bükün</LastName><ForeName>Hülya</ForeName><Initials>H</Initials><Identifier Source=""ORCID"">0009-0000-5432-4981</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Faculty of Medicine, Bursa Uludağ University, 16400 Bursa, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Nazlı</LastName><ForeName>İsmail</ForeName><Initials>İ</Initials><Identifier Source=""ORCID"">0000-0001-7495-3996</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, 34722 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Alkan</LastName><ForeName>Onur</ForeName><Initials>O</Initials><Identifier Source=""ORCID"">0000-0002-8558-1654</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, 34722 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Günaltılı</LastName><ForeName>Murat</ForeName><Initials>M</Initials><Identifier Source=""ORCID"">0000-0001-6116-3936</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Çerme</LastName><ForeName>Emir</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Aliyev</LastName><ForeName>Vali</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Cebeci</LastName><ForeName>Selin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Jeral</LastName><ForeName>Seda</ForeName><Initials>S</Initials><Identifier Source=""ORCID"">0000-0002-6594-1712</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Abbasov</LastName><ForeName>Hamza</ForeName><Initials>H</Initials><Identifier Source=""ORCID"">0000-0003-1227-9996</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Evrensel</LastName><ForeName>Türkkan</ForeName><Initials>T</Initials><Identifier Source=""ORCID"">0000-0002-9732-5340</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Faculty of Medicine, Bursa Uludağ University, 16400 Bursa, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Papila</LastName><ForeName>Çiğdem</ForeName><Initials>Ç</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Demirci</LastName><ForeName>Nebi Serkan</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Alan</LastName><ForeName>Özkan</ForeName><Initials>Ö</Initials><Identifier Source=""ORCID"">0000-0002-6635-2012</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType><PublicationType UI=""D016448"">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""D018719"">Receptor, ErbB-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""C508053"">ERBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI=""D000068878"">Trastuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=""D006801"" MajorTopicYN=""N"">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D005260"" MajorTopicYN=""N"">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D001943"" MajorTopicYN=""Y"">Breast Neoplasms</DescriptorName><QualifierName UI=""Q000401"" MajorTopicYN=""N"">mortality</QualifierName><QualifierName UI=""Q000188"" MajorTopicYN=""N"">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D015992"" MajorTopicYN=""Y"">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D008875"" MajorTopicYN=""N"">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D011379"" MajorTopicYN=""N"">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D018719"" MajorTopicYN=""N"">Receptor, ErbB-2</DescriptorName><QualifierName UI=""Q000032"" MajorTopicYN=""N"">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000368"" MajorTopicYN=""N"">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D000328"" MajorTopicYN=""N"">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D000068878"" MajorTopicYN=""N"">Trastuzumab</DescriptorName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D012189"" MajorTopicYN=""N"">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D053208"" MajorTopicYN=""N"">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D016016"" MajorTopicYN=""N"">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">HER2-positive</Keyword><Keyword MajorTopicYN=""N"">body mass index</Keyword><Keyword MajorTopicYN=""N"">breast cancer</Keyword><Keyword MajorTopicYN=""N"">hormone receptor</Keyword><Keyword MajorTopicYN=""N"">obesity</Keyword><Keyword MajorTopicYN=""N"">overall survival</Keyword><Keyword MajorTopicYN=""N"">progression-free survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus=""revised""><Year>2025</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">41010995</ArticleId><ArticleId IdType=""doi"">10.3390/medicina61091604</ArticleId><ArticleId IdType=""pii"">medicina61091604</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.282491
pubmed,41008905,,41008905,,Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan.,https://pubmed.ncbi.nlm.nih.gov/41008905/,"Molfino Alessio, Imbimbo Giovanni, Pisegna Simona, Scagnoli Simone, Alabiso Claudia, Ardovino Massimiliano, Gallicchio Carmen, Rizzo Veronica, Botticelli Andrea",,"Breast cancer remains a significant global health concern, with HER2-positive metastatic breast cancer continuing to present persistent challenges despite advancements in targeted therapies, including trastuzumab deruxtecan (T-DXd). This study aimed to verify the impact of body composition changes on treatment-related toxicities, dose modifications, and clinical outcomes in patients receiving T-DXd.","<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">41008905</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel=""Electronic""><Journal><ISSN IssnType=""Print"">2072-6694</ISSN><JournalIssue CitedMedium=""Print""><Volume>17</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan.</ArticleTitle><ELocationID EIdType=""pii"" ValidYN=""Y"">3063</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.3390/cancers17183063</ELocationID><Abstract><AbstractText Label=""BACKGROUND/OBJECTIVES"" NlmCategory=""OBJECTIVE"">Breast cancer remains a significant global health concern, with HER2-positive metastatic breast cancer continuing to present persistent challenges despite advancements in targeted therapies, including trastuzumab deruxtecan (T-DXd). This study aimed to verify the impact of body composition changes on treatment-related toxicities, dose modifications, and clinical outcomes in patients receiving T-DXd.</AbstractText><AbstractText Label=""METHODS"" NlmCategory=""METHODS"">A retrospective analysis on 35 patients with HER2-positive metastatic breast cancer was conducted, analyzing body composition parameters such as subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), skeletal muscle area (SMA), and skeletal muscle index (SMI)-assessed using CT scans at baseline (T0) and after a median follow-up of 4 months (T1)-and calculating ΔT0-T1% of each parameter.</AbstractText><AbstractText Label=""RESULTS"" NlmCategory=""RESULTS"">Significant reductions over time were observed in SAT (mean ΔSAT% = -5.7%, <i>p</i> = 0.023) and SMA (mean ΔSMA% = -4.9%, <i>p</i> = 0.001). Treatment-related adverse events (AEs) were common, with 31% of patients experiencing severe (Grade 3-4) toxicities. Patients with higher ΔSAT% (above the median value) experienced Grade 3-4 toxicities more frequently compared to those with lower ΔSAT% (below the median) (<i>p</i> &lt; 0.05). Among patients without toxicities, a significant decrease in SAT was observed between T0 and T1 (<i>p</i> = 0.003), while no significant change was detected in patients with Grade 3-4 toxicities (<i>p</i> = 0.929). Greater reductions in SMA were associated with increased rates of treatment discontinuation (75% vs. 29%, <i>p</i> = 0.009). Kaplan-Meier analysis confirmed that greater reductions in SMA significantly increased the risk of mortality (HR 5.1, 95% CI: 1.05-24.79; <i>p</i> = 0.025) and showed a trend toward higher risk of disease progression (HR 2.58, 95% CI: 0.89-7.49; <i>p</i> = 0.063).</AbstractText><AbstractText Label=""CONCLUSIONS"" NlmCategory=""CONCLUSIONS"">Changes in body composition, particularly reductions in SMA, were associated with increased treatment discontinuation and mortality in HER2-positive metastatic breast cancer receiving T-DXd. Increase in SAT was associated with higher rates of severe toxicities, highlighting its potential role in predicting treatment-related complications, and the clinical relevance of nutritional changes on outcomes in this setting.</AbstractText></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Molfino</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><Identifier Source=""ORCID"">0000-0002-6432-0236</Identifier><AffiliationInfo><Affiliation>Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Imbimbo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source=""ORCID"">0000-0001-8149-9154</Identifier><AffiliationInfo><Affiliation>Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Pisegna</LastName><ForeName>Simona</ForeName><Initials>S</Initials><Identifier Source=""ORCID"">0000-0002-6910-9528</Identifier><AffiliationInfo><Affiliation>Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Scagnoli</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source=""ORCID"">0000-0003-4943-5622</Identifier><AffiliationInfo><Affiliation>Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Alabiso</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Ardovino</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Gallicchio</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source=""ORCID"">0009-0009-3634-014X</Identifier><AffiliationInfo><Affiliation>Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Rizzo</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><Identifier Source=""ORCID"">0000-0003-1781-3174</Identifier><AffiliationInfo><Affiliation>Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Botticelli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">adiposity</Keyword><Keyword MajorTopicYN=""N"">body composition</Keyword><Keyword MajorTopicYN=""N"">metastatic breast cancer</Keyword><Keyword MajorTopicYN=""N"">outcome</Keyword><Keyword MajorTopicYN=""N"">survival</Keyword><Keyword MajorTopicYN=""N"">trastuzumab deruxtecan</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=""revised""><Year>2025</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">41008905</ArticleId><ArticleId IdType=""doi"">10.3390/cancers17183063</ArticleId><ArticleId IdType=""pii"">cancers17183063</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.377963
pubmed,41008840,,41008840,,Characterisation of mAb104 Antibody-Drug Conjugates Targeting a Tumour-Selective HER2 Epitope.,https://pubmed.ncbi.nlm.nih.gov/41008840/,"Parakh Sagun, Huynh Nhi, Osellame Laura D, Cao Diana D, Rigopoulos Angela, Gloria Benjamin, Guo Nancy Yanan, Scott Fiona E, Liu Zhanqi, Gan Hui K, Scott Andrew M",,"The novel anti-HER2 antibody 104 (mAb104) targets a unique tumour-specific epitope, lacks normal tissue binding and can internalise into tumour cells, thus supporting its development into antibody drug conjugates (ADCs).","<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">41008840</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel=""Electronic""><Journal><ISSN IssnType=""Print"">2072-6694</ISSN><JournalIssue CitedMedium=""Print""><Volume>17</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Characterisation of mAb104 Antibody-Drug Conjugates Targeting a Tumour-Selective HER2 Epitope.</ArticleTitle><ELocationID EIdType=""pii"" ValidYN=""Y"">2995</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.3390/cancers17182995</ELocationID><Abstract><AbstractText Label=""BACKGROUND"" NlmCategory=""BACKGROUND"">The novel anti-HER2 antibody 104 (mAb104) targets a unique tumour-specific epitope, lacks normal tissue binding and can internalise into tumour cells, thus supporting its development into antibody drug conjugates (ADCs).</AbstractText><AbstractText Label=""METHODS"" NlmCategory=""METHODS"">We now describe the binding properties and preclinical activity of mAb104-ADCs developed through the conjugation of mAb104 via linkers to the anti-microtubule drug maytansoinoid ematansine (DM1-SMCC; DM1), topoisomerase I inhibitor, exatecan derivative (MC-GGFG-DX8951; DX8951) or microtubule disruptor monomethyl auristatin E (MC-vc-PAB-MMAE; MMAE).</AbstractText><AbstractText Label=""RESULTS"" NlmCategory=""RESULTS"">Mab104-ADCs demonstrate dose-dependent cytotoxicity in vitro. The safety of single-dose mAb104-DX8951 was demonstrated in vivo at doses up to 10 mg/kg. MAb104-ADCs also demonstrated potent and prolonged anti-tumour activity in a range of tumour types with variable HER2 expression. Mab104-DX8951 showed significant responses in trastuzumab-resistant HER2-positive breast cancer, low HER2-expressing cancers, as well as HER2-overexpressing cancers.</AbstractText><AbstractText Label=""CONCLUSION"" NlmCategory=""CONCLUSIONS"">These findings indicate the potential for tumour-specific targeting of HER2-expressing tumours with mAb104-ADCs.</AbstractText></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Parakh</LastName><ForeName>Sagun</ForeName><Initials>S</Initials><Identifier Source=""ORCID"">0000-0003-3891-2489</Identifier><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Austin Health, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Cancer Medicine, Latrobe University, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Huynh</LastName><ForeName>Nhi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Osellame</LastName><ForeName>Laura D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Cancer Medicine, Latrobe University, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Cao</LastName><ForeName>Diana D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Rigopoulos</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source=""ORCID"">0009-0006-0811-7731</Identifier><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Gloria</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Guo</LastName><ForeName>Nancy Yanan</ForeName><Initials>NY</Initials><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Scott</LastName><ForeName>Fiona E</ForeName><Initials>FE</Initials><Identifier Source=""ORCID"">0009-0003-3190-6518</Identifier><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Cancer Medicine, Latrobe University, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Liu</LastName><ForeName>Zhanqi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Gan</LastName><ForeName>Hui K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Austin Health, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Cancer Medicine, Latrobe University, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Melbourne, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Scott</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Cancer Medicine, Latrobe University, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Melbourne, Melbourne 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Imaging and Therapy, Austin Health, Melbourne 3084, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">HER2</Keyword><Keyword MajorTopicYN=""N"">antibody drug conjugates</Keyword><Keyword MajorTopicYN=""N"">epitope</Keyword><Keyword MajorTopicYN=""N"">osimertinib-resistant</Keyword><Keyword MajorTopicYN=""N"">trastuzumab-resistant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus=""revised""><Year>2025</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">41008840</ArticleId><ArticleId IdType=""doi"">10.3390/cancers17182995</ArticleId><ArticleId IdType=""pii"">cancers17182995</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.481551
pubmed,41006954,,41006954,,Trastuzumab Deruxtecan-Induced Myotoxicity: First Case Report About Myopathy in Patient With Normal Body Composition and Clinical Insights.,https://pubmed.ncbi.nlm.nih.gov/41006954/,"Qiao Zhen, Li LiuDan, Wang Hong, Dai ShuHui, Ye LiTong",,"Trastuzumab deruxtecan (T-DXd) significantly improves outcomes in HER2-positive or low metastatic breast cancer (MBC), but systematic documentation of its myotoxicity is lacking. A 45-year-old woman with HER2-low MBC and normal body composition (BMI 22.9 kg/m","<PubmedArticle><MedlineCitation Status=""MEDLINE"" Owner=""NLM"" IndexingMethod=""Automated""><PMID Version=""1"">41006954</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel=""Print""><Journal><ISSN IssnType=""Electronic"">1759-7714</ISSN><JournalIssue CitedMedium=""Internet""><Volume>16</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Thoracic cancer</Title><ISOAbbreviation>Thorac Cancer</ISOAbbreviation></Journal><ArticleTitle>Trastuzumab Deruxtecan-Induced Myotoxicity: First Case Report About Myopathy in Patient With Normal Body Composition and Clinical Insights.</ArticleTitle><Pagination><StartPage>e70168</StartPage><MedlinePgn>e70168</MedlinePgn></Pagination><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1111/1759-7714.70168</ELocationID><Abstract><AbstractText>Trastuzumab deruxtecan (T-DXd) significantly improves outcomes in HER2-positive or low metastatic breast cancer (MBC), but systematic documentation of its myotoxicity is lacking. A 45-year-old woman with HER2-low MBC and normal body composition (BMI 22.9 kg/m<sup>2</sup>, visceral adipose area [VAT] 69.1 cm<sup>2</sup>) developed T-DXd myopathy. She experienced dysphagia, Grade III myalgia, and creatine kinase (CK) peak of 1755 U/L, with MRI confirming lumbar subcutaneous edema and paraspinal muscle swelling. T-DXd was discontinued. Supportive therapy included hydration, urine alkalization by sodium bicarbonate, glutathione, and magnesium isoglycyrrhizinate. By Day 8, CK decreased to 539 U/L with myalgia improvement. After 13 days off therapy, CK rebounded to 1735 U/L with Grade III myalgia, which resolved upon reinitiating support. This case report presents the first documented instance of severe T-DXd-related myopathy in a patient with normal body composition. The observed case outcomes suggest that the combination of glutathione and magnesium isoglycyrrhizinate could potentially reduce CK levels and alleviate T-DXd-associated muscle pain. However, the observed clinical efficacy is based on an individual case. Extrapolation of these clinical outcomes requires large-scale randomized controlled trials with rigorous covariate adjustment.</AbstractText><CopyrightInformation>© 2025 The Author(s). Thoracic Cancer published by John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Qiao</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Li</LastName><ForeName>LiuDan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Dai</LastName><ForeName>ShuHui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nursing, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Ye</LastName><ForeName>LiTong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Infection Control Department, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=""Y""><Grant><GrantID>2220009000242</GrantID><Agency>2023 Zhuhai Medical Research Project</Agency><Country /></Grant><Grant><GrantID>2420004000202</GrantID><Agency>Zhuhai Science and Technology Plan Project in the Field of Social Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI=""D002363"">Case Reports</PublicationType><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Thorac Cancer</MedlineTA><NlmUniqueID>101531441</NlmUniqueID><ISSNLinking>1759-7706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI=""D000068878"">Trastuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D000074322"">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=""D006801"" MajorTopicYN=""N"">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D005260"" MajorTopicYN=""N"">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D008875"" MajorTopicYN=""N"">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D000068878"" MajorTopicYN=""Y"">Trastuzumab</DescriptorName><QualifierName UI=""Q000009"" MajorTopicYN=""N"">adverse effects</QualifierName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000081030"" MajorTopicYN=""Y"">Myotoxicity</DescriptorName><QualifierName UI=""Q000209"" MajorTopicYN=""N"">etiology</QualifierName><QualifierName UI=""Q000473"" MajorTopicYN=""N"">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D001823"" MajorTopicYN=""N"">Body Composition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D001943"" MajorTopicYN=""Y"">Breast Neoplasms</DescriptorName><QualifierName UI=""Q000188"" MajorTopicYN=""N"">drug therapy</QualifierName><QualifierName UI=""Q000473"" MajorTopicYN=""N"">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D009135"" MajorTopicYN=""Y"">Muscular Diseases</DescriptorName><QualifierName UI=""Q000139"" MajorTopicYN=""N"">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000074322"" MajorTopicYN=""Y"">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI=""Q000009"" MajorTopicYN=""N"">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">creatine kinase</Keyword><Keyword MajorTopicYN=""N"">glutathione</Keyword><Keyword MajorTopicYN=""N"">magnesium isoglycyrrhizinate</Keyword><Keyword MajorTopicYN=""N"">myotoxicity</Keyword><Keyword MajorTopicYN=""N"">trastuzumab deruxtecan</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""revised""><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">41006954</ArticleId><ArticleId IdType=""doi"">10.1111/1759-7714.70168</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>S. A. Hurvitz, R. Hegg, W. P. Chung, et al., “Trastuzumab Deruxtecan Versus Trastuzumab Emtansine in Patients With HER2‐Positive Metastatic Breast Cancer: Updated Results From DESTINY‐Breast03, a Randomised, Open‐Label, Phase 3 Trial,” Lancet 401, no. 10371 (2023): 105–117.</Citation></Reference><Reference><Citation>T. Yamashita, J. H. Sohn, E. Tokunaga, et al., “Trastuzumab Deruxtecan Versus Treatment of Physician's Choice in Previously Treated Asian Patients With HER2‐Low Unresectable/Metastatic Breast Cancer:Subgroup Analysis of the DESTINY‐Breast04 Study,” Breast Cancer 31, no. 5 (2024): 858–868.</Citation></Reference><Reference><Citation>Y. Ogitani, T. Aida, K. Hagihara, et al., “DS‐8201a, A Novel HER2‐Targeting ADC With a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy With Differentiation From T‐DM1,” Clinical Cancer Research 22, no. 20 (2016): 5097–5108.</Citation></Reference><Reference><Citation>Z. Xu, D. Guo, Z. Jiang, et al., “Novel HER2‐Targeting Antibody‐Drug Conjugates of Trastuzumab Beyond T‐DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS‐8201a) and (Vic‐)trastuzumab Duocarmazine (SYD985),” European Journal of Medicinal Chemistry 183 (2019): 111682.</Citation></Reference><Reference><Citation>T. Nakada, K. Sugihara, T. Jikoh, Y. Abe, and T. Agatsuma, “The Latest Research and Development Into the Antibody‐Drug Conjugate,[Fam‐]Trastuzumab Deruxtecan (DS‐8201a),for HER2 Cancer Therapy,” Chemical &amp; Pharmaceutical Bulletin (Tokyo) 67, no. 3 (2019): 173–185.</Citation></Reference><Reference><Citation>L. R. Soares, M. Vilbert, V. Rosa, et al., “Incidence of Interstitial Lung Disease and Cardiotoxicity With Trastuzumab Deruxtecan in Breast Cancer Patients: A Systematic Review and Single‐Arm Meta‐Analysis,” ESMO Open 8, no. 4 (2023): 101613.</Citation></Reference><Reference><Citation>P. Loganathan, C. V. Oddis, and R. Aggarwal, “Immune‐Mediated Statin Myopathy,” Expert Review of Clinical Immunology 12, no. 1 (2016): 33–38.</Citation></Reference><Reference><Citation>J. P. Sieb and T. Gillessen, “Iatrogenic and Toxic Myopathies,” Muscle &amp; Nerve 27, no. 2 (2003): 142–156.</Citation></Reference><Reference><Citation>P. Mohassel and A. L. Mammen, “Anti‐HMGCR Myopathy,” Journal of Neuromuscular Diseases 5, no. 1 (2018): 11–20.</Citation></Reference><Reference><Citation>N. Bakour, F. Moriarty, G. Moore, T. Robson, and S. L. Annett, “Prognostic Significance of Glucocorticoid Receptor Expression in Cancer: A Systematic Review and Meta‐Analysis,” Cancers 13, no. 7 (2021): 1649.</Citation></Reference><Reference><Citation>D. Wekking, M. Porcu, B. Pellegrino, et al., “Multidisciplinary Clinical Guidelines in Proactive Monitoring, Early Diagnosis, and Effective Management of Trastuzumab Deruxtecan (T‐DXd)‐Induced Interstitial Lung Disease (ILD) in Breast Cancer Patients,” ESMO Open 8, no. 6 (2023): 102043.</Citation></Reference><Reference><Citation>D. Zardavas, T. M. Suter, D. J. Van Veldhuisen, et al., “Role of Troponins I and T and N‐Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early‐Stage Human Epidermal Growth Factor Receptor 2‐Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy,” Journal of Clinical Oncology 35, no. 8 (2017): 878–884.</Citation></Reference><Reference><Citation>H. Jourdain, A. Di Meglio, I. Mansouri, et al., “Use and Outcomes of Trastuzumab Deruxtecan in HER2‐Positive and HER2‐Low Metastatic Breast Cancer in a Real‐World Setting: A Nationwide Cohort Study,” ESMO Open 9, no. 12 (2024): 104083.</Citation></Reference><Reference><Citation>O. Hammarsten, M. L. Fu, R. Sigurjonsdottir, et al., “Troponin T Percentiles From a Random Population Sample, Emergency Room Patients and Patients With Myocardial Infarction,” Clinical Chemistry 58, no. 3 (2012): 628–637.</Citation></Reference><Reference><Citation>J. Suh and A. A. Amato, “Management of Immune‐Mediated Necrotizing Myopathy,” Muscle &amp; Nerve 70, no. 2 (2024): 166–172.</Citation></Reference><Reference><Citation>R. J. Lane and F. L. Mastaglia, “Drug‐Induced Myopathies in Man,” Lancet 2, no. 8089 (1978): 562–566.</Citation></Reference><Reference><Citation>R. Munday, “Oxidation of Glutathione and Reduced Pyridine Nucleotides by the Myotoxic and Mutagenic Aromatic Amine, 1,2,4‐Triaminobenzene,” Chemico‐Biological Interactions 62, no. 2 (1987): 131–141.</Citation></Reference><Reference><Citation>S. Rossi, R. Costa, A. di Federico, et al., “Histopathological Evidence for a Non‐Inflammatory Mechanism in Osimertinib‐Induced Myopathy: A Case Report,” Journal of Thoracic Oncology 19, no. 9 (2024): 1352–1355.</Citation></Reference><Reference><Citation>M. Tomaszewski, K. M. Stepien, J. Tomaszewska, et al., “Statin‐Induced Myopathies,” Pharmacological Reports 63, no. 4 (2011): 859–866.</Citation></Reference><Reference><Citation>Z. Huang, Y. Chen, and Y. Zhang, “Mitochondrial Reactive Oxygen Species Cause Major Oxidative Mitochondrial DNA Damages and Repair Pathways,” Journal of Biosciences 45 (2020): 84.</Citation></Reference><Reference><Citation>C. Marx, J. Sonnemann, O. Maddocks, et al., “Global Metabolic Alterations in Colorectal Cancer Cells During Irinotecan‐Induced DNA Replication Stress,” Cancer &amp; Metabolism 10, no. 1 (2022): 10.</Citation></Reference><Reference><Citation>B. Nikolova, S. Semkova, I. Tsoneva, et al., “Redox‐Related Molecular Mechanism of Sensitizing Colon Cancer Cells to Camptothecin Analog SN38,” Anticancer Research 40, no. 9 (2020): 5159–5170.</Citation></Reference><Reference><Citation>C. I. Chen, Y. C. Chen, Y. K. Kao, et al., “Taurine Protects Irinotecan‐Induced Muscle Dysfunction by Modulating Oxidative Stress and Endoplasmic Reticulum Stress in Human Skeletal Muscle Cells,” Anticancer Research 44, no. 12 (2024): 5371–5378.</Citation></Reference><Reference><Citation>Pubchem, “1‐[(2R,3aS,7aS)‐2‐(5‐Methyl‐1,2,4‐Oxadiazol‐3‐yl)‐3,3a,4,5,7,7a‐Hexahydro‐2H‐furo[2,3‐c]pyridin‐6‐yl]‐2‐(5‐Fluoropyridin‐2‐yl)Ethanone,” 2025, https://pubchem.ncbi.nlm.nih.gov/compound/131682096.</Citation></Reference><Reference><Citation>Q. Ouyang, Q. Chen, S. Ke, et al., “Rab8a as a Mitochondrial Receptor for Lipid Droplets in Skeletal Muscle,” Developmental Cell 58, no. 4 (2023): 289–305.</Citation></Reference><Reference><Citation>J. Zhao, F. Jia, J. Li, et al., “Sprayable Reactive Oxygen Species‐Responsive Hydrogel Coatings Restore Endothelial Barrier Integrity for Functional Vascular Healing,” ACS Nano 19 (2025): 21757–21774.</Citation></Reference><Reference><Citation>P. S. Yaacobi, R. Kessner, Y. Bar, et al., “Body Composition Metrics as a Determinant of Trastuzumab Deruxtecan Related Toxicity and Response,” npj Breast Cancer 11, no. 1 (2025): 38.</Citation></Reference><Reference><Citation>H. Lappalainen, E. Tiula, L. Uotila, et al., “Elimination Kinetics of Myoglobin and Creatine Kinase in Rhabdomyolysis: Implications for Follow‐Up,” Critical Care Medicine 30, no. 10 (2002): 2212–2215.</Citation></Reference><Reference><Citation>T. Petreski, N. Piko, T. Petrijan, B. Dvoršak, R. Hojs, and S. Bevc, “Statin‐Associated Necrotizing Myopathy Leading to Acute Kidney Injury: A Case Report,” Case Reports in Nephrology and Dialysis 11, no. 2 (2021): 129–135.</Citation></Reference><Reference><Citation>Y. Yan, Y. Mo, and D. Zhang, “Magnesium Isoglycyrrhizinate Prevention of Chemotherapy‐Induced Liver Damage During Initial Treatment of Patients With Gastrointestinal Tumors,” Zhonghua Gan Zang Bing Za Zhi 23, no. 3 (2015): 204–208.</Citation></Reference><Reference><Citation>Q. Wei and J. Zhao, “Therapeutic Effects of Reduced Glutathione on Liver Function, Fibrosis, and HBV DNA Clearance in Chronic Hepatitis B Patients,” BMC Gastroenterology 25, no. 1 (2025): 68.</Citation></Reference><Reference><Citation>E. L. Burnham, M. Moss, and T. R. Ziegler, “Myopathies in Critical Illness: Characterization and Nutritional Aspects,” Journal of Nutrition 135, no. 7 (2005): 1818S–1823S.</Citation></Reference><Reference><Citation>T. H. Chen, H. C. Wang, C. J. Chang, and S.‐Y. Lee, “Mitochondrial Glutathione in Cellular Redox Homeostasis and Disease Manifestation,” International Journal of Molecular Sciences 25, no. 2 (2024): 1314.</Citation></Reference><Reference><Citation>B. Zheng, Y. Yang, J. Li, et al., “Magnesium Isoglycyrrhizinate Alleviates Arsenic Trioxide‐Induced Cardiotoxicity: Contribution of Nrf2 and TLR4/NF‐kappaB Signaling Pathway,” Drug Design, Development and Therapy 15 (2021): 543–556.</Citation></Reference><Reference><Citation>X. Zhang, L. Hou, Z. Guo, et al., “Lipid Peroxidation in Osteoarthritis: Focusing on 4‐Hydroxynonenal, Malondialdehyde, and Ferroptosis,” Cell Death Discovery 9, no. 1 (2023): 320.</Citation></Reference><Reference><Citation>D. A. Averill‐Bates, “The Antioxidant Glutathione,” Vitamins and Hormones 121 (2023): 109–141.</Citation></Reference><Reference><Citation>J. G. Fan, Y. Li, Z. Yu, et al., “Effectiveness and Economic Evaluation of Polyene Phosphatidyl Choline in Patients With Liver Diseases Based on Real‐World Research,” Frontiers in Pharmacology 13 (2022): 806787.</Citation></Reference><Reference><Citation>T. Doi, K. Shitara, Y. Naito, et al., “Safety, Pharmacokinetics, and Antitumour Activity of Trastuzumab Deruxtecan(DS‐8201), a HER2‐Targeting Antibody‐Drug Conjugate, in Patients With Advanced Breast and Gastric or Gastro‐Oesophageal Tumours: A Phase 1 Dose‐Escalation Study,” Lancet Oncology 18, no. 11 (2017): 1512–1522.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.576330
pubmed,40998389,,40998389,,Advances in Proximity-Assisted Bioconjugation.,https://pubmed.ncbi.nlm.nih.gov/40998389/,"Canzano Mary, Bernardes Gonçalo J L",,"ConspectusProximity-induced chemistry (PIC) refers to the transient reactivity between two or more molecules upon physical closeness which are otherwise unreactive. Harnessed by nature to control fundamental biological processes such as transcription and signal transduction, PIC increases the probability of correctly oriented, effective collisions, facilitating fundamental cellular processes. Within the field of chemical biology, PIC has been employed for several clinically relevant purposes, including the degradation of aberrant biomolecules and construction of protein therapeutics. This Account focuses on the application of PIC strategies for the development of site-specific bioconjugation techniques, termed proximity-assisted bioconjugation (PAB). Site-specific bioconjugation refers to the precise modification of biomolecules to generate homogeneous products. Such techniques are vital for the development of protein therapeutics including antibody-drug conjugates (ADCs), the investigation of the biological mechanisms of post-translational modifications (PTMs), and the visualization of biomolecular interactions","<PubmedArticle><MedlineCitation Status=""Publisher"" Owner=""NLM""><PMID Version=""1"">40998389</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel=""Print-Electronic""><Journal><ISSN IssnType=""Electronic"">1520-4898</ISSN><JournalIssue CitedMedium=""Internet""><PubDate><Year>2025</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Accounts of chemical research</Title><ISOAbbreviation>Acc Chem Res</ISOAbbreviation></Journal><ArticleTitle>Advances in Proximity-Assisted Bioconjugation.</ArticleTitle><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1021/acs.accounts.5c00368</ELocationID><Abstract><AbstractText>ConspectusProximity-induced chemistry (PIC) refers to the transient reactivity between two or more molecules upon physical closeness which are otherwise unreactive. Harnessed by nature to control fundamental biological processes such as transcription and signal transduction, PIC increases the probability of correctly oriented, effective collisions, facilitating fundamental cellular processes. Within the field of chemical biology, PIC has been employed for several clinically relevant purposes, including the degradation of aberrant biomolecules and construction of protein therapeutics. This Account focuses on the application of PIC strategies for the development of site-specific bioconjugation techniques, termed proximity-assisted bioconjugation (PAB). Site-specific bioconjugation refers to the precise modification of biomolecules to generate homogeneous products. Such techniques are vital for the development of protein therapeutics including antibody-drug conjugates (ADCs), the investigation of the biological mechanisms of post-translational modifications (PTMs), and the visualization of biomolecular interactions <i>in vitro</i> and <i>in vivo</i>. While numerous strategies have been developed, many suffer from poor yields, limited product stability, demanding experimental procedures, and/or a lack of regioselectivity. Thus, PIC principles have been implemented to address these limitations, leading to the development of PAB strategies which achieve precise, regioselective modification of biomolecules. In this Account, we describe the development of PAB techniques within our group at the University of Cambridge and Instituto de Medicina Molecular (iMM) over the past five years. Our journey with PAB began serendipitously while investigating maleic acid derivatives for cysteine bioconjugation. Here, we discovered the secondary participation of proximal lysines on Trastuzumab-V205C and Gemtuzumab-V205C, conjugatable THIOMAB antibodies commonly used in ADCs, leading to the formation of distinct bioconjugate products relative to IgGs without such lysines. Further investigation into the proximal lysine (K207) of Trastuzumab-V205C revealed that residue 207 could be harnessed directly or mutated to precisely tune the stability of ADCs due to proximity interactions between K207 and covalent modifications of C205. Considering that two Trastuzumab drug conjugates are approved for clinical use, these findings have contributed to the evolving understanding of the chemical landscape of this antibody and help inform future ADC design and development. Further, we describe efforts from our group to develop two distinct PAB approaches: regioselective lysine acetylation of histone H3 and phage display-compatible peptide cyclization. These strategies combine induced-proximity with traditional bioconjugation techniques to enable regioselective modification of biomolecules which are historically difficult to selectively modify. These methods are readily adaptable to related systems and serve as representative examples of how to successfully develop PAB strategies for desired applications. In short, this Account highlights our group's contributions to and insights on PAB methodologies wherein we illustrate how PIC can be thoughtfully applied to bioconjugation techniques for various aims including regioselective bioconjugation and enhanced bioconjugate stability. We expect that PAB approaches will continue to diversify bioconjugation applications and greatly expand the toolkit of chemical biologists.</AbstractText></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Canzano</LastName><ForeName>Mary</ForeName><Initials>M</Initials><Identifier Source=""ORCID"">0000-0003-4233-5370</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, CB2 1EW, Cambridge U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Bernardes</LastName><ForeName>Gonçalo J L</ForeName><Initials>GJL</Initials><Identifier Source=""ORCID"">0000-0001-6594-8917</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, CB2 1EW, Cambridge U.K.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Chemical Biology Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acc Chem Res</MedlineTA><NlmUniqueID>0157313</NlmUniqueID><ISSNLinking>0001-4842</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40998389</ArticleId><ArticleId IdType=""doi"">10.1021/acs.accounts.5c00368</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.647535
pubmed,40996206,,40996206,,Multimodal MR functional imaging for pathological grading and monitoring trastuzumab response in HER2-positive breast cancer.,https://pubmed.ncbi.nlm.nih.gov/40996206/,"Songjiang Luo, Feng Liu, Wei Wang, Siyu Li, Xiaoqing Wu, Tenglong Luo",,"Accurate noninvasive assessment of tumor grade and therapeutic response in HER2-positive breast cancer remains challenging. This prospective, single-center study aimed to evaluate the diagnostic value of multimodal MR functional imaging in grading malignant breast tumors and monitoring trastuzumab response. Eighty HER2-positive patients confirmed by IHC/FISH were enrolled, including 41 low-grade and 39 high-grade tumors (Nottingham grading system). Patients underwent comprehensive MR imaging, including diffusion tensor imaging, MR spectroscopy and perfusion imaging at baseline and during therapy. Tumor morphological features (size, necrosis, hemorrhage, edema, boundary clarity) and functional MR parameters (FA, tCho, MTT, TTP) were analyzed for correlation with pathological grade and treatment response. High-grade tumors showed larger size, more necrosis, hemorrhage and edema (P<0.05). Functional MR parameters, particularly tCho, MTT and TTP, correlated positively with tumor grade (P<0.05). ROC analysis demonstrated high diagnostic accuracy (sensitivity 89.2%, specificity 79.5%, AUC=0.887). Typical MR imaging patterns also reflected trastuzumab responsiveness, indicating potential for noninvasive monitoring of therapy. Multimodal MR functional imaging thus provides a sensitive and specific tool for tumor grading and evaluation of targeted therapeutic response.","<PubmedArticle><MedlineCitation Status=""MEDLINE"" Owner=""NLM"" IndexingMethod=""Automated""><PMID Version=""1"">40996206</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel=""Print""><Journal><ISSN IssnType=""Print"">1011-601X</ISSN><JournalIssue CitedMedium=""Internet""><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Pakistan journal of pharmaceutical sciences</Title><ISOAbbreviation>Pak J Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>Multimodal MR functional imaging for pathological grading and monitoring trastuzumab response in HER2-positive breast cancer.</ArticleTitle><Pagination><StartPage>1898</StartPage><EndPage>1905</EndPage><MedlinePgn>1898-1905</MedlinePgn></Pagination><ELocationID EIdType=""doi"" ValidYN=""Y"">10.36721/PJPS.2025.38.5.REG.15088.1</ELocationID><Abstract><AbstractText>Accurate noninvasive assessment of tumor grade and therapeutic response in HER2-positive breast cancer remains challenging. This prospective, single-center study aimed to evaluate the diagnostic value of multimodal MR functional imaging in grading malignant breast tumors and monitoring trastuzumab response. Eighty HER2-positive patients confirmed by IHC/FISH were enrolled, including 41 low-grade and 39 high-grade tumors (Nottingham grading system). Patients underwent comprehensive MR imaging, including diffusion tensor imaging, MR spectroscopy and perfusion imaging at baseline and during therapy. Tumor morphological features (size, necrosis, hemorrhage, edema, boundary clarity) and functional MR parameters (FA, tCho, MTT, TTP) were analyzed for correlation with pathological grade and treatment response. High-grade tumors showed larger size, more necrosis, hemorrhage and edema (P&lt;0.05). Functional MR parameters, particularly tCho, MTT and TTP, correlated positively with tumor grade (P&lt;0.05). ROC analysis demonstrated high diagnostic accuracy (sensitivity 89.2%, specificity 79.5%, AUC=0.887). Typical MR imaging patterns also reflected trastuzumab responsiveness, indicating potential for noninvasive monitoring of therapy. Multimodal MR functional imaging thus provides a sensitive and specific tool for tumor grading and evaluation of targeted therapeutic response.</AbstractText></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Songjiang</LastName><ForeName>Luo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fuyang Cancer Hospital, Anhui Province (affiliated tumor hospital of Fuyang Normal University), No.1186 Yinghe East Road, Yingdong district, Fuyang City, Anhui Province, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Feng</LastName><ForeName>Liu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fuyang Cancer Hospital, Anhui Province (affiliated tumor hospital of Fuyang Normal University), No.1186 Yinghe East Road, Yingdong district, Fuyang City, Anhui Province, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wei</LastName><ForeName>Wang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Fuyang Cancer Hospital, Anhui Province (affiliated tumor hospital of Fuyang Normal University), No.1186 Yinghe East Road, Yingdong district, Fuyang City, Anhui Province, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Siyu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fuyang Cancer Hospital, Anhui Province (affiliated tumor hospital of Fuyang Normal University), No.1186 Yinghe East Road, Yingdong district, Fuyang City, Anhui Province, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Xiaoqing</LastName><ForeName>Wu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Fuyang Cancer Hospital, Anhui Province (affiliated tumor hospital of Fuyang Normal University), No.1186 Yinghe East Road, Yingdong district, Fuyang City, Anhui Province, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Tenglong</LastName><ForeName>Luo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Pakistan</Country><MedlineTA>Pak J Pharm Sci</MedlineTA><NlmUniqueID>9426356</NlmUniqueID><ISSNLinking>1011-601X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI=""D000068878"">Trastuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""D018719"">Receptor, ErbB-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""C508053"">ERBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D000074322"">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=""D006801"" MajorTopicYN=""N"">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D000068878"" MajorTopicYN=""Y"">Trastuzumab</DescriptorName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D005260"" MajorTopicYN=""N"">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D001943"" MajorTopicYN=""Y"">Breast Neoplasms</DescriptorName><QualifierName UI=""Q000188"" MajorTopicYN=""N"">drug therapy</QualifierName><QualifierName UI=""Q000473"" MajorTopicYN=""N"">pathology</QualifierName><QualifierName UI=""Q000000981"" MajorTopicYN=""N"">diagnostic imaging</QualifierName><QualifierName UI=""Q000378"" MajorTopicYN=""N"">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D008875"" MajorTopicYN=""N"">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D018719"" MajorTopicYN=""Y"">Receptor, ErbB-2</DescriptorName><QualifierName UI=""Q000378"" MajorTopicYN=""N"">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000328"" MajorTopicYN=""N"">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D011446"" MajorTopicYN=""N"">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D060787"" MajorTopicYN=""N"">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D008279"" MajorTopicYN=""Y"">Magnetic Resonance Imaging</DescriptorName><QualifierName UI=""Q000379"" MajorTopicYN=""N"">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000074322"" MajorTopicYN=""Y"">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000368"" MajorTopicYN=""N"">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D064847"" MajorTopicYN=""Y"">Multimodal Imaging</DescriptorName><QualifierName UI=""Q000379"" MajorTopicYN=""N"">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D016896"" MajorTopicYN=""N"">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>8</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40996206</ArticleId><ArticleId IdType=""doi"">10.36721/PJPS.2025.38.5.REG.15088.1</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.761029
pubmed,40995085,,40995085,,Detecting HER2-positive circulating tumor cells in gastric cancer using a flow cytometry-based approach.,https://pubmed.ncbi.nlm.nih.gov/40995085/,"Lee Jan-Mou, Tu Chia-Chun, Fang Chih-Hao, Lin Shian-Ren, Wang Shiu-Lan, Lai Wan-Yu, Tseng Po-Wei, Liao Wan-En, Huang Li-Yun, Chao Yee, Chen Ming-Huang",,"HER2 overexpression predicts the response to trastuzumab in gastric cancer (GC); however, assessing this overexpression requires invasive immunohistochemistry. Circulating tumor cells (CTCs) share comparable proteomic phenotypes to those of the primary tumor and represent a less invasive method for evaluating HER2 expression. Nevertheless, methods for detecting HER2 expression on CTCs still require further investigation.","<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">40995085</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel=""Electronic-eCollection""><Journal><ISSN IssnType=""Print"">2296-858X</ISSN><JournalIssue CitedMedium=""Print""><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Detecting HER2-positive circulating tumor cells in gastric cancer using a flow cytometry-based approach.</ArticleTitle><Pagination><StartPage>1672955</StartPage><MedlinePgn>1672955</MedlinePgn></Pagination><ELocationID EIdType=""pii"" ValidYN=""Y"">1672955</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.3389/fmed.2025.1672955</ELocationID><Abstract><AbstractText Label=""BACKGROUND"" NlmCategory=""UNASSIGNED"">HER2 overexpression predicts the response to trastuzumab in gastric cancer (GC); however, assessing this overexpression requires invasive immunohistochemistry. Circulating tumor cells (CTCs) share comparable proteomic phenotypes to those of the primary tumor and represent a less invasive method for evaluating HER2 expression. Nevertheless, methods for detecting HER2 expression on CTCs still require further investigation.</AbstractText><AbstractText Label=""METHODS"" NlmCategory=""UNASSIGNED"">A flow cytometry method for detecting HER2-overexpressed CTCs was established by spiking NCI-N87 cells into blood from cancer-naive donors. The method was then applied to blood samples from 14 gastric cancer (GC) patients (4 with HER2-overexpressed tumors and 10 with HER2-wild type tumors) and 10 cancer-naive participants (CNPs), with all data analyzed using one-way ANOVA.</AbstractText><AbstractText Label=""RESULTS"" NlmCategory=""UNASSIGNED"">The gating strategy was defined as CD45<sup>-</sup>CK-7/8<sup>+</sup>CK-14/15/16/19<sup>+</sup>EpCAM<sup>+</sup>HER2<sup>+</sup>, with a cut-off value of 5 cells/mL. Using this in-house method, we detected HER2-overexpressed CTCs in 4 of 4 GC patients with HER2-overexpressed tumors (ranging from 8 to 29 cells/mL), while 10 of 10 CNPs had undetectable HER2-overexpressed CTCs. Among GC participants with HER2-wild type tumors, 7 of 10 GC participants had undetectable HER2-overexpressed CTCs, whereas 3 of 10 had detectable HER2-overexpressed CTCs. Furthermore, one participant with HER2-overexpressed CTCs detected by our in-house method received HER2-based targeted therapy and experienced an objective response and was free from disease progression to the date of article writing.</AbstractText><AbstractText Label=""CONCLUSION"" NlmCategory=""UNASSIGNED"">This study introduces a noninvasive method for monitoring HER2 expression in GC, offering new insights into providing personalized treatment strategies.</AbstractText><CopyrightInformation>Copyright © 2025 Lee, Tu, Fang, Lin, Wang, Lai, Tseng, Liao, Huang, Chao and Chen.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Lee</LastName><ForeName>Jan-Mou</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Tu</LastName><ForeName>Chia-Chun</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Fang</LastName><ForeName>Chih-Hao</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Lin</LastName><ForeName>Shian-Ren</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wang</LastName><ForeName>Shiu-Lan</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Lai</LastName><ForeName>Wan-Yu</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Tseng</LastName><ForeName>Po-Wei</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Liao</LastName><ForeName>Wan-En</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Huang</LastName><ForeName>Li-Yun</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Chao</LastName><ForeName>Yee</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>FullHope Biomedical Co., Ltd., New Taipei City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central Clinic and Hospital, Taipei City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Chen</LastName><ForeName>Ming-Huang</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">HER2 overexpression</Keyword><Keyword MajorTopicYN=""N"">circulating tumor cells</Keyword><Keyword MajorTopicYN=""N"">flow cytometry</Keyword><Keyword MajorTopicYN=""N"">gastric cancer</Keyword><Keyword MajorTopicYN=""N"">liquid biopsy</Keyword></KeywordList><CoiStatement>C-CT, C-HF, S-RL, S-LW, W-YL, P-WT, W-EL, and L-YH are employees of FullHope Biomedical Co., Ltd. J-ML is the chief executive officer of FullHope Biomedical Co., Ltd. YC is the board president of FullHope Biomedical Co., Ltd. This study is under patent filing by FullHope Biomedical Co., Ltd. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40995085</ArticleId><ArticleId IdType=""pmc"">PMC12454417</ArticleId><ArticleId IdType=""doi"">10.3389/fmed.2025.1672955</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2024) 74:229–63. doi: 10.3322/caac.21834, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3322/caac.21834</ArticleId><ArticleId IdType=""pubmed"">38572751</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrift AP, El-Serag HB. Burden of gastric Cancer. Clin Gastroenterol Hepatol. (2020) 18:534–42. doi: 10.1016/j.cgh.2019.07.045, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.cgh.2019.07.045</ArticleId><ArticleId IdType=""pmc"">PMC8859863</ArticleId><ArticleId IdType=""pubmed"">31362118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kattan J, Karak FE, Farhat F, Gerges DA, Mokaddem W, Chahine G, et al. Prevalence of her 2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients. BMC Cancer. (2022) 22:1114. doi: 10.1186/s12885-022-10206-1, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s12885-022-10206-1</ArticleId><ArticleId IdType=""pmc"">PMC9623963</ArticleId><ArticleId IdType=""pubmed"">36316658</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsu H, Oki E, Ikawa-Yoshida A, Kawano H, Ando K, Ida S, et al. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. Anticancer Res. (2015) 35:2441–6.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">25862912</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. (2008) 19:1523–9. doi: 10.1093/annonc/mdn169, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/annonc/mdn169</ArticleId><ArticleId IdType=""pubmed"">18441328</ArticleId></ArticleIdList></Reference><Reference><Citation>Denlinger CS, Matkowskyj KA, Mulcahy MF. Gastric and esophageal cancers: guidelines updates. J Natl Compr Cancer Netw. (2021) 19:639–43. doi: 10.6004/jnccn.2021.5006</Citation><ArticleIdList><ArticleId IdType=""doi"">10.6004/jnccn.2021.5006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogia P, Ashraf H, Bhasin S, Xu Y. Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence. Cancers (Basel). (2023) 15:3886. doi: 10.3390/cancers15153886, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/cancers15153886</ArticleId><ArticleId IdType=""pmc"">PMC10417123</ArticleId><ArticleId IdType=""pubmed"">37568702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. (2022) 20:167–92. doi: 10.6004/jnccn.2022.0008</Citation><ArticleIdList><ArticleId IdType=""doi"">10.6004/jnccn.2022.0008</ArticleId><ArticleId IdType=""pubmed"">35130500</ArticleId></ArticleIdList></Reference><Reference><Citation>Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. (2022) 33:1005–20. doi: 10.1016/j.annonc.2022.07.004, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2022.07.004</ArticleId><ArticleId IdType=""pubmed"">35914639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, 3rd, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. (2017) 35:446–64. doi: 10.1200/JCO.2016.69.4836</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2016.69.4836</ArticleId><ArticleId IdType=""pubmed"">28129524</ArticleId></ArticleIdList></Reference><Reference><Citation>Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. (2012) 25:637–50. doi: 10.1038/modpathol.2011.198, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/modpathol.2011.198</ArticleId><ArticleId IdType=""pubmed"">22222640</ArticleId></ArticleIdList></Reference><Reference><Citation>Abangah G, Sarokhani D, Abdan Z, Fakhri M, Nourmohammadi H. The effect of metformin use on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis of cohort studies. Immunopathol Persa. (2022) 10:e34421. doi: 10.34172/ipp.2022.34421</Citation><ArticleIdList><ArticleId IdType=""doi"">10.34172/ipp.2022.34421</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo S, Ryu M-H, Park YS, Ahn JY, Park Y, Park SR, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the gastric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. (2018) 22:527–35. doi: 10.1007/s10120-018-0891-1, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10120-018-0891-1</ArticleId><ArticleId IdType=""pubmed"">30386954</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L. HER2 heterogeneity in gastric/gastroesophageal cancers: from benchside to practice. World J Gastroenterol. (2016) 22:5879–87. doi: 10.3748/wjg.v22.i26.5879, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3748/wjg.v22.i26.5879</ArticleId><ArticleId IdType=""pmc"">PMC4948273</ArticleId><ArticleId IdType=""pubmed"">27468182</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in anti–human epidermal growth factor receptor 2 treatment–naive patients with human epidermal growth factor receptor 2–low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. (2023) 41:816–25. doi: 10.1200/jco.22.00575, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/jco.22.00575</ArticleId><ArticleId IdType=""pmc"">PMC9901967</ArticleId><ArticleId IdType=""pubmed"">36379002</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Siddiqui A, et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. (2022) 26:123–31. doi: 10.1007/s10120-022-01335-4, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10120-022-01335-4</ArticleId><ArticleId IdType=""pmc"">PMC9813086</ArticleId><ArticleId IdType=""pubmed"">36066725</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha P, Kao S, Cheung VK, Cooper WA, van Zandwijk N, Rasko JEJ, et al. Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients. Mol Oncol. (2025) 19:1998–2013. doi: 10.1002/1878-0261.13696, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/1878-0261.13696</ArticleId><ArticleId IdType=""pmc"">PMC12234382</ArticleId><ArticleId IdType=""pubmed"">38956984</ArticleId></ArticleIdList></Reference><Reference><Citation>Habli Z, AlChamaa W, Saab R, Kadara H, Khraiche ML. Circulating tumor cell detection technologies and clinical utility: challenges and opportunities. Cancers. (2020) 12:1930. doi: 10.3390/cancers12071930, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/cancers12071930</ArticleId><ArticleId IdType=""pmc"">PMC7409125</ArticleId><ArticleId IdType=""pubmed"">32708837</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieckmann LM, Spohn M, Ruff L, Agorku D, Becker L, Borchers A, et al. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells. Mol Cancer. (2024) 23:93. doi: 10.1186/s12943-024-01984-2, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s12943-024-01984-2</ArticleId><ArticleId IdType=""pmc"">PMC11077784</ArticleId><ArticleId IdType=""pubmed"">38720314</ArticleId></ArticleIdList></Reference><Reference><Citation>Soleymani S, Naghib SM, Mozafari MR. Circulating tumor cells in Cancer diagnosis, therapy, and Theranostics applications: an overview of emerging materials and technologies. Curr Pharm Des. (2025) 31:674–90. doi: 10.2174/0113816128328459241009191933, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.2174/0113816128328459241009191933</ArticleId><ArticleId IdType=""pubmed"">39473210</ArticleId></ArticleIdList></Reference><Reference><Citation>Riethdorf S, O'Flaherty L, Hille C, Pantel K. Clinical applications of the cell search platform in cancer patients. Adv Drug Deliv Rev. (2018) 125:102–21. doi: 10.1016/j.addr.2018.01.011</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.addr.2018.01.011</ArticleId><ArticleId IdType=""pubmed"">29355669</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao LJ, Tsai CC, Li PY, Lee CY, Lin SR, Lai WY, et al. Characterization of unique pattern of immune cell profile in patients with nasopharyngeal carcinoma through flow cytometry and machine learning. J Cell Mol Med. (2024) 28:e18404. doi: 10.1111/jcmm.18404, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1111/jcmm.18404</ArticleId><ArticleId IdType=""pmc"">PMC11184936</ArticleId><ArticleId IdType=""pubmed"">38888489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, et al. Sensitive and easy screening for circulating tumor cells by flow cytometry. JCI Insight. (2019) 5:8180. doi: 10.1172/jci.insight.128180, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1172/jci.insight.128180</ArticleId><ArticleId IdType=""pmc"">PMC6675556</ArticleId><ArticleId IdType=""pubmed"">31194699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolostova K, Matkowski R, Gürlich R, Grabowski K, Soter K, Lischke R, et al. Detection and cultivation of circulating tumor cells in gastric cancer. Cytotechnology. (2015) 68:1095–102. doi: 10.1007/s10616-015-9866-9, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10616-015-9866-9</ArticleId><ArticleId IdType=""pmc"">PMC4960158</ArticleId><ArticleId IdType=""pubmed"">25862542</ArticleId></ArticleIdList></Reference><Reference><Citation>Shitara K, Fleitas T, Kawakami H, Curigliano G, Narita Y, Wang F, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open. (2024) 9:102226. doi: 10.1016/j.esmoop.2023.102226, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.esmoop.2023.102226</ArticleId><ArticleId IdType=""pmc"">PMC10937212</ArticleId><ArticleId IdType=""pubmed"">38458658</ArticleId></ArticleIdList></Reference><Reference><Citation>Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, et al. Randomized, phase II study of Trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction Cancer: WJOG7112G (T-ACT study). J Clin Oncol. (2020) 38:1919–27. doi: 10.1200/JCO.19.03077, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.19.03077</ArticleId><ArticleId IdType=""pubmed"">32208960</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric Cancer treated with Trastuzumab. J Clin Oncol. (2013) 31:4445–52. doi: 10.1200/jco.2013.48.9070, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/jco.2013.48.9070</ArticleId><ArticleId IdType=""pubmed"">24127447</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research. Int J Cancer. (2016) 139:2859–64. doi: 10.1002/ijc.30408, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/ijc.30408</ArticleId><ArticleId IdType=""pubmed"">27578417</ArticleId></ArticleIdList></Reference><Reference><Citation>Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab Deruxtecan in previously treated HER2-positive gastric Cancer. N Engl J Med. (2020) 382:2419–30. doi: 10.1056/NEJMoa2004413, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2004413</ArticleId><ArticleId IdType=""pubmed"">32469182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes J, Dieras V, Lorenzen S, Montemurro F, Riera-Knorrenschild J, Thuss-Patience P, et al. Efficacy and safety of Trastuzumab Emtansine plus Capecitabine vs Trastuzumab Emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast Cancer: a phase 1 and randomized phase 2 trial. JAMA Oncol. (2020) 6:1203–9. doi: 10.1001/jamaoncol.2020.1796, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1001/jamaoncol.2020.1796</ArticleId><ArticleId IdType=""pmc"">PMC7317656</ArticleId><ArticleId IdType=""pubmed"">32584367</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. (2024) 9:336. doi: 10.1038/s41392-024-02021-w, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41392-024-02021-w</ArticleId><ArticleId IdType=""pmc"">PMC11609310</ArticleId><ArticleId IdType=""pubmed"">39617822</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmaie N, Ozensoy Guler O, Simsek E. A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells. J Liq Biopsy. (2024) 6:100169. doi: 10.1016/j.jlb.2024.100169, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.jlb.2024.100169</ArticleId><ArticleId IdType=""pmc"">PMC11863822</ArticleId><ArticleId IdType=""pubmed"">40027303</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagwat N, Dulmage K, Pletcher CH, Jr, Wang L, DeMuth W, Sen M, et al. An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Sci Rep. (2018) 8:5035. doi: 10.1038/s41598-018-23217-5, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41598-018-23217-5</ArticleId><ArticleId IdType=""pmc"">PMC5864750</ArticleId><ArticleId IdType=""pubmed"">29568081</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan J, Nedosekin DA, Galanzha EI, Zharov VP. Detection of apoptotic circulating tumor cells using in vivo fluorescence flow cytometry. Cytometry A. (2019) 95:664–71. doi: 10.1002/cyto.a.23642, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/cyto.a.23642</ArticleId><ArticleId IdType=""pmc"">PMC9257981</ArticleId><ArticleId IdType=""pubmed"">30508273</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, et al. Immunotherapy and targeted therapy for advanced gastroesophageal Cancer: ASCO guideline. J Clin Oncol. (2023) 41:1470–91. doi: 10.1200/jco.22.02331, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/jco.22.02331</ArticleId><ArticleId IdType=""pubmed"">36603169</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheck MK, Hofheinz RD, Lorenzen S. HER2-positive gastric Cancer and antibody treatment: state of the art and future developments. Cancers (Basel). (2024) 16:1336. doi: 10.3390/cancers16071336, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/cancers16071336</ArticleId><ArticleId IdType=""pmc"">PMC11010911</ArticleId><ArticleId IdType=""pubmed"">38611014</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu SEI, Iimori M, Nakanishi R, Jogo T, Saeki H, Oki E, et al. Changes in HER2 expression and amplification status following preoperative chemotherapy for gastric cancer. In Vivo. (2018) 32:1491–8. doi: 10.21873/invivo.11405, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.21873/invivo.11405</ArticleId><ArticleId IdType=""pmc"">PMC6365720</ArticleId><ArticleId IdType=""pubmed"">30348707</ArticleId></ArticleIdList></Reference><Reference><Citation>Elghissassi I, Inrhaoun H, Vignot S, Mrabti H, Errihani H. Reduction in HER-2 protein expression in a breast tumor HER-2 positive after only one injection of Trastuzumab: a case report. Cases J. (2009) 2:8099. doi: 10.4076/1757-1626-2-8099, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.4076/1757-1626-2-8099</ArticleId><ArticleId IdType=""pmc"">PMC2740012</ArticleId><ArticleId IdType=""pubmed"">19918269</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Liu L, Ding J. Case report: from negative to positive: a remarkable journey of ER, PR and HER2 status in a patient with metastatic breast cancer. Front Oncol. (2024) 14:1381541. doi: 10.3389/fonc.2024.1381541, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3389/fonc.2024.1381541</ArticleId><ArticleId IdType=""pmc"">PMC11088233</ArticleId><ArticleId IdType=""pubmed"">38737908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer. (2017) 20:126–35. doi: 10.1007/s10120-016-0599-z, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10120-016-0599-z</ArticleId><ArticleId IdType=""pubmed"">26874951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, et al. Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric Cancer patients. Target Oncol. (2017) 12:341–51. doi: 10.1007/s11523-017-0493-6, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s11523-017-0493-6</ArticleId><ArticleId IdType=""pubmed"">28508152</ArticleId></ArticleIdList></Reference><Reference><Citation>Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip. (2014) 14:147–56. doi: 10.1039/c3lc51039e, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1039/c3lc51039e</ArticleId><ArticleId IdType=""pmc"">PMC3921117</ArticleId><ArticleId IdType=""pubmed"">24202699</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz M, Singh P, Kotchetkov IS, Skakodub A, Meng A, Tamer C, et al. Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases. J Neuro-Oncol. (2022) 157:81–90. doi: 10.1007/s11060-022-03949-1, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s11060-022-03949-1</ArticleId><ArticleId IdType=""pmc"">PMC9119011</ArticleId><ArticleId IdType=""pubmed"">35113288</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Y, Wu Y, Yuan Z, Niu X, He Y, Peng J, et al. The frequency of circulating tumour cells and the correlation with the clinical response to standard chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective study. Cancer Manag Res. (2019) 11:10187–93. doi: 10.2147/CMAR.S222916, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.2147/CMAR.S222916</ArticleId><ArticleId IdType=""pmc"">PMC6897263</ArticleId><ArticleId IdType=""pubmed"">31819651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. (2009) 113:501–7. doi: 10.1007/s10549-008-9951-2, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10549-008-9951-2</ArticleId><ArticleId IdType=""pmc"">PMC5847290</ArticleId><ArticleId IdType=""pubmed"">18327638</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.853264
pubmed,40993318,,40993318,,Comment on 'The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors'.,https://pubmed.ncbi.nlm.nih.gov/40993318/,Altundag Kadri,,,"<PubmedArticle><MedlineCitation Status=""In-Process"" Owner=""NLM""><PMID Version=""1"">40993318</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel=""Electronic""><Journal><ISSN IssnType=""Electronic"">1559-131X</ISSN><JournalIssue CitedMedium=""Internet""><Volume>42</Volume><Issue>11</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Medical oncology (Northwood, London, England)</Title><ISOAbbreviation>Med Oncol</ISOAbbreviation></Journal><ArticleTitle>Comment on 'The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors'.</ArticleTitle><Pagination><StartPage>491</StartPage><MedlinePgn>491</MedlinePgn></Pagination><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1007/s12032-025-03064-x</ELocationID><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Altundag</LastName><ForeName>Kadri</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey. altundag66@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016422"">Letter</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Oncol</MedlineTA><NlmUniqueID>9435512</NlmUniqueID><ISSNLinking>1357-0560</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40993318</ArticleId><ArticleId IdType=""doi"">10.1007/s12032-025-03064-x</ArticleId><ArticleId IdType=""pii"">10.1007/s12032-025-03064-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhao H, Hu H, Li Z, et al. The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors. Med Oncol. 2025;42:415. https://doi.org/10.1007/s12032-025-02976-y .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s12032-025-02976-y</ArticleId><ArticleId IdType=""pubmed"">40779123</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Nat Rev Clin Oncol. 2019;16(1):32–46. https://doi.org/10.1038/s41571-018-0116-6 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41571-018-0116-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Liu J, Chen J, et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer. Nat Commun. 2018;9:1614. https://doi.org/10.1038/s41467-018-03936-y .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41467-018-03936-y</ArticleId><ArticleId IdType=""pubmed"">29691399</ArticleId><ArticleId IdType=""pmc"">5915573</ArticleId></ArticleIdList></Reference><Reference><Citation>Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, in advanced solid tumors. Invest New Drugs. 2017;35(2):180–8. https://doi.org/10.1007/s10637-016-0407-y .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10637-016-0407-y</ArticleId><ArticleId IdType=""pubmed"">27917453</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti C, Giugliano F, Curigliano G. Antibody–drug conjugates in breast cancer: the chemotherapy of the future? Nat Rev Clin Oncol. 2013;20(1):1–17. https://doi.org/10.1038/nrclinonc.2013.245 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/nrclinonc.2013.245</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:50.946611
pubmed,40991498,,40991498,,A case of trastuzumab-deruxtecan-induced subacute cutaneous lupus erythematous.,https://pubmed.ncbi.nlm.nih.gov/40991498/,"Trepanowski Nicole, Shah Payal, Bai Heidi, Yan Shaofeng, Fragoso Natalie, Barton Dorothea",,"Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an erythematous, photodistributed, scaly, and annular cutaneous eruption that is clinically similar to subacute cutaneous lupus erythematosus. However, DI-SCLE is associated with medication use and generally resolves or greatly improves following discontinuation. Chemotherapeutic agents are common triggers of DI-SCLE. We report a patient with breast cancer who experienced multiple episodes of DI-SCLE associated with the use of different chemotherapeutic agents for treatment-resistant cancer. Notably, to the best of our knowledge, this case highlights the first reported association of DI-SCLE with trastuzumab deruxtecan. Additionally, this case is unique owing to a component of radiation recall dermatitis, as the rash was prominent in areas that had prior ionizing radiation. A prior history of DI-SCLE in oncology patients who continue to undergo treatment should prompt clinicians to consider DI-SCLE when faced with a new photodistributed, erythematous, annular, and scaly eruption. Early initiation of immunomodulating agents like hydroxychloroquine in patients with a history of moderate to severe DI-SCLE to chemotherapy who continue to undergo anti-cancer treatment may provide benefit and warrants further investigation.","<PubmedArticle><MedlineCitation Status=""MEDLINE"" Owner=""NLM"" IndexingMethod=""Curated""><PMID Version=""1"">40991498</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel=""Electronic""><Journal><ISSN IssnType=""Electronic"">1087-2108</ISSN><JournalIssue CitedMedium=""Internet""><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Dermatology online journal</Title><ISOAbbreviation>Dermatol Online J</ISOAbbreviation></Journal><ArticleTitle>A case of trastuzumab-deruxtecan-induced subacute cutaneous lupus erythematous.</ArticleTitle><ELocationID EIdType=""doi"" ValidYN=""Y"">10.5070/D331265294</ELocationID><Abstract><AbstractText>Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an erythematous, photodistributed, scaly, and annular cutaneous eruption that is clinically similar to subacute cutaneous lupus erythematosus. However, DI-SCLE is associated with medication use and generally resolves or greatly improves following discontinuation. Chemotherapeutic agents are common triggers of DI-SCLE. We report a patient with breast cancer who experienced multiple episodes of DI-SCLE associated with the use of different chemotherapeutic agents for treatment-resistant cancer. Notably, to the best of our knowledge, this case highlights the first reported association of DI-SCLE with trastuzumab deruxtecan. Additionally, this case is unique owing to a component of radiation recall dermatitis, as the rash was prominent in areas that had prior ionizing radiation. A prior history of DI-SCLE in oncology patients who continue to undergo treatment should prompt clinicians to consider DI-SCLE when faced with a new photodistributed, erythematous, annular, and scaly eruption. Early initiation of immunomodulating agents like hydroxychloroquine in patients with a history of moderate to severe DI-SCLE to chemotherapy who continue to undergo anti-cancer treatment may provide benefit and warrants further investigation.</AbstractText></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Trepanowski</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN=""Y""><LastName>Shah</LastName><ForeName>Payal</ForeName><Initials>P</Initials></Author><Author ValidYN=""Y""><LastName>Bai</LastName><ForeName>Heidi</ForeName><Initials>H</Initials></Author><Author ValidYN=""Y""><LastName>Yan</LastName><ForeName>Shaofeng</ForeName><Initials>S</Initials></Author><Author ValidYN=""Y""><LastName>Fragoso</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA. natalie.m.fragoso@hitchcock.org.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Barton</LastName><ForeName>Dorothea</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D002363"">Case Reports</PublicationType><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dermatol Online J</MedlineTA><NlmUniqueID>9610776</NlmUniqueID><ISSNLinking>1087-2108</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI=""D000068878"">Trastuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D000074322"">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=""D006801"" MajorTopicYN=""N"">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D008178"" MajorTopicYN=""Y"">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI=""Q000139"" MajorTopicYN=""N"">chemically induced</QualifierName><QualifierName UI=""Q000473"" MajorTopicYN=""N"">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D005260"" MajorTopicYN=""N"">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D000068878"" MajorTopicYN=""Y"">Trastuzumab</DescriptorName><QualifierName UI=""Q000009"" MajorTopicYN=""N"">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D001943"" MajorTopicYN=""N"">Breast Neoplasms</DescriptorName><QualifierName UI=""Q000188"" MajorTopicYN=""N"">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000074322"" MajorTopicYN=""Y"">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI=""Q000009"" MajorTopicYN=""N"">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D008875"" MajorTopicYN=""N"">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>18</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>18</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40991498</ArticleId><ArticleId IdType=""doi"">10.5070/D331265294</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:51.037674
pubmed,40989687,,40989687,,Pharmacologic management of HR+/HER2- mBC: a clinically oriented review.,https://pubmed.ncbi.nlm.nih.gov/40989687/,"Chiru Elena Diana, Sojak Lina, Landin Julia, Vetter Marcus, Grašič Kuhar Cvetka",,"Breast cancer (BC) remains the most prevalent cancer among women worldwide, with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) subtypes representing approximately 75% of cases. Endocrine therapy (ET) has been foundational in HR+ BC treatment, significantly reducing recurrence and mortality rates, yet resistance to ET remains a critical challenge, particularly in the metastatic setting. Recent treatment advancements-especially CDK4/6 inhibitors (CDK4/6i) in first-line therapy, have reshaped management of HR+ HER2- mBC. Additionally, novel agents like selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs), have proven to be effective against ER-resistance inducing mutations, such as ESR1, while poly ADP-ribose polymerase inhibitors (PARPi) showed targeted benefit in BRCA-mutated tumors. In breast cancer expressing AKT/PIK3CA pathway alterations, drugs like alpelisib, capivasertib, and inavolisib have recently been approved, demonstrating improved PFS in this specific patient population. Recent developments of antibody-drug conjugates (ADCs) have also extended therapeutic options to previously labeled HER2-negative tumors, with drugs like trastuzumab deruxtecan (T-DXd) demonstrating efficacy in newly emerged HER2-low and HER2-ultralow pathologic subgroups, extending median overall survival to almost 2 years. Most of these drugs have paved the way for personalized medicine and opened questions around optimal sequencing of ET and application of combination therapies, which continue to be investigated through clinical trials. This review seeks to highlight current and emerging treatment strategies addressing ET resistance to improve survival outcomes for HR+ mBC patients, emphasizing the need for personalized approaches.","<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">40989687</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel=""Electronic-eCollection""><Journal><ISSN IssnType=""Print"">2234-943X</ISSN><JournalIssue CitedMedium=""Print""><Volume>15</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>Pharmacologic management of HR+/HER2- mBC: a clinically oriented review.</ArticleTitle><Pagination><StartPage>1596634</StartPage><MedlinePgn>1596634</MedlinePgn></Pagination><ELocationID EIdType=""pii"" ValidYN=""Y"">1596634</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.3389/fonc.2025.1596634</ELocationID><Abstract><AbstractText>Breast cancer (BC) remains the most prevalent cancer among women worldwide, with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) subtypes representing approximately 75% of cases. Endocrine therapy (ET) has been foundational in HR+ BC treatment, significantly reducing recurrence and mortality rates, yet resistance to ET remains a critical challenge, particularly in the metastatic setting. Recent treatment advancements-especially CDK4/6 inhibitors (CDK4/6i) in first-line therapy, have reshaped management of HR+ HER2- mBC. Additionally, novel agents like selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs), have proven to be effective against ER-resistance inducing mutations, such as ESR1, while poly ADP-ribose polymerase inhibitors (PARPi) showed targeted benefit in BRCA-mutated tumors. In breast cancer expressing AKT/PIK3CA pathway alterations, drugs like alpelisib, capivasertib, and inavolisib have recently been approved, demonstrating improved PFS in this specific patient population. Recent developments of antibody-drug conjugates (ADCs) have also extended therapeutic options to previously labeled HER2-negative tumors, with drugs like trastuzumab deruxtecan (T-DXd) demonstrating efficacy in newly emerged HER2-low and HER2-ultralow pathologic subgroups, extending median overall survival to almost 2 years. Most of these drugs have paved the way for personalized medicine and opened questions around optimal sequencing of ET and application of combination therapies, which continue to be investigated through clinical trials. This review seeks to highlight current and emerging treatment strategies addressing ET resistance to improve survival outcomes for HR+ mBC patients, emphasizing the need for personalized approaches.</AbstractText><CopyrightInformation>Copyright © 2025 Chiru, Sojak, Landin, Vetter and Grašič Kuhar.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Chiru</LastName><ForeName>Elena Diana</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>University Center for Hematology and Oncology, Cantonal Hospital Baselland, Liestal, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Sojak</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Basel Medical University, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Landin</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Center for Hematology and Oncology, Cantonal Hospital Baselland, Liestal, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y"" EqualContrib=""Y""><LastName>Vetter</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Center for Hematology and Oncology, Cantonal Hospital Baselland, Liestal, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y"" EqualContrib=""Y""><LastName>Grašič Kuhar</LastName><ForeName>Cvetka</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType><PublicationType UI=""D016454"">Review</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">CDK4/6 inhibitors</Keyword><Keyword MajorTopicYN=""N"">aromatase inhibitors</Keyword><Keyword MajorTopicYN=""N"">endocrine resistance</Keyword><Keyword MajorTopicYN=""N"">hormone receptor positive breast cancer</Keyword><Keyword MajorTopicYN=""N"">metastatic breast cancer</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40989687</ArticleId><ArticleId IdType=""pmc"">PMC12450692</ArticleId><ArticleId IdType=""doi"">10.3389/fonc.2025.1596634</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2024) 74:229–63. doi:  10.3322/caac.21841, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3322/caac.21841</ArticleId><ArticleId IdType=""pubmed"">38572751</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaglino E, Cavallo F. Breast cancer stem cell antigens as targets for immunotherapy. Semin Immunol. (2020) 47:101386. doi:  10.1016/j.smim.2020.101386, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.smim.2020.101386</ArticleId><ArticleId IdType=""pubmed"">31932198</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakha EA, Ellis IO. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Anatomic Pathol. (2011) 18:255–67. doi:  10.1097/PAP.0b013e318220f5d1, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1097/PAP.0b013e318220f5d1</ArticleId><ArticleId IdType=""pubmed"">21654357</ArticleId></ArticleIdList></Reference><Reference><Citation>Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; (2015).</Citation></Reference><Reference><Citation>
ESMO . Breast cancer guidelines. (2024). European Society for Medical Oncology. Available online at: https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-breast-cancer (Accessed May 2, 2025).</Citation></Reference><Reference><Citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. (2024) 35:159–82. doi:  10.1016/j.annonc.2023.11.016, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2023.11.016</ArticleId><ArticleId IdType=""pubmed"">38101773</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog SK, Fesl C. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. (2022) 126:174–86. doi:  10.1038/s41416-021-01564-x, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41416-021-01564-x</ArticleId><ArticleId IdType=""pmc"">PMC8770568</ArticleId><ArticleId IdType=""pubmed"">34621045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. (2011) 378:771–84. doi:  10.1016/S0140-6736(11)60993-8, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(11)60993-8</ArticleId><ArticleId IdType=""pmc"">PMC3163848</ArticleId><ArticleId IdType=""pubmed"">21802721</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnant M, et al. Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet. (2015) 386:433–43. doi:  10.1016/S0140-6736(15)60995-3, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(15)60995-3</ArticleId><ArticleId IdType=""pubmed"">26040499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. (2022) 23:382–92. doi:  10.1016/S1470-2045(21)00758-0, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(21)00758-0</ArticleId><ArticleId IdType=""pmc"">PMC8885431</ArticleId><ArticleId IdType=""pubmed"">35123662</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology. (2003) 64:289–99. doi:  10.1159/000070284, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1159/000070284</ArticleId><ArticleId IdType=""pubmed"">12759523</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab. (2009) 20:477–82. doi:  10.1016/j.tem.2009.06.004, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.tem.2009.06.004</ArticleId><ArticleId IdType=""pmc"">PMC3589572</ArticleId><ArticleId IdType=""pubmed"">19783454</ArticleId></ArticleIdList></Reference><Reference><Citation>Battisti NML, Sundararajan IE. Preventing late recurrence in hormone receptor-positive early breast cancer: a review. Eur J Cancer. (2022) 168:53–64. doi:  10.1016/j.ejca.2022.05.028, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ejca.2022.05.028</ArticleId><ArticleId IdType=""pubmed"">35753212</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, et al. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, HER2-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer. (2015) 112:1405–10. doi:  10.1038/bjc.2015.98, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/bjc.2015.98</ArticleId><ArticleId IdType=""pmc"">PMC4402462</ArticleId><ArticleId IdType=""pubmed"">25867274</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. (2008) 26:721–8. doi:  10.1200/JCO.2007.15.1068, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2007.15.1068</ArticleId><ArticleId IdType=""pubmed"">18258979</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. (2016) 375:717–29. doi:  10.1056/NEJMoa1602253, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa1602253</ArticleId><ArticleId IdType=""pubmed"">27557300</ArticleId></ArticleIdList></Reference><Reference><Citation>Matikas A, Foukakis T, Swain S, Bergh J. Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? Ann Oncol. (2019) 30:1044–50. doi:  10.1093/annonc/mdz126, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/annonc/mdz126</ArticleId><ArticleId IdType=""pmc"">PMC6695578</ArticleId><ArticleId IdType=""pubmed"">31131397</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquet E, Lardy-Cléaud A, Pistilli B, Franck S, Cottu P, Delaloge S, et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer. (2018) 90:93–101. doi:  10.1016/j.ejca.2017.11.003, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ejca.2017.11.003</ArticleId><ArticleId IdType=""pubmed"">29655061</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AN, Metzger O, Bartlett CH, Liu Y, Huang X, Cristofanilli M, et al. Hormone receptor-positive/human epidermal growth receptor 2-negative metastatic breast cancer in young women: emerging data in the era of molecularly targeted agents. Oncologist. (2020) 25:900–8. doi:  10.1634/theoncologist.2019-0622, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1634/theoncologist.2019-0622</ArticleId><ArticleId IdType=""pmc"">PMC7288640</ArticleId><ArticleId IdType=""pubmed"">32176406</ArticleId></ArticleIdList></Reference><Reference><Citation>McAndrew NP, Finn RS. Management of ER positive metastatic breast cancer. Semin Oncol. (2020) 47:270–7. doi:  10.1053/j.seminoncol.2020.07.001, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1053/j.seminoncol.2020.07.001</ArticleId><ArticleId IdType=""pubmed"">32958261</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. (2024) 391:1584–96. doi:  10.1056/NEJMoa2401972, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2401972</ArticleId><ArticleId IdType=""pubmed"">39476340</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. (2023) 388:2058–70. doi:  10.1056/NEJMoa2215022</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2215022</ArticleId><ArticleId IdType=""pmc"">PMC11335038</ArticleId><ArticleId IdType=""pubmed"">37256976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. (2024) 35:S7534. doi:  10.1016/annonc/ann.2024.7534, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/annonc/ann.2024.7534</ArticleId><ArticleId IdType=""pubmed"">39442617</ArticleId></ArticleIdList></Reference><Reference><Citation>Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. (2012) 366:520–9. doi:  10.1056/NEJMoa1109653, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa1109653</ArticleId><ArticleId IdType=""pmc"">PMC5705195</ArticleId><ArticleId IdType=""pubmed"">22149876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao LQ, Sun H, Xie Y, Patel H, Bo L, Lin H, et al. Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy. Front Pharmacol. (2024) 15:1340764. doi:  10.3389/fphar.2024.1340764, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3389/fphar.2024.1340764</ArticleId><ArticleId IdType=""pmc"">PMC10847323</ArticleId><ArticleId IdType=""pubmed"">38327984</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R, Klein P, Tiersten A, Sparano JA. An emerging generation of endocrine therapies in breast cancer: a clinical perspective. NPJ Breast Cancer. (2023) 9:6. doi:  10.1038/s41523-023-00549-1, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41523-023-00549-1</ArticleId><ArticleId IdType=""pmc"">PMC10076370</ArticleId><ArticleId IdType=""pubmed"">37019913</ArticleId></ArticleIdList></Reference><Reference><Citation>
ESMO . Metastatic breast cancer living guidelines (2023). European Society for Medical Oncology. Available online at: https://www.esmo.org/guidelines/breast-cancer (Accessed May 2, 2025).</Citation></Reference><Reference><Citation>Kaklamani VG, Gradishar WJ. Endocrine therapy in the current management of postmenopausal estrogen receptor-positive metastatic breast cancer. Oncologist. (2017) 22:507–17. doi:  10.1634/theoncologist.2016-0471, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1634/theoncologist.2016-0471</ArticleId><ArticleId IdType=""pmc"">PMC5423509</ArticleId><ArticleId IdType=""pubmed"">28314835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu YS, Mahidin EIBM, Azim H, Eralp Y, Yap YS, Im SA, et al. Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/HER2-negative advanced breast cancer. J Clin Oncol. (2024) 42:2812–21. doi:  10.1200/JCO.23.00214, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.23.00214</ArticleId><ArticleId IdType=""pmc"">PMC11315404</ArticleId><ArticleId IdType=""pubmed"">38771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M, et al. Recent progress of CDK4/6 inhibitors’ current practice in breast cancer. Cancer Gene Ther. (2024) 31:1283–91. doi:  10.1038/s41417-023-00631-w, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41417-023-00631-w</ArticleId><ArticleId IdType=""pmc"">PMC11405274</ArticleId><ArticleId IdType=""pubmed"">38409585</ArticleId></ArticleIdList></Reference><Reference><Citation>Glück S. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. Am J Clin Oncol. (2010) 33:314–9. doi:  10.1097/COC.0b013e31819e3bd0</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1097/COC.0b013e31819e3bd0</ArticleId><ArticleId IdType=""pubmed"">19730353</ArticleId></ArticleIdList></Reference><Reference><Citation>Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. (2021) 23:85. doi:  10.1186/s13058-021-01428-3, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s13058-021-01428-3</ArticleId><ArticleId IdType=""pmc"">PMC8365900</ArticleId><ArticleId IdType=""pubmed"">34392831</ArticleId></ArticleIdList></Reference><Reference><Citation>Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. (2013) 45:1439–45. doi:  10.1038/ng.2822, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/ng.2822</ArticleId><ArticleId IdType=""pmc"">PMC3903423</ArticleId><ArticleId IdType=""pubmed"">24185512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet. (2016) 48:848–55. doi:  10.1038/ng.3602, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/ng.3602</ArticleId><ArticleId IdType=""pmc"">PMC4963271</ArticleId><ArticleId IdType=""pubmed"">27348297</ArticleId></ArticleIdList></Reference><Reference><Citation>Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature. (2012) 490:61–70. doi:  10.1038/nature11412, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/nature11412</ArticleId><ArticleId IdType=""pmc"">PMC3465532</ArticleId><ArticleId IdType=""pubmed"">23000897</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. (2014) 345:216–20. doi:  10.1126/science.1253533, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1126/science.1253533</ArticleId><ArticleId IdType=""pmc"">PMC4358808</ArticleId><ArticleId IdType=""pubmed"">25013076</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell. (2018) 33:173–86. doi:  10.1016/j.ccell.2017.12.010, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ccell.2017.12.010</ArticleId><ArticleId IdType=""pmc"">PMC5813700</ArticleId><ArticleId IdType=""pubmed"">29438694</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggelis V, Johnston SRD. Advances in endocrine-based therapies for estrogen receptor-positive metastatic breast cancer. Drugs. (2019) 79:1849–66. doi:  10.1007/s40265-019-01200-3</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s40265-019-01200-3</ArticleId><ArticleId IdType=""pubmed"">31630379</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo V, Iorfida M, Montalto E, Festa V, Garipoli C, Scimone A, et al. Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann Oncol. (2007) 18:53–7. doi:  10.1093/annonc/mdm272, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/annonc/mdm272</ArticleId><ArticleId IdType=""pubmed"">17591833</ArticleId></ArticleIdList></Reference><Reference><Citation>Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. (2021) 397:1750–69. doi:  10.1016/S0140-6736(20)32381-3, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(20)32381-3</ArticleId><ArticleId IdType=""pubmed"">33812473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HA, Lee JW, Nam SJ, Park BW, Im SA, Lee ES, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: A randomized phase III trial. J Clin Oncol. (2020) 38:434–43. doi:  10.1200/JCO.19.01683</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.19.01683</ArticleId><ArticleId IdType=""pubmed"">31518174</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek SY, Noh WC, Ahn SH, Kim HA, Ryu JM, Kim SI, et al. Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial. J Clin Oncol. (2023) 41:4864–71. doi:  10.1200/JCO.23.00665, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.23.00665</ArticleId><ArticleId IdType=""pubmed"">37607321</ArticleId></ArticleIdList></Reference><Reference><Citation>Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW, et al. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer. (2000) 88:2047–53. doi:  10.1002/(SICI)1097-0142(20000501)88:9&lt;2047::AID-CNCR27&gt;3.0.CO;2-O, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/(SICI)1097-0142(20000501)88:9&lt;2047::AID-CNCR27&gt;3.0.CO;2-O</ArticleId><ArticleId IdType=""pubmed"">10813716</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, et al. Lasofoxifene versus fulvestrant for ER+/HER2– metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. (2023) 34:1141–51. doi:  10.1016/j.annonc.2023.06.013, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2023.06.013</ArticleId><ArticleId IdType=""pubmed"">38072514</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. (2002) 20:3386–95. doi:  10.1200/JCO.2002.11.023, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2002.11.023</ArticleId><ArticleId IdType=""pubmed"">12177098</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. (2002) 20:3396–403. doi:  10.1200/JCO.2002.10.093</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2002.10.093</ArticleId><ArticleId IdType=""pubmed"">12177099</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafaee MN, Emens MJ. Fulvestrant in management of hormone receptor-positive metastatic breast cancer. Future Oncol. (2018) 14:1789–800. doi:  10.2217/fon-2018-0120</Citation><ArticleIdList><ArticleId IdType=""doi"">10.2217/fon-2018-0120</ArticleId><ArticleId IdType=""pubmed"">29783894</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. (2008) 26:1664–70. doi:  10.1200/JCO.2007.13.5564, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2007.13.5564</ArticleId><ArticleId IdType=""pubmed"">18316794</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. (2013) 14:989–98. doi:  10.1016/S1470-2045(13)70383-4</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(13)70383-4</ArticleId><ArticleId IdType=""pubmed"">23902874</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. (2014) 106:djt337. doi:  10.1093/jnci/djt337, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/jnci/djt337</ArticleId><ArticleId IdType=""pmc"">PMC3906991</ArticleId><ArticleId IdType=""pubmed"">24317176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med. (2019) 380:1226–34. doi:  10.1056/NEJMoa1804693</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa1804693</ArticleId><ArticleId IdType=""pmc"">PMC6885383</ArticleId><ArticleId IdType=""pubmed"">30917258</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: A combined analysis of the phase III soFEA and EFECT trials. Clin Cancer Res. (2020) 26:5172–7. doi:  10.1158/1078-0432.CCR-20-1021, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-20-1021</ArticleId><ArticleId IdType=""pubmed"">32546646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Cai L, Song Y, Sun T, Tong Z, Teng Y, et al. Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). Eur J Cancer. (2023) 184:73–82. doi:  10.1016/j.ejca.2023.01.027, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ejca.2023.01.027</ArticleId><ArticleId IdType=""pubmed"">36905771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardia A, Cortés J, Bidard FC, Neven P, Garcia-Sáenz J, Aftimos P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. (2022) 40:3246–56. doi:  10.1200/JCO.21.01392, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.21.01392</ArticleId><ArticleId IdType=""pmc"">PMC9553388</ArticleId><ArticleId IdType=""pubmed"">35584336</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Fructuoso I, González-Billalabeitia E. Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment. Curr Opin Oncol. (2022) 34:635–42. doi:  10.1097/CCO.0000000000000866, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1097/CCO.0000000000000866</ArticleId><ArticleId IdType=""pubmed"">36000362</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Camizestrant, a next-generation oral SERD, vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial. J Clin Oncol. (2022) 40:3246–56. doi:  10.1200/JCO.22.01528</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.22.01528</ArticleId></ArticleIdList></Reference><Reference><Citation>Helwick C. Phase III postMONARCH trial: switching to abemaciclib may improve outcomes after disease progression. ASCO Post. (2024) 25:1424–39. doi:  10.1016/S1470-2045(24)00387-5, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(24)00387-5</ArticleId><ArticleId IdType=""pubmed"">39481395</ArticleId></ArticleIdList></Reference><Reference><Citation>
Cookson F, Gradishar WJ. Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial. Business Wire. (2025). Available at: https://www.businesswire.com/news/home/20250601316083/en/Camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-HR-positive-breast-cancer-with-an-emergent-ESR1-tumor-mutation-in-SERENA-6-Phase-III-trial (Accessed June 2, 2025).</Citation></Reference><Reference><Citation>Jhaveri KL, Neven P, Casalnuovo ML, Kim S-B, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. (2025) 392:1189–202. doi:  10.1056/NEJMoa241085</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa241085</ArticleId><ArticleId IdType=""pubmed"">39660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Update breast cancer 2023 part 2 – advanced-stage breast cancer. Geburtshilfe Frauenheilkd. (2023) 83:664–72. doi:  10.1055/a-2085-9525, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1055/a-2085-9525</ArticleId><ArticleId IdType=""pmc"">PMC10617389</ArticleId><ArticleId IdType=""pubmed"">37916184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lux MP, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. (2020) 395:817–27. doi:  10.1016/S0140-6736(20)30165-3, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(20)30165-3</ArticleId><ArticleId IdType=""pubmed"">32145796</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn RS, Slamon DJ, Crown JP, Winer EP, Hortobagyi GN, Lee HJ, et al. Overall survival with first-line palbociclib plus letrozole versus placebo plus letrozole in women with ER+/HER2– advanced breast cancer: Analyses from PALOMA-2. J Clin Oncol. (2022) 40:817–27. doi:  10.1200/JCO.22.00354</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.22.00354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. (2016) 375:1738–48. doi:  10.1056/NEJMoa1609709, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa1609709</ArticleId><ArticleId IdType=""pubmed"">27717303</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston S, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. (2019) 5:5. doi:  10.1038/s41523-019-0097-4</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41523-019-0097-4</ArticleId><ArticleId IdType=""pmc"">PMC6336880</ArticleId><ArticleId IdType=""pubmed"">30675515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hortobagyi GN, Turner NC, Yap YS, Bittoni A, Aftimos P, Aktas B, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. (2022) 386:942–50. doi:  10.1056/NEJMoa2119114</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2119114</ArticleId><ArticleId IdType=""pubmed"">35263519</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz MP, Harbeck N, Tripathy D, Spring LM, Shah N, Ruiz Borrego M, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. (2024) 35:718–27. doi:  10.1016/j.annonc.2024.03.011, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2024.03.011</ArticleId><ArticleId IdType=""pubmed"">38729566</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. (2016) 17:425–39. doi:  10.1016/S1470-2045(15)00613-0, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(15)00613-0</ArticleId><ArticleId IdType=""pubmed"">26947331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sledge GW, Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2– advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. (2017) 35:2875–84. doi:  10.1200/JCO.2017.73.7585, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2017.73.7585</ArticleId><ArticleId IdType=""pubmed"">28580882</ArticleId></ArticleIdList></Reference><Reference><Citation>Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. (2018) 36:2465–72. doi:  10.1200/JCO.2018.78.9901</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2018.78.9901</ArticleId><ArticleId IdType=""pubmed"">29860922</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu YS, Krop I, Sohn J, Kaufman PA, Blackwell KL, Wang DY, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2– advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. (2022) 28:851–9. doi:  10.1158/1078-0432.CCR-21-3094, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-21-3094</ArticleId><ArticleId IdType=""pmc"">PMC9377723</ArticleId><ArticleId IdType=""pubmed"">34965945</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. (2018) 19:904–15. doi:  10.1016/S1470-2045(18)30292-4, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(18)30292-4</ArticleId><ArticleId IdType=""pubmed"">29804902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn HK, Im SA, Guerrero-Zotano A, Ruiz-Borrego M, Tripathy D, Sohn J, et al. Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study. Lancet Oncol. (2025) 26:343–54. doi:  10.1016/S1470-2045(24)00023-6, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(24)00023-6</ArticleId><ArticleId IdType=""pubmed"">39978378</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Haba Rodriguez J, Cejalvo JM, Gómez P, Daver N, Acevedo A, Oliver L, et al. ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy with or without a short course of induction paclitaxel in patients with HR+/HER2– advanced breast cancer with aggressive disease criteria. Ann Oncol. (2024) 35:1215–6. doi:  10.1016/j.annonc.2024.04.021</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2024.04.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickler MN, Tolaney SM, Rugo HS, Neven P, Johnston S, Goetz MP, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2– metastatic breast cancer. Clin Cancer Res. (2017) 23:5218–24. doi:  10.1158/1078-0432.CCR-17-0754, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-17-0754</ArticleId><ArticleId IdType=""pmc"">PMC5581697</ArticleId><ArticleId IdType=""pubmed"">28533223</ArticleId></ArticleIdList></Reference><Reference><Citation>Wander SA, Payne R, Locklair D, Krop I, Chu L, Partridge A, et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience. J Natl Compr Canc. Netw. (2021) 19:1–8. doi:  10.6004/jnccn.2020.7651, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.6004/jnccn.2020.7651</ArticleId><ArticleId IdType=""pubmed"">33761455</ArticleId></ArticleIdList></Reference><Reference><Citation>Park YH, Im SA, Sohn J, Lee KS, Hwang J, Kim SW, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. (2019) 20:1750–9. doi:  10.1016/S1470-2045(19)30548-4, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(19)30548-4</ArticleId><ArticleId IdType=""pubmed"">31668850</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín M, Rodríguez CA, Ruiz-Borrego M, Im SA, Masuda N, Takahashi M, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormone receptor-positive, HER2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL. Ann Oncol. (2021) 32:488–99. doi:  10.1016/j.annonc.2021.01.068, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2021.01.068</ArticleId><ArticleId IdType=""pubmed"">33385521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidard FC, Simone C, Pierga JY, Pol B, Mansi L, Lotz JP, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. (2022) 23:1367–77. doi:  10.1016/S1470-2045(22)00498-2, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(22)00498-2</ArticleId><ArticleId IdType=""pubmed"">36183733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardia A, Hurvitz SA, Mayer IA, Tolaney SM, Isakoff SJ, Forero A, et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2– advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clin Cancer Res. (2021) 27:4177–85. doi:  10.1158/1078-0432.CCR-21-0096, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-21-0096</ArticleId><ArticleId IdType=""pmc"">PMC8487593</ArticleId><ArticleId IdType=""pubmed"">33722897</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer EL, Liu MC, Gandhi L, O’Shaughnessy J, Abramson VG, Winer EP, et al. Palbociclib after CDK4/6i and endocrine therapy (PACE): a randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2– metastatic breast cancer. J Clin Oncol. (2023) 41 Suppl:16. doi:  10.1200/JCO.2023.41.16_suppl.LBA1004</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2023.41.16_suppl.LBA1004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonke GS, van Diest P, Johnston SR, Loibl S, Turner NC, Piccart M, et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of CDK4/6 inhibitors for patients with HR+/HER2– advanced breast cancer. J Clin Oncol. (2023) 41:2050–60. doi:  10.1200/JCO.2023.41.17_suppl.LBA1001</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2023.41.17_suppl.LBA1001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinsky K, Han HS, Conlin AK, Tolaney SM, Ro-Engel CE, Vamos EP, et al. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2– advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: primary outcome of the phase 3 postMONARCH trial. J Clin Oncol. (2024) 42:LBA1001. doi:  10.1200/JCO.2024.42.17_suppl.LBA1001</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2024.42.17_suppl.LBA1001</ArticleId></ArticleIdList></Reference><Reference><Citation>Slamon D, Fasching PA, Hurvitz SA, Macneill FA, Mayer IA, Rubovits S, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. (2024) 390:1080–91. doi:  10.1056/NEJMoa2309491</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2309491</ArticleId><ArticleId IdType=""pubmed"">38507751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnant M, Rugo H, Bhattacharya S, Fazli L, Glitza-Oliva IC, Madi A, et al. Adjuvant palbociclib for early breast cancer: The PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. (2022) 40:282–93. doi:  10.1200/JCO.21.01556, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.21.01556</ArticleId><ArticleId IdType=""pmc"">PMC10476784</ArticleId><ArticleId IdType=""pubmed"">34874182</ArticleId></ArticleIdList></Reference><Reference><Citation>Loibl S, Turner NC, Ro J, Neven P, Im SA, Hillman DW, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer: the Penelope-B trial. J Clin Oncol. (2021) 39:1518–30. doi:  10.1200/JCO.20.09299, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.20.09299</ArticleId><ArticleId IdType=""pubmed"">33793299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal A, Arun B, Barcelona T, Montgomery LL, Ito Y, Puhalla S, et al. Filling the gap after CDK4/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor-positive breast cancer. Cancers (Basel). (2023) 15:2015. doi:  10.3390/cancers15072015, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/cancers15072015</ArticleId><ArticleId IdType=""pmc"">PMC10093251</ArticleId><ArticleId IdType=""pubmed"">37046675</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Shaughnessy J, Thaddeus Beck J, Royce M. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer: a clinical trial. JAMA Oncol. (2018) 4:977–84. doi:  10.1001/jamaoncol.2018.0262, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1001/jamaoncol.2018.0262</ArticleId><ArticleId IdType=""pmc"">PMC5885212</ArticleId><ArticleId IdType=""pubmed"">29566104</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Shaughnessy J, Beck JT, Royce M. Everolimus-based combination therapies for HR+, HER2– metastatic breast cancer. Cancer Treat Rev. (2018) 71:204–14. doi:  10.1016/j.ctrv.2018.01.008, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ctrv.2018.01.008</ArticleId><ArticleId IdType=""pubmed"">30092555</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Sun T, Shao Z, Zhang Q, Ouyang Q, Tong Z, et al. Effectiveness of adding everolimus to the first-line treatment of advanced breast cancer in premenopausal women who experienced disease progression while receiving selective estrogen receptor modulators: a phase 2 randomized clinical trial. JAMA Oncol. (2021) 7:e213428. doi:  10.1001/jamaoncol.2021.3428, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1001/jamaoncol.2021.3428</ArticleId><ArticleId IdType=""pmc"">PMC8391779</ArticleId><ArticleId IdType=""pubmed"">34436536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sánchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, Alva M, Echavarria I, et al. Everolimus plus endocrine therapy beyond CDK4/6 inhibitor progression for HR+/HER2– advanced breast cancer: a real-world evidence cohort. Breast Cancer Res Treat. (2024) 206:551–9. doi:  10.1007/s10549-023-07083-3, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10549-023-07083-3</ArticleId><ArticleId IdType=""pubmed"">38703285</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez Tejeda Zañudo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia JE, et al. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. (2024) 15:2446. doi:  10.1038/s41467-024-40119-2, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41467-024-40119-2</ArticleId><ArticleId IdType=""pmc"">PMC10951222</ArticleId><ArticleId IdType=""pubmed"">38503755</ArticleId></ArticleIdList></Reference><Reference><Citation>André F, Cruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. (2021) 32:208–17. doi:  10.1016/j.annonc.2020.10.015</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2020.10.015</ArticleId><ArticleId IdType=""pubmed"">33246021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladraa S, Zerbib L, Bayard C, Fraissenon A, Venot Q, Morin G, et al. PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruption. Sci Adv. (2022) 8:eade7823. doi:  10.1126/sciadv.ade7823, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1126/sciadv.ade7823</ArticleId><ArticleId IdType=""pmc"">PMC9733923</ArticleId><ArticleId IdType=""pubmed"">36490341</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrikopoulou A, Chatzinikolaou S, Panourgias E, Kaparelou M, Liontos M, Dimopoulos M-A, et al. The emerging role of capivasertib in breast cancer. Breast. (2022) 62:157–67. doi:  10.1016/j.breast.2022.06.009, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.breast.2022.06.009</ArticleId><ArticleId IdType=""pmc"">PMC9011110</ArticleId><ArticleId IdType=""pubmed"">35398754</ArticleId></ArticleIdList></Reference><Reference><Citation>Baselga J, Im S-A, Iwata H, Cortés J, De Laurentiis M, Jiang Z, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, HR-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. (2017) 18:904–16. doi:  10.1016/S1470-2045(17)30313-6, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(17)30313-6</ArticleId><ArticleId IdType=""pmc"">PMC5549667</ArticleId><ArticleId IdType=""pubmed"">28576675</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, et al. Buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. (2018) 19:87–100. doi:  10.1016/S1470-2045(17)30787-2, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(17)30787-2</ArticleId><ArticleId IdType=""pubmed"">29223745</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. (2020) 31:1001–10. doi:  10.1016/j.annonc.2020.03.300, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2020.03.300</ArticleId><ArticleId IdType=""pubmed"">32416251</ArticleId></ArticleIdList></Reference><Reference><Citation>Dent S, Cortés J, Im YH, Diéras V, Harbeck N, Krop IE, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol. (2021) 32:197–207. doi:  10.1016/j.annonc.2020.11.006, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2020.11.006</ArticleId><ArticleId IdType=""pmc"">PMC8457522</ArticleId><ArticleId IdType=""pubmed"">33186740</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, et al. BEECH: a dose-finding run-in followed by a randomized phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with ER-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol. (2019) 30:774–80. doi:  10.1093/annonc/mdz121, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/annonc/mdz121</ArticleId><ArticleId IdType=""pmc"">PMC6551452</ArticleId><ArticleId IdType=""pubmed"">30860570</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell SJ, Casbard A, Carucci M, Cox C, Butler R, Alchami F, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. (2020) 21(3):345–57. doi: 10.1016/S1470-2045(19)30817-4, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(19)30817-4</ArticleId><ArticleId IdType=""pmc"">PMC7052734</ArticleId><ArticleId IdType=""pubmed"">32035020</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib/placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer. J Clin Oncol. (2025) 42:1003. doi:  10.1200/JCO.2025.42.16_suppl.1003</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2025.42.16_suppl.1003</ArticleId></ArticleIdList></Reference><Reference><Citation>Barroso-Sousa R, Tolaney SM. Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond. BioDrugs. (2021) 35:159–74. doi:  10.1007/s40259-021-00462-6, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s40259-021-00462-6</ArticleId><ArticleId IdType=""pmc"">PMC7933915</ArticleId><ArticleId IdType=""pubmed"">33666903</ArticleId></ArticleIdList></Reference><Reference><Citation>Stecklein SR, Perez EA. Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer. Ann Oncol. (2020) 31:1594–6. doi:  10.1016/j.annonc.2020.07.006, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2020.07.006</ArticleId><ArticleId IdType=""pmc"">PMC10210013</ArticleId><ArticleId IdType=""pubmed"">33038485</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). (2019) 67:173–85. doi:  10.1248/cpb.c18-00986, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1248/cpb.c18-00986</ArticleId><ArticleId IdType=""pubmed"">30827997</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín M, Pandiella A, Vargas-Castrillón E, Díaz-Rodríguez E, Iglesias-Hernangómez T, Martínez Cano C, et al. Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol. (2024) 187:104355. doi:  10.1016/j.critrevonc.2024.104355, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.critrevonc.2024.104355</ArticleId><ArticleId IdType=""pubmed"">38621469</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarantino P, Gandini S, Sparano T. Navigating the HER2-low paradigm in breast oncology: new standards, future horizons. Cancer Discov. (2022) 12:2026–30. doi:  10.1158/2159-8290.CD-21-1713, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/2159-8290.CD-21-1713</ArticleId><ArticleId IdType=""pubmed"">35856622</ArticleId></ArticleIdList></Reference><Reference><Citation>Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer. (2021) 7:137. doi:  10.1038/s41523-021-00345-4</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41523-021-00345-4</ArticleId><ArticleId IdType=""pmc"">PMC8511010</ArticleId><ArticleId IdType=""pubmed"">34642348</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. (2022) 387:9–20. doi:  10.1056/NEJMoa2203690, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2203690</ArticleId><ArticleId IdType=""pmc"">PMC10561652</ArticleId><ArticleId IdType=""pubmed"">35665782</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. (2024) 198:104355. doi:  10.1056/NEJMoa2401167</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2401167</ArticleId><ArticleId IdType=""pubmed"">39282896</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. (2023) 29:2110–20. doi:  10.1038/s41591-023-02571-z, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41591-023-02571-z</ArticleId><ArticleId IdType=""pmc"">PMC10427426</ArticleId><ArticleId IdType=""pubmed"">37488289</ArticleId></ArticleIdList></Reference><Reference><Citation>André F, Hamilton EP, Loi S, Anders CK, Schmid P, Stroyakovskiy D, et al. DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. J Clin Oncol. (2024) 42:1009. doi:  10.1200/JCO.2024.42.16_suppl.1009</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2024.42.16_suppl.1009</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. (2024) 30:3717–27. doi:  10.1038/s41591-024-03027-z</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41591-024-03027-z</ArticleId><ArticleId IdType=""pmc"">PMC11645283</ArticleId><ArticleId IdType=""pubmed"">39271844</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in HR-positive/HER2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. (2023) 402:1423–33. doi:  10.1016/S0140-6736(23)00727-3</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(23)00727-3</ArticleId><ArticleId IdType=""pubmed"">37633306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. (2024) 42:00920. doi:  10.1200/JCO.2023.42.16_suppl.LBA1002, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2023.42.16_suppl.LBA1002</ArticleId><ArticleId IdType=""pmc"">PMC11771365</ArticleId><ArticleId IdType=""pubmed"">39265124</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng F, Zhang Y, Chen S, Weng X, Rao Y, Fang H, et al. Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed Pharmacother. (2020) 123:109661. doi:  10.1016/j.biopha.2019.1091, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.biopha.2019.1091</ArticleId><ArticleId IdType=""pubmed"">31931287</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. (2023) 184:39–47. doi:  10.1016/j.ejca.2023.01.026, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ejca.2023.01.026</ArticleId><ArticleId IdType=""pmc"">PMC10585240</ArticleId><ArticleId IdType=""pubmed"">36893711</ArticleId></ArticleIdList></Reference><Reference><Citation>Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. (2018) 379:753–63. doi:  10.1056/NEJMoa1802905, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa1802905</ArticleId><ArticleId IdType=""pmc"">PMC10600918</ArticleId><ArticleId IdType=""pubmed"">30110579</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacopetta D, Ceramella J, Baldino N, Sinicropi MS, Catalano A, et al. Targeting breast cancer: an overlook on current strategies. Int J Mol Sci. (2023) 24:3643. doi:  10.3390/ijms24043643, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/ijms24043643</ArticleId><ArticleId IdType=""pmc"">PMC9959993</ArticleId><ArticleId IdType=""pubmed"">36835056</ArticleId></ArticleIdList></Reference><Reference><Citation>
Seymour C. Vepdegestrant plus palbociclib sustains efficacy in advanced ER+ breast cancer. OncLive;  (2024). Available online at: https://www.onclive.com/view/vepdegestrant-plus-palbociclib-sustains-efficacy-in-advanced-er-breast-cancer (Accessed March 24, 2024).</Citation></Reference><Reference><Citation>Hurvitz SA, Schott AF, Ma C, Hamilton E, Nanda R, Zahrah G, et al. VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/HER2– advanced breast cancer. ESMO Open. (2023) 8:101394. doi:  10.1016/j.esmoop.2023.101394</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.esmoop.2023.101394</ArticleId></ArticleIdList></Reference><Reference><Citation>Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. (2025) 392:1123–35. doi:  10.1056/NEJMoa2402059</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2402059</ArticleId><ArticleId IdType=""pubmed"">40454645</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong R, Patel HK, Gutgesell LM, Zhao J, Delgado Rivera L, Pham TND, et al. Selective human estrogen receptor partial agonists (ShERPAs) for tamoxifen-resistant breast cancer. J Med Chem. (2016) 59:219–37. doi:  10.1021/acs.jmedchem.5b01057, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1021/acs.jmedchem.5b01057</ArticleId><ArticleId IdType=""pmc"">PMC4779956</ArticleId><ArticleId IdType=""pubmed"">26681208</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg JE, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, et al. The immunology of hormone receptor positive breast cancer. Front Immunol. (2021) 12:674192. doi:  10.3389/fimmu.2021.674192, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3389/fimmu.2021.674192</ArticleId><ArticleId IdType=""pmc"">PMC8202289</ArticleId><ArticleId IdType=""pubmed"">34135901</ArticleId></ArticleIdList></Reference><Reference><Citation>Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. (2023) 9:27. doi:  10.1038/s41523-023-00502-2, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41523-023-00502-2</ArticleId><ArticleId IdType=""pmc"">PMC9925769</ArticleId><ArticleId IdType=""pubmed"">36781869</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/HER2-negative advanced breast cancer. Clin Cancer Res. (2018) 24:2804–11. doi:  10.1158/1078-0432.CCR-17-3458</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-17-3458</ArticleId><ArticleId IdType=""pubmed"">29559561</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. (2018) 167:671–86. doi:  10.1007/s10549-017-4537-6</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10549-017-4537-6</ArticleId><ArticleId IdType=""pmc"">PMC5807460</ArticleId><ArticleId IdType=""pubmed"">29063313</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugo HS, Kabos P, Beck JT, Guy J, Wildiers H, Sevillano E, et al. Abemaciclib in combination with pembrolizumab for HR+, HER2– metastatic breast cancer: Phase 1b study. NPJ Breast Cancer. (2022) 8:15. doi:  10.1038/s41523-022-00368-1, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41523-022-00368-1</ArticleId><ArticleId IdType=""pmc"">PMC9637121</ArticleId><ArticleId IdType=""pubmed"">36335120</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, et al. Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. Eur J Cancer. (2021) 154:11–20. doi:  10.1016/j.ejca.2021.06.018, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ejca.2021.06.018</ArticleId><ArticleId IdType=""pmc"">PMC8691850</ArticleId><ArticleId IdType=""pubmed"">34217908</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaler S, Thiede G, Hengstler JG, Schad A, Schmidt M, Sleeman JP, et al. The proteasome inhibitor bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. Int J Cancer. (2015) 137:686–97. doi:  10.1002/ijc.29418, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/ijc.29418</ArticleId><ArticleId IdType=""pubmed"">25530422</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L, et al. Metastatic ER+ breast cancer: mechanisms of resistance and future therapeutic approaches. Int J Mol Sci. (2023) 24:16198. doi:  10.3390/ijms242016198, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/ijms242016198</ArticleId><ArticleId IdType=""pmc"">PMC10671474</ArticleId><ArticleId IdType=""pubmed"">38003387</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman A, Li Z, Parwani AV. Artificial intelligence’s impact on breast cancer pathology: a literature review. Diagn Pathol. (2024) 19:38. doi:  10.1186/s13000-024-01322-2, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s13000-024-01322-2</ArticleId><ArticleId IdType=""pmc"">PMC10882736</ArticleId><ArticleId IdType=""pubmed"">38388367</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahab N, Toss M, Miligy IM, Jahanifar M, Atallah NM, Lu W, et al. AI-enabled routine H&amp;E image-based prognostic marker for early-stage luminal breast cancer. NPJ Precis Oncol. (2023) 7:122. doi:  10.1038/s41698-023-00393-0, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41698-023-00393-0</ArticleId><ArticleId IdType=""pmc"">PMC10651910</ArticleId><ArticleId IdType=""pubmed"">37968376</ArticleId></ArticleIdList></Reference><Reference><Citation>Venetis K, Pepe F, Pescia C, Cursano G, Criscitiello C, Frascarelli C, et al. ESR1 mutations in HR+/HER2– metastatic breast cancer: enhancing the accuracy of ctDNA testing. Cancer Treat Rev. (2023) 118:102642. doi:  10.1016/j.ctrv.2023.102642, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ctrv.2023.102642</ArticleId><ArticleId IdType=""pubmed"">37864956</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:51.144137
pubmed,40989560,,40989560,,Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies.,https://pubmed.ncbi.nlm.nih.gov/40989560/,"Jourdain Hugo, Di Meglio Antonio, Mansouri Imène, Desplas David, Zureik Mahmoud, Haddy Nadia",,The management of HER2-positive metastatic breast cancer (HER2,"<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">40989560</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel=""Electronic-eCollection""><Journal><ISSN IssnType=""Electronic"">2666-7762</ISSN><JournalIssue CitedMedium=""Internet""><Volume>58</Volume><PubDate><Year>2025</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet regional health. Europe</Title><ISOAbbreviation>Lancet Reg Health Eur</ISOAbbreviation></Journal><ArticleTitle>Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies.</ArticleTitle><Pagination><StartPage>101455</StartPage><MedlinePgn>101455</MedlinePgn></Pagination><ELocationID EIdType=""pii"" ValidYN=""Y"">101455</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1016/j.lanepe.2025.101455</ELocationID><Abstract><AbstractText Label=""BACKGROUND"" NlmCategory=""UNASSIGNED"">The management of HER2-positive metastatic breast cancer (HER2<sup>+</sup> mBC) has rapidly evolved. We assessed the real-world efficacy and safety of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) and tucatinib by emulating two phase III trials.</AbstractText><AbstractText Label=""METHODS"" NlmCategory=""UNASSIGNED"">We emulated two target trials using the French National Health Data System: T-DXd versus T-DM1 and T-DXd versus tucatinib, for second- and third-line HER2<sup>+</sup> mBC treatment. We included patients from September 2020 to September 2023, and followed them until death or April 2024. We emulated treatment assignment randomization with inverse probability of treatment weighting. Efficacy outcomes included time to treatment discontinuation (TTD) and overall survival (OS). Safety outcomes included cause-specific hospitalizations.</AbstractText><AbstractText Label=""FINDINGS"" NlmCategory=""UNASSIGNED"">In the second-line treatment emulation (<i>n</i> = 2931: 1633 T-DM1, 1298 T-DXd), T-DXd had longer TTD (median 14⋅1 versus 6⋅5 months; weighted hazard ratio, wHR [95% confidence interval, CI], 0⋅46 [0⋅42-0⋅51]) and OS (median not reached; wHR [95% CI], 0⋅66 [0⋅55-0⋅80]) than T-DM1. We observed more cases of interstitial lung disease in the T-DXd group. In the third-line treatment emulation (<i>n</i> = 2391: 566 tucatinib, 1825 T-DXd), T-DXd had longer TTD (median 11⋅8 versus 5⋅8 months; wHR [95% CI], 0⋅60 [0⋅53-0⋅68]) and OS (median 31⋅7 versus 26⋅6 months; wHR [95% CI], 0⋅79 [0⋅69-0⋅92]) than tucatinib. T-DXd tended to protect from cardiac disorders (wHR [95% CI], 0⋅44 [0⋅26-0⋅74]) while enhancing respiratory disorders occurrence (wHR [95% CI], 1⋅72 [1⋅03-2⋅89]).</AbstractText><AbstractText Label=""INTERPRETATION"" NlmCategory=""UNASSIGNED"">In this real-world study, T-DXd was more effective than T-DM1 as a second-line treatment and tucatinib as a third-line treatment, in line with clinical trial results.</AbstractText><AbstractText Label=""FUNDING"" NlmCategory=""UNASSIGNED"">None.</AbstractText><CopyrightInformation>© 2025 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Jourdain</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM), 143-147 Boulevard Anatole France, Saint-Denis, 93285, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Di Meglio</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Survivorship Program - INSERM Unit 981 Molecular Predictors and New Targets in Oncology - Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Mansouri</LastName><ForeName>Imène</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM), 143-147 Boulevard Anatole France, Saint-Denis, 93285, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Desplas</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM), 143-147 Boulevard Anatole France, Saint-Denis, 93285, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Zureik</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM), 143-147 Boulevard Anatole France, Saint-Denis, 93285, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Haddy</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM), 143-147 Boulevard Anatole France, Saint-Denis, 93285, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Eur</MedlineTA><NlmUniqueID>101777707</NlmUniqueID><ISSNLinking>2666-7762</ISSNLinking></MedlineJournalInfo><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">French National Health Data System (SNDS)</Keyword><Keyword MajorTopicYN=""N"">HER2-positive metastatic breast cancer</Keyword><Keyword MajorTopicYN=""N"">Target trial emulation</Keyword><Keyword MajorTopicYN=""N"">Trastuzumab deruxtecan</Keyword><Keyword MajorTopicYN=""N"">Trastuzumab emtansine</Keyword><Keyword MajorTopicYN=""N"">Tucatinib</Keyword></KeywordList><CoiStatement>The authors have no conflict of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus=""revised""><Year>2025</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40989560</ArticleId><ArticleId IdType=""pmc"">PMC12451362</ArticleId><ArticleId IdType=""doi"">10.1016/j.lanepe.2025.101455</ArticleId><ArticleId IdType=""pii"">S2666-7762(25)00247-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Loibl S., Poortmans P., Morrow M., Denkert C., Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750–1769.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">33812473</ArticleId></ArticleIdList></Reference><Reference><Citation>Loibl S., Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–2429.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27939064</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas A., Teicher B.A., Hassan R. Antibody–drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254–e262.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC6601617</ArticleId><ArticleId IdType=""pubmed"">27299281</ArticleId></ArticleIdList></Reference><Reference><Citation>André F., Hee Park Y., Kim S.B., et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773–1785.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">37086745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortés J., Kim S.B., Chung W.P., et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–1154.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">35320644</ArticleId></ArticleIdList></Reference><Reference><Citation>Curigliano G., Mueller V., Borges V., et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321–329.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34954044</ArticleId></ArticleIdList></Reference><Reference><Citation>Botticelli A., Caputo R., Scagnoli S., et al. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study. Oncologist. 2023;29(4):303–310.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10994255</ArticleId><ArticleId IdType=""pubmed"">37995313</ArticleId></ArticleIdList></Reference><Reference><Citation>Petit T., Hajjaji N., Antoine E., et al. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: real-life data from the temporary use authorization program in France. Cancer Med. 2024;13(9)</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11087844</ArticleId><ArticleId IdType=""pubmed"">38733172</ArticleId></ArticleIdList></Reference><Reference><Citation>Dannehl D., Jakob D., Mergel F., et al. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis. ESMO Open. 2024;9(5)</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11039313</ArticleId><ArticleId IdType=""pubmed"">38636292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman P.A., Neuberger E., Schwartz N.R.M., et al. Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer. Front Oncol. 2023;13</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10578436</ArticleId><ArticleId IdType=""pubmed"">37849811</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernán M.A., Robins J.M. Using big data to emulate a target trial when a randomized trial is not available: table 1. Am J Epidemiol. 2016;183(8):758–764.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC4832051</ArticleId><ArticleId IdType=""pubmed"">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernán M.A., Wang W., Leaf D.E. Target trial emulation: a framework for causal inference from observational data. JAMA. 2022;328(24):2446–2447.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36508210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuppin P., Rudant J., Constantinou P., et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65:S149–S167.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">28756037</ArticleId></ArticleIdList></Reference><Reference><Citation>Swital M., Drouin J., Miranda S., Bakchine S., Botton J., Dray-Spira R. Use of multiple sclerosis disease-modifying therapies during pregnancy in France: nationwide study between 2010 and 2021. Mult Scler. 2024;30(2):227–237.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10851628</ArticleId><ArticleId IdType=""pubmed"">38281078</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdain H., Hoisnard L., Sbidian E., Zureik M. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System. RMD Open. 2024;10(1)</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10921511</ArticleId><ArticleId IdType=""pubmed"">38453213</ArticleId></ArticleIdList></Reference><Reference><Citation>Roland N., Neumann A., Hoisnard L., et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2024;384</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10966896</ArticleId><ArticleId IdType=""pubmed"">38537944</ArticleId></ArticleIdList></Reference><Reference><Citation>Rios P., Herlemont P., Fauque P., et al. Medically assisted reproduction and risk of cancer among offspring. JAMA Netw Open. 2024;7(5)</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11066701</ArticleId><ArticleId IdType=""pubmed"">38696167</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdain H., Mansouri I., Di Meglio A., Zureik M., Haddy N. Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System. ESMO Real World Data and Digit Oncol. 2024;4</Citation></Reference><Reference><Citation>Jourdain H., Di Meglio A., Mansouri I., Desplas D., Zureik M., Haddy N. Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study. ESMO Open. 2024;9(12)</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11697054</ArticleId><ArticleId IdType=""pubmed"">39662227</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenzato L., Botton J., Drouin J., et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health Eur. 2021;8</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC8282330</ArticleId><ArticleId IdType=""pubmed"">34308411</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachas A., Gastaldi-Ménager C., Denis P., et al. The economic burden of disease in France from the National Health Insurance Perspective: the healthcare expenditures and conditions mapping used to prepare the French social security funding act and the public health act. Med Care. 2022;60(9):655–664.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC9365254</ArticleId><ArticleId IdType=""pubmed"">35880776</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai R.J., Franklin J.M. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31645336</ArticleId></ArticleIdList></Reference><Reference><Citation>Royston P., Parmar M.K.B. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30(19):2409–2421.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">21611958</ArticleId></ArticleIdList></Reference><Reference><Citation>Haneuse S., VanderWeele T.J., Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321(6):602–603.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">30676631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wekking D., Porcu M., Pellegrino B., et al. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open. 2023;8(6)</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10679891</ArticleId><ArticleId IdType=""pubmed"">37951130</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdain H., Albin N., Monard A., Desplas D., Zureik M., Haddy N. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive metastatic gastric cancer in a real-world setting: a nationwide cohort study. Clin Transl Gastroenterol. 2024;15(12)</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11671096</ArticleId><ArticleId IdType=""pubmed"">39373321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaratos A.M., Dankner M., Hamouda A., et al. The real-world clinical outcomes of heavily pretreated HER2+ and HER2-low metastatic breast cancer patients treated with trastuzumab deruxtecan at a single centre. Curr Oncol. 2024;32(1):1.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11763754</ArticleId><ArticleId IdType=""pubmed"">39851917</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabi A., Rossi A., Caputo R., et al. Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan. NPJ Precis Oncol. 2025;9(1):22.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11754752</ArticleId><ArticleId IdType=""pubmed"">39843642</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson J., Khan A., Bhogal T., et al. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone. ESMO Open. 2023;8(6)</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10774880</ArticleId><ArticleId IdType=""pubmed"">37866031</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenel J.S., Zeghondy J., Guérin-Charbonnel C., et al. Tucatinib combination treatment after trastuzumab-deruxtecan in patients with ERBB2-positive metastatic breast cancer. JAMA Netw Open. 2024;7(4)</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10993071</ArticleId><ArticleId IdType=""pubmed"">38568692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz S.A., Hegg R., Chung W.P., et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–117.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36495879</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y.D., Jansen J.P., Guerino J., et al.  Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. BMC Med. 2021;19(1):307. https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-02176-1 Available from:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s12916-021-02176-1</ArticleId><ArticleId IdType=""pmc"">PMC8647453</ArticleId><ArticleId IdType=""pubmed"">34865623</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbeck N., Ciruelos E., Jerusalem G., et al.  Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024;30(12):3717–3727. https://www.nature.com/articles/s41591-024-03261-7 Available from:</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11645283</ArticleId><ArticleId IdType=""pubmed"">39271844</ArticleId></ArticleIdList></Reference><Reference><Citation>André F., Cortés J., Curigliano G., et al. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Ann Oncol. 2024;35(12):1169–1180.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">39241960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin N.U., Murthy R.K., Abramson V., et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 2023;9(2):197–205.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC9716438</ArticleId><ArticleId IdType=""pubmed"">36454580</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecco S., Puligheddu S., Fusaroli M., et al. Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system. Target Oncol. 2024;19(3):435–445.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11111510</ArticleId><ArticleId IdType=""pubmed"">38696126</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy R.K., Loi S., Okines A., et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31825569</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:51.207923
pubmed,40989248,,40989248,,"Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial).",https://pubmed.ncbi.nlm.nih.gov/40989248/,"Li Ruoyang, Wang Meiqi, Kong Xiangshun, Ma Jie, Qi Xiuheng, Song Zhenchuan",,This study aimed to assess the efficacy and safety of combining Eribulin with Pyrotinib in patients diagnosed with advanced HER2-positive breast cancer and exhibiting resistance to trastuzumab. This subgroup of patients typically faces a bleak clinical prognosis with limited guidance available for treatment decisions.,"<PubmedArticle><MedlineCitation Status=""MEDLINE"" Owner=""NLM"" IndexingMethod=""Curated""><PMID Version=""1"">40989248</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel=""Electronic-eCollection""><Journal><ISSN IssnType=""Electronic"">1177-8881</ISSN><JournalIssue CitedMedium=""Internet""><Volume>19</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Drug design, development and therapy</Title><ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation></Journal><ArticleTitle>Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial).</ArticleTitle><Pagination><StartPage>8463</StartPage><EndPage>8474</EndPage><MedlinePgn>8463-8474</MedlinePgn></Pagination><ELocationID EIdType=""doi"" ValidYN=""Y"">10.2147/DDDT.S547569</ELocationID><Abstract><AbstractText Label=""PURPOSE"" NlmCategory=""UNASSIGNED"">This study aimed to assess the efficacy and safety of combining Eribulin with Pyrotinib in patients diagnosed with advanced HER2-positive breast cancer and exhibiting resistance to trastuzumab. This subgroup of patients typically faces a bleak clinical prognosis with limited guidance available for treatment decisions.</AbstractText><AbstractText Label=""PATIENTS AND METHODS"" NlmCategory=""UNASSIGNED"">Patients (N=30) with HER2-positive metastatic breast cancer, ECOG 0-1, and prior trastuzumab/taxane therapy received oral Pyrotinib 400 mg daily and intravenous Eribulin 1.4 mg/m² (days 1/8 of 21-day cycles for 6 cycles), followed by Pyrotinib until progression/intolerable toxicity. The primary endpoint was progression-free survival (PFS).</AbstractText><AbstractText Label=""RESULTS"" NlmCategory=""UNASSIGNED"">Between February 2021 and September 2023, 30 patients were enrolled in the study, with a median age of 57 years. All patients had previously received treatment with trastuzumab and taxanes. As of April 14, 2025, the median follow-up duration was 26 months. 18 patients experienced disease progression or death. The median progression-free survival (PFS) was 13.47 months (95% confidence interval [CI], 8.17-16.27), with a 12-month PFS rate of 61.7% (95% CI, 44.2%-86.0%). 12-month overall survival (OS) rate of 75.3% (95% CI 66.2-84.4). The objective response rate was 56.7% (17/30). The disease control rate (DCR) reached 80.0% (24/30), while the clinical benefit rate (CBR) was 73.3% (22/30). The median overall survival was not reached. Any adverse event (AE) of any grade with an incidence of more than 30% was Neutropenia (73.3%), diarrhea (70%), nausea/vomiting (66.7%), Peripheral neuropathy (63.3%), AST/ALT increased (43.3%), Anorexia (33.3%). There were no treatment-related deaths.</AbstractText><AbstractText Label=""CONCLUSION"" NlmCategory=""UNASSIGNED"">The combination of Eribulin and Pyrotinib emerges as a viable treatment option for HER2-positive advanced breast cancer patients who have exhibited resistance to trastuzumab. Despite advancements in anti-HER2 therapies, further research is required to address remaining challenges in this specific clinical scenario.</AbstractText><CopyrightInformation>© 2025 Li et al.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Li</LastName><ForeName>Ruoyang</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wang</LastName><ForeName>Meiqi</ForeName><Initials>M</Initials><Identifier Source=""ORCID"">0000-0003-3614-3401</Identifier><AffiliationInfo><Affiliation>Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Kong</LastName><ForeName>Xiangshun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Xingtai People's Hospital, Xingtai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Ma</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, TangShan People's Hospital, Tangshan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Qi</LastName><ForeName>Xiuheng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Oncology, Hebei Petrochina Central Hospital, Langfang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Song</LastName><ForeName>Zhenchuan</ForeName><Initials>Z</Initials><Identifier Source=""ORCID"">0000-0003-3674-1946</Identifier><AffiliationInfo><Affiliation>Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D017427"">Clinical Trial, Phase II</PublicationType><PublicationType UI=""D016428"">Journal Article</PublicationType><PublicationType UI=""D016448"">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Des Devel Ther</MedlineTA><NlmUniqueID>101475745</NlmUniqueID><ISSNLinking>1177-8881</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D000178"">Acrylamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""C508053"">ERBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>LR24G6354G</RegistryNumber><NameOfSubstance UI=""C490954"">eribulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D005663"">Furans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D007659"">Ketones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""C000622954"">pyrotinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""D018719"">Receptor, ErbB-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI=""D000068878"">Trastuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D000095662"">Polyether Polyketides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D000634"">Aminoquinolines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=""D000328"" MajorTopicYN=""N"">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D000368"" MajorTopicYN=""N"">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D005260"" MajorTopicYN=""N"">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D006801"" MajorTopicYN=""N"">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D008875"" MajorTopicYN=""N"">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D000178"" MajorTopicYN=""Y"">Acrylamides</DescriptorName><QualifierName UI=""Q000008"" MajorTopicYN=""N"">administration &amp; dosage</QualifierName><QualifierName UI=""Q000494"" MajorTopicYN=""N"">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000971"" MajorTopicYN=""Y"">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI=""Q000008"" MajorTopicYN=""N"">administration &amp; dosage</QualifierName><QualifierName UI=""Q000494"" MajorTopicYN=""N"">pharmacology</QualifierName><QualifierName UI=""Q000009"" MajorTopicYN=""N"">adverse effects</QualifierName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D001943"" MajorTopicYN=""Y"">Breast Neoplasms</DescriptorName><QualifierName UI=""Q000188"" MajorTopicYN=""N"">drug therapy</QualifierName><QualifierName UI=""Q000473"" MajorTopicYN=""N"">pathology</QualifierName><QualifierName UI=""Q000378"" MajorTopicYN=""N"">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D019008"" MajorTopicYN=""Y"">Drug Resistance, Neoplasm</DescriptorName><QualifierName UI=""Q000187"" MajorTopicYN=""N"">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D005663"" MajorTopicYN=""Y"">Furans</DescriptorName><QualifierName UI=""Q000008"" MajorTopicYN=""N"">administration &amp; dosage</QualifierName><QualifierName UI=""Q000494"" MajorTopicYN=""N"">pharmacology</QualifierName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D007659"" MajorTopicYN=""Y"">Ketones</DescriptorName><QualifierName UI=""Q000008"" MajorTopicYN=""N"">administration &amp; dosage</QualifierName><QualifierName UI=""Q000494"" MajorTopicYN=""N"">pharmacology</QualifierName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D018719"" MajorTopicYN=""Y"">Receptor, ErbB-2</DescriptorName><QualifierName UI=""Q000378"" MajorTopicYN=""N"">metabolism</QualifierName><QualifierName UI=""Q000037"" MajorTopicYN=""N"">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000068878"" MajorTopicYN=""Y"">Trastuzumab</DescriptorName><QualifierName UI=""Q000494"" MajorTopicYN=""N"">pharmacology</QualifierName><QualifierName UI=""Q000008"" MajorTopicYN=""N"">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000095662"" MajorTopicYN=""N"" AutoHM=""Y"">Polyether Polyketides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D000634"" MajorTopicYN=""N"" AutoHM=""Y"">Aminoquinolines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">breast cancer</Keyword><Keyword MajorTopicYN=""N"">eribulin</Keyword><Keyword MajorTopicYN=""N"">human epidermal growth factor receptor 2</Keyword><Keyword MajorTopicYN=""N"">pyrotinib</Keyword><Keyword MajorTopicYN=""N"">trastuzumab-resistant</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>13</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40989248</ArticleId><ArticleId IdType=""pmc"">PMC12453054</ArticleId><ArticleId IdType=""doi"">10.2147/DDDT.S547569</ArticleId><ArticleId IdType=""pii"">547569</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Slamon DJ, Godolphin W, Jones LA. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. <i>Science</i>. 1989;244(4905):707–712. doi: 10.1126/science.2470152
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1126/science.2470152</ArticleId><ArticleId IdType=""pubmed"">2470152</ArticleId></ArticleIdList></Reference><Reference><Citation>Baselga J, Kim SB, Im SA, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. <i>N Engl J Med</i>. 2012;366(2):109–119. doi: 10.1056/NEJMoa1113216
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa1113216</ArticleId><ArticleId IdType=""pmc"">PMC5705202</ArticleId><ArticleId IdType=""pubmed"">22149875</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, Phase 3 study. <i>Lancet Oncol</i>. 2020;21(4):519–530. doi: 10.1016/S1470-2045(19)30863-0
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(19)30863-0</ArticleId><ArticleId IdType=""pubmed"">32171426</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. <i>J Clin Oncol</i>. 2011;29(25):3366–3373. doi: 10.1200/JCO.2011.35.0868
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2011.35.0868</ArticleId><ArticleId IdType=""pmc"">PMC3164242</ArticleId><ArticleId IdType=""pubmed"">21768458</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. <i>J Clin Oncol</i>. 2014;32(33):3744–3752. doi: 10.1200/JCO.2014.55.5730
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2014.55.5730</ArticleId><ArticleId IdType=""pmc"">PMC4226805</ArticleId><ArticleId IdType=""pubmed"">25332249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet</i>. 2017;389(10075):1195–1205. doi: 10.1016/S0140-6736(16)32616-2
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(16)32616-2</ArticleId><ArticleId IdType=""pmc"">PMC5465633</ArticleId><ArticleId IdType=""pubmed"">28215665</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. <i>J Clin Oncol</i>. 2021;39(13):1448–1457. doi: 10.1200/JCO.20.01204
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.20.01204</ArticleId><ArticleId IdType=""pubmed"">33539215</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. <i>J Clin Oncol</i>. 2017;35(2):141–148. doi: 10.1200/JCO.2016.67.4887
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2016.67.4887</ArticleId><ArticleId IdType=""pmc"">PMC5455677</ArticleId><ArticleId IdType=""pubmed"">28056202</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. <i>N Engl J Med</i>. 2012;367(19):1783–1791. doi: 10.1056/NEJMoa1209124
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa1209124</ArticleId><ArticleId IdType=""pmc"">PMC5125250</ArticleId><ArticleId IdType=""pubmed"">23020162</ArticleId></ArticleIdList></Reference><Reference><Citation>Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2017;18(6):732–742. doi: 10.1016/S1470-2045(17)30312-1
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(17)30312-1</ArticleId><ArticleId IdType=""pmc"">PMC5531181</ArticleId><ArticleId IdType=""pubmed"">28526536</ArticleId></ArticleIdList></Reference><Reference><Citation>Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. <i>Lancet Oncol</i>. 2017;18(6):743–754. doi: 10.1016/S1470-2045(17)30313-3
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(17)30313-3</ArticleId><ArticleId IdType=""pubmed"">28526538</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. Version 5.2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed July
15, 2020.</Citation></Reference><Reference><Citation>Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). <i>Ann Oncol</i>. 2018;29(8):1634–1657. doi: 10.1093/annonc/mdy192
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/annonc/mdy192</ArticleId><ArticleId IdType=""pmc"">PMC7360146</ArticleId><ArticleId IdType=""pubmed"">30032243</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano SH, Temin S, Davidson NE. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update summary. <i>J Oncol Pract</i>. 2018;14(8):501–504. doi: 10.1200/JOP.18.00290
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JOP.18.00290</ArticleId><ArticleId IdType=""pubmed"">29989839</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Jiang Z. CSCO BC guideline: updates for HER2 positive breast cancer in 2020. <i>Transl Breast Cancer Res</i>. 2020;1:4. doi: 10.21037/tbcr.2020.03.05</Citation><ArticleIdList><ArticleId IdType=""doi"">10.21037/tbcr.2020.03.05</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. <i>J Clin Oncol</i>. 2019;37(29):2610–2619. doi: 10.1200/JCO.19.00108
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.19.00108</ArticleId><ArticleId IdType=""pubmed"">31430226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourd E. Pyrotinib versus lapatinib in HER2-positive breast cancer. <i>Lancet Oncol</i>. 2019;20(10):e562. doi: 10.1016/S1470-2045(19)30568-6
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(19)30568-6</ArticleId><ArticleId IdType=""pubmed"">31477452</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncol</i>. 2021;22(3):351–360. doi: 10.1016/S1470-2045(20)30702-6
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(20)30702-6</ArticleId><ArticleId IdType=""pubmed"">33581774</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. <i>Biochemistry</i>. 2010;49(6):1331. doi: 10.1021/bi901810u
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1021/bi901810u</ArticleId><ArticleId IdType=""pmc"">PMC2846717</ArticleId><ArticleId IdType=""pubmed"">20030375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes J, Loesch D, Blum JL, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. <i>Lancet</i>. 2011;377(9769):914–923. doi: 10.1016/S0140-6736(11)60070-6
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(11)60070-6</ArticleId><ArticleId IdType=""pubmed"">21376385</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Masuda N, Saji S, et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). <i>Trials</i>. 2020;21(1):391. doi: 10.1186/s13063-020-04341-y
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s13063-020-04341-y</ArticleId><ArticleId IdType=""pmc"">PMC7206765</ArticleId><ArticleId IdType=""pubmed"">32381018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Saji S, Takano T, et al. Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD). <i>J Clin Oncol</i>. 2024;42.</Citation></Reference><Reference><Citation>Yuan P, Hu X, Sun T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. <i>Eur J Cancer</i>. 2019;112:57–65. doi: 10.1016/j.ejca.2019.02.002
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ejca.2019.02.002</ArticleId><ArticleId IdType=""pubmed"">30928806</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz SA, Hegg R, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2023;401(10371):105–117. doi: 10.1016/S0140-6736(22)02420-5
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(22)02420-5</ArticleId><ArticleId IdType=""pubmed"">36495879</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbeck N, Huang C-S, Yeh D-C, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncol</i>. 2016;17(3):357–366. doi: 10.1016/S1470-2045(15)00540-9
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(15)00540-9</ArticleId><ArticleId IdType=""pubmed"">26822398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutrino ES, Orlando L, Febbraro A, et al. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. <i>Tumori</i>. 2020;106(4):301–305. doi: 10.1177/0300891619887225
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1177/0300891619887225</ArticleId><ArticleId IdType=""pmc"">PMC7372580</ArticleId><ArticleId IdType=""pubmed"">31847742</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Teng Y, Li H, et al. Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter Phase 2 trial. <i>BMC Med</i>. 2023;21(1):300. doi: 10.1186/s12916-023-02999-0
</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s12916-023-02999-0</ArticleId><ArticleId IdType=""pmc"">PMC10410905</ArticleId><ArticleId IdType=""pubmed"">37559142</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarici F, Altundag K. Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer. <i>J BUON</i>. 2020;25(6):2562–2569.
</Citation><ArticleIdList><ArticleId IdType=""pubmed"">33455097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:51.311087
pubmed,40988963,,40988963,,Incidental Ovarian Vein Thrombosis During Breast Cancer Therapy With Tamoxifen and Trastuzumab.,https://pubmed.ncbi.nlm.nih.gov/40988963/,"Illarramendi Jorge, Mauleon Susana, Sarasibar Helena, Illarramendi Jose Juan",,"Ovarian vein thrombosis (OVT) is an unusual presentation of venous thromboembolic disease. Incidental asymptomatic appearance of OVT is a recognized complication of gynecologic cancer surgery, but published information on incidental OVT during targeted therapy of cancer with hormone therapy and/or monoclonal antibodies is scarce. We present the case of a 41-year-old woman who had a diagnosis of asymptomatic right OVT during the adjuvant treatment of breast cancer with tamoxifen plus trastuzumab. Clinical evolution in this case was favorable without anticoagulant therapy, with confirmed thrombus resolution and without further events. Available literature on this topic is limited, but some data indicate that anticoagulation is also a valuable option to consider, according to potential advantages and risks, on an individual basis.","<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">40988963</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel=""Electronic-eCollection""><Journal><ISSN IssnType=""Print"">2168-8184</ISSN><JournalIssue CitedMedium=""Print""><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Incidental Ovarian Vein Thrombosis During Breast Cancer Therapy With Tamoxifen and Trastuzumab.</ArticleTitle><Pagination><StartPage>e92955</StartPage><MedlinePgn>e92955</MedlinePgn></Pagination><ELocationID EIdType=""pii"" ValidYN=""Y"">e92955</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.7759/cureus.92955</ELocationID><Abstract><AbstractText>Ovarian vein thrombosis (OVT) is an unusual presentation of venous thromboembolic disease. Incidental asymptomatic appearance of OVT is a recognized complication of gynecologic cancer surgery, but published information on incidental OVT during targeted therapy of cancer with hormone therapy and/or monoclonal antibodies is scarce. We present the case of a 41-year-old woman who had a diagnosis of asymptomatic right OVT during the adjuvant treatment of breast cancer with tamoxifen plus trastuzumab. Clinical evolution in this case was favorable without anticoagulant therapy, with confirmed thrombus resolution and without further events. Available literature on this topic is limited, but some data indicate that anticoagulation is also a valuable option to consider, according to potential advantages and risks, on an individual basis.</AbstractText><CopyrightInformation>Copyright © 2025, Illarramendi et al.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Illarramendi</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hematology, Hôpital Haut-Lévêque, Pessac, FRA.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Mauleon</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Radiology, Hospital Universitario de Navarra, Pamplona, ESP.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Sarasibar</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Radiology, Hospital Universitario de Navarra, Pamplona, ESP.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Illarramendi</LastName><ForeName>Jose Juan</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Medical Oncology, Hospital Universitario de Navarra, Pamplona, ESP.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D002363"">Case Reports</PublicationType><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">anticoagulation</Keyword><Keyword MajorTopicYN=""N"">breast cancer</Keyword><Keyword MajorTopicYN=""N"">ovarian vein thrombosis</Keyword><Keyword MajorTopicYN=""N"">tamoxifen</Keyword><Keyword MajorTopicYN=""N"">trastuzumab</Keyword></KeywordList><CoiStatement>Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Comite Etico De Investigacion Con Farmacos En Navarra issued approval Not Applicable. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40988963</ArticleId><ArticleId IdType=""pmc"">PMC12453616</ArticleId><ArticleId IdType=""doi"">10.7759/cureus.92955</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Imaging findings of ovarian vein thrombosis. El-Diasty MT, Noorelahi Y. Cureus. 2023;15:0.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10640670</ArticleId><ArticleId IdType=""pubmed"">38024035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovarian vein thrombosis: A narrative review. Riva N, Calleja-Agius J. Hamostaseologie. 2021;41:257–266.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">33348392</ArticleId></ArticleIdList></Reference><Reference><Citation>A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated Thrombosis Study. Gerotziafas GT, Taher A, Abdel-Razeq H, et al. Oncologist. 2017;22:1222–1231.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC5634762</ArticleId><ArticleId IdType=""pubmed"">28550032</ArticleId></ArticleIdList></Reference><Reference><Citation>High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: A single center retrospective study. Tanasanvimon S, Garg N, Viswanathan C, et al. Thromb Res. 2014;133:154–157.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24331209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovarian vein thrombosis: An unusual cause of abdominal pain in breast cancer. Ahmed M, Mendha T, Do V, Carlan S, Madruga M. Cureus. 2023;15:0.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10170570</ArticleId><ArticleId IdType=""pubmed"">37181988</ArticleId></ArticleIdList></Reference><Reference><Citation>The natural history of uterine venous plexus thrombosis. Amin TN, Cohen H, Wong M, Pointer SL, Aslam N, Jurkovic D. Diagnostics (Basel) 2021;11:1338.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC8393759</ArticleId><ArticleId IdType=""pubmed"">34441273</ArticleId></ArticleIdList></Reference><Reference><Citation>Real-world assessment of thromboembolic risk associated with tamoxifen. Jia J, Tian C, Han W, Ma Q. Sci Rep. 2025;15:27820.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC12310949</ArticleId><ArticleId IdType=""pubmed"">40739320</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines on the investigation and management of venous thrombosis at unusual sites. Tait C, Baglin T, Watson H, Laffan M, Makris M, Perry D, Keeling D. Br J Haematol. 2012;159:28–38.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">22881455</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical relevance of ovarian vein thrombosis and risk of secondary venous thromboembolic events. Greenman M, Bustamante B, Nizam A, Yeisley C, Grimaldi G, Goldberg GL. https://e-century.us/web/journal_toc.php?journal=ajceog&amp;volume=9&amp;number=3 Am J Clin Exp Obstet Gynecol. 2023;9:13–22.</Citation></Reference><Reference><Citation>Incidental gonadal vein thrombosis diagnosed using computed tomography imaging: a single-center, retrospective, cohort study. Alsharif S, Subahi A, Shirah B, Alshamrani KM, Alhazmi TA, Mesurolle B. Cureus. 2021;13:0.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC8286637</ArticleId><ArticleId IdType=""pubmed"">34285850</ArticleId></ArticleIdList></Reference><Reference><Citation>Safety and efficacy of anticoagulant treatment in patients with ovarian vein thrombosis: A systematic review and meta-analysis of observational studies. Riva N, Muscat-Baron L, Vassallo C, et al. Res Pract Thromb Haemost. 2024;8:102501.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC11339252</ArticleId><ArticleId IdType=""pubmed"">39175528</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology, natural history, diagnosis, and management of ovarian vein thrombosis: a scoping review. Monnet M, Dufrost V, Wahl D, Morel O, Agopiantz M, Zuily S. J Thromb Haemost. 2024;22:2991–3003.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">39209258</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:51.436133
pubmed,40984893,,40984893,,Treatment Outcomes of HER2-Directed Therapy in Patients With HER2-Positive Non-metastatic Breast Cancer in Low-Resource Settings.,https://pubmed.ncbi.nlm.nih.gov/40984893/,"Imran Maryam, Majeed Muhammad Awais, Bin Naeem Sameen, Jamil Muhammad Ahsan, Shahzad Minahil, Akhtar Fatima, Karim Amna, Ahmad Aftab, Bano Shehar, Aqib Beenish, Abdullah Javaid Bukhari Syed",,"Introduction This study aimed to evaluate treatment outcomes of human epidermal growth factor receptor 2 (HER2)-directed therapies in patients with non-metastatic HER2-positive breast cancer treated in a low-resource setting. Specifically, we assessed the impact of dual blockade (trastuzumab and pertuzumab), trastuzumab alone, or no HER2-targeted therapy on rates of residual disease, pathological complete response (pCR), progression-free survival (PFS), and overall survival (OS). Methods We conducted a retrospective cohort study at Shaukat Khanum Memorial Cancer Hospital, including 299 patients with non-metastatic HER2-positive breast cancer treated with neoadjuvant chemotherapy and either dual HER2 blockade, trastuzumab alone, or no HER2-targeted therapy due to financial constraints. Patient demographics, clinical features, treatments, and outcomes were analyzed using descriptive statistics, chi-square tests, and Kaplan-Meier survival analysis. Results The median age at diagnosis was 45.7 years (standard deviation±8.9). A majority of patients were premenopausal (n=222; 74.2%), and the majority presented with a palpable lump (n=275; 91.9%). Tumors were mainly located in the left (n=149; 49.8%) or right breast (n=147; 49.2%), with bilateral involvement in 3 (1.0%) cases. Invasive ductal carcinoma was the predominant histology (n=275; 91.9%), with estrogen receptor and progesterone receptor positivity observed in 185 (61.9%) and 179 (59.9%) patients, respectively. Grade III tumors were observed in 156 (52.2%) cases, and most tumors were T2 stage (n=236; 78.9%) with axillary nodal involvement in 232 (77.6%). Patients receiving dual HER2 blockade achieved a pCR in 45 (54.9%) of 82 cases, compared to 51 (45.9%) of 111 with trastuzumab alone, and 39 (36.8%) of 106 with no HER2 therapy (p=0.046). The docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) regimen had the highest pCR rate in 19 (65.5%) of 29 patients (p<0.001). Grade III tumors were associated with higher pCR than Grade II (n=96; 56.5% vs. n=39; 30.2%; p<0.001). At 60 months, PFS was 236 (79.0%) overall, highest in the dual blockade group (n=73; 89.0%), followed by trastuzumab (n=96; 86.5%) and no HER2 therapy (n=69; 65.1%). OS at 60 months was 271 (90.6%), highest in the dual blockade group (n=78; 95.1%), then trastuzumab (n=102; 91.9%) and no HER2 therapy (n=79; 74.5%). Achieving pCR was associated with improved PFS and OS. Differences in both outcomes across groups were statistically significant (p<0.001). Conclusion Dual HER2 blockade significantly improved pCR, PFS, and OS in non-metastatic HER2-positive breast cancer. These findings support the inclusion of HER2-targeted agents in standard neoadjuvant treatment, even in resource-limited settings. Addressing barriers to access remains essential to improving global outcomes in breast cancer care.","<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">40984893</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel=""Electronic-eCollection""><Journal><ISSN IssnType=""Print"">2168-8184</ISSN><JournalIssue CitedMedium=""Print""><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Treatment Outcomes of HER2-Directed Therapy in Patients With HER2-Positive Non-metastatic Breast Cancer in Low-Resource Settings.</ArticleTitle><Pagination><StartPage>e90634</StartPage><MedlinePgn>e90634</MedlinePgn></Pagination><ELocationID EIdType=""pii"" ValidYN=""Y"">e90634</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.7759/cureus.90634</ELocationID><Abstract><AbstractText>Introduction This study aimed to evaluate treatment outcomes of human epidermal growth factor receptor 2 (HER2)-directed therapies in patients with non-metastatic HER2-positive breast cancer treated in a low-resource setting. Specifically, we assessed the impact of dual blockade (trastuzumab and pertuzumab), trastuzumab alone, or no HER2-targeted therapy on rates of residual disease, pathological complete response (pCR), progression-free survival (PFS), and overall survival (OS). Methods We conducted a retrospective cohort study at Shaukat Khanum Memorial Cancer Hospital, including 299 patients with non-metastatic HER2-positive breast cancer treated with neoadjuvant chemotherapy and either dual HER2 blockade, trastuzumab alone, or no HER2-targeted therapy due to financial constraints. Patient demographics, clinical features, treatments, and outcomes were analyzed using descriptive statistics, chi-square tests, and Kaplan-Meier survival analysis. Results The median age at diagnosis was 45.7 years (standard deviation±8.9). A majority of patients were premenopausal (n=222; 74.2%), and the majority presented with a palpable lump (n=275; 91.9%). Tumors were mainly located in the left (n=149; 49.8%) or right breast (n=147; 49.2%), with bilateral involvement in 3 (1.0%) cases. Invasive ductal carcinoma was the predominant histology (n=275; 91.9%), with estrogen receptor and progesterone receptor positivity observed in 185 (61.9%) and 179 (59.9%) patients, respectively. Grade III tumors were observed in 156 (52.2%) cases, and most tumors were T2 stage (n=236; 78.9%) with axillary nodal involvement in 232 (77.6%). Patients receiving dual HER2 blockade achieved a pCR in 45 (54.9%) of 82 cases, compared to 51 (45.9%) of 111 with trastuzumab alone, and 39 (36.8%) of 106 with no HER2 therapy (p=0.046). The docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) regimen had the highest pCR rate in 19 (65.5%) of 29 patients (p&lt;0.001). Grade III tumors were associated with higher pCR than Grade II (n=96; 56.5% vs. n=39; 30.2%; p&lt;0.001). At 60 months, PFS was 236 (79.0%) overall, highest in the dual blockade group (n=73; 89.0%), followed by trastuzumab (n=96; 86.5%) and no HER2 therapy (n=69; 65.1%). OS at 60 months was 271 (90.6%), highest in the dual blockade group (n=78; 95.1%), then trastuzumab (n=102; 91.9%) and no HER2 therapy (n=79; 74.5%). Achieving pCR was associated with improved PFS and OS. Differences in both outcomes across groups were statistically significant (p&lt;0.001). Conclusion Dual HER2 blockade significantly improved pCR, PFS, and OS in non-metastatic HER2-positive breast cancer. These findings support the inclusion of HER2-targeted agents in standard neoadjuvant treatment, even in resource-limited settings. Addressing barriers to access remains essential to improving global outcomes in breast cancer care.</AbstractText><CopyrightInformation>Copyright © 2025, Imran et al.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Imran</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Majeed</LastName><ForeName>Muhammad Awais</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Bin Naeem</LastName><ForeName>Sameen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Jamil</LastName><ForeName>Muhammad Ahsan</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Shahzad</LastName><ForeName>Minahil</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Akhtar</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Karim</LastName><ForeName>Amna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Ahmad</LastName><ForeName>Aftab</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Bano</LastName><ForeName>Shehar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Officer, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Aqib</LastName><ForeName>Beenish</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Abdullah Javaid Bukhari</LastName><ForeName>Syed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">her2-directed therapy</Keyword><Keyword MajorTopicYN=""N"">non-metastatic breast cancer</Keyword><Keyword MajorTopicYN=""N"">pathological complete response</Keyword><Keyword MajorTopicYN=""N"">pertuzumab</Keyword><Keyword MajorTopicYN=""N"">residual disease</Keyword><Keyword MajorTopicYN=""N"">trastuzumab</Keyword></KeywordList><CoiStatement>Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Shaukat Khanum Memorial Cancer Hospital and Reseach center issued approval (EX-21-03-24-01). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>3</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40984893</ArticleId><ArticleId IdType=""pmc"">PMC12450479</ArticleId><ArticleId IdType=""doi"">10.7759/cureus.90634</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization: Breast cancer.  [
Jul;
2025 
]. 2024. https://www.who.int/news-room/fact-sheets/detail/breast-cancer https://www.who.int/news-room/fact-sheets/detail/breast-cancer</Citation></Reference><Reference><Citation>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. CA Cancer J Clin. 2018;68:394–424.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>HER2-positive breast cancer. Loibl S, Gianni L. Lancet. 2017;389:2415–2429.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27939064</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerging targeted therapies for HER2-positive breast cancer. Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Cancers (Basel) 2023;15:1987.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10093019</ArticleId><ArticleId IdType=""pubmed"">37046648</ArticleId></ArticleIdList></Reference><Reference><Citation>5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomized trial. Gianni L, Pienkowski T, Im YH, et al.  https://doi.org/10.1016/S1470-2045. Lancet Oncol. 2016;17:791–800.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27179402</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer: a meta-analysis of randomized controlled trials. Ma R, Shi Y, Yan R, Yin S, Bu H, Huang J. https://doi.org/10.1016/j.critrevonc.2024.104305. Crit Rev Oncol Hematol. 2024;196:104305.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">38442809</ArticleId></ArticleIdList></Reference><Reference><Citation>Targeting HER2-positive breast cancer: advances and future directions. Swain SM, Shastry M, Hamilton E. https://doi.org/10.1038/s41573-022-00579-0. Nat Rev Drug Discov. 2023;22:101–126.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC9640784</ArticleId><ArticleId IdType=""pubmed"">36344672</ArticleId></ArticleIdList></Reference><Reference><Citation>Structural barriers to diagnosis and treatment of cancer in low- and middle-income countries: the urgent need for scaling up. Cazap E, Magrath I, Kingham TP, Elzawawy A. https://doi.org/10.1200/JCO.2015.61.9189. J Clin Oncol. 2016;34:14–19.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC4871996</ArticleId><ArticleId IdType=""pubmed"">26578618</ArticleId></ArticleIdList></Reference><Reference><Citation>Challenges in access to new therapeutic agents: marginalized patients with cancer in Pakistan and the need for new guidelines. Aziz Z, Naseer H, Altaf A. https://doi.org/10.1200/GO.21.00132 JCO Glob Oncol. 2022;8:0.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC8863132</ArticleId><ArticleId IdType=""pubmed"">35175831</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirty years cancer incidence data for Lahore, Pakistan: trends and patterns 1984-2014. Masood A, Masood K, Hussain M, et al. Asian Pac J Cancer Prev. 2018;19:709–717.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC5980846</ArticleId><ArticleId IdType=""pubmed"">29580045</ArticleId></ArticleIdList></Reference><Reference><Citation>Exploring the burden of cancer in Pakistan: an analysis of 2019 data. Tufail M, Wu C. J Epidemiol Glob Health. 2023;13:129–138.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10272049</ArticleId><ArticleId IdType=""pubmed"">37185935</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast cancer: a review of risk factors and diagnosis. Obeagu EI, Obeagu GU. Medicine (Baltimore) 2024;103:0.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10798762</ArticleId><ArticleId IdType=""pubmed"">38241592</ArticleId></ArticleIdList></Reference><Reference><Citation>HER2-directed therapy in advanced breast cancer: benefits and risks. Mandó P, Waisberg F, Pasquinelli R, Rivero S, Ostinelli A, Perazzo F. Onco Targets Ther. 2023;16:115–132.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC9948634</ArticleId><ArticleId IdType=""pubmed"">36844609</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. Stenehjem DD, Yoo M, Unni SK, et al. Breast Cancer (Dove Med Press) 2014;6:169–177.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC4218922</ArticleId><ArticleId IdType=""pubmed"">25378949</ArticleId></ArticleIdList></Reference><Reference><Citation>Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Kunte S, Abraham J, Montero AJ. Cancer. 2020;126:4278–4288.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32721042</ArticleId></ArticleIdList></Reference><Reference><Citation>The evolving landscape of HER2-directed breast cancer therapy. Marti JL, Hyder T, Nasrazadani A, Brufsky AM. Curr Treat Options Oncol. 2020;21:82.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32767149</ArticleId></ArticleIdList></Reference><Reference><Citation>Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomized, open-label, multicentre, phase 3 trial. Hurvitz SA, Martin M, Symmans WF, et al. Lancet Oncol. 2018;19:115–126.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">29175149</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertuzumab for the neoadjuvant treatment of early-stage HER2-positive breast cancer: an evidence review group perspective of a NICE single technology appraisal. Squires H, Pandor A, Thokala P, et al. Pharmacoeconomics. 2018;36:29–38.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">28770452</ArticleId></ArticleIdList></Reference><Reference><Citation>11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. Lancet. 2017;389:1195–1205.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC5465633</ArticleId><ArticleId IdType=""pubmed"">28215665</ArticleId></ArticleIdList></Reference><Reference><Citation>Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Early Breast Cancer Trialists’ Collaborative group (EBCTCG) Lancet Oncol. 2021;22:1139–1150.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC8324484</ArticleId><ArticleId IdType=""pubmed"">34339645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:51.580873
pubmed,40983817,,40983817,,Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer.,https://pubmed.ncbi.nlm.nih.gov/40983817/,"Li Xinyu, Huang Tao",,"Hormone receptor-positive (HR +) and HER2-positive (HER2+) breast cancers represent a biologically unique subset of breast malignancies characterized by the co-expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). These cancers exhibit distinct molecular features, often leading to aggressive growth and higher recurrence rates. HR+/HER2+ breast cancer cells can utilize estrogen and HER2-driven signaling pathways to promote proliferation, survival, and metastatic potential, presenting unique challenges and opportunities for treatment. The current therapeutic strategies focus on a combination of endocrine therapies, such as selective estrogen receptor modulators (e.g., tamoxifen) or aromatase inhibitors, with HER2-targeted therapies like trastuzumab, pertuzumab, or tyrosine kinase inhibitors, to concurrently inhibit both hormone and HER2-driven pathways. Despite initial treatment efficacy, resistance often develops through various mechanisms, including mutations in the PIK3CA gene, cross-talk between ER and HER2 signaling, and activation of alternative growth pathways. Ongoing research aims to improve patient outcomes by exploring novel combination therapies, including CDK4/6 inhibitors and PI3K/AKT/mTOR pathway inhibitors, and by targeting resistance pathways. This review highlights the molecular basis, treatment approaches, and emerging therapeutic strategies in HR+/HER2+ breast cancer, emphasizing the need for personalized and adaptive treatment strategies in managing this complex disease subtype.","<PubmedArticle><MedlineCitation Status=""Publisher"" Owner=""NLM""><PMID Version=""1"">40983817</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel=""Print-Electronic""><Journal><ISSN IssnType=""Electronic"">1880-4233</ISSN><JournalIssue CitedMedium=""Internet""><PubDate><Year>2025</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Breast cancer (Tokyo, Japan)</Title><ISOAbbreviation>Breast Cancer</ISOAbbreviation></Journal><ArticleTitle>Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer.</ArticleTitle><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1007/s12282-025-01779-3</ELocationID><Abstract><AbstractText>Hormone receptor-positive (HR +) and HER2-positive (HER2+) breast cancers represent a biologically unique subset of breast malignancies characterized by the co-expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). These cancers exhibit distinct molecular features, often leading to aggressive growth and higher recurrence rates. HR+/HER2+ breast cancer cells can utilize estrogen and HER2-driven signaling pathways to promote proliferation, survival, and metastatic potential, presenting unique challenges and opportunities for treatment. The current therapeutic strategies focus on a combination of endocrine therapies, such as selective estrogen receptor modulators (e.g., tamoxifen) or aromatase inhibitors, with HER2-targeted therapies like trastuzumab, pertuzumab, or tyrosine kinase inhibitors, to concurrently inhibit both hormone and HER2-driven pathways. Despite initial treatment efficacy, resistance often develops through various mechanisms, including mutations in the PIK3CA gene, cross-talk between ER and HER2 signaling, and activation of alternative growth pathways. Ongoing research aims to improve patient outcomes by exploring novel combination therapies, including CDK4/6 inhibitors and PI3K/AKT/mTOR pathway inhibitors, and by targeting resistance pathways. This review highlights the molecular basis, treatment approaches, and emerging therapeutic strategies in HR+/HER2+ breast cancer, emphasizing the need for personalized and adaptive treatment strategies in managing this complex disease subtype.</AbstractText><CopyrightInformation>© 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Li</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Rd., Wuhan, 430022, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Huang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><Identifier Source=""ORCID"">0000-0003-2130-8621</Identifier><AffiliationInfo><Affiliation>Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Rd., Wuhan, 430022, People's Republic of China. huangtaowh@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType><PublicationType UI=""D016454"">Review</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Breast Cancer</MedlineTA><NlmUniqueID>100888201</NlmUniqueID><ISSNLinking>1340-6868</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">Breast cancer</Keyword><Keyword MajorTopicYN=""N"">Crosstalk</Keyword><Keyword MajorTopicYN=""N"">Endocrine therapy</Keyword><Keyword MajorTopicYN=""N"">Estrogen receptor</Keyword><Keyword MajorTopicYN=""N"">HER2</Keyword><Keyword MajorTopicYN=""N"">Target therapy</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: The authors declare no conflicts of interest. Ethical approval: Not applicable.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>3</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>23</Day><Hour>3</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40983817</ArticleId><ArticleId IdType=""doi"">10.1007/s12282-025-01779-3</ArticleId><ArticleId IdType=""pii"">10.1007/s12282-025-01779-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Panel m: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">23917950</ArticleId><ArticleId IdType=""pmc"">3755334</ArticleId><ArticleId IdType=""doi"">10.1093/annonc/mdt303</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, Cronin KA: US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5).</Citation></Reference><Reference><Citation>Banegas MP, Tao L, Altekruse S, Anderson WF, John EM, Clarke CA, et al. Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California. Breast Cancer Res Treat. 2014;144(3):625–34.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24658879</ArticleId><ArticleId IdType=""pmc"">4045012</ArticleId><ArticleId IdType=""doi"">10.1007/s10549-014-2882-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat. 2015;150(3):621–9.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">25783184</ArticleId><ArticleId IdType=""doi"">10.1007/s10549-015-3341-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619–26.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">29593010</ArticleId><ArticleId IdType=""doi"">10.1158/1055-9965.EPI-17-0627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, Zhao H, Zhao J. Impact of hormone receptor status on the efficacy of HER2-targeted treatment. Endocr Relat Cancer. 2018;25(6):687–97.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">29739815</ArticleId><ArticleId IdType=""doi"">10.1530/ERC-18-0029</ArticleId></ArticleIdList></Reference><Reference><Citation>Montemurro F, Rossi V, Cossu Rocca M, Martinello R, Verri E, Redana S, et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer. 2012;118(1):17–26.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">21598238</ArticleId><ArticleId IdType=""doi"">10.1002/cncr.26162</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, et al. Incidence of late relapses in patients with her2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (Alliance) and NRG oncology/NSABP B-31. J Clin Oncol. 2019;37(35):3425–35.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31622131</ArticleId><ArticleId IdType=""pmc"">6900835</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.19.00443</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(Suppl 1):S3–8.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">11521719</ArticleId><ArticleId IdType=""doi"">10.1093/annonc/12.suppl_1.S3</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21(2):100–7.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24508693</ArticleId><ArticleId IdType=""doi"">10.1097/PAP.0000000000000015</ArticleId></ArticleIdList></Reference><Reference><Citation>Clusan L, Ferriere F, Flouriot G, Pakdel F. A basic review on Estrogen receptor signaling pathways in breast cancer. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24076834 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/ijms24076834</ArticleId><ArticleId IdType=""pubmed"">37047814</ArticleId><ArticleId IdType=""pmc"">10095386</ArticleId></ArticleIdList></Reference><Reference><Citation>Song RX. Membrane-initiated steroid signaling action of estrogen and breast cancer. Semin Reprod Med. 2007;25(3):187–97.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">17447208</ArticleId><ArticleId IdType=""doi"">10.1055/s-2007-973431</ArticleId></ArticleIdList></Reference><Reference><Citation>Razandi M, Pedram A, Park ST, Levin ER. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem. 2003;278(4):2701–12.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">12421825</ArticleId><ArticleId IdType=""doi"">10.1074/jbc.M205692200</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Wei H, Li S, Wu P, Mao X. The role of progesterone receptors in breast cancer. Drug Des Devel Ther. 2022;16:305–14.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">35115765</ArticleId><ArticleId IdType=""pmc"">8801368</ArticleId><ArticleId IdType=""doi"">10.2147/DDDT.S336643</ArticleId></ArticleIdList></Reference><Reference><Citation>Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A. 2010;107(7):2989–94.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">20133621</ArticleId><ArticleId IdType=""pmc"">2840294</ArticleId><ArticleId IdType=""doi"">10.1073/pnas.0915148107</ArticleId></ArticleIdList></Reference><Reference><Citation>Paakinaho V, Palvimo JJ. Genome-wide crosstalk between steroid receptors in breast and prostate cancers. Endocr Relat Cancer. 2021;28(9):R231–50.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34137734</ArticleId><ArticleId IdType=""pmc"">8345902</ArticleId><ArticleId IdType=""doi"">10.1530/ERC-21-0038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. Progesterone receptor modulates ERalpha action in breast cancer. Nature. 2015;523(7560):313–7.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">26153859</ArticleId><ArticleId IdType=""pmc"">4650274</ArticleId><ArticleId IdType=""doi"">10.1038/nature14583</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg D, Ng SSM, Baig KM, Driggers P, Segars J. Progesterone-mediated non-classical signaling. Trends Endocrinol Metab. 2017;28(9):656–68.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">28651856</ArticleId><ArticleId IdType=""doi"">10.1016/j.tem.2017.05.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Béguelin W, Díaz Flaqué MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, et al. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol. 2010;30(23):5456–72.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">20876300</ArticleId><ArticleId IdType=""pmc"">2976427</ArticleId><ArticleId IdType=""doi"">10.1128/MCB.00012-10</ArticleId></ArticleIdList></Reference><Reference><Citation>Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007;13(7):1950–4.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">17404074</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-06-2540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffreys SA, Powter B, Balakrishnar B, Mok K, Soon P, Franken A, Neubauer H, de Souza P, Becker TM. Endocrine resistance in breast cancer: the role of estrogen receptor stability. Cells. 2020;9(9).</Citation></Reference><Reference><Citation>Zheng FF, Wu RC, Smith CL, O’Malley BW. Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor. Mol Cell Biol. 2005;25(18):8273–84.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">16135815</ArticleId><ArticleId IdType=""pmc"">1234335</ArticleId><ArticleId IdType=""doi"">10.1128/MCB.25.18.8273-8284.2005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheskis BJ, Greger J, Cooch N, McNally C, McLarney S, Lam HS, et al. MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids. 2008;73(9–10):901–5.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">18261753</ArticleId><ArticleId IdType=""doi"">10.1016/j.steroids.2007.12.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, et al. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001;61(16):5985–91.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">11507039</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95(5):353–61.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">12618500</ArticleId><ArticleId IdType=""doi"">10.1093/jnci/95.5.353</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkegaard T, McGlynn LM, Campbell FM, Muller S, Tovey SM, Dunne B, et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res. 2007;13(5):1405–11.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">17332282</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-06-1933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiliti AJ, Sharif GM, Martin MB, Wellstein A, Riegel AT. AIB1/SRC-3/NCOA3 function in estrogen receptor alpha positive breast cancer. Front Endocrinol (Lausanne). 2023;14:1250218.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">37711895</ArticleId><ArticleId IdType=""doi"">10.3389/fendo.2023.1250218</ArticleId></ArticleIdList></Reference><Reference><Citation>Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96(12):926–35.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">15199112</ArticleId><ArticleId IdType=""doi"">10.1093/jnci/djh166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lousberg L, Collignon J, Jerusalem G. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol. 2016;8(6):429–49.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27800032</ArticleId><ArticleId IdType=""pmc"">5066545</ArticleId><ArticleId IdType=""doi"">10.1177/1758834016665077</ArticleId></ArticleIdList></Reference><Reference><Citation>Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, et al. Effects of estrogen receptor and human epidermal growth factor receptor-2 levels on the efficacy of trastuzumab: a secondary analysis of the HERA trial. JAMA Oncol. 2016;2(8):1040–7.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27100299</ArticleId><ArticleId IdType=""doi"">10.1001/jamaoncol.2016.0339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers–role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011;13(6):R121.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">22123186</ArticleId><ArticleId IdType=""pmc"">3326563</ArticleId><ArticleId IdType=""doi"">10.1186/bcr3067</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res. 2015;21(17):3995–4003.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">26015514</ArticleId><ArticleId IdType=""pmc"">4558260</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-14-2728</ArticleId></ArticleIdList></Reference><Reference><Citation>Tommasi C, Airò G, Pratticò F, Testi I, Corianò M, Pellegrino B, et al. Hormone receptor-positive/HER2-positive breast cancer: hormone therapy and anti-HER2 treatment: an update on treatment strategies. J Clin Med. 2024. https://doi.org/10.3390/jcm13071873 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/jcm13071873</ArticleId><ArticleId IdType=""pubmed"">39598059</ArticleId><ArticleId IdType=""pmc"">11595135</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo S, Xue J, Wang S, Shan H, Chen G, Niu N, et al. A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer. MedComm (2020). 2024;5(3):e505.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">38469548</ArticleId><ArticleId IdType=""doi"">10.1002/mco2.505</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodie A, Sabnis G. Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. Clin Cancer Res. 2011;17(13):4208–13.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">21415222</ArticleId><ArticleId IdType=""pmc"">3131492</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-10-2920</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli C, Barberis M. Breast cancer heterogeneity. Diagnostics (Basel). 2021. https://doi.org/10.3390/diagnostics11091555 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/diagnostics11091555</ArticleId><ArticleId IdType=""pubmed"">34573897</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/nature11412</ArticleId></ArticleIdList></Reference><Reference><Citation>Schettini F, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast. 2021;59:339–50.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34392185</ArticleId><ArticleId IdType=""pmc"">8374722</ArticleId><ArticleId IdType=""doi"">10.1016/j.breast.2021.07.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Li Q, Aushev VN, Neugut AI, Santella RM, Teitelbaum S, et al. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study. Breast Cancer. 2021;28(6):1235–42.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34003448</ArticleId><ArticleId IdType=""doi"">10.1007/s12282-021-01261-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Schettini F, Pascual T, Conte B, Chic N, Braso-Maristany F, Galvan P, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020;84:101965.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32000054</ArticleId><ArticleId IdType=""pmc"">7230134</ArticleId><ArticleId IdType=""doi"">10.1016/j.ctrv.2020.101965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Liu XY, Jin X, Ma D, Xiao Y, Shao ZM, et al. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer. Theranostics. 2019;9(17):4935–45.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31410192</ArticleId><ArticleId IdType=""pmc"">6691389</ArticleId><ArticleId IdType=""doi"">10.7150/thno.35730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding W, Ye D, Chen H, Lin Y, Li Z, Tu C. Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes. Breast Cancer. 2024;31(2):295–304.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">38231460</ArticleId><ArticleId IdType=""doi"">10.1007/s12282-023-01538-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Gui X, Zhou Z, Su F, Gong C, Li S, et al. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: a real-world analysis of 871 patients treated with neoadjuvant therapy. Breast. 2024;75:103733.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">38615482</ArticleId><ArticleId IdType=""pmc"">11026842</ArticleId><ArticleId IdType=""doi"">10.1016/j.breast.2024.103733</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–66.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31928404</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.19.02309</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisman P, Ospina-Romero M, Yu Q, Wisinski K, Xu J. HER2-positive/ER-low breast carcinoma shows a response to neoadjuvant chemotherapy similar to that of HER2-positive/ER-negative breast carcinoma. Pathol Res Pract. 2022;238:154087.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36029679</ArticleId><ArticleId IdType=""doi"">10.1016/j.prp.2022.154087</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Wu J, Liu D, Chen W, Lin C, Andriani L, et al. Combined estrogen receptor and progesterone receptor level can predict survival outcome in human epidermal growth factor receptor 2-positive early breast cancer. Clin Breast Cancer. 2022;22(2):e147–56.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34244052</ArticleId><ArticleId IdType=""doi"">10.1016/j.clbc.2021.05.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuasha N, Petros B. Heterogeneity of tumors in breast cancer: implications and prospects for prognosis and therapeutics. Scientifica. 2020;2020:4736091.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">33133722</ArticleId><ArticleId IdType=""pmc"">7568790</ArticleId><ArticleId IdType=""doi"">10.1155/2020/4736091</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Jiang M, Wang H, Sun H, Zhu J, Zhao W, et al. A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med. 2021;9(16):1351.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34532488</ArticleId><ArticleId IdType=""pmc"">8422119</ArticleId><ArticleId IdType=""doi"">10.21037/atm-21-1948</ArticleId></ArticleIdList></Reference><Reference><Citation>Teruya N, Inoue H, Horii R, Akiyama F, Ueno T, Ohno S, et al. Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer. Cancer Med. 2023;12(9):10526–35.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36934442</ArticleId><ArticleId IdType=""pmc"">10225233</ArticleId><ArticleId IdType=""doi"">10.1002/cam4.5788</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update. J Clin Oncol. 2023;41(22):3867–72.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">37284804</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.22.02864</ArticleId></ArticleIdList></Reference><Reference><Citation>Atallah NM, Alsaleem M, Toss MS, Mongan NP, Rakha E. Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level. Br J Cancer. 2023;129(10):1692–705.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">37740038</ArticleId><ArticleId IdType=""pmc"">10646129</ArticleId><ArticleId IdType=""doi"">10.1038/s41416-023-02426-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitake R, Mori H, Ha D, Wu X, Wang J, Wang X, et al. Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics. Clin Transl Med. 2024;14(1):e1548.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">38282415</ArticleId><ArticleId IdType=""pmc"">10823285</ArticleId><ArticleId IdType=""doi"">10.1002/ctm2.1548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma D, Dai L-J, Wu X-R, Liu C-L, Zhao S, Zhang H, et al. Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell. 2025. https://doi.org/10.1016/j.ccell.2025.03.017 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ccell.2025.03.017</ArticleId><ArticleId IdType=""pubmed"">40829591</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YF, Liao YY, Yang M, Peng NF, Xie SR, Xie YF. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients. Med Oncol. 2014;31(10):214.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">25216864</ArticleId><ArticleId IdType=""doi"">10.1007/s12032-014-0214-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L. Hormone receptor/Human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going. Cancer Treat Rev. 2016;46:20–6.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27057657</ArticleId><ArticleId IdType=""doi"">10.1016/j.ctrv.2016.03.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Boman C, Liu X, Eriksson Bergman L, Sun W, Tranchell C, Toli MA, et al. A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression. Br J Cancer. 2024;131(4):718–28.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">38942987</ArticleId><ArticleId IdType=""pmc"">11333620</ArticleId><ArticleId IdType=""doi"">10.1038/s41416-024-02777-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol. 2016;27(3):480–7.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">26704052</ArticleId><ArticleId IdType=""doi"">10.1093/annonc/mdv611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A. Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat. 2019;175(2):401–8.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">30806922</ArticleId><ArticleId IdType=""doi"">10.1007/s10549-019-05173-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarneri V, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol. 2013;24(12):2990–4.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24013581</ArticleId><ArticleId IdType=""doi"">10.1093/annonc/mdt364</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVee A, Spector K, Larkin B, Dezem F, Plummer J, Dadmanesh F, et al. Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2+ breast cancer. Cancer Med. 2023;12(9):10647–59.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36971049</ArticleId><ArticleId IdType=""pmc"">10225224</ArticleId><ArticleId IdType=""doi"">10.1002/cam4.5817</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Zhang J, Yun H, Shi R, Wang Y, Wang W, et al. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget. 2015;6(34):36894–902.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">26384297</ArticleId><ArticleId IdType=""pmc"">4742218</ArticleId><ArticleId IdType=""doi"">10.18632/oncotarget.5050</ArticleId></ArticleIdList></Reference><Reference><Citation>Cejalvo JM, Martinez de Duenas E, Galvan P, Garcia-Recio S, Burgues Gasion O, Pare L, et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res. 2017;77(9):2213–21.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">28249905</ArticleId><ArticleId IdType=""pmc"">5822682</ArticleId><ArticleId IdType=""doi"">10.1158/0008-5472.CAN-16-2717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708–28.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36931265</ArticleId><ArticleId IdType=""doi"">10.1016/j.cell.2023.01.040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–22.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24048123</ArticleId><ArticleId IdType=""pmc"">4118725</ArticleId><ArticleId IdType=""doi"">10.1038/ni.2703</ArticleId></ArticleIdList></Reference><Reference><Citation>Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with Lapatinib and Trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448–54.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">26181252</ArticleId><ArticleId IdType=""pmc"">5551492</ArticleId><ArticleId IdType=""doi"">10.1001/jamaoncol.2015.0830</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuciforo P, Pascual T, Cortes J, Llombart-Cussac A, Fasani R, Pare L, et al. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2018;29(1):170–7.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">29045543</ArticleId><ArticleId IdType=""doi"">10.1093/annonc/mdx647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamy AS, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, et al. Interaction between molecular subtypes and stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy. Clin Cancer Res. 2019;25(22):6731–41.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31515462</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-18-3017</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, et al. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol. 2017;28(9):2233–40.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">28911063</ArticleId><ArticleId IdType=""doi"">10.1093/annonc/mdx309</ArticleId></ArticleIdList></Reference><Reference><Citation>Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, et al. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ Precis Oncol. 2021;5(1):23.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">33742063</ArticleId><ArticleId IdType=""pmc"">7979716</ArticleId><ArticleId IdType=""doi"">10.1038/s41698-021-00163-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354–60.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27355489</ArticleId><ArticleId IdType=""doi"">10.1001/jamaoncol.2016.1061</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren C, Bendahl PO, Ekholm M, Ferno M, Forsare C, Kruger U, et al. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. Breast Cancer Res. 2020;22(1):140.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">33357231</ArticleId><ArticleId IdType=""pmc"">7758933</ArticleId><ArticleId IdType=""doi"">10.1186/s13058-020-01364-w</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, et al. Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy. Clin Cancer Res. 2020;26(3):738–45.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31653641</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-19-1402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin K, Kokten S, Sarikamis B, Yildirim S, Gokce ON, Barisik NO, et al. The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer. Breast Cancer Res Treat. 2024;205(1):17–27.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">38273215</ArticleId><ArticleId IdType=""pmc"">11062965</ArticleId><ArticleId IdType=""doi"">10.1007/s10549-023-07242-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">22153890</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(11)70336-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">22257673</ArticleId><ArticleId IdType=""pmc"">5705192</ArticleId><ArticleId IdType=""doi"">10.1016/S0140-6736(11)61847-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 2022;20(1):498.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36575513</ArticleId><ArticleId IdType=""pmc"">9795751</ArticleId><ArticleId IdType=""doi"">10.1186/s12916-022-02708-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Garcia JM, Cortes J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024;403(10437):1649–59.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">38582092</ArticleId><ArticleId IdType=""doi"">10.1016/S0140-6736(24)00054-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27179402</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(16)00163-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuciforo P, Townend J, Piccart MJ, Fielding S, Gkolfi P, El-Abed S, et al. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer. 2023;181:92–101.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36641898</ArticleId><ArticleId IdType=""doi"">10.1016/j.ejca.2022.12.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbeck N, Nitz UA, Christgen M, Kummel S, Braun M, Schumacher C, et al. De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP trial. J Clin Oncol. 2023;41(22):3796–804.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36809046</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.22.01816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24529560</ArticleId><ArticleId IdType=""doi"">10.1016/S0140-6736(13)62422-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, et al. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer. Oncologist. 2015;20(9):1001–10.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">26245675</ArticleId><ArticleId IdType=""pmc"">4571802</ArticleId><ArticleId IdType=""doi"">10.1634/theoncologist.2015-0138</ArticleId></ArticleIdList></Reference><Reference><Citation>Robidoux A, Tang G, Rastogi P, Geyer CE Jr., Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(12):1183–92.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24095300</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(13)70411-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol. 2016;34(6):542–9.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">26527775</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.2015.62.1268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">23704196</ArticleId><ArticleId IdType=""doi"">10.1093/annonc/mdt182</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentje VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630–40.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">30413379</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(18)30570-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Matikas A, Johansson H, Gryback P, Bjohle J, Acs B, Boyaci C, et al. Survival outcomes, digital TILs, and on-treatment PET/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial. Clin Cancer Res. 2023;29(3):532–40.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36449695</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-22-2829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115–26.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">29175149</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(17)30716-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo W-J, Chen L, Shen Y, Wang Z-H, Liu G-Y, Yu K-D, et al. Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial. Ther Adv Med Oncol. 2024. https://doi.org/10.1177/17588359231225032 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1177/17588359231225032</ArticleId><ArticleId IdType=""pubmed"">39563715</ArticleId><ArticleId IdType=""pmc"">11574904</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013;31(14):1726–31.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">23569315</ArticleId><ArticleId IdType=""pmc"">3641695</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.2012.44.8027</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, et al. TBCRC023: a randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer. Clin Cancer Res. 2020;26(4):821–7.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31662331</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-19-0851</ArticleId></ArticleIdList></Reference><Reference><Citation>Llombart-Cussac A, Cortes J, Pare L, Galvan P, Bermejo B, Martinez N, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017;18(4):545–54.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">28238593</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(17)30021-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, et al. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. JNCI J Natl Cancer Inst. 2020;112(1):46–54.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31037288</ArticleId><ArticleId IdType=""doi"">10.1093/jnci/djz042</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Kang MJ, Ahn J-H, Kim JE, Jung KH, Gong G, et al. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. Cancer Chemother Pharmacol. 2016;78(4):685–95.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27491481</ArticleId><ArticleId IdType=""doi"">10.1007/s00280-016-3107-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarneri V, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, et al. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Ann Oncol. 2019;30(6):921–6.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">30778520</ArticleId><ArticleId IdType=""pmc"">6594455</ArticleId><ArticleId IdType=""doi"">10.1093/annonc/mdz055</ArticleId></ArticleIdList></Reference><Reference><Citation>Gluz O, Nitz UA, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J, et al. Efficacy of endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy in patients with hormone receptor-positive/ERBB2-positive early breast cancer: the neoadjuvant WSG-TP-II randomized clinical trial. JAMA Oncol. 2023;9(7):946–54.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">37166817</ArticleId><ArticleId IdType=""pmc"">10176180</ArticleId><ArticleId IdType=""doi"">10.1001/jamaoncol.2023.0646</ArticleId></ArticleIdList></Reference><Reference><Citation>Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817–27.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32145796</ArticleId><ArticleId IdType=""doi"">10.1016/S0140-6736(20)30165-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016;29(3):255–69.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">26977878</ArticleId><ArticleId IdType=""pmc"">4794996</ArticleId><ArticleId IdType=""doi"">10.1016/j.ccell.2016.02.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Ther Adv Med Oncol. 2018;10:1758835918818346.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">30619511</ArticleId><ArticleId IdType=""pmc"">6299331</ArticleId><ArticleId IdType=""doi"">10.1177/1758835918818346</ArticleId></ArticleIdList></Reference><Reference><Citation>Ademuyiwa FO, Northfelt DW, O’Connor T, Levine E, Luo J, Tao Y, et al. A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). NPJ Breast Cancer. 2023. https://doi.org/10.1038/s41523-022-00504-z .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41523-022-00504-z</ArticleId><ArticleId IdType=""pubmed"">36609389</ArticleId><ArticleId IdType=""pmc"">9822956</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu N, Qiu F, Xu Q, He G, Gu X, Guo W, et al. A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. Nat Commun. 2022;13(1):7043.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36396665</ArticleId><ArticleId IdType=""pmc"">9672048</ArticleId><ArticleId IdType=""doi"">10.1038/s41467-022-34838-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianni L, Bisagni G, Colleoni M, Del Mastro L, Zamagni C, Mansutti M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol. 2018;19(2):249–56.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">29326029</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(18)30001-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Malorni L. Abstract RF1–02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55–17). In: 2024 San Antonio Breast Cancer Symposium. SAN Antonio, Texas.</Citation></Reference><Reference><Citation>Ahn HK, Sim SH, Suh KJ, Kim MH, Jeong JH, Kim JY, et al. Response rate and safety of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab regimen for patients with ERBB2-positive stage II/III breast cancer: the Neo-PATH phase 2 nonrandomized clinical trial. JAMA Oncol. 2022;8(9):1271–7.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">35797012</ArticleId><ArticleId IdType=""pmc"">10881214</ArticleId><ArticleId IdType=""doi"">10.1001/jamaoncol.2022.2310</ArticleId></ArticleIdList></Reference><Reference><Citation>Huober J, Barrios CH, Niikura N, Jarząb M, Chang YC, Huggins-Puhalla SL, et al. Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized phase III impassion050 trial. J Clin Oncol. 2022;40(25):2946–56.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">35763704</ArticleId><ArticleId IdType=""pmc"">9426828</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.21.02772</ArticleId></ArticleIdList></Reference><Reference><Citation>von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa1814017</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021;17(34):4665–76.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34636255</ArticleId><ArticleId IdType=""pmc"">8600597</ArticleId><ArticleId IdType=""doi"">10.2217/fon-2021-0753</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz SA, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, et al. Astefania: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. Future Oncol. 2022;18(32):3563–72.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36382554</ArticleId><ArticleId IdType=""doi"">10.2217/fon-2022-0485</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura C, Oliveira M, Feng Y-H, Dai M-S, Chen S-W, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138–49.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32678716</ArticleId><ArticleId IdType=""pmc"">7499616</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.20.00147</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer. 2021;21(1):80-9e187.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">33183970</ArticleId><ArticleId IdType=""doi"">10.1016/j.clbc.2020.09.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–205.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">28215665</ArticleId><ArticleId IdType=""pmc"">5465633</ArticleId><ArticleId IdType=""doi"">10.1016/S0140-6736(16)32616-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, et al. Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2–positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update. J Clin Oncol. 2024;42(31):3643–51.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">39259927</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.23.02505</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023;24(3):273–85.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36858723</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(23)00051-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol. 2021;39(21):2375–85.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34077270</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.20.03398</ArticleId></ArticleIdList></Reference><Reference><Citation>Krop IE, Im S-A, Barrios C, Bonnefoi H, Gralow J, Toi M, et al. Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer: the phase III kaitlin study. J Clin Oncol. 2022;40(5):438–48.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34890214</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.21.00896</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30(16):1989–95.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">22493419</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.2011.39.0823</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CS, Yang Y, Kwong A, Chen SC, Tseng LM, Liu MC, et al. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study. Breast Cancer Res Treat. 2021;187(3):759–68.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">33860389</ArticleId><ArticleId IdType=""doi"">10.1007/s10549-021-06166-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain SM, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32171426</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(19)30863-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ. 2023;383:e076065.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">37907210</ArticleId><ArticleId IdType=""pmc"">10616786</ArticleId><ArticleId IdType=""doi"">10.1136/bmj-2023-076065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Jia X, Wang K, Li M. Unveiling the future of breast cancer therapy: cutting-edge antibody-drug conjugate strategies and clinical outcomes. Breast. 2024;78:103830.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">39500221</ArticleId><ArticleId IdType=""pmc"">11570738</ArticleId><ArticleId IdType=""doi"">10.1016/j.breast.2024.103830</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez EA, Barrios C, Eiermann W, Toi M, Im Y-H, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE. Cancer. 2019;125(22):3974–84.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">31318460</ArticleId><ArticleId IdType=""doi"">10.1002/cncr.32392</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">23020162</ArticleId><ArticleId IdType=""pmc"">5125250</ArticleId><ArticleId IdType=""doi"">10.1056/NEJMoa1209124</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2024;35(3):302–7.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">38092229</ArticleId><ArticleId IdType=""doi"">10.1016/j.annonc.2023.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773–85.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">37086745</ArticleId><ArticleId IdType=""doi"">10.1016/S0140-6736(23)00725-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–17.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36495879</ArticleId><ArticleId IdType=""doi"">10.1016/S0140-6736(22)02420-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">35665782</ArticleId><ArticleId IdType=""pmc"">10561652</ArticleId><ArticleId IdType=""doi"">10.1056/NEJMoa2203690</ArticleId></ArticleIdList></Reference><Reference><Citation>Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–54.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">28526538</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(17)30313-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with Tucatinib plus Trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–9.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32468955</ArticleId><ArticleId IdType=""pmc"">7403000</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.20.00775</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz S, Loi S, O’Shaughnessy J, Okines A, Tolaney S, Sohn JH, et al. Abstract GS01-10: HER2CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. Cancer Res. 2024;84(9_Supplement):GS01-10-GS01-10.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1538-7445.SABCS23-GS01-10</ArticleId></ArticleIdList></Reference><Reference><Citation>Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, et al. Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer. Clin Cancer Res. 2019;25(1):277–89.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">30314968</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-18-1544</ArticleId></ArticleIdList></Reference><Reference><Citation>Carausu M, Carton M, Dieras V, Petit T, Guiu S, Goncalves A, et al. Association of endocrine therapy for HR+/ERBB2+ metastatic breast cancer with survival outcomes. JAMA Netw Open. 2022;5(12):e2247154.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36520434</ArticleId><ArticleId IdType=""pmc"">9856509</ArticleId><ArticleId IdType=""doi"">10.1001/jamanetworkopen.2022.47154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III Tandem study. J Clin Oncol. 2009;27(33):5529–37.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">19786670</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.2008.20.6847</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">19786658</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.2009.23.3734</ArticleId></ArticleIdList></Reference><Reference><Citation>Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast. 2012;21(1):27–33.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">21862331</ArticleId><ArticleId IdType=""doi"">10.1016/j.breast.2011.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimawi M, Ferrero J-M, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826–35.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">30106636</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.2017.76.7863</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston SRD, Hegg R, Im S-A, Park IH, Burdaeva O, Kurteva G, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol. 2021;39(1):79–89.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32822287</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.20.01894</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu ZY, Yan M, Xiong H, Ran L, Zhong J, Luo T, et al. Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial. BMC Med. 2023;21(1):226.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">37365596</ArticleId><ArticleId IdType=""pmc"">10294469</ArticleId><ArticleId IdType=""doi"">10.1186/s12916-023-02943-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Bi XW, Zhao JL, Shi YX, Lin Y, Wu ZY, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor-positive and HER2-positive metastatic breast cancer (SYSUCC-002). Clin Cancer Res. 2022;28(4):637–45.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34810217</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-21-3435</ArticleId></ArticleIdList></Reference><Reference><Citation>Huober J, Weder P, Ribi K, Thurlimann B, Thery JC, Li Q, et al. Pertuzumab plus Trastuzumab with or without chemotherapy followed by Emtansine in ERBB2-positive metastatic breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2023;9(10):1381–9.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">37561451</ArticleId><ArticleId IdType=""pmc"">10416088</ArticleId><ArticleId IdType=""doi"">10.1001/jamaoncol.2023.2909</ArticleId></ArticleIdList></Reference><Reference><Citation>Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">29718092</ArticleId><ArticleId IdType=""doi"">10.1093/annonc/mdy155</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">28968163</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.2017.75.6155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, et al. Palbociclib and Trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial. Clin Cancer Res. 2020;26(22):5820–9.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32938620</ArticleId><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-20-0844</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzger O MS, DeMichele A, et al. AFT-38 PATINA: a randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor-positive/HER2-positive metastatic breast cancer. In: 2024 San Antonio Breast Cancer Symposium 2024, Abstract P2–03–20 (SESS-18111).</Citation></Reference><Reference><Citation>Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763–75.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">32353342</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(20)30112-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Janni W, Fehm T, Müller V, Schochter F, De Gregorio A, Decker T, et al. Abstract PD18-07: omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer – interim results from the randomized phase 3 DETECT V trial. Cancer Res. 2023;83(5_Supplement):PD18-07-PD18-07.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1538-7445.SABCS22-PD18-07</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Meng Y, Wang B, Wu X, Zheng H, Cai L, et al. Pleasurable: results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC). J Clin Oncol. 2023;41(16_suppl):1046–1046.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2023.41.16_suppl.1046</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, et al. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res Treat. 2018;171(2):371–81.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">29850984</ArticleId><ArticleId IdType=""doi"">10.1007/s10549-018-4792-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16(7):816–29.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">26092818</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(15)00051-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre F, O’Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–91.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24742739</ArticleId><ArticleId IdType=""doi"">10.1016/S1470-2045(14)70138-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, et al. Molecular alterations and Everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol. 2016;34(18):2115–24.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">27091708</ArticleId><ArticleId IdType=""doi"">10.1200/JCO.2015.63.9161</ArticleId></ArticleIdList></Reference><Reference><Citation>Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870–84.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24158787</ArticleId><ArticleId IdType=""pmc"">3898123</ArticleId><ArticleId IdType=""doi"">10.1007/s12325-013-0060-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Prat A, Guarneri V, Pascual T, Brasó-Maristany F, Sanfeliu E, Paré L, et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine. 2022;75:103801.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">34990895</ArticleId><ArticleId IdType=""pmc"">8741424</ArticleId><ArticleId IdType=""doi"">10.1016/j.ebiom.2021.103801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, del Monte-Millán M, Massarrah T, Jerez Y, Ayala de la Peña F, García-Sáenz JÁ, Moreno F et al. Assessment of a genomic assay in patients with ERBB2-Positive breast cancer following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab. JAMA Oncol. 2023;9(6).</Citation></Reference><Reference><Citation>Guarneri V, Bras-Maristany F, Dieci MV, Griguolo G, Par L, Mar Ín-Aguilera M, et al. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: a correlative analysis from the PerELISA trial. EBioMedicine. 2022;85:104320.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">36374768</ArticleId><ArticleId IdType=""pmc"">9626543</ArticleId><ArticleId IdType=""doi"">10.1016/j.ebiom.2022.104320</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022;40(6):609-623.e606.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">35623341</ArticleId><ArticleId IdType=""pmc"">9426306</ArticleId><ArticleId IdType=""doi"">10.1016/j.ccell.2022.05.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P, Zhu Z, Wolf D, Yau C, Audeh W, Glas A, et al. Abstract 2612: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY 2 breast cancer patients. Can Res. 2018;78:2612–2612.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1538-7445.AM2018-2612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:51.740058
pubmed,40982170,,40982170,,Efficacy and Safety of Dual Therapy with HER2-inhibitors (Pertuzumab and Trastuzumab) in Gastric or Gastroesophageal Tumors: A Systematic Review and Meta-analysis.,https://pubmed.ncbi.nlm.nih.gov/40982170/,"Costa Geraldo Lucas Lopes, da Cruz João Victor Ramos, Alves José Roberto, de Oliveira Saint Clair Vieira, Dos Santos Ribeiro Leticia Vieira, Gohr Arthur Henrique, Vieira Daniella Serafin Couto",,The benefit of adding dual HER2 inhibition with Pertuzumab (P) and Trastuzumab (T) to chemotherapy (cT) in HER2-positive gastric or gastroesophageal junction (GEJ) cancer is not yet fully elucidated.,"<PubmedArticle><MedlineCitation Status=""MEDLINE"" Owner=""NLM"" IndexingMethod=""Curated""><PMID Version=""1"">40982170</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel=""Electronic""><Journal><ISSN IssnType=""Electronic"">1941-6636</ISSN><JournalIssue CitedMedium=""Internet""><Volume>56</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of gastrointestinal cancer</Title><ISOAbbreviation>J Gastrointest Cancer</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Dual Therapy with HER2-inhibitors (Pertuzumab and Trastuzumab) in Gastric or Gastroesophageal Tumors: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>191</StartPage><MedlinePgn>191</MedlinePgn></Pagination><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1007/s12029-025-01310-z</ELocationID><Abstract><AbstractText Label=""BACKGROUND"" NlmCategory=""BACKGROUND"">The benefit of adding dual HER2 inhibition with Pertuzumab (P) and Trastuzumab (T) to chemotherapy (cT) in HER2-positive gastric or gastroesophageal junction (GEJ) cancer is not yet fully elucidated.</AbstractText><AbstractText Label=""METHODS"" NlmCategory=""METHODS"">A systematic search of PubMed, Cochrane Central, Embase, Web of Science, SciELO, and LILACS identified clinical trials investigating adjuvant or neoadjuvant regimens combining (P), (T) and (cT). Hazard ratios (HRs) and odds ratios (ORs) for binary endpoints were calculated, with 95% confidence intervals (CIs).</AbstractText><AbstractText Label=""RESULTS"" NlmCategory=""RESULTS"">Four clinical trials comprising a total of 1,225 patients were included. Dual HER2 blockade plus (cT) showed a significant benefit in survival analysis (HR 0.77, 95% CI 0.69-0.86), especially in terms of overall survival (HR 0.78, 95% CI 0.61-0.99) and progression-free survival (HR 0.73, 95% CI 0.62-0.85). Pathological response rates were higher compared with (cT) alone (OR 1.62, 95% CI 0.98-2.66). Treatment was associated with an increased overall adverse event rate (OR 1.48, 95% CI 1.32-1.66), particularly any-grade diarrhea, hypokalemia, fatigue, and pulmonary infection. Serious adverse events, including deaths and complications, were not significantly different (OR 0.87, 95% CI 0.51-1.49).</AbstractText><AbstractText Label=""CONCLUSIONS"" NlmCategory=""CONCLUSIONS"">This systematic review and meta-analysis of clinical trials demonstrates that adding (P), (T) and (cT) improves survival and pathological response in HER2-positive gastric and GEJ tumors, with a manageable safety profile.</AbstractText><CopyrightInformation>© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Costa</LastName><ForeName>Geraldo Lucas Lopes</ForeName><Initials>GLL</Initials><Identifier Source=""ORCID"">0009-0002-0794-4605</Identifier><AffiliationInfo><Affiliation>Medical School of the Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, 88040-900, Brazil. gerrard_lucas@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>da Cruz</LastName><ForeName>João Victor Ramos</ForeName><Initials>JVR</Initials><Identifier Source=""ORCID"">0009-0009-3110-931X</Identifier><AffiliationInfo><Affiliation>Medical School of the Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, 88040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Alves</LastName><ForeName>José Roberto</ForeName><Initials>JR</Initials><Identifier Source=""ORCID"">0000-0002-0520-5190</Identifier><AffiliationInfo><Affiliation>Department of Surgery of the Federal University of Santa Catarina, Florianópolis, SC, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>de Oliveira</LastName><ForeName>Saint Clair Vieira</ForeName><Initials>SCV</Initials><Identifier Source=""ORCID"">0000-0002-7565-0724</Identifier><AffiliationInfo><Affiliation>Department of Surgery of the Federal University of Santa Catarina, Florianópolis, SC, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Dos Santos Ribeiro</LastName><ForeName>Leticia Vieira</ForeName><Initials>LV</Initials><Identifier Source=""ORCID"">0009-0001-5934-8488</Identifier><AffiliationInfo><Affiliation>Medical School of the Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, 88040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Gohr</LastName><ForeName>Arthur Henrique</ForeName><Initials>AH</Initials><Identifier Source=""ORCID"">0009-0009-7305-4054</Identifier><AffiliationInfo><Affiliation>Medical School of the Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, 88040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Vieira</LastName><ForeName>Daniella Serafin Couto</ForeName><Initials>DSC</Initials><Identifier Source=""ORCID"">0000-0003-0188-6010</Identifier><AffiliationInfo><Affiliation>Department of Pathology of the Federal University of Santa Catarina, Florianópolis, SC, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType><PublicationType UI=""D000078182"">Systematic Review</PublicationType><PublicationType UI=""D017418"">Meta-Analysis</PublicationType><PublicationType UI=""D016454"">Review</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Gastrointest Cancer</MedlineTA><NlmUniqueID>101479627</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>K16AIQ8CTM</RegistryNumber><NameOfSubstance UI=""C485206"">pertuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI=""D000068878"">Trastuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""D018719"">Receptor, ErbB-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D061067"">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""C508053"">ERBB2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=""D006801"" MajorTopicYN=""N"">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D013274"" MajorTopicYN=""Y"">Stomach Neoplasms</DescriptorName><QualifierName UI=""Q000188"" MajorTopicYN=""N"">drug therapy</QualifierName><QualifierName UI=""Q000401"" MajorTopicYN=""N"">mortality</QualifierName><QualifierName UI=""Q000473"" MajorTopicYN=""N"">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000068878"" MajorTopicYN=""Y"">Trastuzumab</DescriptorName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName><QualifierName UI=""Q000008"" MajorTopicYN=""N"">administration &amp; dosage</QualifierName><QualifierName UI=""Q000494"" MajorTopicYN=""N"">pharmacology</QualifierName><QualifierName UI=""Q000009"" MajorTopicYN=""N"">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D018719"" MajorTopicYN=""Y"">Receptor, ErbB-2</DescriptorName><QualifierName UI=""Q000037"" MajorTopicYN=""N"">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D061067"" MajorTopicYN=""Y"">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName><QualifierName UI=""Q000008"" MajorTopicYN=""N"">administration &amp; dosage</QualifierName><QualifierName UI=""Q000494"" MajorTopicYN=""N"">pharmacology</QualifierName><QualifierName UI=""Q000009"" MajorTopicYN=""N"">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D004938"" MajorTopicYN=""Y"">Esophageal Neoplasms</DescriptorName><QualifierName UI=""Q000188"" MajorTopicYN=""N"">drug therapy</QualifierName><QualifierName UI=""Q000401"" MajorTopicYN=""N"">mortality</QualifierName><QualifierName UI=""Q000473"" MajorTopicYN=""N"">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000971"" MajorTopicYN=""Y"">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName><QualifierName UI=""Q000009"" MajorTopicYN=""N"">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D004943"" MajorTopicYN=""N"">Esophagogastric Junction</DescriptorName><QualifierName UI=""Q000473"" MajorTopicYN=""N"">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">Chemotherapy</Keyword><Keyword MajorTopicYN=""N"">HER-2</Keyword><Keyword MajorTopicYN=""N"">Pertuzumab</Keyword><Keyword MajorTopicYN=""N"">Stomach neoplasms</Keyword><Keyword MajorTopicYN=""N"">Trastuzumab</Keyword></KeywordList><CoiStatement>Declarations. Ethics Approval and Consent to Participate: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40982170</ArticleId><ArticleId IdType=""doi"">10.1007/s12029-025-01310-z</ArticleId><ArticleId IdType=""pii"">10.1007/s12029-025-01310-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinMed. 2022;47:101404. https://doi.org/10.1016/j.eclinm.2022.101404 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.eclinm.2022.101404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3322/caac.21660</ArticleId><ArticleId IdType=""pubmed"">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Soerjomataram I, Cabasag C, Bardot A, Fidler-Benaoudia MM, Miranda-Filho A, Ferlay J, et al. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. Lancet Oncol. 2023;24(1):22–32. https://doi.org/10.1016/S1470-2045(22)00704-5 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(22)00704-5</ArticleId><ArticleId IdType=""pubmed"">36603919</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO International Agency for Research on Cancer (2020) Cancer fact sheets: stomach cancer. GLOBOCAN 2020. Available from:  https://gco.iarc.who.int/factsheets/cancers/stomach . Accessed 10 May 2025</Citation></Reference><Reference><Citation>Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN, et al. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol. 2017;15(1):68. https://doi.org/10.1186/s12957-017-1132-5 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s12957-017-1132-5</ArticleId><ArticleId IdType=""pubmed"">28327158</ArticleId><ArticleId IdType=""pmc"">5359900</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014: 852748. https://doi.org/10.1155/2014/852748 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1155/2014/852748</ArticleId><ArticleId IdType=""pubmed"">25276427</ArticleId><ArticleId IdType=""pmc"">4170925</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22:4619. https://doi.org/10.3748/wjg.v22.i19.4619 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3748/wjg.v22.i19.4619</ArticleId><ArticleId IdType=""pubmed"">27217694</ArticleId><ArticleId IdType=""pmc"">4870069</ArticleId></ArticleIdList></Reference><Reference><Citation>Egebjerg K, Garbyal RS, Hasselby JP, Baeksgaard L, Mau-Sørensen M. Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;161: 103339. https://doi.org/10.1016/j.critrevonc.2021.103339 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.critrevonc.2021.103339</ArticleId><ArticleId IdType=""pubmed"">33865993</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20:120–9. https://doi.org/10.1038/modpathol.3800712 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/modpathol.3800712</ArticleId><ArticleId IdType=""pubmed"">17143264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowryshankar A, Nagaraja V, Eslick GD. HER2 status in Barrett’s esophagus &amp; esophageal cancer: a meta analysis. J Gastrointest Oncol. 2014;5:25–35. https://doi.org/10.3978/j.issn.2078-6891.2013.039 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3978/j.issn.2078-6891.2013.039</ArticleId><ArticleId IdType=""pubmed"">24490040</ArticleId><ArticleId IdType=""pmc"">3904023</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. https://doi.org/10.1016/S0140-6736(10)61121-X .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(10)61121-X</ArticleId><ArticleId IdType=""pubmed"">20728210</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34. https://doi.org/10.1056/NEJMoa1413513 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa1413513</ArticleId><ArticleId IdType=""pubmed"">25693012</ArticleId><ArticleId IdType=""pmc"">5584549</ArticleId></ArticleIdList></Reference><Reference><Citation>Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–30. https://doi.org/10.1016/S1470-2045(18)30904-5 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S1470-2045(18)30904-5</ArticleId><ArticleId IdType=""pubmed"">30857956</ArticleId><ArticleId IdType=""pmc"">6781620</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27:1899–903. https://doi.org/10.1038/s41591-021-01553-w .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41591-021-01553-w</ArticleId><ArticleId IdType=""pubmed"">34764486</ArticleId><ArticleId IdType=""pmc"">8604726</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan YH, Lei XY, Hu WP. Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: a network meta-analysis. Saudi J Gastroenterol. 2022;28:175–85. https://doi.org/10.4103/sjg.sjg_367_21 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.4103/sjg.sjg_367_21</ArticleId><ArticleId IdType=""pubmed"">34747874</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Siddiqui A, et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. 2023;26:123–31. https://doi.org/10.1007/s10120-022-01335-4 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10120-022-01335-4</ArticleId><ArticleId IdType=""pubmed"">36066725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofheinz RD, Merx K, Haag GM, Springfeld C, Ettrich T, Borchert K, et al. FLOT versus FLOT/trastuzumab/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group. J Clin Oncol. 2022;40:3750–61. https://doi.org/10.1200/JCO.22.00380 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.22.00380</ArticleId><ArticleId IdType=""pubmed"">35709415</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1136/bmj.n71</ArticleId><ArticleId IdType=""pubmed"">33782057</ArticleId><ArticleId IdType=""pmc"">8005924</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart L. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1: 2. https://doi.org/10.1186/2046-4053-1-2 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/2046-4053-1-2</ArticleId><ArticleId IdType=""pubmed"">22587842</ArticleId><ArticleId IdType=""pmc"">3348673</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuters T. EndNote® (version X7). Philadelphia: PA, USA; 2013.</Citation></Reference><Reference><Citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.ejca.2008.10.026</ArticleId><ArticleId IdType=""pubmed"">19097774</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC (2019) Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from: www.training.cochrane.org/handbook . Accessed 10 May 2025</Citation></Reference><Reference><Citation>Sterne JAC, Higgins JPT et al (2024) Assessing The Risk Of Bias In Non-randomized Studies – of Interventions, Version 2 (ROBINS-I V2) assessment tool (for follow-up studies). https://www.riskofbias.info/ . Accessed 10 May 2025</Citation></Reference><Reference><Citation>R Foundation for Statistical Computing (2025) R statistical software (version 4.2.3). Available from: https://www.R-project.org . Accessed 10 May 2025</Citation></Reference><Reference><Citation>Integration of Trastuzumab, with or without Pertuzumab, into Perioperative Chemotherapy of HER2-Positive Stomach Cancer: The INNOVATION Trial (EORTC-1203-GITCG). Oncol Res Treat. 2016;39:153–154. https://doi.org/10.1159/000444702 .</Citation></Reference><Reference><Citation>Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof MCCM, van der Woude SO, et al. Phase II feasibility and biomarker study of neoadjuvant Trastuzumab and Pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study. J Clin Oncol. 2020;38:462–71. https://doi.org/10.1200/JCO.19.01814 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.19.01814</ArticleId><ArticleId IdType=""pubmed"">31809243</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30. https://doi.org/10.1002/cncr.11660 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/cncr.11660</ArticleId><ArticleId IdType=""pubmed"">14508841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/1097-0142(19940601)73:11&lt;2680::AID-CNCR2820731105&gt;3.0.CO;2-C</ArticleId><ArticleId IdType=""pubmed"">8194005</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M, Kennedy E, Alarcon-Rozas A, Alcindor T, Bartley A, Malowany A, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023;41(7):1470–91. https://doi.org/10.1200/JCO.22.02331 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.22.02331</ArticleId><ArticleId IdType=""pubmed"">36603169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J, Wang W, Cong D, Bai Y, Zhang W. Development of treatment strategies for advanced HER2-positive gastric cancer: insights from clinical trials. Crit Rev Oncol Hematol. 2025. https://doi.org/10.1016/j.critrevonc.2025.104617 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.critrevonc.2025.104617</ArticleId><ArticleId IdType=""pubmed"">40912589</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartley A, Washington M, Colasacco C, Ventura C, Ismaila N, Benson A, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35(4):446–64. https://doi.org/10.1200/JCO.2016.69.4836 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2016.69.4836</ArticleId><ArticleId IdType=""pubmed"">28129524</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieb B, Agarwal R. HER2-directed therapy in advanced gastric and gastroesophageal adenocarcinoma: triumphs and troubles. Curr Treat Options Oncol. 2021. https://doi.org/10.1007/s11864-021-00884-7 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s11864-021-00884-7</ArticleId><ArticleId IdType=""pubmed"">34424404</ArticleId><ArticleId IdType=""pmc"">8436174</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res. 2011;17:5060–70. https://doi.org/10.1158/1078-0432.CCR-10-2927 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1078-0432.CCR-10-2927</ArticleId><ArticleId IdType=""pubmed"">21700765</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita Y, Yorozu K, Kurasawa M, Fujimoto-Ouchi K. Abstract 3477: Pertuzumab in combination with trastuzumab enhanced the anti-tumor activity in HER2-positive human gastric cancers. Cancer Res. 2010;70(Supp 8):3477. https://doi.org/10.1158/1538-7445.AM10-3477 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1538-7445.AM10-3477</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69:9330–6. https://doi.org/10.1158/0008-5472.CAN-08-4597 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/0008-5472.CAN-08-4597</ArticleId><ArticleId IdType=""pubmed"">19934333</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Qin Y, Li J, Xu R, Xu J, Yang S, et al. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Commun (Lond) 2019;39:38. https://doi.org/10.1186/s40880-019-0384-6 .</Citation></Reference><Reference><Citation>Kang YK, Rha SY, Tassone P, Barriuso J, Yu R, Szado T, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer. 2014;111:660–6. https://doi.org/10.1038/bjc.2014.356 .</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/bjc.2014.356</ArticleId><ArticleId IdType=""pubmed"">24960402</ArticleId><ArticleId IdType=""pmc"">4134501</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:51.860168
pubmed,40979420,,40979420,,Isolated splenic metastasis presenting at diagnosis of HER2-positive ,https://pubmed.ncbi.nlm.nih.gov/40979420/,"Yoshioka Maika, Shimoda Masafumi, Abe Kaori, Masunaga Nanae, Tsukabe Masami, Yoshinami Tetsuhiro, Sota Yoshiaki, Miyake Tomohiro, Tanei Tomonori, Shimazu Kenzo",,"Splenic metastasis is uncommon, and truly isolated splenic metastasis (ISM) from breast cancer is a clinical rarity. Contemporary autopsy series reports splenic involvement in <1% of breast cancer-related deaths, and fewer than 15 well-documented ISM cases have been published. We report a 71-year-old woman presenting with a right-breast mass, regional lymphadenopathy, and a solitary splenic lesion detected on staging computed tomography (CT) and positron emission tomography-CT. Biopsy confirmed hormone receptor-negative, HER2-positive invasive ductal carcinoma. Six cycles of docetaxel, trastuzumab, and pertuzumab led to a 59% reduction in the primary tumour and complete radiological resolution of the splenic lesion. The patient remains progression-free 22 months after initiating therapy, maintained on trastuzumab and pertuzumab. Although extremely rare, ISM can present as the initial manifestation of","<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">40979420</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel=""Electronic-eCollection""><Journal><ISSN IssnType=""Print"">2042-8812</ISSN><JournalIssue CitedMedium=""Print""><Volume>2025</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of surgical case reports</Title><ISOAbbreviation>J Surg Case Rep</ISOAbbreviation></Journal><ArticleTitle>Isolated splenic metastasis presenting at diagnosis of HER2-positive <i>de novo</i> metastatic breast cancer: a case report.</ArticleTitle><Pagination><StartPage>rjaf751</StartPage><MedlinePgn>rjaf751</MedlinePgn></Pagination><ELocationID EIdType=""pii"" ValidYN=""Y"">rjaf751</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1093/jscr/rjaf751</ELocationID><Abstract><AbstractText>Splenic metastasis is uncommon, and truly isolated splenic metastasis (ISM) from breast cancer is a clinical rarity. Contemporary autopsy series reports splenic involvement in &lt;1% of breast cancer-related deaths, and fewer than 15 well-documented ISM cases have been published. We report a 71-year-old woman presenting with a right-breast mass, regional lymphadenopathy, and a solitary splenic lesion detected on staging computed tomography (CT) and positron emission tomography-CT. Biopsy confirmed hormone receptor-negative, HER2-positive invasive ductal carcinoma. Six cycles of docetaxel, trastuzumab, and pertuzumab led to a 59% reduction in the primary tumour and complete radiological resolution of the splenic lesion. The patient remains progression-free 22 months after initiating therapy, maintained on trastuzumab and pertuzumab. Although extremely rare, ISM can present as the initial manifestation of <i>de novo</i> metastatic breast cancer. Awareness of this possibility may facilitate early systemic therapy and obviate the need for diagnostic splenectomy.</AbstractText><CopyrightInformation>© The Author(s) 2025. Published by Oxford University Press and JSCR Publishing Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Yoshioka</LastName><ForeName>Maika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Breast Surgery, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai, Osaka 593-8304, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Shimoda</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Abe</LastName><ForeName>Kaori</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Masunaga</LastName><ForeName>Nanae</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Tsukabe</LastName><ForeName>Masami</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Yoshinami</LastName><ForeName>Tetsuhiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Sota</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Miyake</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Tanei</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Shimazu</LastName><ForeName>Kenzo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Breast and Endocrine Surgery, Graduate School of Medicine, University of Osaka, 2-2-E10 Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D002363"">Case Reports</PublicationType><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Surg Case Rep</MedlineTA><NlmUniqueID>101560169</NlmUniqueID><ISSNLinking>2042-8812</ISSNLinking></MedlineJournalInfo><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">HER2</Keyword><Keyword MajorTopicYN=""N"">breast cancer</Keyword><Keyword MajorTopicYN=""N"">isolated metastasis</Keyword><Keyword MajorTopicYN=""N"">spleen</Keyword></KeywordList><CoiStatement>MS, TY, and KS received honoraria from Chugai. Others have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>8</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40979420</ArticleId><ArticleId IdType=""pmc"">PMC12449763</ArticleId><ArticleId IdType=""doi"">10.1093/jscr/rjaf751</ArticleId><ArticleId IdType=""pii"">rjaf751</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schön  CA, Görg  C, Ramaswamy  A, et al.  Splenic metastases in a large unselected autopsy series. Pathol Res Pract  2006;202:351–6. 10.1016/j.prp.2005.12.008</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.prp.2005.12.008</ArticleId><ArticleId IdType=""pubmed"">16488085</ArticleId></ArticleIdList></Reference><Reference><Citation>Nash  DA  Jr, Sampson  CC. Secondary carcinoma of the spleen. Its incidence in 544 cases and a review of the literature. J Natl Med Assoc  1966;58:442–6.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC2611242</ArticleId><ArticleId IdType=""pubmed"">5979365</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert  LA. The incidence of splenic metastasis of carcinoma. Calif Med  1952;76:281–2.</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC1521229</ArticleId><ArticleId IdType=""pubmed"">14925830</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam  KY, Tang  V. Metastatic tumors to the spleen: a 25-year clinicopathologic study. Arch Pathol Lab Med  2000;124:526–30. 10.5858/2000-124-0526-MTTTS</Citation><ArticleIdList><ArticleId IdType=""doi"">10.5858/2000-124-0526-MTTTS</ArticleId><ArticleId IdType=""pubmed"">10747308</ArticleId></ArticleIdList></Reference><Reference><Citation>Berge  T. Splenic metastases: frequencies and patterns. Acta Pathol Microbiol Scand  1974;82A:499–506. 10.1111/j.1699-0463.1974.tb00379.x</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1111/j.1699-0463.1974.tb00379.x</ArticleId><ArticleId IdType=""pubmed"">4854372</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreca  M, Angelini  D, Gallo  A, et al.  Single asymptomatic splenic metastasis of breast carcinoma. G Chir  2001;22:227–8.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">11515458</ArticleId></ArticleIdList></Reference><Reference><Citation>Iype  S, Akbar  MA, Krishna  G. Isolated splenic metastasis from carcinoma of the breast. Postgrad Med J  2002;78:173–4. 10.1136/pmj.78.917.173</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1136/pmj.78.917.173</ArticleId><ArticleId IdType=""pmc"">PMC1742304</ArticleId><ArticleId IdType=""pubmed"">11884703</ArticleId></ArticleIdList></Reference><Reference><Citation>Iga  M, Robertson  JH, Al-Hejazi  M. A diagnostic mishap: solitary splenic carcinomatous metastases from the breast. Breast J  2009;15:660–1. 10.1111/j.1524-4741.2009.00808.x</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1111/j.1524-4741.2009.00808.x</ArticleId><ArticleId IdType=""pubmed"">19686227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sufficool  KS, Wang  J, Doherty  S. Isolated splenic metastasis from carcinoma of the breast. Diagn Cytopathol  2013;41:914–6. 10.1002/dc.22860</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/dc.22860</ArticleId><ArticleId IdType=""pubmed"">22644993</ArticleId></ArticleIdList></Reference><Reference><Citation>Hironaka  A, Yamaguchi  M, Taiyoh  H, et al.  A case of splenic metastasis after breast cancer surgery. J Jpn Surg Assoc  2014;75:40–4. 10.3919/jjsa.75.40</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3919/jjsa.75.40</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen  Y, Zhang  L, Sun  T, et al.  Solitary splenic metastasis occurring 19 months after treatment for occult breast cancer. Front Oncol  2022;12:957490. 10.3389/fonc.2022.957490</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3389/fonc.2022.957490</ArticleId><ArticleId IdType=""pmc"">PMC9366166</ArticleId><ArticleId IdType=""pubmed"">35965502</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang  S, Vindhya  M, Swagat  D. Isolated distant splenic metastasis in a newly diagnosed case of breast carcinoma detected on 18F-fludeoxyglucose-18 positron emission tomography/computed tomography. Sarvodaya Int J Med  2025;1:28–9. 10.4103/SIJM.SIJM_4_24</Citation><ArticleIdList><ArticleId IdType=""doi"">10.4103/SIJM.SIJM_4_24</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavandi  H, Itani  M, Strnad  B, et al.  A multicenter study of needle size and safety for splenic biopsy. Radiology  2024;310:e230453. 10.1148/radiol.230453</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1148/radiol.230453</ArticleId><ArticleId IdType=""pubmed"">38259204</ArticleId></ArticleIdList></Reference><Reference><Citation>Merloni  F, Palleschi  M, Casadei  C, et al.  Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure. Ther Adv Med Oncol  2023;15:17588359231161412. 10.1177/17588359231161412</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1177/17588359231161412</ArticleId><ArticleId IdType=""pmc"">PMC10026139</ArticleId><ArticleId IdType=""pubmed"">36950272</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:51.961472
pubmed,40976668,,40976668,,Canadian real-world hybrid longitudinal cohort study of treatment discontinuations and modifications for patients with HER2+ and HER2-low metastatic breast cancer on trastuzumab deruxtecan enrolled in a patient support programme: the HER-TEMPO study protocol.,https://pubmed.ncbi.nlm.nih.gov/40976668/,"Brezden-Masley Christine, Qadeer Rana, Senhaji Mouhri Zhor, Salvo Bianca, Bonar Nicolle, Spin Paul, Shokar Simran",,"In current clinical practice, breast cancer is treated according to hormone receptor and human epidermal growth receptor 2 expression (HER2) status, which play an important role in disease management and overall prognosis. Trastuzumab deruxtecan (T-DXd) has been studied in multiple global prospective DESTINY-breast trials. Recent marketing authorisation for T-DXd has been granted from Health Canada for HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine, or at least one prior anti-HER2-based regimen in the metastatic setting, or who have received a prior anti-HER2-based regimen in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy. T-DXd is also indicated for HER2-low unresectable and/or metastatic breast cancer (mBC) patients who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. However, there is a paucity of evidence assessing T-DXd in the real-world setting. As such, the overarching aim of this study is to generate Canadian real-world evidence on discontinuations and treatment modifications for patients with HER2+ and HER2-low mBC undergoing treatment with T-DXd.","<PubmedArticle><MedlineCitation Status=""MEDLINE"" Owner=""NLM"" IndexingMethod=""Curated""><PMID Version=""1"">40976668</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel=""Electronic""><Journal><ISSN IssnType=""Electronic"">2044-6055</ISSN><JournalIssue CitedMedium=""Internet""><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Canadian real-world hybrid longitudinal cohort study of treatment discontinuations and modifications for patients with HER2+ and HER2-low metastatic breast cancer on trastuzumab deruxtecan enrolled in a patient support programme: the HER-TEMPO study protocol.</ArticleTitle><Pagination><StartPage>e100889</StartPage><MedlinePgn>e100889</MedlinePgn></Pagination><ELocationID EIdType=""pii"" ValidYN=""Y"">e100889</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1136/bmjopen-2025-100889</ELocationID><Abstract><AbstractText Label=""BACKGROUND"" NlmCategory=""BACKGROUND"">In current clinical practice, breast cancer is treated according to hormone receptor and human epidermal growth receptor 2 expression (HER2) status, which play an important role in disease management and overall prognosis. Trastuzumab deruxtecan (T-DXd) has been studied in multiple global prospective DESTINY-breast trials. Recent marketing authorisation for T-DXd has been granted from Health Canada for HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine, or at least one prior anti-HER2-based regimen in the metastatic setting, or who have received a prior anti-HER2-based regimen in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy. T-DXd is also indicated for HER2-low unresectable and/or metastatic breast cancer (mBC) patients who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. However, there is a paucity of evidence assessing T-DXd in the real-world setting. As such, the overarching aim of this study is to generate Canadian real-world evidence on discontinuations and treatment modifications for patients with HER2+ and HER2-low mBC undergoing treatment with T-DXd.</AbstractText><AbstractText Label=""METHODS AND ANALYSIS"" NlmCategory=""METHODS"">This is a hybrid, longitudinal cohort study design leveraging patient support programme (PSP) secondary data with additional primary data collection to assess study treatment-related outcomes among patients with HER2+ and HER2-low mBC receiving treatment with T-DXd. Mainly, this study will leverage secondary data from the PSP, which will include clinical and demographic characteristics as well as duration, modification and intensity of treatment information for patients while enrolled in the PSP. These data will be supplemented with primary data, which will be collected via a patient questionnaire and include additional self-reported clinical and demographic characteristics not captured within the PSP, including follow-up data on therapies received, treatment discontinuation information after the PSP closure and frequency of CT scans and cardiac monitoring scans.</AbstractText><AbstractText Label=""ETHICS AND DISSEMINATION"" NlmCategory=""BACKGROUND"">The study protocol was approved by the Advarra Institutional Review Board on 13 December 2023 (ID: D133HR00037). Findings will be disseminated by publication in peer-reviewed journals, through oral and poster presentations for various audiences, websites and scientific meetings. Written informed consent will be obtained from all patients prior to agreeing to participate in this study.</AbstractText><AbstractText Label=""STATUS"" NlmCategory=""UNASSIGNED"">Participant recruitment for primary data collection began on 22 April 2024 and was completed on 8 October 2024. Primary data collection for follow-up will continue through up to 12 months after the date of the last enrolment.</AbstractText><AbstractText Label=""TRIAL REGISTRATION NUMBER"" NlmCategory=""BACKGROUND"">NCT06386263.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Brezden-Masley</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Oncology, Mount Sinai Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Qadeer</LastName><ForeName>Rana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>AstraZeneca Canada Inc, Mississauga, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Senhaji Mouhri</LastName><ForeName>Zhor</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>AstraZeneca Canada Inc, Mississauga, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Salvo</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CRG-EVERSANA Canada Inc, Burlington, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Bonar</LastName><ForeName>Nicolle</ForeName><Initials>N</Initials><Identifier Source=""ORCID"">0009-0000-3070-4664</Identifier><AffiliationInfo><Affiliation>CRG-EVERSANA Canada Inc, Burlington, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Spin</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CRG-EVERSANA Canada Inc, Burlington, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Shokar</LastName><ForeName>Simran</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AstraZeneca Canada Inc, Mississauga, Ontario, Canada simran.shokar@astrazeneca.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN=""Y""><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06386263</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType><PublicationType UI=""D000078325"">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI=""D000068878"">Trastuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""D018719"">Receptor, ErbB-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=""C508053"">ERBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>5384HK7574</RegistryNumber><NameOfSubstance UI=""C000614160"">trastuzumab deruxtecan</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D018796"">Immunoconjugates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=""D000074322"">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>XT3Z54Z28A</RegistryNumber><NameOfSubstance UI=""D002166"">Camptothecin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=""D006801"" MajorTopicYN=""N"">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D001943"" MajorTopicYN=""Y"">Breast Neoplasms</DescriptorName><QualifierName UI=""Q000188"" MajorTopicYN=""N"">drug therapy</QualifierName><QualifierName UI=""Q000473"" MajorTopicYN=""N"">pathology</QualifierName><QualifierName UI=""Q000378"" MajorTopicYN=""N"">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000068878"" MajorTopicYN=""Y"">Trastuzumab</DescriptorName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D005260"" MajorTopicYN=""N"">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D018719"" MajorTopicYN=""Y"">Receptor, ErbB-2</DescriptorName><QualifierName UI=""Q000378"" MajorTopicYN=""N"">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D002170"" MajorTopicYN=""N"" Type=""Geographic"">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D008137"" MajorTopicYN=""N"">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D018796"" MajorTopicYN=""Y"">Immunoconjugates</DescriptorName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D000074322"" MajorTopicYN=""Y"">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI=""Q000627"" MajorTopicYN=""N"">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=""D009362"" MajorTopicYN=""N"">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D008875"" MajorTopicYN=""N"">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=""D002166"" MajorTopicYN=""N"" AutoHM=""Y"">Camptothecin</DescriptorName><QualifierName UI=""Q000031"" MajorTopicYN=""N"">analogs &amp; derivatives</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">Adult oncology</Keyword><Keyword MajorTopicYN=""N"">Breast tumours</Keyword><Keyword MajorTopicYN=""N"">Protocols &amp; guidelines</Keyword></KeywordList><CoiStatement>Competing interests: RQ, ZSM and SS are employees of AstraZeneca Canada and report stock options. CB-M reports consulting fees and honoraria from AstraZeneca Canada. PS, NB and BS are employees of CRG-EVERSANA Canada and report consulting fees from AstraZeneca Canada. CB-M reports speaker honoraria from Astra-Zeneca, Daiichi-Sankyo, Novartis, Knight, Eli Lilly, Gilead Sciences, Merk, BMS and Pfizer; consulting fees from Astra-Zeneca, Daiichi-Sankyo, Novartis, Pfizer, Eli Lily, Beigene, Gilead Sciences, Roche, Knight, BMS and Merk; support for attending meetings from Knight and voluntary board membership for ReThink Breast Cancer and My Gut Feeling.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>21</Day><Hour>21</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40976668</ArticleId><ArticleId IdType=""pmc"">PMC12458746</ArticleId><ArticleId IdType=""doi"">10.1136/bmjopen-2025-100889</ArticleId><ArticleId IdType=""pii"">bmjopen-2025-100889</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Society CC  Breast cancer statistics. 2022. https://cancer.ca/en/cancer-information/cancer-types/breast/statistics Available.</Citation></Reference><Reference><Citation>Brenner DR, Weir HK, Demers AA, et al. Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192:E199–205. doi: 10.1503/cmaj.191292.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1503/cmaj.191292</ArticleId><ArticleId IdType=""pmc"">PMC7055947</ArticleId><ArticleId IdType=""pubmed"">32122974</ArticleId></ArticleIdList></Reference><Reference><Citation>Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288–300. doi: 10.1001/jama.2018.19323.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1001/jama.2018.19323</ArticleId><ArticleId IdType=""pubmed"">30667505</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer NC, Network Guidelines in oncology for breast cancer. v4.2023. 2023</Citation></Reference><Reference><Citation>Simmons C, Rayson D, Joy AA, et al. Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. Ther Adv Med Oncol. 2022;14:17588359211066677. doi: 10.1177/17588359211066677.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1177/17588359211066677</ArticleId><ArticleId IdType=""pmc"">PMC8753087</ArticleId><ArticleId IdType=""pubmed"">35035535</ArticleId></ArticleIdList></Reference><Reference><Citation>deruxtecan T, editor. AstraZeneca. Canada: 2023.</Citation></Reference><Reference><Citation>ESMO  ESMO metastatic breast cancer living guidelines. 2024. https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline/her2-positive-breast-cancer/her2-positive-breast-cancer/first-and-second-lines Available.</Citation></Reference><Reference><Citation>Giuliani S, Ciniselli CM, Leonardi E, et al. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. Virchows Arch. 2016;469:45–50. doi: 10.1007/s00428-016-1940-y.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s00428-016-1940-y</ArticleId><ArticleId IdType=""pubmed"">27097809</ArticleId></ArticleIdList></Reference><Reference><Citation>Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7:1. doi: 10.1038/s41523-020-00208-2.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41523-020-00208-2</ArticleId><ArticleId IdType=""pmc"">PMC7782714</ArticleId><ArticleId IdType=""pubmed"">33397968</ArticleId></ArticleIdList></Reference><Reference><Citation>Viale G, Basik M, Niikura N, et al. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO Open. 2023;8:101615. doi: 10.1016/j.esmoop.2023.101615.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.esmoop.2023.101615</ArticleId><ArticleId IdType=""pmc"">PMC10515285</ArticleId><ArticleId IdType=""pubmed"">37562195</ArticleId></ArticleIdList></Reference><Reference><Citation>Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004;121:631–6. doi: 10.1309/VE78-62V2-646B-R6EX.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1309/VE78-62V2-646B-R6EX</ArticleId><ArticleId IdType=""pubmed"">15151202</ArticleId></ArticleIdList></Reference><Reference><Citation>Schalper KA, Kumar S, Hui P, et al. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med. 2014;138:213–9. doi: 10.5858/arpa.2012-0617-OA.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.5858/arpa.2012-0617-OA</ArticleId><ArticleId IdType=""pubmed"">24164555</ArticleId></ArticleIdList></Reference><Reference><Citation>CADTH  Trastuzumab deruxtecan. 2023. https://www.cda-amc.ca/trastuzumab-deruxtecan-0 Available.</Citation></Reference><Reference><Citation>Curigliano G, Hu X, Dent RA, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06) JCO. 2024;42:LBA1000. doi: 10.1200/JCO.2024.42.17_suppl.LBA1000.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2024.42.17_suppl.LBA1000</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankyo D. ENHERTU granted breakthrough therapy designation in U.S. forcertain patients with her2 low or her2 ultralow metastatic breast cancer. 2024. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202408/20240819_E1.pdf2024 Available.</Citation></Reference><Reference><Citation>Sankyo D. ENHERTU type ii variation application validated by ema for patients with her2 low or her2 ultralow metastatic breast cancer following at least one endocrine therapy. 2024. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202408/20240819_E2.pdf2024 Available.</Citation></Reference><Reference><Citation>Bardia A, Hu X, Dent R, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med . 2024;391:2110–22. doi: 10.1056/NEJMoa2407086.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2407086</ArticleId><ArticleId IdType=""pubmed"">39282896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz SA, Hegg R, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet. 2023;401:105–17. doi: 10.1016/S0140-6736(22)02420-5.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/S0140-6736(22)02420-5</ArticleId><ArticleId IdType=""pubmed"">36495879</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387:9–20. doi: 10.1056/NEJMoa2203690.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2203690</ArticleId><ArticleId IdType=""pmc"">PMC10561652</ArticleId><ArticleId IdType=""pubmed"">35665782</ArticleId></ArticleIdList></Reference><Reference><Citation>Younis T, Skedgel C. Timeliness of the Oncology Drug Review Process for Public Funding in Canada. Curr Oncol. 2017;24:279–81. doi: 10.3747/co.24.3825.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3747/co.24.3825</ArticleId><ArticleId IdType=""pmc"">PMC5659147</ArticleId><ArticleId IdType=""pubmed"">29089793</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoskyn SL. EXPLAINING public reimbursement delays for new medicines for canadian patients. 2020. https://innovativemedicines.ca/wp-content/uploads/2020/07/CADTH-TTL-8.5x11-EN-Final.pdf Available.</Citation></Reference><Reference><Citation>Ding PQ, Dolley A, Cheung WY. Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada. Curr Oncol . 2022;30:130–44. doi: 10.3390/curroncol30010011.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/curroncol30010011</ArticleId><ArticleId IdType=""pmc"">PMC9857321</ArticleId><ArticleId IdType=""pubmed"">36661660</ArticleId></ArticleIdList></Reference><Reference><Citation>Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Guideline IH Integrated addendum to ICH E6 (R1): guideline for good clinical practice E6 (R2) Current Step. 2015;2:1–60.</Citation></Reference><Reference><Citation>Public Policy Committee, International Society of Pharmacoepidemiology Guidelines for good pharmacoepidemiology practice (GPP) Pharmacoepidemiol Drug Saf. 2016;25:2–10. doi: 10.1002/pds.3891.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/pds.3891</ArticleId><ArticleId IdType=""pubmed"">26537534</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:52.044067
pubmed,40973900,,40973900,,Hormone Receptor Expression and QT interval at Baseline Correlate with Trastuzumab Associated Cardiotoxicity in HER2- Positive Breast Cancer Patients: A Prospective Study.,https://pubmed.ncbi.nlm.nih.gov/40973900/,"Abo Samra Dana, Hanafi Ibrahem, Abo Samra Dani, Naeem Ahmad, Dayyoub Assef",,"Trastuzumab is a common and effective therapeutic choice for breast cancer treatment. However, the cardiotoxicity induced by this therapy remains a significant challenge, because we lack predictors that help avoid allocating some patients with high risk to this management plan. This study was aimed to evaluate several baseline risk factors such as prolonged QTc interval, age, and lower expression level of estrogen and progesterone receptors that might predict cardiac toxicity after Trastuzumab therapy. This prospective observational study was conducted in Al-Bairouni Hospital at Damascus University. Patients were evaluated with echocardiography and electrocardiography before therapy and three weeks after the last administration of the fourth cycle. A significant Trastuzumab-related cardiotoxicity was determined by a 5% or more reduction in the left ventricular ejection fraction after excluding all other potential causes. A total number of 140 patients with breast cancer, who were indicated Trastuzumab therapy, were recruited for this study. Thirty of them (21.4%) developed Trastuzumab-related cardiotoxicity but all were asymptomatic. Corrected QT interval of more than 450 ms and lower expression level of estrogen and progesterone receptors at baseline were associated with higher susceptibility to develop Trastuzumab-related cardiotoxicity (P = 0.045, P = 0.004, and P = 0.042, respectively). Of note, preexisting cardiac morbidities, age, and chemotherapy accompanying Trastuzumab administration did not reach significant association with cardiotoxicity. Breast cancer patients with prolonged corrected QT interval or lower expression levels of hormone receptors are at a higher risk of developing Trastuzumab-related cardiotoxicity, necessitating careful administration of the therapy.","<PubmedArticle><MedlineCitation Status=""Publisher"" Owner=""NLM""><PMID Version=""1"">40973900</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel=""Print-Electronic""><Journal><ISSN IssnType=""Electronic"">1559-0259</ISSN><JournalIssue CitedMedium=""Internet""><PubDate><Year>2025</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Cardiovascular toxicology</Title><ISOAbbreviation>Cardiovasc Toxicol</ISOAbbreviation></Journal><ArticleTitle>Hormone Receptor Expression and QT interval at Baseline Correlate with Trastuzumab Associated Cardiotoxicity in HER2- Positive Breast Cancer Patients: A Prospective Study.</ArticleTitle><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1007/s12012-025-10059-7</ELocationID><Abstract><AbstractText>Trastuzumab is a common and effective therapeutic choice for breast cancer treatment. However, the cardiotoxicity induced by this therapy remains a significant challenge, because we lack predictors that help avoid allocating some patients with high risk to this management plan. This study was aimed to evaluate several baseline risk factors such as prolonged QTc interval, age, and lower expression level of estrogen and progesterone receptors that might predict cardiac toxicity after Trastuzumab therapy. This prospective observational study was conducted in Al-Bairouni Hospital at Damascus University. Patients were evaluated with echocardiography and electrocardiography before therapy and three weeks after the last administration of the fourth cycle. A significant Trastuzumab-related cardiotoxicity was determined by a 5% or more reduction in the left ventricular ejection fraction after excluding all other potential causes. A total number of 140 patients with breast cancer, who were indicated Trastuzumab therapy, were recruited for this study. Thirty of them (21.4%) developed Trastuzumab-related cardiotoxicity but all were asymptomatic. Corrected QT interval of more than 450 ms and lower expression level of estrogen and progesterone receptors at baseline were associated with higher susceptibility to develop Trastuzumab-related cardiotoxicity (P = 0.045, P = 0.004, and P = 0.042, respectively). Of note, preexisting cardiac morbidities, age, and chemotherapy accompanying Trastuzumab administration did not reach significant association with cardiotoxicity. Breast cancer patients with prolonged corrected QT interval or lower expression levels of hormone receptors are at a higher risk of developing Trastuzumab-related cardiotoxicity, necessitating careful administration of the therapy.</AbstractText><CopyrightInformation>© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Abo Samra</LastName><ForeName>Dana</ForeName><Initials>D</Initials><Identifier Source=""ORCID"">0000-0003-1076-2634</Identifier><AffiliationInfo><Affiliation>Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Damascus University, Damascus, Syria. Dr.danaabousamra@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Hanafi</LastName><ForeName>Ibrahem</ForeName><Initials>I</Initials><Identifier Source=""ORCID"">0000-0001-5306-0128</Identifier><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Damascus University, Damascus, Syria.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Abo Samra</LastName><ForeName>Dani</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Orthodontics and Dentofacial Orthopaedics, Faculty of Dentistry, Damascus University, Damascus, Syria.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Naeem</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Faculty of Medicine, Damascus University, Damascus, Syria.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Dayyoub</LastName><ForeName>Assef</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Damascus University, Damascus, Syria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Toxicol</MedlineTA><NlmUniqueID>101135818</NlmUniqueID><ISSNLinking>1530-7905</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">Breast Cancer</Keyword><Keyword MajorTopicYN=""N"">Cardiotoxicity</Keyword><Keyword MajorTopicYN=""N"">Herceptin</Keyword><Keyword MajorTopicYN=""N"">Hormone receptors</Keyword><Keyword MajorTopicYN=""N"">QT prolongation</Keyword><Keyword MajorTopicYN=""N"">Trastuzumab</Keyword></KeywordList><CoiStatement>Declarations. Conflict of Interest: The authors declare no competing interests. Ethical Approval: The study was approved by the institutional review board at the faculty of medicine of Damascus University.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2024</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40973900</ArticleId><ArticleId IdType=""doi"">10.1007/s12012-025-10059-7</ArticleId><ArticleId IdType=""pii"">10.1007/s12012-025-10059-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alkabban FM, Ferguson T. Breast Cancer. [Updated 2021 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482286/</Citation></Reference><Reference><Citation>Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., &amp; Cardoso, F. (2019). Breast cancer. Nature Reviews Disease Primers, 5(1), Article 66. https://doi.org/10.1038/s41572-019-0111-2</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41572-019-0111-2</ArticleId><ArticleId IdType=""pubmed"">31548545</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., Shi, W., Jiang, J., Yao, P. P., &amp; Zhu, H. P. (2017). Risk factors and preventions of breast cancer. International Journal of Biological Sciences, 13(11), 1387–1397. https://doi.org/10.7150/ijbs.21635</Citation><ArticleIdList><ArticleId IdType=""doi"">10.7150/ijbs.21635</ArticleId><ArticleId IdType=""pubmed"">29209143</ArticleId><ArticleId IdType=""pmc"">5715522</ArticleId></ArticleIdList></Reference><Reference><Citation>Momenimovahed, Z., &amp; Salehiniya, H. (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press), 10(11), 151–164. https://doi.org/10.2147/BCTT.S176070 . PMID:31040712;PMCID:PMC6462164.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.2147/BCTT.S176070</ArticleId></ArticleIdList></Reference><Reference><Citation>Nwafor, C. C., &amp; Keshinro, S. O. (2015). Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience. Niger Journal of Clinical Practice, 18, 553–558.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.4103/1119-3077.156905</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura, R., Murata, Y., Mori, K., Yamashiro, K., Kuraoka, K., Ichihara, S., Taguchi, K., Suzuki, H., Ito, M., &amp; Yamashita, N. (2018). Evaluation of the HER2 and hormone receptor status in metastatic breast cancer using cell blocks: A multi-institutional study. Acta Cytologica, 62(4), 288–294. https://doi.org/10.1159/000488382</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1159/000488382</ArticleId><ArticleId IdType=""pubmed"">29763896</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., &amp; Ueno, N. T. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Research and Treatment, 136(2), 331–345. https://doi.org/10.1007/s10549-012-2289-9</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10549-012-2289-9</ArticleId><ArticleId IdType=""pubmed"">23073759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee, A., Rajendra, J., Dikshit, R., et al. (2020). HER2 borderline is a negative prognostic factor for primary malignant breast cancer. Breast Cancer Research and Treatment, 181, 225–231. https://doi.org/10.1007/s10549-020-05608-3</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10549-020-05608-3</ArticleId><ArticleId IdType=""pubmed"">32236825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke, T., Reeves, J., Lanigan, A., &amp; Stanton, P. (2001). HER2 as a prognostic and predictive marker for breast cancer. Annals of Oncology, 12(Suppl 1), S23–S28. https://doi.org/10.1093/annonc/12.suppl_1.s23 . PMID: 11521717.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/annonc/12.suppl_1.s23</ArticleId><ArticleId IdType=""pubmed"">11521717</ArticleId></ArticleIdList></Reference><Reference><Citation>Salkeni, M. A., Rizvi, W., Hein, K., &amp; Higa, G. M. (2021). Neu perspectives, therapies, and challenges for metastatic HER2-positive breast cancer. Breast Cancer (Dove Med Press)., 13, 539–557. https://doi.org/10.2147/BCTT.S288344</Citation><ArticleIdList><ArticleId IdType=""doi"">10.2147/BCTT.S288344</ArticleId><ArticleId IdType=""pubmed"">34602823</ArticleId><ArticleId IdType=""pmc"">8481821</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlam, I., &amp; Swain, S. M. (2021). HER2-positive breast cancer and tyrosine kinase inhibitors: The time is now. Npj Breast Cancer, 7(1), 56. https://doi.org/10.1038/s41523-021-00265-1.PMID:34016991;PMCID:PMC8137941</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41523-021-00265-1.PMID:34016991;PMCID:PMC8137941</ArticleId><ArticleId IdType=""pubmed"">34016991</ArticleId><ArticleId IdType=""pmc"">8137941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J., &amp; Xu, B. (2019). Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduction and Targeted Therapy, 4(1), Article 34. https://doi.org/10.1038/s41392-019-0069-2</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41392-019-0069-2</ArticleId><ArticleId IdType=""pubmed"">31637013</ArticleId><ArticleId IdType=""pmc"">6799843</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajria, D., &amp; Chandarlapaty, S. (2011). HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy, 11(2), 263–275. https://doi.org/10.1586/era.10.226</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1586/era.10.226</ArticleId><ArticleId IdType=""pubmed"">21342044</ArticleId><ArticleId IdType=""pmc"">3092522</ArticleId></ArticleIdList></Reference><Reference><Citation>Haq, B., &amp; Geyer, C. E. (2009). Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. Women’s Health, 5(2), 135–147. https://doi.org/10.2217/17455057.5.2.135</Citation><ArticleIdList><ArticleId IdType=""doi"">10.2217/17455057.5.2.135</ArticleId><ArticleId IdType=""pubmed"">19245352</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenblatt, K., &amp; Khaddour, K. (2022). Trastuzumab. Treasure Island (FL): StatPearls Publishing.</Citation></Reference><Reference><Citation>Yu, S., Liu, Q., Han, X., et al. (2017). Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Experimental Hematology &amp; Oncology, 6, 31. https://doi.org/10.1186/s40164-017-0091-4</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s40164-017-0091-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., &amp; Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344(11), 783–792. https://doi.org/10.1056/NEJM200103153441101</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJM200103153441101</ArticleId><ArticleId IdType=""pubmed"">11248153</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanell, J., &amp; Baselga, J. (1999). Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs of Today (Barcelona, Spain), 35(12), 931–946. PMID: 12973420.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1358/dot.1999.35.12.564040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajria, D., &amp; Chandarlapaty, S. (2011). HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy, 11(2), 263–275. https://doi.org/10.1586/era.10.226</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1586/era.10.226</ArticleId><ArticleId IdType=""pubmed"">21342044</ArticleId><ArticleId IdType=""pmc"">3092522</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M., Posner, R. H., Nau, M. M., Dennis, P. A., &amp; Lipkowitz, S. (2001). Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Research, 61(12), 4892–4900.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">11406568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodergren, S. C., Copson, E., White, A., Efficace, F., Sprangers, M., Fitzsimmons, D., Bottomley, A., &amp; Johnson, C. D. (2016). Systematic review of the side effects associated with anti-HER2-targeted therapies used in the treatment of breast cancer, on behalf of the EORTC Quality of Life Group. Targeted Oncology, 11(3), 277–292. https://doi.org/10.1007/s11523-015-0409-2</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s11523-015-0409-2</ArticleId><ArticleId IdType=""pubmed"">26677846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sendur, M. A., Aksoy, S., &amp; Altundag, K. (2013). Cardiotoxicity of novel HER2-targeted therapies. Current Medical Research and Opinion, 29(8), 1015–1024. https://doi.org/10.1185/03007995.2013.807232</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1185/03007995.2013.807232</ArticleId><ArticleId IdType=""pubmed"">23692263</ArticleId></ArticleIdList></Reference><Reference><Citation>Dent, S. F., Morse, A., Burnette, S., Guha, A., &amp; Moore, H. (2021). Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. Current Oncology Reports. https://doi.org/10.1007/s11912-021-01114-x</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s11912-021-01114-x</ArticleId><ArticleId IdType=""pubmed"">34453232</ArticleId><ArticleId IdType=""pmc"">8395382</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., &amp; Bishopric, N. H. (2021). Trastuzumab-induced cardiotoxicity: A review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 188(1), 21–36. https://doi.org/10.1007/s10549-021-06280-x . 2021 Jun 11. PMID: 34115243.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s10549-021-06280-x</ArticleId><ArticleId IdType=""pubmed"">34115243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramin, C., Schaeffer, M. L., Zheng, Z., Connor, A. E., Judith Hoffman-Bolton, A. A., Lau, B., &amp; Visvanathan, K. (2021). All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. JNCI: Journal of the National Cancer Institute, 113(2), 137–145. https://doi.org/10.1093/jnci/djaa096</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/jnci/djaa096</ArticleId><ArticleId IdType=""pubmed"">32634223</ArticleId></ArticleIdList></Reference><Reference><Citation>Keefe, D. L. (2002). Trastuzumab-associated cardiotoxicity. Cancer, 95(7), 1592–1600. https://doi.org/10.1002/cncr.10854.Erratum.In:Cancer.2003Feb15;97(4):1136 . PMID: 12237930.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1002/cncr.10854.Erratum.In:Cancer.2003Feb15;97(4):1136</ArticleId><ArticleId IdType=""pubmed"">12237930</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanriverdi, O., Meydan, N., &amp; Barutca, S. (2012). Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: A pilot study. Medical Oncology, 29(5), 3265–3271. https://doi.org/10.1007/s12032-012-0291-z</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s12032-012-0291-z</ArticleId><ArticleId IdType=""pubmed"">22752572</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, J., Tao, J., Zhai, M., Li, C., Zhou, N., Lv, J., Wang, L., Lin, L., &amp; Bai, R. (2018). Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: Current evidence and future research perspectives. Oncotarget, 9(39), 25738–25749. https://doi.org/10.18632/oncotarget.25008</Citation><ArticleIdList><ArticleId IdType=""doi"">10.18632/oncotarget.25008</ArticleId><ArticleId IdType=""pubmed"">29876021</ArticleId><ArticleId IdType=""pmc"">5986642</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, P. M., &amp; Dybdal, N. (2003). Trastuzumab and cardiac dysfunction: Update on preclinical studies. Seminars in Oncology, 30(5 Suppl 16), 49–53. https://doi.org/10.1053/j.seminoncol.2003.08.007 . PMID: 14613026.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1053/j.seminoncol.2003.08.007</ArticleId><ArticleId IdType=""pubmed"">14613026</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias-Loza, P. A., Muehlfelder, M., &amp; Pelzer, T. (2013). Estrogen and estrogen receptors in cardiovascular oxidative stress. Pflügers Archiv : European Journal of Physiology, 465(5), 739–746. https://doi.org/10.1007/s00424-013-1247-7 . 2013 Feb 17. PMID: 23417608.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s00424-013-1247-7</ArticleId><ArticleId IdType=""pubmed"">23417608</ArticleId></ArticleIdList></Reference><Reference><Citation>Iorga, A., Cunningham, C. M., Moazeni, S., Ruffenach, G., Umar, S., &amp; Eghbali, M. (2017). The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biology of Sex Differences, 8(1), Article 33. https://doi.org/10.1186/s13293-017-0152-8</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s13293-017-0152-8</ArticleId><ArticleId IdType=""pubmed"">29065927</ArticleId><ArticleId IdType=""pmc"">5655818</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan, N., Shen, Y., Endo, Y., ElZarrad, M. K., &amp; Wu, W. J. (2016). Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Molecular Cancer Therapeutics, 15(6), 1321–1331.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1535-7163.MCT-15-0741</ArticleId><ArticleId IdType=""pubmed"">27197303</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine, 353(16), 1659–1672. https://doi.org/10.1056/NEJMoa052306</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa052306</ArticleId><ArticleId IdType=""pubmed"">16236737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, E. K., Cho, J., Kim, J. Y., Chang, S. A., Park, S. J., Choi, J. O., et al. (2019). Early decline in left ventricular ejection fraction can predict trastuzumab-related cardiotoxicity in patients with breast cancer: A study using 13 years of registry data. Cancer Research and Treatment, 51(2), 727–736. https://doi.org/10.4143/crt.2018.262</Citation><ArticleIdList><ArticleId IdType=""doi"">10.4143/crt.2018.262</ArticleId><ArticleId IdType=""pubmed"">30177584</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., et al. (2020). Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. Journal of Clinical Oncology, 38(12), 1346–1366. https://doi.org/10.1200/JCO.19.02309</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.19.02309</ArticleId><ArticleId IdType=""pubmed"">31928404</ArticleId></ArticleIdList></Reference><Reference><Citation>Otterstad, J. E. (2002). Measuring left ventricular volume and ejection fraction with the biplane Simpson’s method. Heart, 88, 559–560.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1136/heart.88.6.559</ArticleId><ArticleId IdType=""pubmed"">12433875</ArticleId><ArticleId IdType=""pmc"">1767457</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlberg, P., Diamant, U. B., Gilljam, T., Rydberg, A., &amp; Bergfeldt, L. (2021). QT correction using Bazett’s formula remains preferable in long QT syndrome type 1 and 2. Annals of Noninvasive Electrocardiology, 26(1), Article e12804. https://doi.org/10.1111/anec.12804</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1111/anec.12804</ArticleId><ArticleId IdType=""pubmed"">33070409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewer, S. M., &amp; Ewer, M. S. (2008). Cardiotoxicity profile of trastuzumab. Drug Safety, 31, 459.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.2165/00002018-200831060-00002</ArticleId><ArticleId IdType=""pubmed"">18484781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowels, E. J., Wellman, R., Feigelson, H. S., et al. (2012). Risk of heart failure in breast cancer patients after anthracycline and tratuzuab treatment: A retrospective cohort study. Journal of the National Cancer Institute, 104, 1293. https://doi.org/10.1093/jnci/djs317</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/jnci/djs317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale, D., Lacopo, W., Cipolla, C., et al. (2020). Cardiotoxicity of Anthracycline. Frontiers in Cardiovascular Medicine, 18(7), 26. https://doi.org/10.3389/fcvm.2020.00026</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3389/fcvm.2020.00026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan, N., Jiang, J., Dokmanovic, M., et al. (2018). Trastuzumab-mediated cardiotoxicity: Current understanding, challenges, and frontiers. Antibody Therapeutics, 1(1), 13–17. https://doi.org/10.1093/abt/tby003</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1093/abt/tby003</ArticleId><ArticleId IdType=""pubmed"">30215054</ArticleId><ArticleId IdType=""pmc"">6131716</ArticleId></ArticleIdList></Reference><Reference><Citation>Levicki, R., Bencic, M., Vranesic, I., et al. (2023). Effects of Trastuzumab and Trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer. The Egyptian Heart Journal, 75, 11. https://doi.org/10.1186/s43044-023-00331-y</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s43044-023-00331-y</ArticleId><ArticleId IdType=""pubmed"">36781707</ArticleId><ArticleId IdType=""pmc"">9925620</ArticleId></ArticleIdList></Reference><Reference><Citation>Na, Xu., Redfern, C., Gordon, M., et al. (2014). Trastuzumab in combination with carboplatine and docetaxel, doesn’t prolong the Qt interval of patients with HER-2 positive metastatic or locally advanced inoperabe solid tumors: Results from a phase Ib study. Cancer Chemotherapy and Pharmacology, 74, 1251–1260.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s00280-014-2603-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Passman, R., &amp; Kadish, A. (2001). Polymorphic ventricular tachycardia, Long Qt syndrom, and torsades de pointes. Medical Clinics of North America, 85, 321–341. https://doi.org/10.1016/s10025-7125(05)70318-7</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/s10025-7125(05)70318-7</ArticleId><ArticleId IdType=""pubmed"">11233951</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, T., Snyders, D., Roden, D. M., et al. (2001). Drug block of I(kr): Model systems and relevance to human arrhythmias. Journal of Cardiovascular Pharmacology, 38(5), 737–744.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1097/00005344-200111000-00010</ArticleId><ArticleId IdType=""pubmed"">11602820</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey, P. P., Barlow, C., &amp; Hart, G. (2000). Prolongation of the QT interval in heart failure occurs at low but not at high heart rates. Clinical Science (London), 98(5), 603–610.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1042/cs0980603</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolo, P. M., Opadijo, O. G., Omotoso, A. B. O., et al. (2008). Prognostic signifigance of QT interval prolongation in adult Nigerians with chronic heart Failure. Nigerian Journal of Clinical Practice., 11, 336–341.</Citation><ArticleIdList><ArticleId IdType=""pubmed"">19320406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunzo, J., Les, D., Sarzczny-Slota, D., et al. (2013). Cardiac side effects of Trastuzumab in breast cancer patients single center experiences. Wspolczesna Onkol, 2, 190–195.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.5114/wo.2013.34624</ArticleId></ArticleIdList></Reference><Reference><Citation>Deroo, B., Korach, K., et al. (2006). Estrogen receptors and human disease. The Journal of Clinical Investigation, 116(3), 561–70. https://doi.org/10.1172/JCI27987</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1172/JCI27987</ArticleId><ArticleId IdType=""pubmed"">16511588</ArticleId><ArticleId IdType=""pmc"">2373424</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidman, A., Hudis, C., Pierri, M. K., et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology, 20, 1215–1221.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2002.20.5.1215</ArticleId><ArticleId IdType=""pubmed"">11870163</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarneri, V., Lenihan, D. J., Valero, V., et al. (2006). Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D Anderson Cancer Center experience. Journal of Clinical Oncology, 24, 4107–4115.</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/JCO.2005.04.9551</ArticleId><ArticleId IdType=""pubmed"">16908934</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:52.170050
pubmed,40972494,,40972494,,Synthesis and evaluation of HOPO-O,https://pubmed.ncbi.nlm.nih.gov/40972494/,"Carbo-Bague Imma, Randhawa Parmissa, Tosato Marianna, McNeil Brooke L, Čolović Milena, London Lucas, Rodríguez-Rodríguez Cristina, Osooly Maryam, Wharton Luke, Merkens Helen, Van De Voorde Michiel, Ooms Maarten, Yang Hua, Bénard François, Ramogida Caterina F",,"The growing availability of new radiometals with favorable decay properties for cancer diagnosis and therapy highlights the need for chelators that can stably bind a variety of metal ions. 1-Hydroxy-2(1H)-pyridinones (1,2-HOPOs) are effective bidentate ligands with strong affinity for trivalent and tetravalent metals. In this study, we developed a bifunctional octadentate 1,2-HOPO chelator with a methyl tetrazine (Me-Tz) moiety, HOPO-O","<PubmedArticle><MedlineCitation Status=""Publisher"" Owner=""NLM""><PMID Version=""1"">40972494</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel=""Print-Electronic""><Journal><ISSN IssnType=""Electronic"">1873-3344</ISSN><JournalIssue CitedMedium=""Internet""><Volume>274</Volume><PubDate><Year>2025</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of inorganic biochemistry</Title><ISOAbbreviation>J Inorg Biochem</ISOAbbreviation></Journal><ArticleTitle>Synthesis and evaluation of HOPO-O<sub>8</sub>-Methyl-tetrazine as a bifunctional chelator for use in [<sup>89</sup>Zr]Zr<sup>4+</sup>, [<sup>161</sup>Tb]Tb<sup>3+</sup> and [<sup>227</sup>Th]Th<sup>4+</sup> radioimmunoconjugates.</ArticleTitle><Pagination><StartPage>113077</StartPage><MedlinePgn>113077</MedlinePgn></Pagination><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1016/j.jinorgbio.2025.113077</ELocationID><ELocationID EIdType=""pii"" ValidYN=""Y"">S0162-0134(25)00257-0</ELocationID><Abstract><AbstractText>The growing availability of new radiometals with favorable decay properties for cancer diagnosis and therapy highlights the need for chelators that can stably bind a variety of metal ions. 1-Hydroxy-2(1H)-pyridinones (1,2-HOPOs) are effective bidentate ligands with strong affinity for trivalent and tetravalent metals. In this study, we developed a bifunctional octadentate 1,2-HOPO chelator with a methyl tetrazine (Me-Tz) moiety, HOPO-O<sub>8</sub>-Me-Tz, and evaluated its coordination to [<sup>89</sup>Zr]Zr<sup>4+</sup>, [<sup>161</sup>Tb]Tb<sup>3+</sup>, and [<sup>227</sup>Th]Th<sup>4+</sup> for theranostic applications. HOPO-O<sub>8</sub>-Me-Tz was conjugated to HER2/neu targeting antibody Trastuzumab (Tmab), modified with transcyclooctene (TCO), using the inverse electron demand Diels-Alder (IEDDA) click reaction to yield HOPO-O<sub>8</sub>-Tmab. Radiolabeled conjugates were synthesized under mild conditions (30 min, ambient temperature) and evaluated in vitro and in vivo in SKOV-3 tumour-bearing nude mice. All radiometal complexes demonstrated high stability in serum over 7 days. In vivo, [<sup>89</sup>Zr]Zr-, [<sup>161</sup>Tb]Tb- and [<sup>227</sup>Th]Th-HOPO-O<sub>8</sub>-Tmab showed high tumour uptake (9.87 ± 3.57, 11.29 ± 4.14 and 19.40 ± 5.40 %ID/g, respectively). Notably, [<sup>161</sup>Tb]Tb- and [<sup>227</sup>Th]Th-conjugates exhibited low bone uptake at 96 h post-injection, indicating excellent in vivo stability. The potential redistribution of the alpha-emitting daughter nuclide [<sup>223</sup>Ra]Ra<sup>2+</sup> from [<sup>227</sup>Th]Th-HOPO-O<sub>8</sub>-Tmab was assessed, revealing elevated <sup>223</sup>Ra in the bone and joint. These findings underscore the promise of HOPO-O<sub>8</sub>-Me-Tz as a versatile bifunctional chelator for next-generation theranostic radioimmunoconjugates, while also highlighting the importance of managing daughter radionuclide redistribution in alpha therapy.</AbstractText><CopyrightInformation>Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Carbo-Bague</LastName><ForeName>Imma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 4Y8, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Randhawa</LastName><ForeName>Parmissa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 4Y8, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Tosato</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 4Y8, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>McNeil</LastName><ForeName>Brooke L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 4Y8, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Čolović</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>London</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 4Y8, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Rodríguez-Rodríguez</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; Department of Physics and Astronomy, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Osooly</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; Department of Physics and Astronomy, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wharton</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Merkens</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Van De Voorde</LastName><ForeName>Michiel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NURA Research Group, Belgian Nuclear Research Center, SCK CEN, 2400 Mol, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Ooms</LastName><ForeName>Maarten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NURA Research Group, Belgian Nuclear Research Center, SCK CEN, 2400 Mol, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Yang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 4Y8, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Bénard</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada; Department of Radiology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Ramogida</LastName><ForeName>Caterina F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 4Y8, Canada; Life Sciences, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada. Electronic address: cfr@sfu.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Inorg Biochem</MedlineTA><NlmUniqueID>7905788</NlmUniqueID><ISSNLinking>0162-0134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">Bifunctional chelator</Keyword><Keyword MajorTopicYN=""N"">Hydroxypyridinone</Keyword><Keyword MajorTopicYN=""N"">Radioimmunoconjugate</Keyword><Keyword MajorTopicYN=""N"">Terbium-161</Keyword><Keyword MajorTopicYN=""N"">Thorium-227</Keyword><Keyword MajorTopicYN=""N"">Trastuzumab</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus=""revised""><Year>2025</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>18</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40972494</ArticleId><ArticleId IdType=""doi"">10.1016/j.jinorgbio.2025.113077</ArticleId><ArticleId IdType=""pii"">S0162-0134(25)00257-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:52.249507
pubmed,40969887,,40969887,,"Correction to: ""Shifting the Antibody-Drug Conjugate Paradigm: A Trastuzumab-Gold-Based Conjugate Demonstrates High Efficacy Against Human Epidermal Growth Factor Receptor 2‑Positive Breast Cancer Mouse Model"".",https://pubmed.ncbi.nlm.nih.gov/40969887/,"Ahad Afruja, K Saeed Hiwa, Del Solar Virginia, López-Hernández Javier E, Michel Alexa, Mathew Joshua, Lewis Jason S, Contel Maria",,[This corrects the article DOI: 10.1021/acsptsci.3c00270.].,"<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">40969887</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel=""Electronic-eCollection""><Journal><ISSN IssnType=""Electronic"">2575-9108</ISSN><JournalIssue CitedMedium=""Internet""><Volume>8</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>ACS pharmacology &amp; translational science</Title><ISOAbbreviation>ACS Pharmacol Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Correction to: ""Shifting the Antibody-Drug Conjugate Paradigm: A Trastuzumab-Gold-Based Conjugate Demonstrates High Efficacy Against Human Epidermal Growth Factor Receptor 2‑Positive Breast Cancer Mouse Model"".</ArticleTitle><Pagination><StartPage>3389</StartPage><EndPage>3390</EndPage><MedlinePgn>3389-3390</MedlinePgn></Pagination><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1021/acsptsci.5c00539</ELocationID><Abstract><AbstractText>[This corrects the article DOI: 10.1021/acsptsci.3c00270.].</AbstractText><CopyrightInformation>© 2025 American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Ahad</LastName><ForeName>Afruja</ForeName><Initials>A</Initials><Identifier Source=""ORCID"">0009-0007-3887-9363</Identifier></Author><Author ValidYN=""Y""><LastName>K Saeed</LastName><ForeName>Hiwa</ForeName><Initials>H</Initials><Identifier Source=""ORCID"">0000-0002-5430-3942</Identifier></Author><Author ValidYN=""Y""><LastName>Del Solar</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Author><Author ValidYN=""Y""><LastName>López-Hernández</LastName><ForeName>Javier E</ForeName><Initials>JE</Initials></Author><Author ValidYN=""Y""><LastName>Michel</LastName><ForeName>Alexa</ForeName><Initials>A</Initials></Author><Author ValidYN=""Y""><LastName>Mathew</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Author><Author ValidYN=""Y""><LastName>Lewis</LastName><ForeName>Jason S</ForeName><Initials>JS</Initials><Identifier Source=""ORCID"">0000-0001-7065-4534</Identifier></Author><Author ValidYN=""Y""><LastName>Contel</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source=""ORCID"">0000-0002-9825-4441</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016425"">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Pharmacol Transl Sci</MedlineTA><NlmUniqueID>101721411</NlmUniqueID><ISSNLinking>2575-9108</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType=""ErratumFor""><RefSource>ACS Pharmacol Transl Sci. 2023 Nov 22;6(12):1972-1986. doi: 10.1021/acsptsci.3c00270.</RefSource><PMID Version=""1"">38093840</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus=""revised""><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>5</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40969887</ArticleId><ArticleId IdType=""pmc"">PMC12441859</ArticleId><ArticleId IdType=""doi"">10.1021/acsptsci.5c00539</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:52.328390
pubmed,40969261,,40969261,,Case Report: Trastuzumab deruxtecan plus toripalimab in ERBB2-amplified cervical mucosal melanoma.,https://pubmed.ncbi.nlm.nih.gov/40969261/,"Wang Xiao-Xia, Wang Min-Xin, Sui Chao",,"Cervical mucosal melanoma is a rare, aggressive malignancy with poor prognosis due to delayed diagnosis and limited treatment efficacy. Current therapies, including immune checkpoint inhibitors (e.g., anti-PD-1 agents), chemotherapy, and targeted therapies, yield suboptimal response rates (<30%) and frequent resistance. Here, we report the first case of HER2-positive cervical mucosal melanoma successfully treated with T-DXd combined with Toripalimab. This combination induced significant tumor shrinkage (partial response) and demonstrated safety, highlighting the potential of ADC-based cross-tumor therapies and immune-targeted synergy. These findings support further clinical trials to validate this strategy in mucosal melanoma, addressing unmet needs in this refractory subtype.","<PubmedArticle><MedlineCitation Status=""PubMed-not-MEDLINE"" Owner=""NLM""><PMID Version=""1"">40969261</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel=""Electronic-eCollection""><Journal><ISSN IssnType=""Print"">2234-943X</ISSN><JournalIssue CitedMedium=""Print""><Volume>15</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>Case Report: Trastuzumab deruxtecan plus toripalimab in ERBB2-amplified cervical mucosal melanoma.</ArticleTitle><Pagination><StartPage>1625521</StartPage><MedlinePgn>1625521</MedlinePgn></Pagination><ELocationID EIdType=""pii"" ValidYN=""Y"">1625521</ELocationID><ELocationID EIdType=""doi"" ValidYN=""Y"">10.3389/fonc.2025.1625521</ELocationID><Abstract><AbstractText>Cervical mucosal melanoma is a rare, aggressive malignancy with poor prognosis due to delayed diagnosis and limited treatment efficacy. Current therapies, including immune checkpoint inhibitors (e.g., anti-PD-1 agents), chemotherapy, and targeted therapies, yield suboptimal response rates (&lt;30%) and frequent resistance. Here, we report the first case of HER2-positive cervical mucosal melanoma successfully treated with T-DXd combined with Toripalimab. This combination induced significant tumor shrinkage (partial response) and demonstrated safety, highlighting the potential of ADC-based cross-tumor therapies and immune-targeted synergy. These findings support further clinical trials to validate this strategy in mucosal melanoma, addressing unmet needs in this refractory subtype.</AbstractText><CopyrightInformation>Copyright © 2025 Wang, Wang and Sui.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Wang</LastName><ForeName>Xiao-Xia</ForeName><Initials>XX</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Central Hospital Affiliated to Qingdao University, Weihai, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wang</LastName><ForeName>Min-Xin</ForeName><Initials>MX</Initials><AffiliationInfo><Affiliation>Department of Ultrasound, Weihai Central Hospital Affiliated to Qingdao University, Weihai, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Sui</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Central Hospital Affiliated to Qingdao University, Weihai, Shandong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D002363"">Case Reports</PublicationType><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">HER2-positive tumors</Keyword><Keyword MajorTopicYN=""N"">cervical mucosal melanoma</Keyword><Keyword MajorTopicYN=""N"">genomic profiling</Keyword><Keyword MajorTopicYN=""N"">toripalimab</Keyword><Keyword MajorTopicYN=""N"">trastuzumab deruxtecan (T-DXd)</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pmc-release""><Year>2025</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40969261</ArticleId><ArticleId IdType=""pmc"">PMC12440719</ArticleId><ArticleId IdType=""doi"">10.3389/fonc.2025.1625521</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ma Y, Xia R, Ma X, Judson-Torres RL, Zeng H. Mucosal melanoma: pathological evolution, pathway dependency and targeted therapy. Front Oncol. (2021) 11:702287. doi:  10.3389/fonc.2021.702287, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3389/fonc.2021.702287</ArticleId><ArticleId IdType=""pmc"">PMC8327265</ArticleId><ArticleId IdType=""pubmed"">34350118</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacastacas JD, Bray J, Cohen YK, Arbesman J, Kim J, Koon HB, et al. Update on primary mucosal melanoma. J Am Acad Dermatol. (2014) 71:366–75. doi:  10.1016/j.jaad.2014.03.031, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.jaad.2014.03.031</ArticleId><ArticleId IdType=""pubmed"">24815565</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol. (2020) 61:139–48. doi:  10.1016/j.semcancer.2019.09.013, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.semcancer.2019.09.013</ArticleId><ArticleId IdType=""pmc"">PMC7078020</ArticleId><ArticleId IdType=""pubmed"">31655118</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng X, Yan X, Chi Z, Si L, Cui C, Tang B, et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G(4) monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial. J Clin Oncol. (2019) 37:2987–99. doi:  10.1200/jco.19.00210, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1200/jco.19.00210</ArticleId><ArticleId IdType=""pmc"">PMC6839911</ArticleId><ArticleId IdType=""pubmed"">31403867</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian B, Li Z, Wu N, Li M, Chen X, Zheng H, et al. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Ann Oncol. (2024) 35:211–20. doi:  10.1016/j.annonc.2023.10.793, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2023.10.793</ArticleId><ArticleId IdType=""pubmed"">37956739</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian B, Si L, Chi ZH, Sheng XN, Kong Y, Wang X, et al. Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. Ann Oncol. (2022) 33:1061–70. doi:  10.1016/j.annonc.2022.07.002, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2022.07.002</ArticleId><ArticleId IdType=""pubmed"">35842199</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. (2022) 387:9–20. doi:  10.1056/NEJMoa2203690, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2203690</ArticleId><ArticleId IdType=""pmc"">PMC10561652</ArticleId><ArticleId IdType=""pubmed"">35665782</ArticleId></ArticleIdList></Reference><Reference><Citation>Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. (2022) 386:241–51. doi:  10.1056/NEJMoa2112431, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1056/NEJMoa2112431</ArticleId><ArticleId IdType=""pmc"">PMC9066448</ArticleId><ArticleId IdType=""pubmed"">34534430</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. (2017) 18:1512–22. doi:  10.1016/s1470-2045(17)30604-6, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/s1470-2045(17)30604-6</ArticleId><ArticleId IdType=""pubmed"">29037983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. (2023) 401:105–17. doi:  10.1016/s0140-6736(22)02420-5, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/s0140-6736(22)02420-5</ArticleId><ArticleId IdType=""pubmed"">36495879</ArticleId></ArticleIdList></Reference><Reference><Citation>Keam SJ. Toripalimab: first global approval. Drugs. (2019) . 79:573–8. doi:  10.1007/s40265-019-01076-2, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s40265-019-01076-2</ArticleId><ArticleId IdType=""pubmed"">30805896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Yang KW, Zhang S, Yan XQ, Li SM, Xu HY, et al. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study. Ann Oncol. (2025) 36:331–9. doi:  10.1016/j.annonc.2024.12.002, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.annonc.2024.12.002</ArticleId><ArticleId IdType=""pubmed"">39662628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. (2024) 68:102415. doi:  10.1016/j.eclinm.2023.102415, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.eclinm.2023.102415</ArticleId><ArticleId IdType=""pmc"">PMC10789637</ArticleId><ArticleId IdType=""pubmed"">38235421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes Macêdo M, Assunção Ribeiro da Costa RE, Amaral Dos Reis C, Da Silva Júnior RG, Oliveira Pires A, Vieira SC. Disease progression and death from cervical melanoma in a patient undergoing nivolumab therapy: A case report. Cureus. (2024) 16:e52811. doi:  10.7759/cureus.52811, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.7759/cureus.52811</ArticleId><ArticleId IdType=""pmc"">PMC10883749</ArticleId><ArticleId IdType=""pubmed"">38389591</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan Z, Liu F. Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes. Front Immunol. (2024) 15:1441410. doi:  10.3389/fimmu.2024.1441410, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3389/fimmu.2024.1441410</ArticleId><ArticleId IdType=""pmc"">PMC11373357</ArticleId><ArticleId IdType=""pubmed"">39234260</ArticleId></ArticleIdList></Reference><Reference><Citation>Smart AC, Giobbie-Hurder A, Desai V, Xing JL, Lukens JN, Taunk NK, et al. Multicenter evaluation of radiation and immune checkpoint inhibitor therapy in mucosal melanoma and review of recent literature. Adv Radiat Oncol. (2024) 9:101310. doi:  10.1016/j.adro.2023.101310, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.adro.2023.101310</ArticleId><ArticleId IdType=""pmc"">PMC10801653</ArticleId><ArticleId IdType=""pubmed"">38260223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Zhang J, Guo J, Si L, Bai X. Evolving treatment approaches to mucosal melanoma. Curr Oncol Rep. (2022) 24:1261–71. doi:  10.1007/s11912-022-01225-z, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s11912-022-01225-z</ArticleId><ArticleId IdType=""pubmed"">35511393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wehbe J, Jaikaransingh D, Walker A. Immunotherapy as a treatment modality for mucosal melanoma of the head and neck: A systematic review. Med (Baltimore). (2022) 101:e29979. doi:  10.1097/md.0000000000029979, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1097/md.0000000000029979</ArticleId><ArticleId IdType=""pmc"">PMC9351848</ArticleId><ArticleId IdType=""pubmed"">35945708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai ZL, Yang HT, Huang T, Yu ZR, Ren N, Su JY, et al. Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials. Am J Cancer Res. (2023) 13:3266–74., PMID:</Citation><ArticleIdList><ArticleId IdType=""pmc"">PMC10492104</ArticleId><ArticleId IdType=""pubmed"">37693138</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlam I, Tolaney SM, Tarantino P. The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. Expert Rev Anticancer Ther. (2024) 24:1059–66. doi:  10.1080/14737140.2023.2171993, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1080/14737140.2023.2171993</ArticleId><ArticleId IdType=""pubmed"">36691884</ArticleId></ArticleIdList></Reference><Reference><Citation>Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. (2024) 30:1933–42. doi:  10.1038/s41591-024-02992-x, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41591-024-02992-x</ArticleId><ArticleId IdType=""pmc"">PMC11271396</ArticleId><ArticleId IdType=""pubmed"">38745009</ArticleId></ArticleIdList></Reference><Reference><Citation>Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, et al. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. (2024) 25:707–19. doi:  10.1016/s1470-2045(24)00140-2, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/s1470-2045(24)00140-2</ArticleId><ArticleId IdType=""pubmed"">38710187</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrikopoulou A, Zagouri F, Goula K, Haidopoulos D, Thomakos N, Svarna A, et al. Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological Malignancies. BMC Cancer. (2024) 24:1503. doi:  10.1186/s12885-024-13226-1, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s12885-024-13226-1</ArticleId><ArticleId IdType=""pmc"">PMC11622448</ArticleId><ArticleId IdType=""pubmed"">39639215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Febres-Aldana CA, Liu Z, Dix JM, Cheng R, Dematteo RG, et al. HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor. Clin Cancer Res. (2024) 30:4701–13. doi:  10.1158/1078-0432.ccr-24-1835, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1078-0432.ccr-24-1835</ArticleId><ArticleId IdType=""pmc"">PMC11479846</ArticleId><ArticleId IdType=""pubmed"">39120576</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolfo C, Del Re M, Russo A. Empower the potential of trastuzumab deruxtecan with novel combinations. Clin Cancer Res. (2023) 29:4317–9. doi:  10.1158/1078-0432.ccr-23-1700, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1078-0432.ccr-23-1700</ArticleId><ArticleId IdType=""pubmed"">37656059</ArticleId></ArticleIdList></Reference><Reference><Citation>Odintsov I, Makarem M, Nishino M, Bachert SE, Zhang T, LoPiccolo J, et al. Prevalence and therapeutic targeting of high-level ERBB2 amplification in NSCLC. J Thorac Oncol. (2024) 19:732–48. doi:  10.1016/j.jtho.2023.12.019, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.jtho.2023.12.019</ArticleId><ArticleId IdType=""pmc"">PMC11957432</ArticleId><ArticleId IdType=""pubmed"">38154514</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra A, Chandarlapaty S, Modi S. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nat Rev Clin Oncol. (2024) 21:185–202. doi:  10.1038/s41571-023-00849-9, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1038/s41571-023-00849-9</ArticleId><ArticleId IdType=""pmc"">PMC12327481</ArticleId><ArticleId IdType=""pubmed"">38191924</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukov WR, Zhou J, Geiersbach KB, Keeney GL, Carter JM, Schoolmeester JK. Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma. Hum Pathol. (2023) 137:94–101. doi:  10.1016/j.humpath.2023.04.009, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.humpath.2023.04.009</ArticleId><ArticleId IdType=""pubmed"">37094656</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín M, Pandiella A, Vargas-Castrillón E, Díaz-Rodríguez E, Iglesias-Hernangómez T, Martínez Cano C, et al. Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol. (2024) 198:104355. doi:  10.1016/j.critrevonc.2024.104355, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.critrevonc.2024.104355</ArticleId><ArticleId IdType=""pubmed"">38621469</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue H, Xu H, Ma L, Li X, Yang B, Wang X, et al. A DXd/TLR7-agonist dual-conjugate anti-HER2 ADC exerts robust antitumor activity through tumor cell killing and immune activation. Mol Cancer Ther. (2024) 23:1639–51. doi:  10.1158/1535-7163.mct-24-0078, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1535-7163.mct-24-0078</ArticleId><ArticleId IdType=""pubmed"">39082754</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KS, Nam AR, Bang JH, Jeong Y, Choo SY, Kim HJ, et al. Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells. Cell Commun Signal: CCS. (2024) 22:518. doi:  10.1186/s12964-024-01893-3, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1186/s12964-024-01893-3</ArticleId><ArticleId IdType=""pmc"">PMC11515331</ArticleId><ArticleId IdType=""pubmed"">39449023</ArticleId></ArticleIdList></Reference><Reference><Citation>Waliany S, Wakelee H, Ramchandran K, Das M, Huang J, Myall N, et al. Characterization of ERBB2 (HER2) alterations in metastatic non-small cell lung cancer and comparison of outcomes of different trastuzumab-based regimens. Clin Lung Cancer. (2022) 23:498–509. doi:  10.1016/j.cllc.2022.05.015, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1016/j.cllc.2022.05.015</ArticleId><ArticleId IdType=""pubmed"">35753988</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh H, Sahgal P, Kapner K, Corsello SM, Gupta H, Gujrathi R, et al. RAS/RAF comutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer. Clin Cancer Res. (2024) 30:1669–84. doi:  10.1158/1078-0432.ccr-23-2581, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1158/1078-0432.ccr-23-2581</ArticleId><ArticleId IdType=""pmc"">PMC11018475</ArticleId><ArticleId IdType=""pubmed"">38345769</ArticleId></ArticleIdList></Reference><Reference><Citation>Dealberti D, Bosoni D, Spissu F, Pisani C, Pizio C, Nappi L, et al. Primary Malignant melanoma of the endocervix uteri and outpatient hysteroscopy as a diagnostic tool: case report and literature overview. Dis (Basel Switzerland). (2024) 12:126. doi:  10.3390/diseases12060126, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.3390/diseases12060126</ArticleId><ArticleId IdType=""pmc"">PMC11203048</ArticleId><ArticleId IdType=""pubmed"">38920558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, et al. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. (2024) 73:60. doi:  10.1007/s00262-024-03635-3, PMID:</Citation><ArticleIdList><ArticleId IdType=""doi"">10.1007/s00262-024-03635-3</ArticleId><ArticleId IdType=""pmc"">PMC10894093</ArticleId><ArticleId IdType=""pubmed"">38400933</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>",2025-09-28T10:26:52.510743
pubmed,40968745,,40968745,,"Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study.",https://pubmed.ncbi.nlm.nih.gov/40968745/,"Xiao Zhi, Chen Feiyu, Liao Liqiu, Luo Shayang, Liu Xuan, Liu Xiangyan, Xu Tao, Hu Yu, Luo Na, Wang Wenlong, Cao Jing, Wang Kuansong, Zhou Haiyan, Ding Nianhua, Li Yan, Huang Juan, Wang Shouman",,"To evaluate the efficacy and safety of a chemotherapy-free regimen consisting of monoclonal antibody trastuzumab, tyrosine kinase inhibitor pyrotinib and CDK4/6 inhibitor dalpiciclib in patients with hormone receptor-negative/HER2-positive (HR-HER2 +) early breast cancer (EBC).","<PubmedArticle><MedlineCitation Status=""Publisher"" Owner=""NLM""><PMID Version=""1"">40968745</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel=""Print-Electronic""><Journal><ISSN IssnType=""Electronic"">1743-9159</ISSN><JournalIssue CitedMedium=""Internet""><PubDate><Year>2025</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study.</ArticleTitle><ELocationID EIdType=""doi"" ValidYN=""Y"">10.1097/JS9.0000000000003328</ELocationID><Abstract><AbstractText Label=""BACKGROUND"" NlmCategory=""BACKGROUND"">To evaluate the efficacy and safety of a chemotherapy-free regimen consisting of monoclonal antibody trastuzumab, tyrosine kinase inhibitor pyrotinib and CDK4/6 inhibitor dalpiciclib in patients with hormone receptor-negative/HER2-positive (HR-HER2 +) early breast cancer (EBC).</AbstractText><AbstractText Label=""MATERIALS AND METHODS"" NlmCategory=""METHODS"">This open-label, single-arm, phase II study was designed using the Simon two-stage method (Chi-CTR-2 200 060 748). Patients with operable HR-HER2 + EBC (T1-3 and N0-2) were enrolled. Eligible patients received trastuzumab (HLX02, 8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks intravenously), pyrotinib (400 mg daily orally) and dalpiciclib (125 mg daily orally for 3 weeks, followed by 1 week off) for 16 weeks. Surgery was performed 3-6 weeks after the completion of drug treatment. The primary endpoint was total pathological complete response (tpCR, ypT0/Tis, ypN0) rates at surgery, and secondary endpoints included breast pCR (bpCR) rates (ypT0/Tis), residual cancer burden (RCB), objective response rate (ORR), change of Ki-67 scores, survival and safety.</AbstractText><AbstractText Label=""RESULTS"" NlmCategory=""RESULTS"">Between Jun, 2022, and Jun, 2024, a total of 34 patients with a median age of 55 years (range: 35-67) were enrolled. 30 patients received all cycles of treatment and underwent surgery with a median follow-up of 20 months. The tpCR was achieved in 19 patients (63.3%; 95% CI, 45.5-78.1%). The bpCR was 66.7% (20/30). The number of patients with RCB-0 or RCB-I was 22 (73.3%). The most common Grade 3 treatment-related adverse events were diarrhea (50.0%), neutropenia (20.6%), and leukopenia (17.7%). No Grade 4 events or treatment-related deaths occurred.</AbstractText><AbstractText Label=""CONCLUSION"" NlmCategory=""CONCLUSIONS"">In patients with HR-HER2 + EBC, the neoadjuvant therapy with trastuzumab, pyrotinib and dalpiciclib has promising activity and manageable toxicity. Further investigation is needed.</AbstractText><CopyrightInformation>Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN=""Y""><Author ValidYN=""Y""><LastName>Xiao</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Chen</LastName><ForeName>Feiyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Liao</LastName><ForeName>Liqiu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Luo</LastName><ForeName>Shayang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Liu</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The First People's Hospital of Xiangtan City, Xiangtan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Liu</LastName><ForeName>Xiangyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Xu</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>ShaoYang Central Hospital, Shaoyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Hu</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Luo</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wang</LastName><ForeName>Wenlong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Cao</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wang</LastName><ForeName>Kuansong</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Zhou</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Ding</LastName><ForeName>Nianhua</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Changsha Medical University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Huang</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=""Y""><LastName>Wang</LastName><ForeName>Shouman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Breast Cancer in Hunan Province, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=""D016428"">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=""Electronic""><Year>2025</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=""NOTNLM""><Keyword MajorTopicYN=""N"">HR-negative/HER2-positive breast cancer</Keyword><Keyword MajorTopicYN=""N"">chemotherapy-free</Keyword><Keyword MajorTopicYN=""N"">dalpiciclib</Keyword><Keyword MajorTopicYN=""N"">neoadjuvant therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=""received""><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=""accepted""><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus=""medline""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus=""pubmed""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus=""entrez""><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=""pubmed"">40968745</ArticleId><ArticleId IdType=""doi"">10.1097/JS9.0000000000003328</ArticleId><ArticleId IdType=""pii"">01279778-990000000-03270</ArticleId></ArticleIdList></PubmedData></PubmedArticle>",2025-09-28T10:26:52.722214
crossref,10.1002/14651858.cd003917,10.1002/14651858.cd003917,,,Cardioprotective interventions for cancer patients receiving anthracyclines,https://doi.org/10.1002/14651858.cd003917,"Van Dalen, Kremer",,,"{'indexed': {'date-parts': [[2024, 9, 4]], 'date-time': '2024-09-04T16:55:49Z', 'timestamp': 1725468949334}, 'publisher-location': 'Chichester, UK', 'reference-count': 0, 'publisher': 'John Wiley & Sons, Ltd', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.1002/14651858.cd003917', 'type': 'reference-entry', 'created': {'date-parts': [[2003, 11, 21]], 'date-time': '2003-11-21T17:16:55Z', 'timestamp': 1069435015000}, 'source': 'Crossref', 'is-referenced-by-count': 5, 'title': ['Cardioprotective interventions for cancer patients receiving anthracyclines'], 'prefix': '10.1002', 'author': [{'given': 'EC', 'family': 'Van Dalen', 'sequence': 'first', 'affiliation': []}, {'given': 'LCM', 'family': 'Kremer', 'sequence': 'additional', 'affiliation': []}], 'member': '311', 'published-online': {'date-parts': [[2002, 7, 22]]}, 'container-title': ['Cochrane Database of Systematic Reviews'], 'language': 'en', 'link': [{'URL': 'https://onlinelibrary.wiley.com/doi/full/10.1002/14651858.CD003917', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2021, 8, 9]], 'date-time': '2021-08-09T17:27:40Z', 'timestamp': 1628530060000}, 'score': 44.184387, 'resource': {'primary': {'URL': 'https://doi.wiley.com/10.1002/14651858.CD003917'}}, 'issued': {'date-parts': [[2002, 7, 22]]}, 'references-count': 0, 'URL': 'https://doi.org/10.1002/14651858.cd003917', 'ISSN': ['1465-1858'], 'issn-type': [{'type': 'electronic', 'value': '1465-1858'}], 'published': {'date-parts': [[2002, 7, 22]]}}",2025-09-28T10:26:57.029723
crossref,10.1002/cam4.4929,10.1002/cam4.4929,,,Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines,https://doi.org/10.1002/cam4.4929,"Ishii, Watanabe, Higashi",,"AbstractBackgroundAlthough trastuzumab and anthracyclines are frequently used to treat breast cancer (BC) and gastric cancer (GC), cardiotoxicity is a serious concern. The cardiac function assessment is recommended at baseline before initiating treatment. However, the prevalence rates of baseline cardiac checkups are unknown.MethodsThe national database of hospital‐based cancer registries linked to the health services‐utilization data was used to study patients with newly diagnosed stage IV BC and GC (n = 6271) who received trastuzumab (n = 4324, 69.0%) or anthracyclines between January 2012 and December 2015. The baseline ultrasound echocardiogram (UCG) performance rate and factors related to adequate UCG performance for all patients and those receiving trastuzumab were analyzed.ResultsThe adequate baseline UCG checkup rate was higher in patients treated with trastuzumab than in those treated with anthracyclines (71.8% vs 44.1%, respectively). Additionally, patients with GC were less likely to receive an adequate baseline UCG performance than those with BC (70.4% vs 75.0%, respectively). After adjusting for potential confounders, patients with anthracycline‐treated BC and GC were less likely to receive adequate baseline UCG performance than those with trastuzumab‐treated BC (odds ratio [OR]: 0.24, 95% confidence interval [CI]: 0.20–0.28, and OR: 0.07, 95% CI: 0.03–0.16, respectively). Furthermore, patients with trastuzumab‐treated GC were less likely to receive adequate baseline UCG performance than those with BC (OR: 0.65, 95% CI: 0.50–0.84).ConclusionsThe baseline UCG was less likely to be performed in patients receiving anthracyclines than in those receiving trastuzumab, as well as in patients with GC than in those with BC.","{'indexed': {'date-parts': [[2025, 5, 13]], 'date-time': '2025-05-13T14:40:06Z', 'timestamp': 1747147206461, 'version': '3.40.5'}, 'reference-count': 31, 'publisher': 'Wiley', 'issue': '1', 'license': [{'start': {'date-parts': [[2022, 6, 11]], 'date-time': '2022-06-11T00:00:00Z', 'timestamp': 1654905600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'short-container-title': ['Cancer Medicine'], 'published-print': {'date-parts': [[2023, 1]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Although trastuzumab and anthracyclines are frequently used to treat breast cancer (BC) and gastric cancer (GC), cardiotoxicity is a serious concern. The cardiac function assessment is recommended at baseline before initiating treatment. However, the prevalence rates of baseline cardiac checkups are unknown.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The national database of hospital‐based cancer registries linked to the health services‐utilization data was used to study patients with newly diagnosed stage IV BC and GC (<jats:italic>n</jats:italic>\xa0=\xa06271) who received trastuzumab (<jats:italic>n</jats:italic>\xa0=\xa04324, 69.0%) or anthracyclines between January 2012 and December 2015. The baseline ultrasound echocardiogram (UCG) performance rate and factors related to adequate UCG performance for all patients and those receiving trastuzumab were analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The adequate baseline UCG checkup rate was higher in patients treated with trastuzumab than in those treated with anthracyclines (71.8% vs 44.1%, respectively). Additionally, patients with GC were less likely to receive an adequate baseline UCG performance than those with BC (70.4% vs 75.0%, respectively). After adjusting for potential confounders, patients with anthracycline‐treated BC and GC were less likely to receive adequate baseline UCG performance than those with trastuzumab‐treated BC (odds ratio [OR]: 0.24, 95% confidence interval [CI]: 0.20–0.28, and OR: 0.07, 95% CI: 0.03–0.16, respectively). Furthermore, patients with trastuzumab‐treated GC were less likely to receive adequate baseline UCG performance than those with BC (OR: 0.65, 95% CI: 0.50–0.84).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The baseline UCG was less likely to be performed in patients receiving anthracyclines than in those receiving trastuzumab, as well as in patients with GC than in those with BC.</jats:p></jats:sec>', 'DOI': '10.1002/cam4.4929', 'type': 'journal-article', 'created': {'date-parts': [[2022, 6, 11]], 'date-time': '2022-06-11T09:03:42Z', 'timestamp': 1654938222000}, 'page': '122-130', 'update-policy': 'https://doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': ['Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines'], 'prefix': '10.1002', 'volume': '12', 'author': [{'ORCID': 'https://orcid.org/0000-0002-7601-4295', 'authenticated-orcid': False, 'given': 'Taisuke', 'family': 'Ishii', 'sequence': 'first', 'affiliation': [{'name': 'Division of Health Services Research National Cancer Center  Tokyo Japan'}]}, {'given': 'Tomone', 'family': 'Watanabe', 'sequence': 'additional', 'affiliation': [{'name': 'Division of Health Services Research National Cancer Center  Tokyo Japan'}]}, {'ORCID': 'https://orcid.org/0000-0002-9933-2106', 'authenticated-orcid': False, 'given': 'Takahiro', 'family': 'Higashi', 'sequence': 'additional', 'affiliation': [{'name': 'Division of Health Services Research National Cancer Center  Tokyo Japan'}]}], 'member': '311', 'published-online': {'date-parts': [[2022, 6, 11]]}, 'reference': [{'key': 'e_1_2_10_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nrclinonc.2011.177'}, {'key': 'e_1_2_10_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41698-017-0016-z'}, {'key': 'e_1_2_10_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJM200103153441101'}, {'key': 'e_1_2_10_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(10)61121-X'}, {'key': 'e_1_2_10_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejca.2015.09.012'}, {'key': 'e_1_2_10_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.18632/oncotarget.18700'}, {'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nrcardio.2015.65'}, {'key': 'e_1_2_10_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.annonc.2019.10.023'}, {'key': 'e_1_2_10_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.2005.04.9551'}, {'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11523-009-0112-2'}, {'key': 'e_1_2_10_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/eurheartj/ehw211'}, {'key': 'e_1_2_10_13_1', 'unstructured': 'National Comprehensive Cancer Network.Breast cancer (version 3.2021) clinical practice guidelines in oncology. Accessed December 23 2021.https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.'}, {'key': 'e_1_2_10_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/jco.2005.23.16_suppl.4014'}, {'key': 'e_1_2_10_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jjco/hyt001'}, {'key': 'e_1_2_10_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/cas.12837'}, {'key': 'e_1_2_10_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jcmg.2018.06.005'}, {'key': 'e_1_2_10_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K'}, {'key': 'e_1_2_10_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10741-020-09968-2'}, {'key': 'e_1_2_10_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fcvm.2020.00026'}, {'key': 'e_1_2_10_21_1', 'unstructured': 'National Comprehensive Cancer Network.Gastric cancer (version 4.2020). Accessed December 19 2020.https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.'}, {'key': 'e_1_2_10_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3747/co.2008.199'}, {'key': 'e_1_2_10_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1470-2045(12)70525-9'}, {'key': 'e_1_2_10_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JOP.2013.001121'}, {'key': 'e_1_2_10_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fonc.2020.532403'}, {'key': 'e_1_2_10_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.breast.2013.04.011'}, {'key': 'e_1_2_10_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/ejhf.1920'}, {'key': 'e_1_2_10_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10549-021-06192-w'}, {'key': 'e_1_2_10_29_1', 'first-page': '15', 'article-title': 'Anthracycline‐induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment', 'volume': '11', 'author': 'Cai F', 'year': '2019', 'journal-title': 'Mol Clin Oncol'}, {'key': 'e_1_2_10_30_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/0003-4819-127-8_Part_2-199710151-00048'}, {'key': 'e_1_2_10_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2021.2474'}, {'key': 'e_1_2_10_32_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.je.2016.09.009'}], 'container-title': ['Cancer Medicine'], 'language': 'en', 'link': [{'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4929', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cam4.4929', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4929', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2023, 8, 16]], 'date-time': '2023-08-16T22:49:33Z', 'timestamp': 1692226173000}, 'score': 38.168213, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/cam4.4929'}}, 'issued': {'date-parts': [[2022, 6, 11]]}, 'references-count': 31, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2023, 1]]}}, 'alternative-id': ['10.1002/cam4.4929'], 'URL': 'https://doi.org/10.1002/cam4.4929', 'archive': ['Portico'], 'ISSN': ['2045-7634', '2045-7634'], 'issn-type': [{'type': 'print', 'value': '2045-7634'}, {'type': 'electronic', 'value': '2045-7634'}], 'published': {'date-parts': [[2022, 6, 11]]}, 'assertion': [{'value': '2022-04-26', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, {'value': '2022-05-28', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, {'value': '2022-06-11', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}",2025-09-28T10:26:57.272160
crossref,10.21203/rs.3.rs-4423878/v1,10.21203/rs.3.rs-4423878/v1,,,Cardioprotective effects of Platycodon grandiflorum Granules in HER2-positive early breast cancer patients receiving Trastuzumab plus Pertuzumab: study protocol for a double blind randomized controlled trial,https://doi.org/10.21203/rs.3.rs-4423878/v1,"Hao, Sun, Wu, Shi, Qin, Liu",,"Abstract
        Background
 Breast cancer, particularly the Human epidermal growth factor receptor 2 (HER2) positive subtype, poses a significant health challenge for women worldwide. Trastuzumab plus Pertuzumab therapy has shown efficacy in treating HER2-positive breast cancer, but its use is limited by associated cardiotoxicity. Traditional Chinese Medicine (TCM) suggests that Platycodon grandiflorus A. DC. (PG) may have cardioprotective effects due to its ability to nourish qi and blood. This study aims to investigate the effective and safety of PG in preventing cardiotoxicity associated with anti-HER2 therapy.
Method
 In this double-blinded, randomized, placebo-controlled trial, approximately 120 patients will be randomly assigned to either the PG or placebo groups, alongside undergoing 12 months of dual anti-HER2 therapies in a 1:1 ratio. Cardiotoxicity will be assessed at a median follow-up of 1 year. The primary outcome measure is left ventricular global longitudinal strain, with secondary outcomes including: (1) changes in left ventricular ejection fraction, (2) the occurrence of cardiotoxicity, (3) the occurrence of trastuzumab plus pertuzumab interruption, and (4) event free survival and overall survival rates among patients.
Discussion
 This will be the first clinical study to determine whether PG can reduce the cardiotoxicity induced by trastuzumab plus pertuzumab treatment in HER2-positive early breast cancer patients.
Trial registration
 Chinese Clinical Trial Registry (Registration Number ChiCTR2200061011)","{'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2024, 6, 8]], 'date-time': '2024-06-08T00:34:10Z', 'timestamp': 1717806850951}, 'posted': {'date-parts': [[2024, 6, 7]]}, 'group-title': 'In Review', 'reference-count': 0, 'publisher': 'Research Square Platform LLC', 'license': [{'start': {'date-parts': [[2024, 6, 7]], 'date-time': '2024-06-07T00:00:00Z', 'timestamp': 1717718400000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2024, 5, 15]]}, 'abstract': '<title>Abstract</title>\n        <p>Background\n Breast cancer, particularly the Human epidermal growth factor receptor 2 (HER2) positive subtype, poses a significant health challenge for women worldwide. Trastuzumab plus Pertuzumab therapy has shown efficacy in treating HER2-positive breast cancer, but its use is limited by associated cardiotoxicity. Traditional Chinese Medicine (TCM) suggests that Platycodon grandiflorus A. DC. (PG) may have cardioprotective effects due to its ability to nourish qi and blood. This study aims to investigate the effective and safety of PG in preventing cardiotoxicity associated with anti-HER2 therapy.\nMethod\n In this double-blinded, randomized, placebo-controlled trial, approximately 120 patients will be randomly assigned to either the PG or placebo groups, alongside undergoing 12 months of dual anti-HER2 therapies in a 1:1 ratio. Cardiotoxicity will be assessed at a median follow-up of 1 year. The primary outcome measure is left ventricular global longitudinal strain, with secondary outcomes including: (1) changes in left ventricular ejection fraction, (2) the occurrence of cardiotoxicity, (3) the occurrence of trastuzumab plus pertuzumab interruption, and (4) event free survival and overall survival rates among patients.\nDiscussion\n This will be the first clinical study to determine whether PG can reduce the cardiotoxicity induced by trastuzumab plus pertuzumab treatment in HER2-positive early breast cancer patients.\nTrial registration\n Chinese Clinical Trial Registry (Registration Number ChiCTR2200061011)</p>', 'DOI': '10.21203/rs.3.rs-4423878/v1', 'type': 'posted-content', 'created': {'date-parts': [[2024, 6, 7]], 'date-time': '2024-06-07T17:39:09Z', 'timestamp': 1717781949000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Cardioprotective effects of Platycodon grandiflorum Granules in HER2-positive early breast cancer patients receiving Trastuzumab plus Pertuzumab: study protocol for a double blind randomized controlled trial'], 'prefix': '10.21203', 'author': [{'given': 'Wei', 'family': 'Hao', 'sequence': 'first', 'affiliation': [{'name': 'Longhua Hospital'}]}, {'given': 'Chenping', 'family': 'Sun', 'sequence': 'additional', 'affiliation': [{'name': 'Longhua Hospital'}]}, {'given': 'Chunyu', 'family': 'Wu', 'sequence': 'additional', 'affiliation': [{'name': 'Longhua Hospital'}]}, {'given': 'Youyang', 'family': 'Shi', 'sequence': 'additional', 'affiliation': [{'name': 'Longhua Hospital'}]}, {'given': 'Yuenong', 'family': 'Qin', 'sequence': 'additional', 'affiliation': [{'name': 'Longhua Hospital'}]}, {'given': 'Sheng', 'family': 'Liu', 'sequence': 'additional', 'affiliation': [{'name': 'Shanghai University of Traditional Chinese Medicine'}]}], 'member': '8761', 'link': [{'URL': 'https://www.researchsquare.com/article/rs-4423878/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://www.researchsquare.com/article/rs-4423878/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2024, 6, 7]], 'date-time': '2024-06-07T17:39:14Z', 'timestamp': 1717781954000}, 'score': 33.462914, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-4423878/v1'}}, 'issued': {'date-parts': [[2024, 6, 7]]}, 'references-count': 0, 'URL': 'https://doi.org/10.21203/rs.3.rs-4423878/v1', 'published': {'date-parts': [[2024, 6, 7]]}, 'subtype': 'preprint'}",2025-09-28T10:26:57.378562
crossref,10.1007/978-94-009-7630-6_31,10.1007/978-94-009-7630-6_31,,,Cardiac Monitoring of Patients Receiving Anthracyclines,https://doi.org/10.1007/978-94-009-7630-6_31,Bristow,,,"{'indexed': {'date-parts': [[2024, 9, 6]], 'date-time': '2024-09-06T21:09:09Z', 'timestamp': 1725656949674}, 'publisher-location': 'Dordrecht', 'reference-count': 14, 'publisher': 'Springer Netherlands', 'isbn-type': [{'type': 'print', 'value': '9789400976320'}, {'type': 'electronic', 'value': '9789400976306'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[1982]]}, 'DOI': '10.1007/978-94-009-7630-6_31', 'type': 'book-chapter', 'created': {'date-parts': [[2012, 2, 4]], 'date-time': '2012-02-04T06:24:18Z', 'timestamp': 1328336658000}, 'page': '348-351', 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': ['Cardiac Monitoring of Patients Receiving Anthracyclines'], 'prefix': '10.1007', 'author': [{'given': 'M. R.', 'family': 'Bristow', 'sequence': 'first', 'affiliation': []}], 'member': '297', 'reference': [{'key': '31_CR1', 'doi-asserted-by': 'publisher', 'first-page': '887', 'DOI': '10.1016/0002-9149(78)90729-4', 'volume': '41', 'author': 'J Mason', 'year': '1978', 'unstructured': 'Mason J. 1978. Techniques for right and left ventricular endomyocardial biopsy. Am J Cardiol 41:887.', 'journal-title': 'Am J Cardiol'}, {'key': '31_CR2', 'doi-asserted-by': 'crossref', 'first-page': '168', 'DOI': '10.7326/0003-4819-88-2-168', 'volume': '88', 'author': 'MR Bristow', 'year': '1978', 'unstructured': 'Bristow MR, Mason JW, Billingham ME, Daniels JR. 1978. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88:168.', 'journal-title': 'Ann Intern Med'}, {'key': '31_CR3', 'first-page': '873', 'volume': '62', 'author': 'MR Bristow', 'year': '1978', 'unstructured': 'Bristow MR, Billingham ME, Mason JW, Daniels JR. 1978. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873.', 'journal-title': 'Cancer Treat Rep'}, {'key': '31_CR4', 'doi-asserted-by': 'publisher', 'first-page': '17', 'DOI': '10.1097/00000478-197701010-00002', 'volume': '1', 'author': 'ME Billingham', 'year': '1977', 'unstructured': 'Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek M, Daniels JR. 1977. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17.', 'journal-title': 'Am J Surg Pathol'}, {'key': '31_CR5', 'first-page': '865', 'volume': '62', 'author': 'ME Billingham', 'year': '1978', 'unstructured': 'Billingham ME, Hason JW, Bristow MR, Daniels JR. 1978. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865.', 'journal-title': 'Cancer Treat Rep'}, {'key': '31_CR6', 'unstructured': 'Billingham ME, Bristow MR. In press. Endomyocardial biopsy for cardiac monitoring of patients receiving anthracycline. In Endomyocardial biopsy: techniques and applications. Fenoglio J, ed. C.R.C. Press.'}, {'key': '31_CR7', 'unstructured': 'Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. In press. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer.'}, {'key': '31_CR8', 'doi-asserted-by': 'publisher', 'first-page': '278', 'DOI': '10.1056/NEJM197902083000603', 'volume': '300', 'author': 'J Alexander', 'year': '1979', 'unstructured': 'Alexander J, Dainiak N, Berger HJ et al. 1979. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. New Engl J Med 300:278.', 'journal-title': 'New Engl J Med'}, {'key': '31_CR9', 'first-page': '154', 'volume': '21', 'author': 'M Bristow', 'year': '1980', 'unstructured': 'Bristow M, Lopez M, McKillop J. 1980. Specificity and sensitivity of radionuclide ejection fractions in doxorubicin cardiomyopathy. Proc AACR/ASCO 21:154.', 'journal-title': 'Proc AACR/ASCO'}, {'key': '31_CR10', 'first-page': '857', 'volume': '62', 'author': 'JW Mason', 'year': '1978', 'unstructured': 'Mason JW, Bristow MR, Billingham ME, Daniels JR. 1978. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62:857.', 'journal-title': 'Cancer Treat Rep'}, {'key': '31_CR11', 'doi-asserted-by': 'crossref', 'unstructured': 'Bristow MR, Mason JW, Billingham ME, Daniels JR. 1981, in press. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J.', 'DOI': '10.1016/0002-8703(81)90096-X'}, {'key': '31_CR12', 'doi-asserted-by': 'publisher', 'first-page': '671', 'DOI': '10.1016/0002-8703(80)90743-7', 'volume': '99', 'author': 'IC Henderson', 'year': '1980', 'unstructured': 'Henderson IC, Frei E. 1980. Adriamycin cardiotoxicity. Am Heart J 99:671.', 'journal-title': 'Am Heart J'}, {'key': '31_CR13', 'doi-asserted-by': 'publisher', 'first-page': '139', 'DOI': '10.1056/NEJM198107163050305', 'volume': '305', 'author': 'RC Young', 'year': '1981', 'unstructured': 'Young RC, Ozols RF, Hyers CE. 1981. The anthracvcline antineoplastic drugs. New Engl J Med 305:139.', 'journal-title': 'New Engl J Med'}, {'key': '31_CR14', 'doi-asserted-by': 'publisher', 'first-page': '474', 'DOI': '10.1016/0002-9149(81)90969-3', 'volume': '47', 'author': 'W Choi', 'year': '1981', 'unstructured': 'Choi W, Berger H, Alexander J et al. 1981. Serial radionuclide assessment of doxorubicin cardiotoxicitv in Cancer patients with abnormal baseline resting left ventricular performance. Am J Cardiol 47:474.', 'journal-title': 'Am J Cardiol'}], 'container-title': ['Anthracycline Antibiotics in Cancer Therapy'], 'language': 'en', 'link': [{'URL': 'http://link.springer.com/content/pdf/10.1007/978-94-009-7630-6_31.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2020, 11, 27]], 'date-time': '2020-11-27T11:54:32Z', 'timestamp': 1606478072000}, 'score': 32.80562, 'resource': {'primary': {'URL': 'http://link.springer.com/10.1007/978-94-009-7630-6_31'}}, 'issued': {'date-parts': [[1982]]}, 'ISBN': ['9789400976320', '9789400976306'], 'references-count': 14, 'URL': 'https://doi.org/10.1007/978-94-009-7630-6_31', 'published': {'date-parts': [[1982]]}}",2025-09-28T10:26:57.466699
crossref,10.3390/clinpract11030064,10.3390/clinpract11030064,,,An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study,https://doi.org/10.3390/clinpract11030064,"Yoodee, Sookprasert, Sanguanboonyaphong, Chanthawong, Seateaw, Subongkot",,"Anthracycline-based regimens with or without anti-human epidermal growth factor receptor (HER) 2 agents such as trastuzumab are effective in breast cancer treatment. Nevertheless, heart failure (HF) has become a significant side effect of these regimens. This study aimed to investigate the incidence and factors associated with HF in breast cancer patients treated with anthracyclines with or without trastuzumab. A retrospective cohort study was performed in patients with breast cancer who were treated with anthracyclines with or without trastuzumab between 1 January 2014 and 31 December 2018. The primary outcome was the incidence of HF. The secondary outcome was the risk factors associated with HF by using the univariable and multivariable cox-proportional hazard model. A total of 475 breast cancer patients were enrolled with a median follow-up time of 2.88 years (interquartile range (IQR), 1.59–3.93). The incidence of HF was 3.2%, corresponding to an incidence rate of 11.1 per 1000 person-years. The increased risk of HF was seen in patients receiving a combination of anthracycline and trastuzumab therapy, patients treated with radiotherapy or palliative-intent chemotherapy, and baseline left ventricular ejection fraction &lt;65%, respectively. There were no statistically significant differences in other risk factors for HF, such as age, cardiovascular comorbidities, and cumulative doxorubicin dose. In conclusion, the incidence of HF was consistently high in patients receiving combination anthracyclines trastuzumab regimens. A reduced baseline left ventricular ejection fraction, radiotherapy, and palliative-intent chemotherapy were associated with an increased risk of HF. Intensive cardiac monitoring in breast cancer patients with an increased risk of HF should be advised to prevent undesired cardiac outcomes.","{'indexed': {'date-parts': [[2025, 8, 23]], 'date-time': '2025-08-23T05:23:13Z', 'timestamp': 1755926593092, 'version': '3.37.3'}, 'reference-count': 31, 'publisher': 'MDPI AG', 'issue': '3', 'license': [{'start': {'date-parts': [[2021, 8, 2]], 'date-time': '2021-08-02T00:00:00Z', 'timestamp': 1627862400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Clinics and Practice'], 'abstract': '<jats:p>Anthracycline-based regimens with or without anti-human epidermal growth factor receptor (HER) 2 agents such as trastuzumab are effective in breast cancer treatment. Nevertheless, heart failure (HF) has become a significant side effect of these regimens. This study aimed to investigate the incidence and factors associated with HF in breast cancer patients treated with anthracyclines with or without trastuzumab. A retrospective cohort study was performed in patients with breast cancer who were treated with anthracyclines with or without trastuzumab between 1 January 2014 and 31 December 2018. The primary outcome was the incidence of HF. The secondary outcome was the risk factors associated with HF by using the univariable and multivariable cox-proportional hazard model. A total of 475 breast cancer patients were enrolled with a median follow-up time of 2.88 years (interquartile range (IQR), 1.59–3.93). The incidence of HF was 3.2%, corresponding to an incidence rate of 11.1 per 1000 person-years. The increased risk of HF was seen in patients receiving a combination of anthracycline and trastuzumab therapy, patients treated with radiotherapy or palliative-intent chemotherapy, and baseline left ventricular ejection fraction &lt;65%, respectively. There were no statistically significant differences in other risk factors for HF, such as age, cardiovascular comorbidities, and cumulative doxorubicin dose. In conclusion, the incidence of HF was consistently high in patients receiving combination anthracyclines trastuzumab regimens. A reduced baseline left ventricular ejection fraction, radiotherapy, and palliative-intent chemotherapy were associated with an increased risk of HF. Intensive cardiac monitoring in breast cancer patients with an increased risk of HF should be advised to prevent undesired cardiac outcomes.</jats:p>', 'DOI': '10.3390/clinpract11030064', 'type': 'journal-article', 'created': {'date-parts': [[2021, 8, 2]], 'date-time': '2021-08-02T12:44:11Z', 'timestamp': 1627908251000}, 'page': '484-493', 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': ['An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study'], 'prefix': '10.3390', 'volume': '11', 'author': [{'ORCID': 'https://orcid.org/0000-0001-9780-0060', 'authenticated-orcid': False, 'given': 'Jukapun', 'family': 'Yoodee', 'sequence': 'first', 'affiliation': [{'name': 'Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand'}, {'name': 'The College of Pharmacotherapy of Thailand, Nonthaburi 11000, Thailand'}]}, {'given': 'Aumkhae', 'family': 'Sookprasert', 'sequence': 'additional', 'affiliation': [{'name': 'Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand'}]}, {'given': 'Phitjira', 'family': 'Sanguanboonyaphong', 'sequence': 'additional', 'affiliation': [{'name': 'The College of Pharmacotherapy of Thailand, Nonthaburi 11000, Thailand'}, {'name': 'Division of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani 34190, Thailand'}]}, {'ORCID': 'https://orcid.org/0000-0001-9043-8687', 'authenticated-orcid': False, 'given': 'Suthan', 'family': 'Chanthawong', 'sequence': 'additional', 'affiliation': [{'name': 'Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand'}]}, {'given': 'Manit', 'family': 'Seateaw', 'sequence': 'additional', 'affiliation': [{'name': 'Division of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani 34190, Thailand'}]}, {'ORCID': 'https://orcid.org/0000-0002-0013-2252', 'authenticated-orcid': False, 'given': 'Suphat', 'family': 'Subongkot', 'sequence': 'additional', 'affiliation': [{'name': 'Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand'}]}], 'member': '1968', 'published-online': {'date-parts': [[2021, 8, 2]]}, 'reference': [{'key': 'ref_1', 'unstructured': 'World Health Organization (2018). World Health Statistics 2018: Monitoring Health for the SDGs, Sustainable Development Goals, World Health Organization.'}, {'key': 'ref_2', 'unstructured': 'World Health Organization (2019). World Health Organization Cancer Fact. All Cancer Fact Sheet.'}, {'key': 'ref_3', 'doi-asserted-by': 'crossref', 'first-page': '16', 'DOI': '10.1093/annonc/mdw544', 'article-title': '3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)', 'volume': '28', 'author': 'Cardoso', 'year': '2017', 'journal-title': 'Ann. Oncol.'}, {'key': 'ref_4', 'first-page': '552', 'article-title': 'NCCN guidelines updates: Breast cancer', 'volume': '17', 'author': 'Telli', 'year': '2019', 'journal-title': 'J. Natl. Compr. Cancer Netw.'}, {'key': 'ref_5', 'doi-asserted-by': 'crossref', 'first-page': '432', 'DOI': '10.1016/S0140-6736(11)61625-5', 'article-title': 'Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials', 'volume': '379', 'author': 'Peto', 'year': '2012', 'journal-title': 'Lancet'}, {'key': 'ref_6', 'doi-asserted-by': 'crossref', 'first-page': '588', 'DOI': '10.1200/JCO.2003.08.013', 'article-title': 'Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193)', 'volume': '21', 'author': 'Sledge', 'year': '2003', 'journal-title': 'J. Clin. Oncol.'}, {'key': 'ref_7', 'doi-asserted-by': 'crossref', 'first-page': '1195', 'DOI': '10.1016/S0140-6736(16)32616-2', 'article-title': '11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial', 'volume': '389', 'author': 'Cameron', 'year': '2017', 'journal-title': 'Lancet'}, {'key': 'ref_8', 'doi-asserted-by': 'crossref', 'first-page': '3744', 'DOI': '10.1200/JCO.2014.55.5730', 'article-title': 'Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831', 'volume': '32', 'author': 'Perez', 'year': '2014', 'journal-title': 'J. Clin. Oncol.'}, {'key': 'ref_9', 'doi-asserted-by': 'crossref', 'first-page': '1273', 'DOI': '10.1056/NEJMoa0910383', 'article-title': 'Adjuvant trastuzumab in HER2-positive breast cancer', 'volume': '365', 'author': 'Slamon', 'year': '2011', 'journal-title': 'N. Engl. J. Med.'}, {'key': 'ref_10', 'doi-asserted-by': 'crossref', 'first-page': '783', 'DOI': '10.1056/NEJM200103153441101', 'article-title': 'Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2', 'volume': '344', 'author': 'Slamon', 'year': '2001', 'journal-title': 'N. Engl. J. Med.'}, {'key': 'ref_11', 'doi-asserted-by': 'crossref', 'first-page': '893', 'DOI': '10.1200/JCO.2016.70.5400', 'article-title': 'Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline', 'volume': '35', 'author': 'Armenian', 'year': '2017', 'journal-title': 'J. Clin. Oncol.'}, {'key': 'ref_12', 'doi-asserted-by': 'crossref', 'first-page': '1517', 'DOI': '10.1002/cphy.c140059', 'article-title': 'Anthracycline-Induced Cardiomyopathy in Adults', 'volume': '5', 'author': 'Tan', 'year': '2015', 'journal-title': 'Compr. Physiol.'}, {'key': 'ref_13', 'doi-asserted-by': 'crossref', 'first-page': '3525', 'DOI': '10.1200/JCO.2007.11.0106', 'article-title': 'Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility', 'volume': '25', 'author': 'Telli', 'year': '2007', 'journal-title': 'J. Clin. Oncol.'}, {'key': 'ref_14', 'doi-asserted-by': 'crossref', 'first-page': '171', 'DOI': '10.1016/j.annonc.2019.10.023', 'article-title': 'Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations', 'volume': '31', 'author': 'Curigliano', 'year': '2020', 'journal-title': 'Ann. Oncol.'}, {'key': 'ref_15', 'doi-asserted-by': 'crossref', 'first-page': '1293', 'DOI': '10.1093/jnci/djs317', 'article-title': 'Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study', 'volume': '104', 'author': 'Bowles', 'year': '2012', 'journal-title': 'J. Natl. Cancer Inst.'}, {'key': 'ref_16', 'doi-asserted-by': 'crossref', 'first-page': '2159', 'DOI': '10.1200/JCO.2013.53.9288', 'article-title': 'Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01)', 'volume': '32', 'author': 'Procter', 'year': '2014', 'journal-title': 'J. Clin. Oncol.'}, {'key': 'ref_17', 'doi-asserted-by': 'crossref', 'first-page': '4491', 'DOI': '10.1200/JCO.2011.36.7045', 'article-title': 'Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer', 'volume': '29', 'author': 'Perez', 'year': '2011', 'journal-title': 'J. Clin. Oncol.'}, {'key': 'ref_18', 'doi-asserted-by': 'crossref', 'first-page': '217', 'DOI': '10.1016/j.jchf.2018.09.001', 'article-title': 'Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy with or Without Trastuzumab', 'volume': '7', 'author': 'Banke', 'year': '2019', 'journal-title': 'JACC Heart Fail.'}, {'key': 'ref_19', 'doi-asserted-by': 'crossref', 'first-page': '317', 'DOI': '10.1001/jamaoncol.2016.1269', 'article-title': 'Trastuzumab-related cardiotoxic effects in Taiwanese women: A nationwide cohort study', 'volume': '2', 'author': 'Chien', 'year': '2016', 'journal-title': 'JAMA Oncol.'}, {'key': 'ref_20', 'unstructured': 'National Cancer Institute (2018). Common Terminology Criteria for Adverse Events v5.0 (CTCAE).'}, {'key': 'ref_21', 'doi-asserted-by': 'crossref', 'first-page': '776', 'DOI': '10.1016/j.jacc.2017.04.025', 'article-title': '2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america', 'volume': '70', 'author': 'Yancy', 'year': '2017', 'journal-title': 'J. Am. Coll. Cardiol.'}, {'key': 'ref_22', 'unstructured': 'Vittinghoff, E., Glidden, D.V., Shiboski, S.C., and McCulloch, C.E. (2005). Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models, Springer Science & Business Media.'}, {'key': 'ref_23', 'first-page': '68', 'article-title': 'A retrospective study of cardiotoxicity of breast cancer patients treated with doxorubicin at Phrachomklao Hospital', 'volume': '17', 'author': 'Prachuabaree', 'year': '2021', 'journal-title': 'Isan J. Pharm. Sci.'}, {'key': 'ref_24', 'doi-asserted-by': 'crossref', 'first-page': '581', 'DOI': '10.1200/JCO.2015.61.8413', 'article-title': 'Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial', 'volume': '34', 'author': 'Advani', 'year': '2016', 'journal-title': 'J. Clin. Oncol.'}, {'key': 'ref_25', 'doi-asserted-by': 'crossref', 'first-page': '3792', 'DOI': '10.1200/JCO.2011.40.0010', 'article-title': 'Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab as Adjuvant Therapy for Patients with Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer', 'volume': '30', 'author': 'Romond', 'year': '2012', 'journal-title': 'J. Clin. Oncol.'}, {'key': 'ref_26', 'first-page': '1949', 'article-title': 'Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population', 'volume': '22', 'author': 'Boerman', 'year': '2014', 'journal-title': 'Support. Care Cancer'}, {'key': 'ref_27', 'doi-asserted-by': 'crossref', 'first-page': '2746', 'DOI': '10.1200/JCO.2001.19.10.2746', 'article-title': 'Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients', 'volume': '19', 'author': 'Meinardi', 'year': '2001', 'journal-title': 'J. Clin. Oncol.'}, {'key': 'ref_28', 'doi-asserted-by': 'crossref', 'first-page': '119', 'DOI': '10.1016/j.canrad.2014.01.001', 'article-title': 'Potential impact of cardiac dose–volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy', 'volume': '18', 'author': 'Cao', 'year': '2014', 'journal-title': 'Cancer Radiothérapie'}, {'key': 'ref_29', 'doi-asserted-by': 'crossref', 'first-page': '911', 'DOI': '10.1016/j.echo.2014.07.012', 'article-title': 'Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging', 'volume': '27', 'author': 'Plana', 'year': '2014', 'journal-title': 'J. Am. Soc. Echocardiogr.'}, {'key': 'ref_30', 'doi-asserted-by': 'crossref', 'first-page': '155', 'DOI': '10.1111/j.1743-7563.2012.01588.x', 'article-title': 'Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction', 'volume': '9', 'author': 'Kittiwarawut', 'year': '2013', 'journal-title': 'Asia Pac. J. Clin. Oncol.'}, {'key': 'ref_31', 'doi-asserted-by': 'crossref', 'first-page': 'e30', 'DOI': '10.1161/CIR.0000000000000556', 'article-title': 'Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association', 'volume': '137', 'author': 'Mehta', 'year': '2018', 'journal-title': 'Circulation'}], 'container-title': ['Clinics and Practice'], 'language': 'en', 'link': [{'URL': 'https://www.mdpi.com/2039-7283/11/3/64/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2024, 7, 16]], 'date-time': '2024-07-16T15:28:06Z', 'timestamp': 1721143686000}, 'score': 32.53112, 'resource': {'primary': {'URL': 'https://www.mdpi.com/2039-7283/11/3/64'}}, 'issued': {'date-parts': [[2021, 8, 2]]}, 'references-count': 31, 'journal-issue': {'issue': '3', 'published-online': {'date-parts': [[2021, 9]]}}, 'alternative-id': ['clinpract11030064'], 'URL': 'https://doi.org/10.3390/clinpract11030064', 'ISSN': ['2039-7283'], 'issn-type': [{'type': 'electronic', 'value': '2039-7283'}], 'published': {'date-parts': [[2021, 8, 2]]}}",2025-09-28T10:26:57.588422
crossref,10.31083/j.rcm2507254,10.31083/j.rcm2507254,,,Changes in Epicardial Adipose Tissue Assessed by Chest CT in Breast Cancer Patients Receiving Adjuvant Chemotherapy with Anthracyclines and Trastuzumab,https://doi.org/10.31083/j.rcm2507254,"Liu, Zhang, Huang, Shen, Yang",,"Background: Cardiotoxicity (CTX) induced by adjuvant chemotherapy is a significant factor that impacts the prognosis and quality of life in breast cancer (BC) patients. In this study, we aimed to investigate the changes in epicardial adipose tissue (EAT) before and after treatment in BC patients who received anthracyclines adjuvant chemotherapy protocol (AC-T) and anthracyclines combined with trastuzumabadjuvant chemotherapy protocol (AC-TH). Additionally, we assessed whether there were any differences in the changes in EAT between the two groups of patients. Our objective was to examine the effects of anthracyclines and trastuzumab on EAT and determine the potential role of EAT changes on CTX. Methods: We reviewed female BC patients who were treated with adjuvant chemotherapy protocols of AC-T and AC-TH, all of whom underwent baseline (T0) and follow-up (T1) chest computed tomography (CT) and echocardiography. A cohort of healthy women, matched in age, underwent two chest CTs. EAT was quantified on chest CT using semi-automated software. CTX was defined as a &gt;10% reduction in left ventricular ejection fraction (LVEF) from baseline, with an absolute value of &lt;53%. Results: A total of 41 BC patients were included in the study, with 23 patients in the AC-T group and 18 patients in the AC-TH group. Additionally, 22 healthy females were included as the normal group. None of the BC patients developed CTX after chemotherapy. The age did not differ significantly between the normal group and the AC-T group (p = 0.341) or the AC-TH group (p = 0.853). Similarly, the body mass index (BMI) of the normal group was comparable to that of the AC-T group (p = 0.377, 0.346) and the AC-TH group (p = 0.148, 0.119) before and after chemotherapy. The EAT volume index (mL/kg/m2) was significantly higher in both the AC-T group (5.11 ± 1.85 vs. 4.34 ± 1.55, p &lt; 0.001) and the AC-TH group (4.53 ± 1.61 vs. 3.48 ± 1.62, p &lt; 0.001) at T1 compared with T0. In addition, both the AC-T group (–72.95 ± 5.01 vs. –71.22 ± 3.91, p = 0.005) and the AC-TH group (–72.55 ± 5.27 vs. –68.20 ± 5.98, p &lt; 0.001) exhibited a significant decrease in EAT radiodensity (HU) at T1 compared to T0. However, there was no significant difference observed in the normal group. At T0, no difference was seen in EAT volume index (4.34 ± 1.55 vs. 3.48 ± 1.62, p = 0.090) and radiodensity (–71.22 ± 3.91 vs. –68.20 ± 5.98, p = 0.059) between the AC-T and AC-TH groups. Similarly, at T1, there was still no significant difference observed in the EAT volume index (–5.11 ± 1.85 vs. 4.53 ± 1.61, p = 0.308) and radiodensity (–72.95 ± 5.00 vs. –72.54 ± 5.27, p = 0.802) between the two groups. Conclusions: BC patients who underwent AC-T and AC-TH adjuvant chemotherapy protocols demonstrated a significant rise in the volume index of EAT, along with a substantial reduction in its radiodensity post-chemotherapy. These findings indicate that alterations in EAT could potentially aid in identifying cardiac complications caused by chemotherapeutic agents and remind clinicians to focus on changes in EAT after adjuvant chemotherapy in BC patients to prevent the practical occurrence of CTX.","{'indexed': {'date-parts': [[2025, 7, 30]], 'date-time': '2025-07-30T15:40:14Z', 'timestamp': 1753890014525, 'version': '3.41.2'}, 'reference-count': 46, 'publisher': 'IMR Press', 'issue': '7', 'license': [{'start': {'date-parts': [[2024, 7, 9]], 'date-time': '2024-07-09T00:00:00Z', 'timestamp': 1720483200000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Rev. Cardiovasc. Med.'], 'abstract': '<jats:p>Background: Cardiotoxicity (CTX) induced by adjuvant chemotherapy is a significant factor that impacts the prognosis and quality of life in breast cancer (BC) patients. In this study, we aimed to investigate the changes in epicardial adipose tissue (EAT) before and after treatment in BC patients who received anthracyclines adjuvant chemotherapy protocol (AC-T) and anthracyclines combined with trastuzumabadjuvant chemotherapy protocol (AC-TH). Additionally, we assessed whether there were any differences in the changes in EAT between the two groups of patients. Our objective was to examine the effects of anthracyclines and trastuzumab on EAT and determine the potential role of EAT changes on CTX. Methods: We reviewed female BC patients who were treated with adjuvant chemotherapy protocols of AC-T and AC-TH, all of whom underwent baseline (T0) and follow-up (T1) chest computed tomography (CT) and echocardiography. A cohort of healthy women, matched in age, underwent two chest CTs. EAT was quantified on chest CT using semi-automated software. CTX was defined as a &gt;10% reduction in left ventricular ejection fraction (LVEF) from baseline, with an absolute value of &lt;53%. Results: A total of 41 BC patients were included in the study, with 23 patients in the AC-T group and 18 patients in the AC-TH group. Additionally, 22 healthy females were included as the normal group. None of the BC patients developed CTX after chemotherapy. The age did not differ significantly between the normal group and the AC-T group (p = 0.341) or the AC-TH group (p = 0.853). Similarly, the body mass index (BMI) of the normal group was comparable to that of the AC-T group (p = 0.377, 0.346) and the AC-TH group (p = 0.148, 0.119) before and after chemotherapy. The EAT volume index (mL/kg/m2) was significantly higher in both the AC-T group (5.11 ± 1.85 vs. 4.34 ± 1.55, p &lt; 0.001) and the AC-TH group (4.53 ± 1.61 vs. 3.48 ± 1.62, p &lt; 0.001) at T1 compared with T0. In addition, both the AC-T group (–72.95 ± 5.01 vs. –71.22 ± 3.91, p = 0.005) and the AC-TH group (–72.55 ± 5.27 vs. –68.20 ± 5.98, p &lt; 0.001) exhibited a significant decrease in EAT radiodensity (HU) at T1 compared to T0. However, there was no significant difference observed in the normal group. At T0, no difference was seen in EAT volume index (4.34 ± 1.55 vs. 3.48 ± 1.62, p = 0.090) and radiodensity (–71.22 ± 3.91 vs. –68.20 ± 5.98, p = 0.059) between the AC-T and AC-TH groups. Similarly, at T1, there was still no significant difference observed in the EAT volume index (–5.11 ± 1.85 vs. 4.53 ± 1.61, p = 0.308) and radiodensity (–72.95 ± 5.00 vs. –72.54 ± 5.27, p = 0.802) between the two groups. Conclusions: BC patients who underwent AC-T and AC-TH adjuvant chemotherapy protocols demonstrated a significant rise in the volume index of EAT, along with a substantial reduction in its radiodensity post-chemotherapy. These findings indicate that alterations in EAT could potentially aid in identifying cardiac complications caused by chemotherapeutic agents and remind clinicians to focus on changes in EAT after adjuvant chemotherapy in BC patients to prevent the practical occurrence of CTX.</jats:p>', 'DOI': '10.31083/j.rcm2507254', 'type': 'journal-article', 'created': {'date-parts': [[2024, 7, 12]], 'date-time': '2024-07-12T07:34:14Z', 'timestamp': 1720769654000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': ['Changes in Epicardial Adipose Tissue Assessed by Chest CT in Breast Cancer Patients Receiving Adjuvant Chemotherapy with Anthracyclines and Trastuzumab'], 'prefix': '10.31083', 'volume': '25', 'author': [{'given': 'Yuyao', 'family': 'Liu', 'sequence': 'first', 'affiliation': [{'name': 'Department of Radiology, Yongchuan Hospital of Chongqing Medical University, 402160 Chongqing, China'}]}, {'given': 'Tingjian', 'family': 'Zhang', 'sequence': 'first', 'affiliation': [{'name': 'Department of General Surgery, Yongchuan Hospital of Chongqing Medical University, 402160 Chongqing, China'}]}, {'given': 'Xiao', 'family': 'Huang', 'sequence': 'first', 'affiliation': [{'name': 'Department of Radiology, Yongchuan Hospital of Chongqing Medical University, 402160 Chongqing, China'}]}, {'given': 'Li', 'family': 'Shen', 'sequence': 'first', 'affiliation': [{'name': 'Department of Radiology, Yongchuan Hospital of Chongqing Medical University, 402160 Chongqing, China'}]}, {'given': 'Quan', 'family': 'Yang', 'sequence': 'first', 'affiliation': [{'name': 'Department of Radiology, Yongchuan Hospital of Chongqing Medical University, 402160 Chongqing, China'}]}], 'member': '16242', 'published-online': {'date-parts': [[2024, 7, 9]]}, 'reference': [{'key': 'ref1', 'doi-asserted-by': 'crossref', 'unstructured': 'Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a Cancer Journal for Clinicians. 2021; 71: 209–249.', 'DOI': '10.3322/caac.21660'}, {'key': 'ref2', 'doi-asserted-by': 'crossref', 'unstructured': 'Vuger AT, Tiscoski K, Apolinario T, Cardoso F. Anthracyclines in the treatment of early breast cancer friend or foe? Breast (Edinburgh, Scotland). 2022; 65: 67–76.', 'DOI': '10.1016/j.breast.2022.06.007'}, {'key': 'ref3', 'doi-asserted-by': 'crossref', 'unstructured': 'Li W, Liu M, Yu F, Jiang T, Zhu W, Liu H. Changes in epicardial adipose tissue among women treated with trastuzumab for breast cancer. International Journal of Cardiology. 2022; 348: 163–168.', 'DOI': '10.1016/j.ijcard.2021.12.006'}, {'key': 'ref4', 'doi-asserted-by': 'crossref', 'unstructured': 'Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews. Drug Discovery. 2023; 22: 101–126.', 'DOI': '10.1038/s41573-022-00579-0'}, {'key': 'ref5', 'doi-asserted-by': 'crossref', 'unstructured': 'Tu C, Shen H, Liu R, Wang X, Li X, Yuan X, et al. Myocardial extracellular volume derived from contrast-enhanced chest computed tomography for longitudinal evaluation of cardiotoxicity in patients with breast cancer treated with anthracyclines. Insights into Imaging. 2022; 13: 85.', 'DOI': '10.1186/s13244-022-01224-5'}, {'key': 'ref6', 'doi-asserted-by': 'crossref', 'unstructured': 'Varghese SS, Eekhoudt CR, Jassal DS. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer. Molecular and Cellular Biochemistry. 2021; 476: 3099–3109.', 'DOI': '10.1007/s11010-021-04152-y'}, {'key': 'ref7', 'doi-asserted-by': 'crossref', 'unstructured': 'Lin M, Xiong W, Wang S, Li Y, Hou C, Li C, et al. The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment. Frontiers in Cardiovascular Medicine. 2022; 8: 821663.', 'DOI': '10.3389/fcvm.2021.821663'}, {'key': 'ref8', 'doi-asserted-by': 'crossref', 'unstructured': 'Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nature Reviews. Cardiology. 2022; 19: 593–606.', 'DOI': '10.1038/s41569-022-00679-9'}, {'key': 'ref9', 'doi-asserted-by': 'crossref', 'unstructured': 'Doukbi E, Soghomonian A, Sengenès C, Ahmed S, Ancel P, Dutour A, et al. Browning Epicardial Adipose Tissue: Friend or Foe? Cells. 2022; 11: 991.', 'DOI': '10.3390/cells11060991'}, {'key': 'ref10', 'doi-asserted-by': 'crossref', 'unstructured': 'Monti CB, Codari M, De Cecco CN, Secchi F, Sardanelli F, Stillman AE. Novel imaging biomarkers: epicardial adipose tissue evaluation. The British Journal of Radiology. 2020; 93: 20190770.', 'DOI': '10.1259/bjr.20190770'}, {'key': 'ref11', 'unstructured': 'Chinese Anti-Cancer Association, Committee of Breast Cancer Society. The Chinese Anti-Cancer Association Guidelines and Standards for Breast Cancer Diagnosis and Treatment 2021. China Olcology. 2021; 31: 954–1040.'}, {'key': 'ref12', 'doi-asserted-by': 'crossref', 'unstructured': 'Kwon SS, Nam BD, Lee MY, Lee MH, Lee J, Park BW, et al. Increased EAT volume after anthracycline chemotherapy is associated with a low risk of cardiotoxicity in breast cancer. Breast Cancer Research and Treatment. 2022; 196: 111–119.', 'DOI': '10.1007/s10549-022-06696-z'}, {'key': 'ref13', 'doi-asserted-by': 'crossref', 'unstructured': 'Monti CB, Schiaffino S, Galimberti Ortiz MDM, Capra D, Zanardo M, De Benedictis E, et al. Potential role of epicardial adipose tissue as a biomarker of anthracycline cardiotoxicity. Insights into Imaging. 2021; 12: 161.', 'DOI': '10.1186/s13244-021-01069-4'}, {'key': 'ref14', 'doi-asserted-by': 'crossref', 'unstructured': 'Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2014; 27: 911–939.', 'DOI': '10.1016/j.echo.2014.07.012'}, {'key': 'ref15', 'doi-asserted-by': 'crossref', 'unstructured': 'Cosson E, Nguyen MT, Rezgani I, Berkane N, Pinto S, Bihan H, et al. Epicardial adipose tissue volume and myocardial ischemia in asymptomatic people living with diabetes: a cross-sectional study. Cardiovascular Diabetology. 2021; 20: 224.', 'DOI': '10.1186/s12933-021-01420-5'}, {'key': 'ref16', 'doi-asserted-by': 'crossref', 'unstructured': 'Al-Saleh K, Abdel-Warith A, Alghamdi M, Aldiab A, Ali A, Alsaeed EF, et al. Incidence of trastuzumab-induced cardiotoxicity and impact of body mass index in patients with breast cancer: Results from a Saudi tertiary cancer center. Molecular and Clinical Oncology. 2022; 16: 78.', 'DOI': '10.3892/mco.2022.2511'}, {'key': 'ref17', 'doi-asserted-by': 'crossref', 'unstructured': 'Raggi P, Gadiyaram V, Zhang C, Chen Z, Lopaschuk G, Stillman AE. Statins Reduce Epicardial Adipose Tissue Attenuation Independent of Lipid Lowering: A Potential Pleiotropic Effect. Journal of the American Heart Association. 2019; 8: e013104.', 'DOI': '10.1161/JAHA.119.013104'}, {'key': 'ref18', 'doi-asserted-by': 'crossref', 'unstructured': 'Yin L, Yan C, Yang C, Dong H, Xu S, Li C, et al. Measurement of epicardial adipose tissue using non-contrast routine chest-CT: a consideration of threshold adjustment for fatty attenuation. BMC Medical Imaging. 2022; 22: 114.', 'DOI': '10.1186/s12880-022-00840-3'}, {'key': 'ref19', 'doi-asserted-by': 'crossref', 'unstructured': 'Hamirani Y, Fanous I, Kramer CM, Wong A, Salerno M, Dillon P. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. Medical Oncology (Northwood, London, England). 2016; 33: 82.', 'DOI': '10.1007/s12032-016-0797-x'}, {'key': 'ref20', 'doi-asserted-by': 'crossref', 'unstructured': 'Alexopoulos N, Melek BH, Arepalli CD, Hartlage GR, Chen Z, Kim S, et al. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). Journal of the American College of Cardiology. 2013; 61: 1956–1961.', 'DOI': '10.1016/j.jacc.2012.12.051'}, {'key': 'ref21', 'doi-asserted-by': 'crossref', 'unstructured': 'Wang Q, Chi J, Wang C, Yang Y, Tian R, Chen X. Epicardial Adipose Tissue in Patients with Coronary Artery Disease: A Meta-Analysis. Journal of Cardiovascular Development and Disease. 2022; 9: 253.', 'DOI': '10.3390/jcdd9080253'}, {'key': 'ref22', 'doi-asserted-by': 'crossref', 'unstructured': 'Konwerski M, Gąsecka A, Opolski G, Grabowski M, Mazurek T. Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review. Biology. 2022; 11: 355.', 'DOI': '10.3390/biology11030355'}, {'key': 'ref23', 'doi-asserted-by': 'crossref', 'unstructured': 'Jin X, Hung CL, Tay WT, Soon D, Sim D, Sung KT, et al. Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. European Journal of Heart Failure. 2022; 24: 1346–1356.', 'DOI': '10.1002/ejhf.2513'}, {'key': 'ref24', 'doi-asserted-by': 'crossref', 'unstructured': 'Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction. JACC. Heart Failure. 2020; 8: 657–666.', 'DOI': '10.1016/j.jchf.2020.04.016'}, {'key': 'ref25', 'doi-asserted-by': 'crossref', 'unstructured': 'Wu A, Yang Z, Zhang X, Lin Z, Lu H. Association Between Epicardial Adipose Tissue and Left Atrial and Ventricular Function in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Current Problems in Cardiology. 2023; 48: 101979.', 'DOI': '10.1016/j.cpcardiol.2023.101979'}, {'key': 'ref26', 'doi-asserted-by': 'crossref', 'unstructured': 'Ahmadi N, Hajsadeghi F, Conneely M, Mingos M, Arora R, Budoff M, et al. Accurate detection of metabolically active “brown” and “white” adipose tissues with computed tomography. Academic Radiology. 2013; 20: 1443–1447.', 'DOI': '10.1016/j.acra.2013.08.012'}, {'key': 'ref27', 'doi-asserted-by': 'crossref', 'unstructured': 'Yuvaraj J, Cheng K, Lin A, Psaltis PJ, Nicholls SJ, Wong DTL. The Emerging Role of CT-Based Imaging in Adipose Tissue and Coronary Inflammation. Cells. 2021; 10: 1196.', 'DOI': '10.3390/cells10051196'}, {'key': 'ref28', 'doi-asserted-by': 'crossref', 'unstructured': 'Huang YM, Hsieh CH, Wang SY, Tsao CH, Lee JC, Chen YJ. Treatment Resulting Changes in Volumes of High-18F-FDG-Uptake Adipose Tissues over Orbit and Epicardium Correlate with Treatment Response for Non-Hodgkin’s Lymphoma. International Journal of Molecular Sciences. 2023; 24: 2158.', 'DOI': '10.3390/ijms24032158'}, {'key': 'ref29', 'doi-asserted-by': 'crossref', 'unstructured': 'Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, López GJ, de Molina-Iracheta A, Pérez-Martínez C, et al. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. Journal of the American College of Cardiology. 2019; 73: 779–791.', 'DOI': '10.1016/j.jacc.2018.11.046'}, {'key': 'ref30', 'doi-asserted-by': 'crossref', 'unstructured': 'Chiocchi M, Cerocchi M, Di Tosto F, Rosenfeld R, Pasqualetto M, Vanni G, et al. Quantification of Extracellular Volume in CT in Neoadjuvant Chemotherapy in Breast Cancer: New Frontiers in Assessing the Cardiotoxicity of Anthracyclines and Trastuzumab. Journal of Personalized Medicine. 2023; 13: 199.', 'DOI': '10.3390/jpm13020199'}, {'key': 'ref31', 'doi-asserted-by': 'crossref', 'unstructured': 'Cui C, Qin H, Zhu X, Lu X, Wang B, Wang X, et al. Unsupervised machine learning reveals epicardial adipose tissue subtypes with distinct atrial fibrosis profiles in patients with persistent atrial fibrillation: A prospective 2-center cohort study. Heart Rhythm. 2022; 19: 2033–2041.', 'DOI': '10.1016/j.hrthm.2022.07.030'}, {'key': 'ref32', 'doi-asserted-by': 'crossref', 'unstructured': 'Iacobellis G, Secchi F, Capitanio G, Basilico S, Schiaffino S, Boveri S, et al. Epicardial Fat Inflammation in Severe COVID-19. Obesity (Silver Spring, Md.). 2020; 28: 2260–2262.', 'DOI': '10.1002/oby.23019'}, {'key': 'ref33', 'doi-asserted-by': 'crossref', 'unstructured': 'Liu J, Yu Q, Li Z, Zhou Y, Liu Z, You L, et al. Epicardial adipose tissue density is a better predictor of cardiometabolic risk in HFpEF patients: a prospective cohort study. Cardiovascular Diabetology. 2023; 22: 45.', 'DOI': '10.1186/s12933-023-01778-8'}, {'key': 'ref34', 'doi-asserted-by': 'crossref', 'unstructured': 'Franssens BT, Nathoe HM, Visseren FLJ, van der Graaf Y, Leiner T, SMART Study Group. Relation of Epicardial Adipose Tissue Radiodensity to Coronary Artery Calcium on Cardiac Computed Tomography in Patients at High Risk for Cardiovascular Disease. The American Journal of Cardiology. 2017; 119: 1359–1365.', 'DOI': '10.1016/j.amjcard.2017.01.031'}, {'key': 'ref35', 'unstructured': 'Nicolazzi MA, Carnicelli A, Fuorlo M, Scaldaferri A, Masetti R, Landolfi R, et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. European Review for Medical and Pharmacological Sciences. 2018; 22: 2175–2185.'}, {'key': 'ref36', 'doi-asserted-by': 'crossref', 'unstructured': 'Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology. 2010; 55: 213–220.', 'DOI': '10.1016/j.jacc.2009.03.095'}, {'key': 'ref37', 'doi-asserted-by': 'crossref', 'unstructured': 'Grazziotin LR, Picon PD. Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer. Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners. 2017; 23: 264–272.', 'DOI': '10.1177/1078155216639755'}, {'key': 'ref38', 'doi-asserted-by': 'crossref', 'unstructured': 'Moudgil R, Haddad H. Chemotherapy-related cardiac dysfunction: grey area in type I and type II classification. Current Opinion in Cardiology. 2017; 32: 181–188.', 'DOI': '10.1097/HCO.0000000000000361'}, {'key': 'ref39', 'doi-asserted-by': 'crossref', 'unstructured': 'Jones IC, Dass CR. Doxorubicin-induced cardiotoxicity: causative factors and possible interventions. The Journal of Pharmacy and Pharmacology. 2022; 74: 1677–1688.', 'DOI': '10.1093/jpp/rgac063'}, {'key': 'ref40', 'doi-asserted-by': 'crossref', 'unstructured': 'Barthur A, Brezden-Masley C, Connelly KA, Dhir V, Chan KKW, Haq R, et al. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. Journal of Cardiovascular Magnetic Resonance: Official Journal of the Society for Cardiovascular Magnetic Resonance. 2017; 19: 44.', 'DOI': '10.1186/s12968-017-0356-4'}, {'key': 'ref41', 'doi-asserted-by': 'crossref', 'unstructured': 'Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, et al. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. European Journal of Heart Failure. 2019; 21: 529–535.', 'DOI': '10.1002/ejhf.1385'}, {'key': 'ref42', 'doi-asserted-by': 'crossref', 'unstructured': 'Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D’Ascenzo F, Malavasi V, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. The American Journal of Cardiology. 2013; 112: 1980–1984.', 'DOI': '10.1016/j.amjcard.2013.08.026'}, {'key': 'ref43', 'doi-asserted-by': 'crossref', 'unstructured': 'Di Lisi D, Manno G, Novo G. Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques. Current Problems in Cardiology. 2021; 46: 100818.', 'DOI': '10.1016/j.cpcardiol.2021.100818'}, {'key': 'ref44', 'doi-asserted-by': 'crossref', 'unstructured': 'Naresh NK, Misener S, Zhang Z, Yang C, Ruh A, Bertolino N, et al. Cardiac MRI Myocardial Functional and Tissue Characterization Detects Early Cardiac Dysfunction in a Mouse Model of Chemotherapy-Induced Cardiotoxicity. NMR in Biomedicine. 2020; 33: e4327.', 'DOI': '10.1002/nbm.4327'}, {'key': 'ref45', 'doi-asserted-by': 'crossref', 'unstructured': 'Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. The New England Journal of Medicine. 2018; 379: 111–121.', 'DOI': '10.1056/NEJMoa1804710'}, {'key': 'ref46', 'doi-asserted-by': 'crossref', 'unstructured': 'Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, et al. Risk of Cardiovascular Disease in Women with and without Breast Cancer: The Pathways Heart Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2022; 40: 1647–1658.', 'DOI': '10.1200/JCO.21.01736'}], 'container-title': ['Reviews in Cardiovascular Medicine'], 'language': 'en', 'link': [{'URL': 'https://www.imrpress.com/journal/RCM/25/7/10.31083/j.rcm2507254', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2024, 11, 27]], 'date-time': '2024-11-27T19:31:37Z', 'timestamp': 1732735897000}, 'score': 32.146225, 'resource': {'primary': {'URL': 'https://www.imrpress.com/journal/RCM/25/7/10.31083/j.rcm2507254'}}, 'issued': {'date-parts': [[2024, 7, 9]]}, 'references-count': 46, 'journal-issue': {'issue': '7', 'published-print': {'date-parts': [[2024]]}}, 'alternative-id': ['S1530-6550(24)01346-2'], 'URL': 'https://doi.org/10.31083/j.rcm2507254', 'ISSN': ['1530-6550', '2153-8174'], 'issn-type': [{'type': 'print', 'value': '1530-6550'}, {'type': 'electronic', 'value': '2153-8174'}], 'published': {'date-parts': [[2024, 7, 9]]}, 'article-number': '254'}",2025-09-28T10:26:57.716160
crossref,10.1093/eurheartj/ehae666.3218,10.1093/eurheartj/ehae666.3218,,,Cardioprotective role of statins in breast cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis,https://doi.org/10.1093/eurheartj/ehae666.3218,"Lingamsetty, Kritya, Huang, Fatima, Gewehr, Doma, Pastrana, Hemdanieh, Naji, Kuhar, Martignoni",,"Abstract
               
                  Background
                  Statins may have cardioprotective effects in patients undergoing cardiotoxic chemotherapy regimens. Yet, their role in mitigating anthracycline and/or trastuzumab-induced cardiotoxicity in patients with breast cancer remains unclear.
               
               
                  Purpose
                  To perform a systematic review and meta-analysis to evaluate the efficacy of statins in mitigating anthracycline and/or trastuzumab-induced cardiotoxicity among patients with breast cancer.
               
               
                  Methods
                  We systematically searched PubMed, Embase, and Cochrane databases until January 2024 for studies comparing the efficacy of statin therapy versus no statin therapy in breast cancer patients receiving either anthracyclines, trastuzumab, or both. Cardiotoxicity was defined as per the definition of each individual study. A random-effects model was used to assess pooled risk ratios (RR) and mean differences (MD) with corresponding 95% confidence intervals. Statistical analyses were performed using Review Manager version 5.4.1.
               
               
                  Results
                  We included five studies, of which two were randomised trials. The pooled population comprised 1,839 anthracyclines and/or trastuzumab-treated patients with breast cancer, of whom 864 (47%) received statin therapy. In the pooled analyses, cardiotoxicity was significantly lower in the statin therapy group as compared with the no statin therapy group (RR 0.45; 95% CI 0.27 to 0.72; p=0.001; Figure 1A), additionally statin therapy was associated with a significantly lower reduction in left ventricular ejection fraction as compared with no statin therapy (MD 4.11%; 95% CI 2.68 to 5.53; p&amp;lt;0.00001; Figure 1B).
               
               
                  Conclusion
                  In this meta-analysis, statin therapy in anthracyclines and/or trastuzumab-treated patients with breast cancer was associated with lower cardiotoxicity and decline in left ventricular ejection fraction.","{'indexed': {'date-parts': [[2025, 7, 30]], 'date-time': '2025-07-30T11:54:22Z', 'timestamp': 1753876462240, 'version': '3.41.2'}, 'reference-count': 0, 'publisher': 'Oxford University Press (OUP)', 'issue': 'Supplement_1', 'license': [{'start': {'date-parts': [[2024, 10, 1]], 'date-time': '2024-10-01T00:00:00Z', 'timestamp': 1727740800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://academic.oup.com/pages/standard-publication-reuse-rights'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 10, 28]]}, 'abstract': '<jats:title>Abstract</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>Statins may have cardioprotective effects in patients undergoing cardiotoxic chemotherapy regimens. Yet, their role in mitigating anthracycline and/or trastuzumab-induced cardiotoxicity in patients with breast cancer remains unclear.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Purpose</jats:title>\n                  <jats:p>To perform a systematic review and meta-analysis to evaluate the efficacy of statins in mitigating anthracycline and/or trastuzumab-induced cardiotoxicity among patients with breast cancer.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>We systematically searched PubMed, Embase, and Cochrane databases until January 2024 for studies comparing the efficacy of statin therapy versus no statin therapy in breast cancer patients receiving either anthracyclines, trastuzumab, or both. Cardiotoxicity was defined as per the definition of each individual study. A random-effects model was used to assess pooled risk ratios (RR) and mean differences (MD) with corresponding 95% confidence intervals. Statistical analyses were performed using Review Manager version 5.4.1.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>We included five studies, of which two were randomised trials. The pooled population comprised 1,839 anthracyclines and/or trastuzumab-treated patients with breast cancer, of whom 864 (47%) received statin therapy. In the pooled analyses, cardiotoxicity was significantly lower in the statin therapy group as compared with the no statin therapy group (RR 0.45; 95% CI 0.27 to 0.72; p=0.001; Figure 1A), additionally statin therapy was associated with a significantly lower reduction in left ventricular ejection fraction as compared with no statin therapy (MD 4.11%; 95% CI 2.68 to 5.53; p&amp;lt;0.00001; Figure 1B).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion</jats:title>\n                  <jats:p>In this meta-analysis, statin therapy in anthracyclines and/or trastuzumab-treated patients with breast cancer was associated with lower cardiotoxicity and decline in left ventricular ejection fraction.</jats:p>\n               </jats:sec>', 'DOI': '10.1093/eurheartj/ehae666.3218', 'type': 'journal-article', 'created': {'date-parts': [[2024, 10, 28]], 'date-time': '2024-10-28T07:19:56Z', 'timestamp': 1730099996000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Cardioprotective role of statins in breast cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis'], 'prefix': '10.1093', 'volume': '45', 'author': [{'given': 'S S P', 'family': 'Lingamsetty', 'sequence': 'first', 'affiliation': [{'name': 'Mamata medical college , Khammam ,', 'place': ['India']}]}, {'given': 'M', 'family': 'Kritya', 'sequence': 'additional', 'affiliation': [{'name': 'Inamdar Multispeciality Hospital , Pune ,', 'place': ['India']}]}, {'given': 'W', 'family': 'Huang', 'sequence': 'additional', 'affiliation': [{'name': 'Faculty of Medicine of Padjadjaran University , West Java ,', 'place': ['Indonesia']}]}, {'given': 'S R', 'family': 'Fatima', 'sequence': 'additional', 'affiliation': [{'name': 'CMH Lahore Medical college and Institute of Dentistry , Lahore ,', 'place': ['Pakistan']}]}, {'given': 'D M', 'family': 'Gewehr', 'sequence': 'additional', 'affiliation': [{'name': 'Curitiba Heart Institute , Paraná ,', 'place': ['Brazil']}]}, {'given': 'M', 'family': 'Doma', 'sequence': 'additional', 'affiliation': [{'name': 'Alexandria Faculty of Medicine , Alexandria ,', 'place': ['Egypt']}]}, {'given': 'S H', 'family': 'Pastrana', 'sequence': 'additional', 'affiliation': [{'name': 'Universidad Xochicalco Campus , Tijuana ,', 'place': ['Mexico']}]}, {'given': 'M', 'family': 'Hemdanieh', 'sequence': 'additional', 'affiliation': [{'name': 'American University of Beirut AUB , Beirut ,', 'place': ['Lebanon']}]}, {'given': 'Z', 'family': 'Naji', 'sequence': 'additional', 'affiliation': [{'name': 'Faculty of medicine of Tunis, Al-Manar university , Tunis ,', 'place': ['Tunisia']}]}, {'given': 'K', 'family': 'Kuhar', 'sequence': 'additional', 'affiliation': [{'name': 'Dr. Baba Saheb Ambedkar Medical College and Hospital , Delhi ,', 'place': ['India']}]}, {'given': 'F', 'family': 'Martignoni', 'sequence': 'additional', 'affiliation': [{'name': 'Minneapolis Heart Institute Foundation , Minneapolis ,', 'place': ['United States of America']}]}], 'member': '286', 'published-online': {'date-parts': [[2024, 10, 28]]}, 'container-title': ['European Heart Journal'], 'language': 'en', 'link': [{'URL': 'https://academic.oup.com/eurheartj/article-pdf/45/Supplement_1/ehae666.3218/60056964/ehae666.3218.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, {'URL': 'https://academic.oup.com/eurheartj/article-pdf/45/Supplement_1/ehae666.3218/60056964/ehae666.3218.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2024, 10, 28]], 'date-time': '2024-10-28T23:05:58Z', 'timestamp': 1730156758000}, 'score': 31.890419, 'resource': {'primary': {'URL': 'https://academic.oup.com/eurheartj/article/doi/10.1093/eurheartj/ehae666.3218/7838175'}}, 'issued': {'date-parts': [[2024, 10]]}, 'references-count': 0, 'journal-issue': {'issue': 'Supplement_1', 'published-online': {'date-parts': [[2024, 10, 28]]}, 'published-print': {'date-parts': [[2024, 10, 28]]}}, 'URL': 'https://doi.org/10.1093/eurheartj/ehae666.3218', 'ISSN': ['0195-668X', '1522-9645'], 'issn-type': [{'type': 'print', 'value': '0195-668X'}, {'type': 'electronic', 'value': '1522-9645'}], 'published-other': {'date-parts': [[2024, 10]]}, 'published': {'date-parts': [[2024, 10]]}, 'article-number': 'ehae666.3218'}",2025-09-28T10:26:57.848376
crossref,10.1200/jco.2018.36.15_suppl.10072,10.1200/jco.2018.36.15_suppl.10072,,,Cardioprotective effect and safety of dexrazoxane in all breast cancer stages in patients treated with anthracyclines with or without trastuzumab: A systematic review and meta-analysis.,https://doi.org/10.1200/jco.2018.36.15_suppl.10072,"Macedo, Rodrigues, Costa, Ribeiro",,,"{'indexed': {'date-parts': [[2022, 4, 5]], 'date-time': '2022-04-05T18:38:11Z', 'timestamp': 1649183891736}, 'reference-count': 0, 'publisher': 'American Society of Clinical Oncology (ASCO)', 'issue': '15_suppl', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['JCO'], 'published-print': {'date-parts': [[2018, 5, 20]]}, 'DOI': '10.1200/jco.2018.36.15_suppl.10072', 'type': 'journal-article', 'created': {'date-parts': [[2018, 9, 5]], 'date-time': '2018-09-05T10:50:25Z', 'timestamp': 1536144625000}, 'page': '10072-10072', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Cardioprotective effect and safety of dexrazoxane in all breast cancer stages in patients treated with anthracyclines with or without trastuzumab: A systematic review and meta-analysis.'], 'prefix': '10.1200', 'volume': '36', 'author': [{'given': 'Ariane', 'family': 'Macedo', 'sequence': 'first', 'affiliation': [{'name': 'Federal University of Minas Gerais, Belo Horizonte, Brazil;'}]}, {'given': 'Angelica Nogueira', 'family': 'Rodrigues', 'sequence': 'additional', 'affiliation': [{'name': 'Federal University of Minas Gerais Brazil and Brazilian Group of Gynecologic Oncology, Belo Horizonte, Brazil;'}]}, {'given': 'Rafael Brant', 'family': 'Costa', 'sequence': 'additional', 'affiliation': [{'name': 'Oncoclinicas do Brasil, Belo Horizonte, Brazil;'}]}, {'given': 'Antonio Luiz Pinho', 'family': 'Ribeiro', 'sequence': 'additional', 'affiliation': [{'name': 'Federal University of Minas Gerais, Belo Horizonte, Brazil;'}]}], 'member': '233', 'container-title': ['Journal of Clinical Oncology'], 'language': 'en', 'link': [{'URL': 'http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.36.15_suppl.10072', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2019, 11, 27]], 'date-time': '2019-11-27T16:45:04Z', 'timestamp': 1574873104000}, 'score': 31.504776, 'resource': {'primary': {'URL': 'http://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.10072'}}, 'issued': {'date-parts': [[2018, 5, 20]]}, 'references-count': 0, 'journal-issue': {'issue': '15_suppl', 'published-print': {'date-parts': [[2018, 5, 20]]}}, 'alternative-id': ['10.1200/JCO.2018.36.15_suppl.10072'], 'URL': 'https://doi.org/10.1200/jco.2018.36.15_suppl.10072', 'ISSN': ['0732-183X', '1527-7755'], 'issn-type': [{'value': '0732-183X', 'type': 'print'}, {'value': '1527-7755', 'type': 'electronic'}], 'published': {'date-parts': [[2018, 5, 20]]}}",2025-09-28T10:26:58.032441
crossref,10.1016/j.amjcard.2021.07.001,10.1016/j.amjcard.2021.07.001,,,Meta-analysis Evaluating the Use of Statins to attenuate Cardiotoxicity in Cancer Patients receiving Anthracyclines and Trastuzumab-based Chemotherapy,https://doi.org/10.1016/j.amjcard.2021.07.001,"Shahid, Yamani, Ali, Kumar, Figueredo, Unzek, Mookadam",,,"{'indexed': {'date-parts': [[2025, 9, 27]], 'date-time': '2025-09-27T04:07:39Z', 'timestamp': 1758946059865, 'version': '3.44.0'}, 'reference-count': 9, 'publisher': 'Elsevier BV', 'license': [{'start': {'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, {'start': {'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/legal/tdmrep-license'}], 'content-domain': {'domain': ['ajconline.org', 'clinicalkey.com', 'clinicalkey.com.au', 'clinicalkey.es', 'clinicalkey.fr', 'clinicalkey.jp', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['The American Journal of Cardiology'], 'published-print': {'date-parts': [[2021, 10]]}, 'DOI': '10.1016/j.amjcard.2021.07.001', 'type': 'journal-article', 'created': {'date-parts': [[2021, 8, 3]], 'date-time': '2021-08-03T08:12:13Z', 'timestamp': 1627978333000}, 'page': '142-145', 'update-policy': 'https://doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 15, 'special_numbering': 'C', 'title': ['Meta-analysis Evaluating the Use of Statins to attenuate Cardiotoxicity in Cancer Patients receiving Anthracyclines and Trastuzumab-based Chemotherapy'], 'prefix': '10.1016', 'volume': '156', 'author': [{'given': 'Izza', 'family': 'Shahid', 'sequence': 'first', 'affiliation': []}, {'given': 'Naser', 'family': 'Yamani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abraish', 'family': 'Ali', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pankaj', 'family': 'Kumar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vincent', 'family': 'Figueredo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Samuel', 'family': 'Unzek', 'sequence': 'additional', 'affiliation': []}, {'given': 'Farouk', 'family': 'Mookadam', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [{'key': '10.1016/j.amjcard.2021.07.001_bib0001', 'first-page': '302', 'article-title': 'Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function', 'volume': '31', 'author': 'Chotenimitkhun', 'year': '2015', 'journal-title': 'Can J Cardiol'}, {'key': '10.1016/j.amjcard.2021.07.001_bib0002', 'doi-asserted-by': 'crossref', 'first-page': '511', 'DOI': '10.1586/14779072.2015.1032940', 'article-title': 'Cardio-oncology Part I: Chemotherapy and cardiovascular toxicity', 'volume': '13', 'author': ""O'Hare"", 'year': '2015', 'journal-title': 'Expert Rev Cardiovasc Ther'}, {'key': '10.1016/j.amjcard.2021.07.001_bib0003', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1161/JAHA.119.018393', 'article-title': 'Statin exposure and risk of heart failure after anthracycline-or trastuzumab-based chemotherapy for early breast cancer: A propensity score‒matched cohort study', 'volume': '10', 'author': 'Abdel-Qadir', 'year': '2021', 'journal-title': 'J Am Heart Assoc'}, {'key': '10.1016/j.amjcard.2021.07.001_bib0004', 'doi-asserted-by': 'crossref', 'first-page': '519', 'DOI': '10.1586/14779072.2015.1027686', 'article-title': 'Cardio-oncology Part II: The monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity', 'volume': '13', 'author': ""O'Hare"", 'year': '2015', 'journal-title': 'Expert Rev Cardiovasc Ther'}, {'key': '10.1016/j.amjcard.2021.07.001_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '2384', 'DOI': '10.1016/j.jacc.2012.07.067', 'article-title': 'Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: An observational clinical cohort study', 'volume': '60', 'author': 'Seicean', 'year': '2012', 'journal-title': 'J Am Coll Cardiol'}, {'key': '10.1016/j.amjcard.2021.07.001_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '233', 'DOI': '10.1177/1074248418821721', 'article-title': 'Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial', 'volume': '24', 'author': 'Nabati', 'year': '2019', 'journal-title': 'J Cardiovasc Pharmacol Ther'}, {'key': '10.1016/j.amjcard.2021.07.001_bib0007', 'first-page': '153', 'article-title': 'Cardioprotective effect of statins in patients with HER2-positive breast cancer receiving trastuzumab therapy', 'volume': '35', 'author': 'Calvillo-Argüelles', 'year': '2019', 'journal-title': 'Can J Cardiol'}, {'key': '10.1016/j.amjcard.2021.07.001_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '988', 'DOI': '10.1016/j.jacc.2011.05.025', 'article-title': 'Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy', 'volume': '58', 'author': 'Acar', 'year': '2011', 'journal-title': 'J Am Coll Cardiol'}, {'key': '10.1016/j.amjcard.2021.07.001_bib0009', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/eurheartj/eht307.141', 'article-title': 'HMG-CoA-reductase inhibitor co-therapy lowers the risk for incident heart failure in farmorubicin recipients for two cancer locations', 'volume': '34', 'author': 'Tase', 'year': '2013', 'journal-title': 'Eur Heart J'}], 'container-title': ['The American Journal of Cardiology'], 'language': 'en', 'link': [{'URL': 'https://api.elsevier.com/content/article/PII:S0002914921006184?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://api.elsevier.com/content/article/PII:S0002914921006184?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': {'date-parts': [[2025, 9, 11]], 'date-time': '2025-09-11T06:39:23Z', 'timestamp': 1757572763000}, 'score': 31.210636, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0002914921006184'}}, 'issued': {'date-parts': [[2021, 10]]}, 'references-count': 9, 'alternative-id': ['S0002914921006184'], 'URL': 'https://doi.org/10.1016/j.amjcard.2021.07.001', 'ISSN': ['0002-9149'], 'issn-type': [{'type': 'print', 'value': '0002-9149'}], 'published': {'date-parts': [[2021, 10]]}, 'assertion': [{'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, {'value': 'Meta-analysis Evaluating the Use of Statins to attenuate Cardiotoxicity in Cancer Patients receiving Anthracyclines and Trastuzumab-based Chemotherapy', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'The American Journal of Cardiology', 'name': 'journaltitle', 'label': 'Journal Title'}, {'value': 'https://doi.org/10.1016/j.amjcard.2021.07.001', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2021 Elsevier Inc. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}",2025-09-28T10:26:58.254744
crossref,10.1016/j.ctrv.2004.06.002,10.1016/j.ctrv.2004.06.002,,,Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines,https://doi.org/10.1016/j.ctrv.2004.06.002,Pouillart,,,"{'indexed': {'date-parts': [[2025, 9, 23]], 'date-time': '2025-09-23T13:08:28Z', 'timestamp': 1758632908095}, 'reference-count': 0, 'publisher': 'Elsevier BV', 'issue': '7', 'license': [{'start': {'date-parts': [[2004, 11, 1]], 'date-time': '2004-11-01T00:00:00Z', 'timestamp': 1099267200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Cancer Treatment Reviews'], 'published-print': {'date-parts': [[2004, 11]]}, 'DOI': '10.1016/j.ctrv.2004.06.002', 'type': 'journal-article', 'created': {'date-parts': [[2004, 11, 5]], 'date-time': '2004-11-05T18:00:22Z', 'timestamp': 1099677622000}, 'page': '643-650', 'source': 'Crossref', 'is-referenced-by-count': 19, 'title': ['Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines'], 'prefix': '10.1016', 'volume': '30', 'author': [{'given': 'Pierre', 'family': 'Pouillart', 'sequence': 'first', 'affiliation': []}], 'member': '78', 'container-title': ['Cancer Treatment Reviews'], 'language': 'en', 'link': [{'URL': 'https://api.elsevier.com/content/article/PII:S0305737204001021?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://api.elsevier.com/content/article/PII:S0305737204001021?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': {'date-parts': [[2019, 2, 2]], 'date-time': '2019-02-02T10:28:08Z', 'timestamp': 1549103288000}, 'score': 30.73032, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0305737204001021'}}, 'issued': {'date-parts': [[2004, 11]]}, 'references-count': 0, 'journal-issue': {'issue': '7', 'published-print': {'date-parts': [[2004, 11]]}}, 'alternative-id': ['S0305737204001021'], 'URL': 'https://doi.org/10.1016/j.ctrv.2004.06.002', 'ISSN': ['0305-7372'], 'issn-type': [{'value': '0305-7372', 'type': 'print'}], 'published': {'date-parts': [[2004, 11]]}}",2025-09-28T10:26:58.435019
crossref,10.32792/utq/utjmed/15/1/9,10.32792/utq/utjmed/15/1/9,,,Left Ventricular Dysfunction in Breast Cancer Patients Receiving Trastuzumab: An Observational Study in a Cohort of Iraqi Breast Cancer Patients,https://doi.org/10.32792/utq/utjmed/15/1/9,,,,"{'indexed': {'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T02:29:27Z', 'timestamp': 1648866567724}, 'reference-count': 0, 'publisher': 'University of Thi Qar', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.32792/utq/utjmed/15/1/9', 'type': 'journal-article', 'created': {'date-parts': [[2020, 10, 23]], 'date-time': '2020-10-23T17:58:37Z', 'timestamp': 1603475917000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Left Ventricular Dysfunction in Breast Cancer Patients Receiving Trastuzumab: An Observational Study in a Cohort of Iraqi Breast Cancer Patients'], 'prefix': '10.32792', 'member': '17261', 'published-online': {'date-parts': [[2019, 4, 29]]}, 'container-title': ['University of Thi-Qar Journal of Medicine'], 'deposited': {'date-parts': [[2020, 10, 23]], 'date-time': '2020-10-23T17:58:38Z', 'timestamp': 1603475918000}, 'score': 30.303612, 'resource': {'primary': {'URL': 'https://jmed.utq.edu.iq/index.php/main/article/view/31'}}, 'issued': {'date-parts': [[2019, 4, 29]]}, 'references-count': 0, 'URL': 'https://doi.org/10.32792/utq/utjmed/15/1/9', 'published': {'date-parts': [[2019, 4, 29]]}}",2025-09-28T10:26:58.677595
crossref,10.33425/2768-0436.1002,10.33425/2768-0436.1002,,,Anthracyclines and Trastuzumab-induced Cardiotoxicity in Breast Cancer Patients: Testing a Clinical Risk Score in the First Cardio-Oncology Unit in Morocco,https://doi.org/10.33425/2768-0436.1002,,,,"{'indexed': {'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T08:48:56Z', 'timestamp': 1648889336524}, 'reference-count': 0, 'publisher': 'SciVision Publishers LLC', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Cardiol Vasc Med'], 'DOI': '10.33425/2768-0436.1002', 'type': 'journal-article', 'created': {'date-parts': [[2021, 6, 4]], 'date-time': '2021-06-04T10:22:11Z', 'timestamp': 1622802131000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Anthracyclines and Trastuzumab-induced Cardiotoxicity in Breast Cancer Patients: Testing a Clinical Risk Score in the First Cardio-Oncology Unit in Morocco'], 'prefix': '10.33425', 'member': '18988', 'published-online': {'date-parts': [[2021, 4, 30]]}, 'container-title': ['Cardiology and Vascular Medicine'], 'deposited': {'date-parts': [[2021, 6, 4]], 'date-time': '2021-06-04T10:22:12Z', 'timestamp': 1622802132000}, 'score': 30.160637, 'resource': {'primary': {'URL': 'https://www.sciencexcel.com/articles/Anthracyclines%20and%20Trastuzumab-induced%20Cardiotoxicity%20in%20Breast%20Cancer%20Patients%20%20Testing%20a%20Clinical%20Risk%20Score%20in%20the%20First%20Cardio-Oncology%20Unit%20in%20Morocco'}}, 'issued': {'date-parts': [[2021, 4, 30]]}, 'references-count': 0, 'URL': 'https://doi.org/10.33425/2768-0436.1002', 'ISSN': ['2768-0436'], 'issn-type': [{'value': '2768-0436', 'type': 'electronic'}], 'published': {'date-parts': [[2021, 4, 30]]}}",2025-09-28T10:26:58.827754
crossref,10.3030/945118,10.3030/945118,,,,https://doi.org/10.3030/945118,,,,"{'indexed': {'date-parts': [[2025, 7, 8]], 'date-time': '2025-07-08T04:05:20Z', 'timestamp': 1751947520579, 'version': '3.41.2'}, 'publisher': 'Publications Office of the European Union', 'award-start': {'date-parts': [[2021, 6, 1]]}, 'award': '945118', 'DOI': '10.3030/945118', 'type': 'grant', 'created': {'date-parts': [[2022, 12, 12]], 'date-time': '2022-12-12T14:40:51Z', 'timestamp': 1670856051000}, 'source': 'Crossref', 'prefix': '10.3030', 'member': '4854', 'project': [{'project-title': [{'title': 'Remote Ischemic Conditioning in Lymphoma Patients Receiving Anthracyclines.', 'language': 'en'}, {'title': 'RESILIENCE', 'language': 'en'}], 'project-description': [{'description': 'The increasing life expectancy of the population and the development of effective therapies result in a growing population of aged cancer survivors, which frequently have comorbidities for developing heart failure (HF). Anthracyclines (AC) are still first line treatment for many cancer types, but up to 35% of patients who received them develop cardiotoxicity and HF. The trade-off between cancer and chronic HF is of massive psychological burden for patients, and of devastating economic consequences for healthcare systems. We aim to test the efficacy of a novel intervention (remote ischemic preconditioning) to reduce the incidence of AC-induced HF. We have selected Non-Hodgkin lymphoma as the target population, since it is diagnosed at advanced comorbid age in both genders. This will also allow us study gender differences in AC-induced HF. A phase II randomized clinical trial enrolling 608 patients undergoing AC chemotherapy will be done. Primary endpoint will be based on serial cardiac magnetic resonances exams. Taking advantage of the recruited population and data gathered, we will further validate 2 novel cardiac magnetic resonance imaging methods: a novel early marker of cardiotoxicity, and a new sequence allowing a massive reduction of acquisition time. We will also study a personalized strategy to empower patients in clinical trial execution, which includes Patient-Reported Outcome and Experience Measures (PROMs and PREMs). Our final goal is to reach the patient level by implementing the novel strategy at the clinical level while paving the way for a future large phase III trial. For this endeavour, we count on a multidisciplinary consortium, where different stakeholders of this process are part of the study, from scientists to industry, and from healthcare providers (physicians and nurses) to patients. RESILIENCE deals with 2 of the most frequent non-communicable diseases in Europe (cancer and HF), responsible for a big proportion of healthcare expenditures.', 'language': 'en'}], 'award-amount': {'amount': 5998388.0, 'currency': 'EUR'}, 'award-start': {'date-parts': [[2021, 6, 1]]}, 'funding': [{'type': 'grant', 'scheme': 'H2020-EU.3.1.', 'award-amount': {'amount': 5998388.0, 'currency': 'EUR', 'percentage': 100}, 'funder': {'id': [{'id': '10.13039/100010677', 'id-type': 'DOI', 'asserted-by': 'publisher'}], 'name': 'H2020 Health'}}]}], 'deposited': {'date-parts': [[2025, 7, 7]], 'date-time': '2025-07-07T08:13:16Z', 'timestamp': 1751875996000}, 'score': 29.933193, 'resource': {'primary': {'URL': 'https://cordis.europa.eu/project/id/945118'}}, 'issued': {'date-parts': [[2021, 6, 1]]}, 'URL': 'https://doi.org/10.3030/945118'}",2025-09-28T10:26:58.912460
crossref,10.1136/postgradmedj-2015-133535,10.1136/postgradmedj-2015-133535,,,Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis,https://doi.org/10.1136/postgradmedj-2015-133535,"Yun, Vincelette, Abraham",,"ABSTRACT
               
                  Background
                  Anthracyclines are commonly used chemotherapeutic agents with proven efficacy in such malignancies as breast cancer, Hodgkin and non-Hodgkin lymphomas. These agents are associated with irreversible accumulative dose-related cardiomyopathy. Many agents have been examined to reduce cardiotoxicity risk.
               
               
                  Aims
                  We performed a systematic review and meta-analysis to determine the efficacy of β-blockers and angiotensin antagonists to prevent early-onset anthracyclines-induced left ventricular dysfunction and cardiac events.
               
               
                  Methods
                  Relevant articles were searched in PubMed, EMBASE and Cochrane database of systematic reviews up to July 2015. Eligible studies were limited to randomised controlled trials comparing the efficacy of cardioprotective agents (β-blocker and angiotensin antagonist) with control (either no treatment or placebo) in adult patients (age &amp;gt;18 years) treated with anthracyclines-based regimens.
               
               
                  Results
                  Pooled analysis showed an association of β-blockers and/or angiotensin antagonists treatment with higher post-chemotherapy left ventricular ejection fraction (LVEF) of 64.03% compared with 57.48% for control treatment. The mean difference estimate (95% CI) was 6.06% (0.54 to 11.58), p=0.03, with significant heterogeneity, I2 (95% CI)=96% (82.7 to 109.3). Though the point estimate for the relative rate of cardiac events was lower in the experimental arm, the difference was not statistically significant. In an exploratory subgroup analysis, the benefit of experimental agents on LVEF preservation was prominent in patients treated with higher accumulative dose of anthracyclines, but not in the lower dose group.
               
               
                  Conclusions
                  β-Blockers and angiotensin antagonists treatments were associated with better LVEF preservation, and the benefit was prominent in patients treated with higher anthracyclines accumulative dose. Unexplained heterogeneity remains, indicating the need for more controlled studies. This analysis provides some support for the routine use of β-blockers or angiotensin antagonists in patients undergoing anthracyclines treatment, especially when higher accumulative dose is expected.","{'indexed': {'date-parts': [[2025, 9, 21]], 'date-time': '2025-09-21T17:38:29Z', 'timestamp': 1758476309930}, 'reference-count': 40, 'publisher': 'Oxford University Press (OUP)', 'issue': '1081', 'license': [{'start': {'date-parts': [[2015, 9, 23]], 'date-time': '2015-09-23T00:00:00Z', 'timestamp': 1442966400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://academic.oup.com/pages/standard-publication-reuse-rights'}], 'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2015, 11, 1]]}, 'abstract': '<jats:title>ABSTRACT</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>Anthracyclines are commonly used chemotherapeutic agents with proven efficacy in such malignancies as breast cancer, Hodgkin and non-Hodgkin lymphomas. These agents are associated with irreversible accumulative dose-related cardiomyopathy. Many agents have been examined to reduce cardiotoxicity risk.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Aims</jats:title>\n                  <jats:p>We performed a systematic review and meta-analysis to determine the efficacy of β-blockers and angiotensin antagonists to prevent early-onset anthracyclines-induced left ventricular dysfunction and cardiac events.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>Relevant articles were searched in PubMed, EMBASE and Cochrane database of systematic reviews up to July 2015. Eligible studies were limited to randomised controlled trials comparing the efficacy of cardioprotective agents (β-blocker and angiotensin antagonist) with control (either no treatment or placebo) in adult patients (age &amp;gt;18\u2005years) treated with anthracyclines-based regimens.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>Pooled analysis showed an association of β-blockers and/or angiotensin antagonists treatment with higher post-chemotherapy left ventricular ejection fraction (LVEF) of 64.03% compared with 57.48% for control treatment. The mean difference estimate (95% CI) was 6.06% (0.54 to 11.58), p=0.03, with significant heterogeneity, I2 (95% CI)=96% (82.7 to 109.3). Though the point estimate for the relative rate of cardiac events was lower in the experimental arm, the difference was not statistically significant. In an exploratory subgroup analysis, the benefit of experimental agents on LVEF preservation was prominent in patients treated with higher accumulative dose of anthracyclines, but not in the lower dose group.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>β-Blockers and angiotensin antagonists treatments were associated with better LVEF preservation, and the benefit was prominent in patients treated with higher anthracyclines accumulative dose. Unexplained heterogeneity remains, indicating the need for more controlled studies. This analysis provides some support for the routine use of β-blockers or angiotensin antagonists in patients undergoing anthracyclines treatment, especially when higher accumulative dose is expected.</jats:p>\n               </jats:sec>', 'DOI': '10.1136/postgradmedj-2015-133535', 'type': 'journal-article', 'created': {'date-parts': [[2015, 10, 24]], 'date-time': '2015-10-24T22:29:59Z', 'timestamp': 1445725799000}, 'page': '627-633', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'source': 'Crossref', 'is-referenced-by-count': 42, 'title': ['Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis'], 'prefix': '10.1093', 'volume': '91', 'author': [{'given': 'Seongseok', 'family': 'Yun', 'sequence': 'first', 'affiliation': [{'name': 'Department of Medicine, University of Arizona , Tucson, Arizona, USA'}]}, {'given': 'Nicole D', 'family': 'Vincelette', 'sequence': 'additional', 'affiliation': [{'name': 'Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic , Rochester, Minnesota, USA'}]}, {'given': 'Ivo', 'family': 'Abraham', 'sequence': 'additional', 'affiliation': [{'name': 'Center for Health Outcomes and PharmacoEconomic Research , Tucson, Arizona, USA'}, {'name': 'Arizona Cancer Center, University of Arizona , Tucson, Arizona, USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2015, 9, 23]]}, 'reference': [{'key': '2023041905424235400_R1', 'doi-asserted-by': 'crossref', 'first-page': '185', 'DOI': '10.1124/pr.56.2.6', 'article-title': 'Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity', 'volume': '56', 'author': 'Minotti', 'year': '2004', 'journal-title': 'Pharmacol Rev'}, {'key': '2023041905424235400_R2', 'doi-asserted-by': 'crossref', 'first-page': '2869', 'DOI': '10.1002/cncr.11407', 'article-title': 'Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials', 'volume': '97', 'author': 'Swain', 'year': '2003', 'journal-title': 'Cancer'}, {'key': '2023041905424235400_R3', 'doi-asserted-by': 'crossref', 'first-page': '1672', 'DOI': '10.1001/jama.1991.03470120074036', 'article-title': 'Cardiac toxicity 4 to 20 years after completing anthracycline therapy', 'volume': '266', 'author': 'Steinherz', 'year': '1991', 'journal-title': 'JAMA'}, {'key': '2023041905424235400_R4', 'doi-asserted-by': 'crossref', 'first-page': '3808', 'DOI': '10.1200/JCO.2006.10.4976', 'article-title': 'Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer', 'volume': '25', 'author': 'Pinder', 'year': '2007', 'journal-title': 'J Clin Oncol'}, {'key': '2023041905424235400_R5', 'doi-asserted-by': 'crossref', 'first-page': '1639', 'DOI': '10.1038/nm.2919', 'article-title': 'Identification of the molecular basis of doxorubicin-induced cardiotoxicity', 'volume': '18', 'author': 'Zhang', 'year': '2012', 'journal-title': 'Nat Med'}, {'key': '2023041905424235400_R6', 'doi-asserted-by': 'crossref', 'first-page': '781', 'DOI': '10.1016/j.yjmcc.2011.06.019', 'article-title': 'β2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways', 'volume': '51', 'author': 'Fajardo', 'year': '2011', 'journal-title': 'J Mol Cell Cardiol'}, {'key': '2023041905424235400_R7', 'doi-asserted-by': 'crossref', 'first-page': '2635', 'DOI': '10.1200/JCO.2010.33.5422', 'article-title': 'Beta blockers and breast cancer mortality: a population- based study', 'volume': '29', 'author': 'Barron', 'year': '2011', 'journal-title': 'J Clin Oncol'}, {'key': '2023041905424235400_R8', 'doi-asserted-by': 'crossref', 'first-page': '378', 'DOI': '10.1016/j.ijcard.2005.08.061', 'article-title': 'Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats', 'volume': '110', 'author': 'Soga', 'year': '2006', 'journal-title': 'Int J Cardiol'}, {'key': '2023041905424235400_R9', 'doi-asserted-by': 'crossref', 'first-page': '597', 'DOI': '10.1291/hypres.25.597', 'article-title': 'Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy', 'volume': '25', 'author': 'Toko', 'year': '2002', 'journal-title': 'Hypertens Res'}, {'key': '2023041905424235400_R10', 'doi-asserted-by': 'crossref', 'first-page': '2900', 'DOI': '10.1016/j.ejca.2013.04.030', 'article-title': 'Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis', 'volume': '49', 'author': 'Kalam', 'year': '2013', 'journal-title': 'Eur J Cancer'}, {'key': '2023041905424235400_R11', 'doi-asserted-by': 'crossref', 'first-page': '2504', 'DOI': '10.1016/j.jacc.2012.07.068', 'article-title': 'Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer', 'volume': '60', 'author': 'Chen', 'year': '2012', 'journal-title': 'J Am Coll Cardiol'}, {'key': '2023041905424235400_R12', 'doi-asserted-by': 'crossref', 'first-page': '1006', 'DOI': '10.1016/j.jclinepi.2009.06.005', 'article-title': 'Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement', 'volume': '62', 'author': 'Moher', 'year': '2009', 'journal-title': 'J Clin Epidemiol'}, {'key': '2023041905424235400_R13', 'volume-title': 'Cochrane Handbook for systematic reviews of interventions version 5.1.0', 'author': 'Higgins', 'year': '2011'}, {'key': '2023041905424235400_R14', 'doi-asserted-by': 'crossref', 'first-page': '557', 'DOI': '10.1136/bmj.327.7414.557', 'article-title': 'Measuring inconsistency in meta-analyses', 'volume': '327', 'author': 'Higgins', 'year': '2003', 'journal-title': 'BMJ'}, {'key': '2023041905424235400_R15', 'doi-asserted-by': 'crossref', 'first-page': '4517', 'DOI': '10.1200/JCO.2002.12.102', 'article-title': 'Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer', 'volume': '20', 'author': 'Lipshultz', 'year': '2002', 'journal-title': 'J Clin Oncol'}, {'key': '2023041905424235400_R16', 'doi-asserted-by': 'crossref', 'first-page': '420', 'DOI': '10.1161/CIRCHEARTFAILURE.112.000055', 'article-title': 'Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure', 'volume': '6', 'author': 'Seicean', 'year': '2013', 'journal-title': 'Circ Heart Fail'}, {'key': '2023041905424235400_R17', 'doi-asserted-by': 'crossref', 'first-page': '337', 'DOI': '10.1186/1471-2407-10-337', 'article-title': 'Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials', 'volume': '10', 'author': 'Smith', 'year': '2010', 'journal-title': 'BMC Cancer'}, {'key': '2023041905424235400_R18', 'doi-asserted-by': 'crossref', 'first-page': '2492', 'DOI': '10.1002/cncr.21478', 'article-title': 'Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone', 'volume': '104', 'author': 'Nakamae', 'year': '2005', 'journal-title': 'Cancer'}, {'key': '2023041905424235400_R19', 'doi-asserted-by': 'crossref', 'first-page': '820', 'DOI': '10.1200/JCO.2004.06.022', 'article-title': 'Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines', 'volume': '22', 'author': 'Silber', 'year': '2004', 'journal-title': 'J Clin Oncol'}, {'key': '2023041905424235400_R20', 'doi-asserted-by': 'crossref', 'first-page': '607', 'DOI': '10.1016/j.cardfail.2012.06.416', 'article-title': 'Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia', 'volume': '18', 'author': 'El-Shitany', 'year': '2012', 'journal-title': 'J Card Fail'}, {'key': '2023041905424235400_R21', 'first-page': '936', 'article-title': '[Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]', 'volume': '35', 'author': 'Liu', 'year': '2013', 'journal-title': 'Zhonghua Zhong Liu Za Zhi'}, {'key': '2023041905424235400_R22', 'doi-asserted-by': 'crossref', 'first-page': '643', 'DOI': '10.1016/j.cardfail.2011.03.008', 'article-title': 'Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial', 'volume': '17', 'author': 'Bosch', 'year': '2011', 'journal-title': 'J Card Fail'}, {'key': '2023041905424235400_R23', 'doi-asserted-by': 'crossref', 'first-page': '2452', 'DOI': '10.1016/j.jacc.2013.08.712', 'article-title': 'Reply: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies', 'volume': '62', 'author': 'Bosch', 'year': '2013', 'journal-title': 'J Am Coll Cardiol'}, {'key': '2023041905424235400_R24', 'doi-asserted-by': 'crossref', 'first-page': '2142', 'DOI': '10.1016/j.jacc.2007.03.016', 'article-title': 'Carvedilol for anthracycline cardiomyopathy prevention', 'volume': '49', 'author': 'Florenzano', 'year': '2007', 'journal-title': 'J Am Coll Cardiol'}, {'key': '2023041905424235400_R25', 'doi-asserted-by': 'crossref', 'first-page': '487.e1', 'DOI': '10.1016/j.ahj.2010.05.037', 'article-title': 'Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment', 'volume': '160', 'author': 'Cadeddu', 'year': '2010', 'journal-title': 'Am Heart J'}, {'key': '2023041905424235400_R26', 'doi-asserted-by': 'crossref', 'first-page': '1003', 'DOI': '10.3892/etm.2011.305', 'article-title': 'Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction', 'volume': '2', 'author': 'Dessì', 'year': '2011', 'journal-title': 'Exp Ther Med'}, {'key': '2023041905424235400_R27', 'doi-asserted-by': 'crossref', 'first-page': '2258', 'DOI': '10.1016/j.jacc.2006.07.052', 'article-title': 'Protective effects of carvedilol against anthracycline-induced cardiomyopathy', 'volume': '48', 'author': 'Kalay', 'year': '2006', 'journal-title': 'J Am Coll Cardiol'}, {'key': '2023041905424235400_R28', 'doi-asserted-by': 'crossref', 'first-page': '2474', 'DOI': '10.1161/CIRCULATIONAHA.106.635144', 'article-title': 'Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition', 'volume': '114', 'author': 'Cardinale', 'year': '2006', 'journal-title': 'Circulation'}, {'key': '2023041905424235400_R29', 'doi-asserted-by': 'crossref', 'first-page': '894', 'DOI': '10.1002/ajh.21840', 'article-title': 'Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up', 'volume': '85', 'author': 'Georgakopoulos', 'year': '2010', 'journal-title': 'Am J Hematol'}, {'key': '2023041905424235400_R30', 'doi-asserted-by': 'crossref', 'first-page': '2355', 'DOI': '10.1016/j.jacc.2013.02.072', 'article-title': 'Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)', 'volume': '61', 'author': 'Bosch', 'year': '2013', 'journal-title': 'J Am Coll Cardiol'}, {'key': '2023041905424235400_R31', 'doi-asserted-by': 'crossref', 'first-page': '2306', 'DOI': '10.1016/j.ijcard.2012.06.023', 'article-title': 'Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study', 'volume': '167', 'author': 'Kaya', 'year': '2013', 'journal-title': 'Int J Cardiol'}, {'key': '2023041905424235400_R32', 'doi-asserted-by': 'crossref', 'first-page': '198', 'DOI': '10.1186/2193-1801-2-198', 'article-title': 'Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate', 'volume': '2', 'author': 'Dessì', 'year': '2013', 'journal-title': 'Springerplus'}, {'issue': '(4 Suppl 12)', 'key': '2023041905424235400_R33', 'doi-asserted-by': 'crossref', 'first-page': '2', 'DOI': '10.1053/sonc.2001.26431', 'article-title': 'Anthracycline-induced cardiomyopathy', 'volume': '28', 'author': 'Keefe', 'year': '2001', 'journal-title': 'Semin Oncol'}, {'key': '2023041905424235400_R34', 'doi-asserted-by': 'crossref', 'first-page': '3122', 'DOI': '10.1161/01.CIR.0000133187.74800.B9', 'article-title': 'Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management', 'volume': '109', 'author': 'Yeh', 'year': '2004', 'journal-title': 'Circulation'}, {'key': '2023041905424235400_R35', 'doi-asserted-by': 'crossref', 'first-page': '252', 'DOI': '10.1093/jnci/djn014', 'article-title': 'Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer', 'volume': '100', 'author': 'Chapman', 'year': '2008', 'journal-title': 'J Natl Cancer Inst'}, {'key': '2023041905424235400_R36', 'volume-title': 'NCCN Clinical Practice Guideline', 'year': '2014'}, {'key': '2023041905424235400_R37', 'doi-asserted-by': 'crossref', 'first-page': '112', 'DOI': '10.1200/JCO.1984.2.2.112', 'article-title': 'A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin', 'volume': '2', 'author': 'Ewer', 'year': '1984', 'journal-title': 'J Clin Oncol'}, {'key': '2023041905424235400_R38', 'doi-asserted-by': 'crossref', 'first-page': '977', 'DOI': '10.1161/01.CIR.0000085166.44904.79', 'article-title': 'Natural history of asymptomatic left ventricular systolic dysfunction in the community', 'volume': '108', 'author': 'Wang', 'year': '2003', 'journal-title': 'Circulation'}, {'key': '2023041905424235400_R39', 'doi-asserted-by': 'crossref', 'first-page': '2749', 'DOI': '10.1161/01.CIR.0000130926.51766.CC', 'article-title': 'Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy', 'volume': '109', 'author': 'Cardinale', 'year': '2004', 'journal-title': 'Circulation'}, {'key': '2023041905424235400_R40', 'doi-asserted-by': 'crossref', 'first-page': '1042', 'DOI': '10.1200/JCO.2010.30.3404', 'article-title': 'Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes', 'volume': '30', 'author': 'Lipshultz', 'year': '2012', 'journal-title': 'J Clin Oncol'}], 'container-title': ['Postgraduate Medical Journal'], 'language': 'en', 'link': [{'URL': 'https://academic.oup.com/pmj/article-pdf/91/1081/627/49960462/postgradmedj-91-627.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, {'URL': 'https://academic.oup.com/pmj/article-pdf/91/1081/627/49960462/postgradmedj-91-627.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2023, 4, 19]], 'date-time': '2023-04-19T05:45:38Z', 'timestamp': 1681883138000}, 'score': 29.677416, 'resource': {'primary': {'URL': 'https://academic.oup.com/pmj/article/91/1081/627/6994966'}}, 'issued': {'date-parts': [[2015, 9, 23]]}, 'references-count': 40, 'journal-issue': {'issue': '1081', 'published-online': {'date-parts': [[2015, 9, 23]]}, 'published-print': {'date-parts': [[2015, 11, 1]]}}, 'URL': 'https://doi.org/10.1136/postgradmedj-2015-133535', 'ISSN': ['1469-0756', '0032-5473'], 'issn-type': [{'value': '1469-0756', 'type': 'electronic'}, {'value': '0032-5473', 'type': 'print'}], 'published-other': {'date-parts': [[2015, 11]]}, 'published': {'date-parts': [[2015, 9, 23]]}}",2025-09-28T10:26:59.204168
crossref,10.1016/j.critrevonc.2020.103006,10.1016/j.critrevonc.2020.103006,,,The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies,https://doi.org/10.1016/j.critrevonc.2020.103006,"Elghazawy, Venkatesulu, Verma, Pushparaji, Monlezun, Marmagkiolis, Iliescu",,,"{'indexed': {'date-parts': [[2025, 9, 25]], 'date-time': '2025-09-25T15:00:24Z', 'timestamp': 1758812424585, 'version': '3.40.5'}, 'reference-count': 30, 'publisher': 'Elsevier BV', 'license': [{'start': {'date-parts': [[2020, 9, 1]], 'date-time': '2020-09-01T00:00:00Z', 'timestamp': 1598918400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': {'domain': ['clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['Critical Reviews in Oncology/Hematology'], 'published-print': {'date-parts': [[2020, 9]]}, 'DOI': '10.1016/j.critrevonc.2020.103006', 'type': 'journal-article', 'created': {'date-parts': [[2020, 5, 22]], 'date-time': '2020-05-22T15:44:14Z', 'timestamp': 1590162254000}, 'page': '103006', 'update-policy': 'https://doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 21, 'special_numbering': 'C', 'title': ['The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies'], 'prefix': '10.1016', 'volume': '153', 'author': [{'given': 'Hagar', 'family': 'Elghazawy', 'sequence': 'first', 'affiliation': []}, {'ORCID': 'https://orcid.org/0000-0003-2541-2055', 'authenticated-orcid': False, 'given': 'Bhanu Prasad', 'family': 'Venkatesulu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vivek', 'family': 'Verma', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bala', 'family': 'Pushparaji', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dominique J.', 'family': 'Monlezun', 'sequence': 'additional', 'affiliation': []}, {'given': 'Konstantinos', 'family': 'Marmagkiolis', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cezar A.', 'family': 'Iliescu', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [{'key': '10.1016/j.critrevonc.2020.103006_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '394', 'DOI': '10.3322/caac.21492', 'article-title': 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', 'volume': '68', 'author': 'Bray', 'year': '2018', 'journal-title': 'CA Cancer J.o Clin.o'}, {'issue': '14', 'key': '10.1016/j.critrevonc.2020.103006_bib0010', 'doi-asserted-by': 'crossref', 'first-page': '1963', 'DOI': '10.1016/S0959-8049(99)00217-8', 'article-title': 'From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century', 'volume': '35', 'author': 'Fisher', 'year': '1999', 'journal-title': 'Eur. J. Cancer.'}, {'issue': '3', 'key': '10.1016/j.critrevonc.2020.103006_bib0015', 'doi-asserted-by': 'crossref', 'first-page': 'R64', 'DOI': '10.1186/bcr2901', 'article-title': 'Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study', 'volume': '13', 'author': 'Patnaik', 'year': '2011', 'journal-title': 'Breast Cancer Res.'}, {'key': '10.1016/j.critrevonc.2020.103006_bib0020', 'doi-asserted-by': 'crossref', 'first-page': '525', 'DOI': '10.1136/hrt.2007.136093', 'article-title': 'Anthracycline associated cardiotoxicity in survivors of childhood cancer', 'volume': '94', 'author': 'Lipshultz', 'year': '2008', 'journal-title': 'Heart (British Cardiac Society)'}, {'issue': 'October (4)', 'key': '10.1016/j.critrevonc.2020.103006_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '66', 'DOI': '10.3389/fcvm.2017.00066', 'article-title': 'Radiation-Induced Cardiovascular Disease: A Clinical Perspective', 'volume': '26', 'author': 'Yusuf', 'year': '2017', 'journal-title': 'Front Cardiovasc Med.'}, {'issue': 'November (11)', 'key': '10.1016/j.critrevonc.2020.103006_bib0030', 'doi-asserted-by': 'crossref', 'first-page': '620', 'DOI': '10.1038/nrcardio.2015.133', 'article-title': 'Cardiotoxicity of anticancer treatments', 'volume': '12', 'author': 'Ewer', 'year': '2015', 'journal-title': 'Nat. Rev. Cardiol.'}, {'issue': '7', 'key': '10.1016/j.critrevonc.2020.103006_bib0035', 'doi-asserted-by': 'crossref', 'first-page': '1005', 'DOI': '10.2165/00003495-200565070-00008', 'article-title': 'Dexarazoxane', 'volume': '65', 'author': 'Cvetkovic', 'year': '2005', 'journal-title': 'Drugs'}, {'issue': 'December (23)', 'key': '10.1016/j.critrevonc.2020.103006_bib0040', 'doi-asserted-by': 'crossref', 'first-page': '2474', 'DOI': '10.1161/CIRCULATIONAHA.106.635144', 'article-title': 'Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition', 'volume': '114', 'author': 'Cardinale', 'year': '2006', 'journal-title': 'Circulation'}, {'issue': '1', 'key': '10.1016/j.critrevonc.2020.103006_bib0045', 'doi-asserted-by': 'crossref', 'first-page': '198', 'DOI': '10.1186/2193-1801-2-198', 'article-title': 'Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate', 'volume': '2', 'author': 'Dessì', 'year': '2013', 'journal-title': 'Springerplus'}, {'issue': '4', 'key': '10.1016/j.critrevonc.2020.103006_bib0050', 'first-page': '1052', 'article-title': 'Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?', 'volume': '18', 'author': 'Radulescu', 'year': '2013', 'journal-title': 'J. BUON.'}, {'issue': '8', 'key': '10.1016/j.critrevonc.2020.103006_bib0055', 'doi-asserted-by': 'crossref', 'first-page': '1030', 'DOI': '10.1001/jamaoncol.2016.1726', 'article-title': 'Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial', 'volume': '2', 'author': 'Boekhout', 'year': '2016', 'journal-title': 'JAMA Oncol.'}, {'issue': 'April (4)', 'key': '10.1016/j.critrevonc.2020.103006_bib0060', 'doi-asserted-by': 'crossref', 'first-page': '270', 'DOI': '10.2459/JCM.0000000000000232', 'article-title': 'Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction', 'volume': '17', 'author': 'Di Lisi', 'year': '2016', 'journal-title': 'J. Cardiovasc. Med.'}, {'issue': '5', 'key': '10.1016/j.critrevonc.2020.103006_bib0065', 'article-title': '208P: Prevention of cardiotoxicity in breast cancer patients: A randomized prospective study', 'volume': '28', 'author': 'Elkhateeb', 'year': '2017', 'journal-title': 'Abstract. Annals of Oncology.'}, {'issue': '130', 'key': '10.1016/j.critrevonc.2020.103006_bib0070', 'article-title': 'Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy', 'volume': '17', 'author': 'Janbabai', 'year': '2017', 'journal-title': 'Cardiovasc Toxicol.'}, {'issue': 'March (8)', 'key': '10.1016/j.critrevonc.2020.103006_bib0075', 'doi-asserted-by': 'crossref', 'first-page': '870', 'DOI': '10.1200/JCO.2016.68.7830', 'article-title': 'Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity', 'volume': '35', 'author': 'Pituskin', 'year': '2017', 'journal-title': 'J Clin Oncol.'}, {'issue': '20', 'key': '10.1016/j.critrevonc.2020.103006_bib0080', 'first-page': '5', 'article-title': 'P1650: Low body mass index and arterial hypotension as early predictors ofcardiotoxicity in patients with HER2 + breast cancer', 'author': 'Vitsenya', 'year': '2018', 'journal-title': 'Abstract. Eur J Heart Fail.'}, {'issue': '11', 'key': '10.1016/j.critrevonc.2020.103006_bib0085', 'doi-asserted-by': 'crossref', 'first-page': '2258', 'DOI': '10.1016/j.jacc.2006.07.052', 'article-title': 'Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy', 'volume': '48', 'author': 'Kalay', 'year': '2006', 'journal-title': 'J Am Coll Cardiol.'}, {'issue': '2', 'key': '10.1016/j.critrevonc.2020.103006_bib0090', 'doi-asserted-by': 'crossref', 'first-page': '95', 'DOI': '10.15420/ahhj.2011.9.2.95', 'article-title': 'Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma', 'volume': '9', 'author': 'Salehi', 'year': '2011', 'journal-title': 'Am Heart Hosp J.'}, {'issue': '5', 'key': '10.1016/j.critrevonc.2020.103006_bib0095', 'doi-asserted-by': 'crossref', 'first-page': '2306', 'DOI': '10.1016/j.ijcard.2012.06.023', 'article-title': 'Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study', 'volume': '167', 'author': 'Kaya', 'year': '2013', 'journal-title': 'Int J Cardiol'}, {'issue': '5', 'key': '10.1016/j.critrevonc.2020.103006_bib0100', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.5603/CJ.a2013.0150', 'article-title': 'Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up', 'volume': '21', 'author': 'Elitok', 'year': '2014', 'journal-title': 'Cardiol J.'}, {'issue': '3', 'key': '10.1016/j.critrevonc.2020.103006_bib0105', 'doi-asserted-by': 'crossref', 'first-page': '324', 'DOI': '10.1093/ehjci/jet159', 'article-title': 'Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection', 'volume': '15', 'author': 'Negishi', 'year': '2014', 'journal-title': 'Eur Heart J Cardiovasc Imaging.'}, {'issue': '134', 'key': '10.1016/j.critrevonc.2020.103006_bib0110', 'doi-asserted-by': 'crossref', 'first-page': '47', 'DOI': '10.1159/000442722', 'article-title': 'Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial', 'author': 'Beheshti', 'year': '2016', 'journal-title': 'Cardiology'}, {'issue': '21', 'key': '10.1016/j.critrevonc.2020.103006_bib0115', 'doi-asserted-by': 'crossref', 'first-page': '1671', 'DOI': '10.1093/eurheartj/ehw022', 'article-title': 'Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol', 'volume': '37', 'author': 'Gulati', 'year': '2016', 'journal-title': 'Eur Heart J.'}, {'key': '10.1016/j.critrevonc.2020.103006_bib0120', 'article-title': 'P3587:Acute anthracycline cardiotoxicity: carvedilol and omega-3 effects on cardiac and redox biomarkers', 'author': 'Loza', 'year': '2016', 'journal-title': 'Abstract. ESC Congress'}, {'issue': 'May (5)', 'key': '10.1016/j.critrevonc.2020.103006_bib0125', 'doi-asserted-by': 'crossref', 'first-page': '279', 'DOI': '10.1097/FJC.0000000000000470', 'article-title': 'Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity', 'volume': '69', 'author': 'Nabati', 'year': '2017', 'journal-title': 'J Cardiovasc Pharmacol.'}, {'issue': '3', 'key': '10.1016/j.critrevonc.2020.103006_bib0130', 'doi-asserted-by': 'crossref', 'first-page': 'S96', 'DOI': '10.1016/j.ihj.2018.06.011', 'article-title': 'Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin', 'volume': '70', 'author': 'Abuosa', 'year': '2018', 'journal-title': 'Indian Heart Journal.'}, {'issue': '20', 'key': '10.1016/j.critrevonc.2020.103006_bib0135', 'doi-asserted-by': 'crossref', 'first-page': '2281', 'DOI': '10.1016/j.jacc.2018.02.049', 'article-title': 'Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial', 'volume': '71', 'author': 'Avila', 'year': '2018', 'journal-title': 'J Am Coll of Cardiol'}, {'key': '10.1016/j.critrevonc.2020.103006_bib0140', 'doi-asserted-by': 'crossref', 'first-page': '2071', 'DOI': '10.2147/CMAR.S166481', 'article-title': 'Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer', 'volume': '10', 'author': 'Cochera', 'year': '2018', 'journal-title': 'Cancer Manag Res.'}, {'issue': '136', 'key': '10.1016/j.critrevonc.2020.103006_bib0145', 'first-page': 'A20834', 'article-title': 'A20834: Comparative Effect of Candesartan and Cavedilol in Prevention of Doxorubicin Induced Subclinical Cardiotoxicity', 'author': 'Kim', 'year': '2017', 'journal-title': 'Abstract. Circulation.'}, {'key': '10.1016/j.critrevonc.2020.103006_bib0150', 'doi-asserted-by': 'crossref', 'first-page': '11', 'DOI': '10.1038/hr.2009.184', 'article-title': 'Reinventing the ACE inhibitors: some old and new implications of ACE inhibition', 'volume': '33', 'author': 'Hanif', 'year': '2010', 'journal-title': 'Hypertens. Res.'}], 'container-title': ['Critical Reviews in Oncology/Hematology'], 'language': 'en', 'link': [{'URL': 'https://api.elsevier.com/content/article/PII:S104084282030144X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://api.elsevier.com/content/article/PII:S104084282030144X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': {'date-parts': [[2020, 9, 11]], 'date-time': '2020-09-11T23:15:59Z', 'timestamp': 1599866159000}, 'score': 29.60542, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S104084282030144X'}}, 'issued': {'date-parts': [[2020, 9]]}, 'references-count': 30, 'alternative-id': ['S104084282030144X'], 'URL': 'https://doi.org/10.1016/j.critrevonc.2020.103006', 'ISSN': ['1040-8428'], 'issn-type': [{'type': 'print', 'value': '1040-8428'}], 'published': {'date-parts': [[2020, 9]]}, 'assertion': [{'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, {'value': 'The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Critical Reviews in Oncology/Hematology', 'name': 'journaltitle', 'label': 'Journal Title'}, {'value': 'https://doi.org/10.1016/j.critrevonc.2020.103006', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2020 Elsevier B.V. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '103006'}",2025-09-28T10:26:59.420470
crossref,10.1186/1532-429x-16-s1-p273,10.1186/1532-429x-16-s1-p273,,,Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab,https://doi.org/10.1186/1532-429x-16-s1-p273,"Thavendiranathan, Amir, Bedard, Crean, Paul, Nguyen, Wintersperger",,,"{'indexed': {'date-parts': [[2024, 8, 29]], 'date-time': '2024-08-29T05:49:20Z', 'timestamp': 1724910560120}, 'reference-count': 0, 'publisher': 'Elsevier BV', 'license': [{'start': {'date-parts': [[2014, 1, 1]], 'date-time': '2014-01-01T00:00:00Z', 'timestamp': 1388534400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, {'start': {'date-parts': [[2014, 1, 1]], 'date-time': '2014-01-01T00:00:00Z', 'timestamp': 1388534400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/legal/tdmrep-license'}, {'start': {'date-parts': [[2014, 1, 16]], 'date-time': '2014-01-16T00:00:00Z', 'timestamp': 1389830400000}, 'content-version': 'vor', 'delay-in-days': 15, 'URL': 'http://creativecommons.org/licenses/by/2.0/'}], 'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['Journal of Cardiovascular Magnetic Resonance'], 'published-print': {'date-parts': [[2014, 1]]}, 'DOI': '10.1186/1532-429x-16-s1-p273', 'type': 'journal-article', 'created': {'date-parts': [[2014, 1, 16]], 'date-time': '2014-01-16T10:30:08Z', 'timestamp': 1389868208000}, 'page': 'P273', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 15, 'special_numbering': 'S1', 'title': ['Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab'], 'prefix': '10.1016', 'volume': '16', 'author': [{'given': 'Paaladinesh', 'family': 'Thavendiranathan', 'sequence': 'first', 'affiliation': []}, {'given': 'Eitan', 'family': 'Amir', 'sequence': 'additional', 'affiliation': []}, {'given': 'Philippe', 'family': 'Bedard', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andrew', 'family': 'Crean', 'sequence': 'additional', 'affiliation': []}, {'given': 'Narinder', 'family': 'Paul', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elsie T', 'family': 'Nguyen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bernd J', 'family': 'Wintersperger', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'container-title': ['Journal of Cardiovascular Magnetic Resonance'], 'language': 'en', 'link': [{'URL': 'https://api.elsevier.com/content/article/PII:S1097664723054339?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://api.elsevier.com/content/article/PII:S1097664723054339?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'http://link.springer.com/content/pdf/10.1186/1532-429X-16-S1-P273.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2024, 6, 6]], 'date-time': '2024-06-06T05:21:31Z', 'timestamp': 1717651291000}, 'score': 29.604738, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1097664723054339'}}, 'issued': {'date-parts': [[2014, 1]]}, 'references-count': 0, 'alternative-id': ['S1097664723054339'], 'URL': 'https://doi.org/10.1186/1532-429x-16-s1-p273', 'ISSN': ['1097-6647'], 'issn-type': [{'value': '1097-6647', 'type': 'print'}], 'published': {'date-parts': [[2014, 1]]}, 'assertion': [{'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, {'value': 'Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Journal of Cardiovascular Magnetic Resonance', 'name': 'journaltitle', 'label': 'Journal Title'}, {'value': 'https://doi.org/10.1186/1532-429X-16-S1-P273', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'}, {'value': 'Copyright © 2014 THE AUTHORS. Published by Elsevier Inc on behalf of the Society for Cardiovascular Magnetic Resonance', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': 'P273'}",2025-09-28T10:26:59.618036
crossref,10.22541/au.161278751.19764242/v1,10.22541/au.161278751.19764242/v1,,,The identification of ketotifen as a novel cardioprotective agent in patients undergoing anthracyclines chemotherapy,https://doi.org/10.22541/au.161278751.19764242/v1,"elewa, elberay, Keshk, Abulkhair",,"Objective: The present study aimed to investigate the possible
cardioprotective effects of ketotifen and to assess its activity as an
iron-chelating agent in patients receiving anthracyclines for the
treatment of breast cancer. Patients &amp; Methods: This was a randomized,
prospective, controlled clinical trial. One hundred eleven eligible
patients with breast cancer (age range, 30-60 years) were scheduled to
receive anthracyclines chemotherapy. The patients were divided into two
groups: Patients (n = 56) assigned to the ketotifen group received
ketotifen 1 mg three times daily for six consecutive cycles of
treatment, and patients assigned to the control group (n = 55) without
ketotifen treatment. The echocardiogram for each patient was recorded
two times at baseline and the end of the study. As well, blood samples
were collected from all patients. Results: The findings showed a
statistically significant reduction in the mean serum levels of common
cardiotoxicity accompanied biomarkers in the ketotifen group compared
with the control group (P ≤ 0.05). The mean serum levels of total
iron-binding capacity were significantly elevated in the ketotifen group
(P ≤ 0.001). There was a direct correlation between the mean serum
levels of iron and that of lactate dehydrogenase (LDH) (r = + 0.79). On
the other hand, there were indirect correlations between mean serum
levels of LDH and both the percentage of ejection fraction and the total
iron-binding capacity (r = - 0.69 and -0.697, respectively). Conclusion:
Oral administration of ketotifen appears to be efficient and safe as a
novel cardioprotective agent for the prevention of anthracyclines
induced cardiotoxicity. Additionally, ketotifen suggested a beneficial
effect in iron overload inducing diseases such as COVID-19.","{'institution': [{'name': 'Authorea, Inc.'}], 'indexed': {'date-parts': [[2025, 6, 3]], 'date-time': '2025-06-03T16:34:56Z', 'timestamp': 1748968496461, 'version': '3.41.0'}, 'posted': {'date-parts': [[2021, 2, 8]]}, 'group-title': 'Preprints', 'reference-count': 0, 'publisher': 'Wiley', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2021, 2, 8]]}, 'abstract': '<jats:p id=""p1"">Objective: The present study aimed to investigate the possible\ncardioprotective effects of ketotifen and to assess its activity as an\niron-chelating agent in patients receiving anthracyclines for the\ntreatment of breast cancer. Patients &amp; Methods: This was a randomized,\nprospective, controlled clinical trial. One hundred eleven eligible\npatients with breast cancer (age range, 30-60 years) were scheduled to\nreceive anthracyclines chemotherapy. The patients were divided into two\ngroups: Patients (n = 56) assigned to the ketotifen group received\nketotifen 1 mg three times daily for six consecutive cycles of\ntreatment, and patients assigned to the control group (n = 55) without\nketotifen treatment. The echocardiogram for each patient was recorded\ntwo times at baseline and the end of the study. As well, blood samples\nwere collected from all patients. Results: The findings showed a\nstatistically significant reduction in the mean serum levels of common\ncardiotoxicity accompanied biomarkers in the ketotifen group compared\nwith the control group (P ≤ 0.05). The mean serum levels of total\niron-binding capacity were significantly elevated in the ketotifen group\n(P ≤ 0.001). There was a direct correlation between the mean serum\nlevels of iron and that of lactate dehydrogenase (LDH) (r = + 0.79). On\nthe other hand, there were indirect correlations between mean serum\nlevels of LDH and both the percentage of ejection fraction and the total\niron-binding capacity (r = - 0.69 and -0.697, respectively). Conclusion:\nOral administration of ketotifen appears to be efficient and safe as a\nnovel cardioprotective agent for the prevention of anthracyclines\ninduced cardiotoxicity. Additionally, ketotifen suggested a beneficial\neffect in iron overload inducing diseases such as COVID-19.</jats:p>', 'DOI': '10.22541/au.161278751.19764242/v1', 'type': 'posted-content', 'created': {'date-parts': [[2021, 2, 8]], 'date-time': '2021-02-08T12:32:21Z', 'timestamp': 1612787541000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['The identification of ketotifen as a novel cardioprotective agent in patients undergoing anthracyclines chemotherapy'], 'prefix': '10.22541', 'author': [{'ORCID': 'https://orcid.org/0000-0003-1874-924X', 'authenticated-orcid': True, 'given': 'hosny', 'family': 'elewa', 'sequence': 'first', 'affiliation': [{'name': 'Horus University'}]}, {'given': 'Naser', 'family': 'elberay', 'sequence': 'additional', 'affiliation': [{'name': 'Menoufia University'}]}, {'given': 'Walaa', 'family': 'Keshk', 'sequence': 'additional', 'affiliation': [{'name': 'Tanta University'}]}, {'given': 'Hamada', 'family': 'Abulkhair', 'sequence': 'additional', 'affiliation': [{'name': 'Al-Azhar University'}]}], 'member': '311', 'deposited': {'date-parts': [[2021, 2, 8]], 'date-time': '2021-02-08T12:32:21Z', 'timestamp': 1612787541000}, 'score': 29.568617, 'resource': {'primary': {'URL': 'https://www.authorea.com/users/387711/articles/507848-the-identification-of-ketotifen-as-a-novel-cardioprotective-agent-in-patients-undergoing-anthracyclines-chemotherapy?commit=09ba90ab55df032eac30024f60a0e007bc42f51b'}}, 'issued': {'date-parts': [[2021, 2, 8]]}, 'references-count': 0, 'URL': 'https://doi.org/10.22541/au.161278751.19764242/v1', 'published': {'date-parts': [[2021, 2, 8]]}, 'subtype': 'preprint'}",2025-09-28T10:26:59.804120
crossref,10.1016/s0735-1097(18)31232-4,10.1016/s0735-1097(18)31232-4,,,PROSPECTIVE EVALUATION OF CIRCULATING BIOMARKERS AS PREDICTORS OF CARDIOTOXICITY IN PATIENTS WITH HER2-POSITIVE BREAST CANCER RECEIVING ANTHRACYCLINES AND TRASTUZUMAB,https://doi.org/10.1016/s0735-1097(18)31232-4,"Yu, Knezevic, Moskowitz, Dang, Ramanathan, Oeffinger, Liu, Steingart",,,"{'indexed': {'date-parts': [[2024, 9, 16]], 'date-time': '2024-09-16T21:39:48Z', 'timestamp': 1726522788413}, 'reference-count': 0, 'publisher': 'Elsevier BV', 'issue': '11', 'license': [{'start': {'date-parts': [[2018, 3, 1]], 'date-time': '2018-03-01T00:00:00Z', 'timestamp': 1519862400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, {'start': {'date-parts': [[2019, 3, 10]], 'date-time': '2019-03-10T00:00:00Z', 'timestamp': 1552176000000}, 'content-version': 'vor', 'delay-in-days': 374, 'URL': 'http://www.elsevier.com/open-access/userlicense/1.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Journal of the American College of Cardiology'], 'published-print': {'date-parts': [[2018, 3]]}, 'DOI': '10.1016/s0735-1097(18)31232-4', 'type': 'journal-article', 'created': {'date-parts': [[2018, 3, 8]], 'date-time': '2018-03-08T15:02:10Z', 'timestamp': 1520521330000}, 'page': 'A691', 'source': 'Crossref', 'is-referenced-by-count': 1, 'special_numbering': 'S', 'title': ['PROSPECTIVE EVALUATION OF CIRCULATING BIOMARKERS AS PREDICTORS OF CARDIOTOXICITY IN PATIENTS WITH HER2-POSITIVE BREAST CANCER RECEIVING ANTHRACYCLINES AND TRASTUZUMAB'], 'prefix': '10.1016', 'volume': '71', 'author': [{'given': 'Anthony F.', 'family': 'Yu', 'sequence': 'first', 'affiliation': []}, {'given': 'Andrea', 'family': 'Knezevic', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chaya', 'family': 'Moskowitz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chau', 'family': 'Dang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lakshmi', 'family': 'Ramanathan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kevin', 'family': 'Oeffinger', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jennifer', 'family': 'Liu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Richard', 'family': 'Steingart', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'container-title': ['Journal of the American College of Cardiology'], 'language': 'en', 'link': [{'URL': 'https://api.elsevier.com/content/article/PII:S0735109718312324?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://api.elsevier.com/content/article/PII:S0735109718312324?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': {'date-parts': [[2019, 3, 10]], 'date-time': '2019-03-10T03:26:08Z', 'timestamp': 1552188368000}, 'score': 29.553686, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0735109718312324'}}, 'issued': {'date-parts': [[2018, 3]]}, 'references-count': 0, 'journal-issue': {'issue': '11', 'published-print': {'date-parts': [[2018, 3]]}}, 'alternative-id': ['S0735109718312324'], 'URL': 'https://doi.org/10.1016/s0735-1097(18)31232-4', 'ISSN': ['0735-1097'], 'issn-type': [{'type': 'print', 'value': '0735-1097'}], 'published': {'date-parts': [[2018, 3]]}}",2025-09-28T10:27:00.059111
crossref,10.1016/j.cjca.2018.11.028,10.1016/j.cjca.2018.11.028,,,Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy,https://doi.org/10.1016/j.cjca.2018.11.028,"Calvillo-Argüelles, Abdel-Qadir, Michalowska, Billia, Suntheralingam, Amir, Thavendiranathan",,,"{'indexed': {'date-parts': [[2025, 9, 12]], 'date-time': '2025-09-12T19:40:18Z', 'timestamp': 1757706018485, 'version': '3.37.3'}, 'reference-count': 28, 'publisher': 'Elsevier BV', 'issue': '2', 'license': [{'start': {'date-parts': [[2019, 2, 1]], 'date-time': '2019-02-01T00:00:00Z', 'timestamp': 1548979200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'funder': [{'name': 'Heart and Stroke Polo Research'}, {'DOI': '10.13039/501100000024', 'name': 'CIHR', 'doi-asserted-by': 'publisher', 'award': ['147814'], 'id': [{'id': '10.13039/501100000024', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}], 'content-domain': {'domain': ['onlinecjc.ca', 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['Canadian Journal of Cardiology'], 'published-print': {'date-parts': [[2019, 2]]}, 'DOI': '10.1016/j.cjca.2018.11.028', 'type': 'journal-article', 'created': {'date-parts': [[2018, 12, 4]], 'date-time': '2018-12-04T12:11:06Z', 'timestamp': 1543925466000}, 'page': '153-159', 'update-policy': 'https://doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 59, 'title': ['Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab\xa0Therapy'], 'prefix': '10.1016', 'volume': '35', 'author': [{'given': 'Oscar', 'family': 'Calvillo-Argüelles', 'sequence': 'first', 'affiliation': []}, {'given': 'Husam', 'family': 'Abdel-Qadir', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria', 'family': 'Michalowska', 'sequence': 'additional', 'affiliation': []}, {'ORCID': 'https://orcid.org/0000-0002-2824-1215', 'authenticated-orcid': False, 'given': 'Filio', 'family': 'Billia', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sivisan', 'family': 'Suntheralingam', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eitan', 'family': 'Amir', 'sequence': 'additional', 'affiliation': []}, {'ORCID': 'https://orcid.org/0000-0001-5746-8016', 'authenticated-orcid': False, 'given': 'Paaladinesh', 'family': 'Thavendiranathan', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [{'key': '10.1016/j.cjca.2018.11.028_bib1', 'doi-asserted-by': 'crossref', 'first-page': '2239', 'DOI': '10.1200/JCO.2015.65.1505', 'article-title': 'Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study', 'volume': '34', 'author': 'Thavendiranathan', 'year': '2016', 'journal-title': 'J\xa0Clin Oncol'}, {'key': '10.1016/j.cjca.2018.11.028_bib2', 'doi-asserted-by': 'crossref', 'unstructured': 'Thavendiranathan P, Abdel-Qadir H, Fischer HD, et\xa0al. Risk-imaging mismatch in cardiac imaging practices for women receiving systemic therapy for early-stage breast cancer: a population-based cohort study [published online May 23, 2018]. J Clin Oncol https://doi.org/10.1200/JCO.2018.77.9736.', 'DOI': '10.1200/JCO.2018.77.9736'}, {'key': '10.1016/j.cjca.2018.11.028_bib3', 'doi-asserted-by': 'crossref', 'first-page': '2900', 'DOI': '10.1016/j.ejca.2013.04.030', 'article-title': 'Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis', 'volume': '49', 'author': 'Kalam', 'year': '2013', 'journal-title': 'Eur J Cancer'}, {'key': '10.1016/j.cjca.2018.11.028_bib4', 'doi-asserted-by': 'crossref', 'first-page': '278', 'DOI': '10.1016/j.atherosclerosis.2007.11.016', 'article-title': 'Rosuvastatin protects against oxidative stress and DNA damage in\xa0vitro via upregulation of glutathione synthesis', 'volume': '199', 'author': 'Schupp', 'year': '2008', 'journal-title': 'Atherosclerosis'}, {'key': '10.1016/j.cjca.2018.11.028_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1792', 'DOI': '10.1056/NEJMoa1201735', 'article-title': 'Statin use and reduced cancer-related mortality', 'volume': '367', 'author': 'Nielsen', 'year': '2012', 'journal-title': 'N\xa0Engl J Med'}, {'key': '10.1016/j.cjca.2018.11.028_bib6', 'doi-asserted-by': 'crossref', 'first-page': '695', 'DOI': '10.1158/0008-5472.CAN-08-3076', 'article-title': 'Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice', 'volume': '69', 'author': 'Riad', 'year': '2009', 'journal-title': 'Cancer Res'}, {'key': '10.1016/j.cjca.2018.11.028_bib7', 'doi-asserted-by': 'crossref', 'first-page': '988', 'DOI': '10.1016/j.jacc.2011.05.025', 'article-title': 'Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy', 'volume': '58', 'author': 'Acar', 'year': '2011', 'journal-title': 'J\xa0Am Coll Cardiol'}, {'key': '10.1016/j.cjca.2018.11.028_bib8', 'doi-asserted-by': 'crossref', 'first-page': '2384', 'DOI': '10.1016/j.jacc.2012.07.067', 'article-title': 'Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study', 'volume': '60', 'author': 'Seicean', 'year': '2012', 'journal-title': 'J\xa0Am Coll Cardiol'}, {'key': '10.1016/j.cjca.2018.11.028_bib9', 'doi-asserted-by': 'crossref', 'first-page': '302', 'DOI': '10.1016/j.cjca.2014.11.020', 'article-title': 'Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function', 'volume': '31', 'author': 'Chotenimitkhun', 'year': '2015', 'journal-title': 'Can J Cardiol'}, {'key': '10.1016/j.cjca.2018.11.028_bib10', 'doi-asserted-by': 'crossref', 'first-page': '3792', 'DOI': '10.1200/JCO.2011.40.0010', 'volume': '30', 'author': 'Romond', 'year': '2012', 'journal-title': 'J\xa0Clin Oncol'}, {'key': '10.1016/j.cjca.2018.11.028_bib11', 'doi-asserted-by': 'crossref', 'first-page': '1215', 'DOI': '10.1200/JCO.2002.20.5.1215', 'article-title': 'Cardiac dysfunction in the trastuzumab clinical trials experience', 'volume': '20', 'author': 'Seidman', 'year': '2002', 'journal-title': 'J\xa0Clin Oncol'}, {'key': '10.1016/j.cjca.2018.11.028_bib12', 'doi-asserted-by': 'crossref', 'unstructured': 'Grundy SM, Stone NJ, Bailey AL, et\xa0al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [Epub ahead of print]. J Am Coll Cardiol https://doi.org/10.1016/j.jacc.2018.11.003.', 'DOI': '10.1016/j.jacc.2018.11.003'}, {'key': '10.1016/j.cjca.2018.11.028_bib13', 'doi-asserted-by': 'crossref', 'first-page': '870', 'DOI': '10.1200/JCO.2016.68.7830', 'article-title': 'Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity', 'volume': '35', 'author': 'Pituskin', 'year': '2017', 'journal-title': 'J\xa0Clin Oncol'}, {'key': '10.1016/j.cjca.2018.11.028_bib14', 'doi-asserted-by': 'crossref', 'first-page': '1671', 'DOI': '10.1093/eurheartj/ehw022', 'article-title': 'Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol', 'volume': '37', 'author': 'Gulati', 'year': '2016', 'journal-title': 'Eur Heart J'}, {'key': '10.1016/j.cjca.2018.11.028_bib15', 'first-page': '1147', 'article-title': 'Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer', 'volume': '34', 'author': 'Sandoo', 'year': '2014', 'journal-title': 'Anticancer Res'}, {'key': '10.1016/j.cjca.2018.11.028_bib16', 'first-page': '70', 'article-title': 'Trastuzumab-induced cardiac dysfunction: a “dual-hit.”', 'volume': '16', 'author': 'Zeglinski', 'year': '2011', 'journal-title': 'Exp Clin Cardiol'}, {'key': '10.1016/j.cjca.2018.11.028_bib17', 'doi-asserted-by': 'crossref', 'first-page': '228', 'DOI': '10.1016/j.yjmcc.2006.04.007', 'article-title': 'Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes', 'volume': '41', 'author': 'Kuramochi', 'year': '2006', 'journal-title': 'J\xa0Mol Cell Cardiol'}, {'key': '10.1016/j.cjca.2018.11.028_bib18', 'doi-asserted-by': 'crossref', 'first-page': '42', 'DOI': '10.1007/s11897-010-0003-y', 'article-title': 'Neuregulin signaling and heart failure', 'volume': '7', 'author': 'Jiang', 'year': '2010', 'journal-title': 'Curr Heart Fail Rep'}, {'issue': 'suppl', 'key': '10.1016/j.cjca.2018.11.028_bib19', 'first-page': '1272', 'article-title': 'Synergistic protective effect of rosuvastatin and candesartan againist chemotherapy induced cardiotoxicity: mechanism of action', 'volume': '39', 'author': 'Cho', 'year': '2018', 'journal-title': 'Eur Heart J'}, {'key': '10.1016/j.cjca.2018.11.028_bib20', 'doi-asserted-by': 'crossref', 'first-page': '94', 'DOI': '10.1056/NEJMc070065', 'article-title': 'Cardiotoxicity of trastuzumab in clinical practice', 'volume': '357', 'author': 'McArthur', 'year': '2007', 'journal-title': 'N\xa0Engl J Med'}, {'key': '10.1016/j.cjca.2018.11.028_bib21', 'doi-asserted-by': 'crossref', 'first-page': '2176', 'DOI': '10.1200/JCO.2014.58.9465', 'article-title': 'Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer', 'volume': '33', 'author': 'Chavez-MacGregor', 'year': '2015', 'journal-title': 'J\xa0Clin Oncol'}, {'key': '10.1016/j.cjca.2018.11.028_bib22', 'doi-asserted-by': 'crossref', 'first-page': '113', 'DOI': '10.1016/j.cardfail.2011.10.015', 'article-title': 'Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer', 'volume': '18', 'author': 'Tarantini', 'year': '2012', 'journal-title': 'J\xa0Card Fail'}, {'key': '10.1016/j.cjca.2018.11.028_bib23', 'doi-asserted-by': 'crossref', 'first-page': '596', 'DOI': '10.1161/CIRCIMAGING.112.973321', 'article-title': 'Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab', 'volume': '5', 'author': 'Sawaya', 'year': '2012', 'journal-title': 'Circ Cardiovasc Imaging'}, {'key': '10.1016/j.cjca.2018.11.028_bib24', 'doi-asserted-by': 'crossref', 'first-page': '493', 'DOI': '10.1016/j.echo.2013.02.008', 'article-title': 'Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity', 'volume': '26', 'author': 'Negishi', 'year': '2013', 'journal-title': 'J\xa0Am Soc Echocardiogr'}, {'key': '10.1016/j.cjca.2018.11.028_bib25', 'unstructured': 'Guglin ME, Krischer J, Tamura R, et\xa0al. Lisinopril or carvedilol for prevention of trastuzumab induced cardiotoxicity. Presented at: 67th Annual American College of Cardiology Meeting; March 10-12, 2018; Orlando, FL.'}, {'key': '10.1016/j.cjca.2018.11.028_bib26', 'doi-asserted-by': 'crossref', 'first-page': '911', 'DOI': '10.1016/j.echo.2014.07.012', 'article-title': 'Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging', 'volume': '27', 'author': 'Plana', 'year': '2014', 'journal-title': 'J\xa0Am Soc Echocardiogr'}, {'key': '10.1016/j.cjca.2018.11.028_bib27', 'doi-asserted-by': 'crossref', 'first-page': '3429', 'DOI': '10.1200/JCO.2009.26.7294', 'article-title': 'Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging', 'volume': '28', 'author': 'Walker', 'year': '2010', 'journal-title': 'J\xa0Clin Oncol'}, {'key': '10.1016/j.cjca.2018.11.028_bib28', 'doi-asserted-by': 'crossref', 'first-page': '710', 'DOI': '10.1093/aje/kwk052', 'article-title': 'Relaxing the rule of ten events per variable in logistic and Cox regression', 'volume': '165', 'author': 'Vittinghoff', 'year': '2007', 'journal-title': 'Am J Epidemiol'}], 'container-title': ['Canadian Journal of Cardiology'], 'language': 'en', 'link': [{'URL': 'https://api.elsevier.com/content/article/PII:S0828282X18313187?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://api.elsevier.com/content/article/PII:S0828282X18313187?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': {'date-parts': [[2019, 8, 8]], 'date-time': '2019-08-08T06:40:33Z', 'timestamp': 1565246433000}, 'score': 29.109983, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0828282X18313187'}}, 'issued': {'date-parts': [[2019, 2]]}, 'references-count': 28, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2019, 2]]}}, 'alternative-id': ['S0828282X18313187'], 'URL': 'https://doi.org/10.1016/j.cjca.2018.11.028', 'ISSN': ['0828-282X'], 'issn-type': [{'type': 'print', 'value': '0828-282X'}], 'published': {'date-parts': [[2019, 2]]}, 'assertion': [{'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, {'value': 'Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab\xa0Therapy', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Canadian Journal of Cardiology', 'name': 'journaltitle', 'label': 'Journal Title'}, {'value': 'https://doi.org/10.1016/j.cjca.2018.11.028', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}",2025-09-28T10:27:00.312224
crossref,10.33552/acrci.2018.01.000506,10.33552/acrci.2018.01.000506,,,Defining Fingerprint Pattern of Cardiotoxicity and Targeting Specific Underlying Mechanisms of Cardiotoxicity Could be the Way for Successful Cardioprotective Measures in Paediatric Cancer Patients Treated with Anthracyclines,https://doi.org/10.33552/acrci.2018.01.000506,Khalifa,,,"{'indexed': {'date-parts': [[2022, 4, 5]], 'date-time': '2022-04-05T11:34:59Z', 'timestamp': 1649158499544}, 'reference-count': 0, 'publisher': 'Iris Publishers LLC', 'issue': '2', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['ACRCI'], 'DOI': '10.33552/acrci.2018.01.000506', 'type': 'journal-article', 'created': {'date-parts': [[2019, 9, 12]], 'date-time': '2019-09-12T05:49:52Z', 'timestamp': 1568267392000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Defining Fingerprint Pattern of Cardiotoxicity and Targeting Specific Underlying Mechanisms of Cardiotoxicity Could be the Way for Successful Cardioprotective Measures in Paediatric Cancer Patients Treated with Anthracyclines'], 'prefix': '10.33552', 'volume': '1', 'author': [{'given': 'Amani E', 'family': 'Khalifa', 'sequence': 'first', 'affiliation': []}], 'member': '19081', 'published-online': {'date-parts': [[2018]]}, 'container-title': ['Advances in Cancer Research &amp; Clinical Imaging'], 'deposited': {'date-parts': [[2019, 9, 12]], 'date-time': '2019-09-12T05:49:53Z', 'timestamp': 1568267393000}, 'score': 28.795008, 'resource': {'primary': {'URL': 'https://irispublishers.com/acrci/fulltext/defining-fingerprint-pattern-of-cardiotoxicity-and-targeting-specific-underlying-mechanisms-of-cardiotoxicity-in-paediatric-cancer-patients-treated-with-anthracyclines.ID.000506.php'}}, 'issued': {'date-parts': [[2018]]}, 'references-count': 0, 'journal-issue': {'issue': '2', 'published-online': {'date-parts': [[2018]]}}, 'URL': 'https://doi.org/10.33552/acrci.2018.01.000506', 'ISSN': ['2688-8203'], 'issn-type': [{'value': '2688-8203', 'type': 'electronic'}], 'published': {'date-parts': [[2018]]}}",2025-09-28T10:27:00.464913
crossref,10.1016/b978-0-12-803508-5.00016-0,10.1016/b978-0-12-803508-5.00016-0,,,Brain Metastases from Breast Cancer in Patients Receiving Trastuzumab,https://doi.org/10.1016/b978-0-12-803508-5.00016-0,"Duchnowska, Jassem",,,"{'indexed': {'date-parts': [[2024, 5, 7]], 'date-time': '2024-05-07T07:48:09Z', 'timestamp': 1715068089700}, 'reference-count': 64, 'publisher': 'Elsevier', 'isbn-type': [{'value': '9780128035085', 'type': 'print'}], 'license': [{'start': {'date-parts': [[2016, 1, 1]], 'date-time': '2016-01-01T00:00:00Z', 'timestamp': 1451606400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2016]]}, 'DOI': '10.1016/b978-0-12-803508-5.00016-0', 'type': 'book-chapter', 'created': {'date-parts': [[2019, 1, 15]], 'date-time': '2019-01-15T21:46:47Z', 'timestamp': 1547588807000}, 'page': '225-236', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Brain Metastases from Breast Cancer in Patients Receiving Trastuzumab'], 'prefix': '10.1016', 'author': [{'given': 'Renata', 'family': 'Duchnowska', 'sequence': 'first', 'affiliation': []}, {'given': 'Jacek', 'family': 'Jassem', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [{'key': '10.1016/B978-0-12-803508-5.00016-0_bib1', 'doi-asserted-by': 'crossref', 'first-page': '122', 'DOI': '10.1016/S0014-4827(02)00104-0', 'article-title': 'ErbB-targeted therapeutic approaches in human cancer', 'volume': '284', 'author': 'Arteaga', 'year': '2003', 'journal-title': 'Exp. Cell Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib2', 'doi-asserted-by': 'crossref', 'first-page': '64', 'DOI': '10.1016/S1470-2045(12)70432-1', 'article-title': 'Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study', 'volume': '14', 'author': 'Bachelot', 'year': '2013', 'journal-title': 'Lancet Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib3', 'doi-asserted-by': 'crossref', 'first-page': '2972', 'DOI': '10.1002/cncr.11436', 'article-title': 'Central nervous system metastases in women who receive trastuzumab based therapy for metastatic breast carcinoma', 'volume': '97', 'author': 'Bendell', 'year': '2003', 'journal-title': 'Cancer'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib4', 'doi-asserted-by': 'crossref', 'first-page': '3153', 'DOI': '10.1007/s13277-013-0884-y', 'article-title': 'Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer', 'volume': '34', 'author': 'Bian', 'year': '2013', 'journal-title': 'Tumour Biol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib5', 'doi-asserted-by': 'crossref', 'first-page': '231', 'DOI': '10.1007/s10549-007-9663-z', 'article-title': 'Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials', 'volume': '109', 'author': 'Bria', 'year': '2008', 'journal-title': 'Breast Cancer Res. Treat.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib6', 'doi-asserted-by': 'crossref', 'first-page': '1772', 'DOI': '10.1093/annonc/mdi371', 'article-title': 'Isolated central nervous system metastases in patients with HER2 overexpressing advanced breast cancer treated with first-line trastuzumab based therapy', 'volume': '16', 'author': 'Burstein', 'year': '2005', 'journal-title': 'Ann. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib7', 'doi-asserted-by': 'crossref', 'first-page': '631', 'DOI': '10.1016/j.ijrobp.2010.06.057', 'article-title': 'Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients', 'volume': '81', 'author': 'Chargari', 'year': '2011', 'journal-title': 'Int. J. Radiat. Oncol. Biol. Phys.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib8', 'doi-asserted-by': 'crossref', 'first-page': '250', 'DOI': '10.1097/COC.0b013e31815a43c4', 'article-title': 'Extended survival in women with brain metastases from HER2 overexpressing breast cancer', 'volume': '31', 'author': 'Church', 'year': '2008', 'journal-title': 'Am. J. Clin. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib9', 'doi-asserted-by': 'crossref', 'first-page': '639', 'DOI': '10.1038/sj.bjc.6601970', 'article-title': 'Incidence of cerebral metastases in patients treated with trastuzumab with trastuzumab for metastatic breast cancer', 'volume': '16', 'author': 'Clayton', 'year': '2004', 'journal-title': 'Br. J. Cancer'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib10', 'doi-asserted-by': 'crossref', 'first-page': '1157', 'DOI': '10.1007/s00280-008-0859-7', 'article-title': 'Exteneded survival of a HER2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab', 'volume': '63', 'author': 'Colozza', 'year': '2009', 'journal-title': 'Cancer Chemother. Pharmacol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib11', 'doi-asserted-by': 'crossref', 'first-page': 'R46', 'DOI': '10.1186/bcr2603', 'article-title': 'HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer', 'volume': '12', 'author': 'Da Silva', 'year': '2010', 'journal-title': 'Breast Cancer Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib12', 'doi-asserted-by': 'crossref', 'first-page': '1242', 'DOI': '10.1093/annonc/mdn036', 'article-title': 'Defining prognosis for women with breast cancer and CNS metastases by HER2 status', 'volume': '19', 'author': 'Dawood', 'year': '2008', 'journal-title': 'Ann. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib13', 'doi-asserted-by': 'crossref', 'first-page': '297', 'DOI': '10.1007/s10549-008-0275-z', 'article-title': 'Risk factors for brain relapse in HER2-positive metastatic breast cancer patients', 'volume': '117', 'author': 'Duchnowska', 'year': '2009', 'journal-title': 'Breast Cancer Res. Treat.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib14', 'doi-asserted-by': 'crossref', 'first-page': 'R119', 'DOI': '10.1186/bcr3244', 'article-title': 'Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain', 'volume': '14', 'author': 'Duchnowska', 'year': '2012', 'journal-title': 'Breast Cancer Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib15', 'doi-asserted-by': 'crossref', 'first-page': '26', 'DOI': '10.1634/theoncologist.2011-0212', 'article-title': 'Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy', 'volume': '17', 'author': 'Duchnowska', 'year': '2012', 'journal-title': 'Oncologist'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib16', 'doi-asserted-by': 'crossref', 'first-page': '2359', 'DOI': '10.1002/cncr.23468', 'article-title': 'Survival in patients with brain metastases from breast cancer: the importance of HER-2 status', 'volume': '112', 'author': 'Eichler', 'year': '2008', 'journal-title': 'Cancer'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib17', 'doi-asserted-by': 'crossref', 'first-page': '2733', 'DOI': '10.1056/NEJMoa064320', 'article-title': 'Lapatinib plus capecitabine for HER2-positive advanced breast cancer', 'volume': '355', 'author': 'Geyer', 'year': '2006', 'journal-title': 'N. Engl. J. Med.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib18', 'doi-asserted-by': 'crossref', 'first-page': '766', 'DOI': '10.1634/theoncologist.12-7-766', 'article-title': 'Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors', 'volume': '12', 'author': 'Gori', 'year': '2007', 'journal-title': 'Oncologist'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib19', 'doi-asserted-by': 'crossref', 'first-page': '1092', 'DOI': '10.1093/jnci/djn216', 'article-title': 'Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain', 'volume': '100', 'author': 'Gril', 'year': '2008', 'journal-title': 'J. Natl. Cancer Inst.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib20', 'doi-asserted-by': 'crossref', 'first-page': '142', 'DOI': '10.1158/1078-0432.CCR-10-1603', 'article-title': 'Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis', 'volume': '17', 'author': 'Gril', 'year': '2011', 'journal-title': 'Clin. Cancer Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib21', 'doi-asserted-by': 'crossref', 'first-page': '83', 'DOI': '10.1016/j.ajpath.2013.03.023', 'article-title': 'Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases', 'volume': '183', 'author': 'Hohensee', 'year': '2013', 'journal-title': 'Am. J. Pathol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib22', 'first-page': '165', 'article-title': 'The biology of erbB-2/neu/HER 2 and its role in cancer', 'volume': '1198', 'author': 'Hynes', 'year': '1994', 'journal-title': 'Biochim. Biophys. Acta'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib23', 'doi-asserted-by': 'crossref', 'first-page': '809', 'DOI': '10.1056/NEJMoa053028', 'article-title': 'Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer', 'volume': '354', 'author': 'Joensuu', 'year': '2006', 'journal-title': 'N. Engl. J. Med.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib24', 'doi-asserted-by': 'crossref', 'first-page': '677', 'DOI': '10.1007/s12282-013-0441-y', 'volume': '21', 'author': 'Kaplan', 'year': '2014', 'journal-title': 'Breast Cancer'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib25', 'doi-asserted-by': 'crossref', 'first-page': '810', 'DOI': '10.1002/cncr.20418', 'article-title': 'The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma', 'volume': '15', 'author': 'Lai', 'year': '2004', 'journal-title': 'Cancer'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib26', 'doi-asserted-by': 'crossref', 'first-page': '5878', 'DOI': '10.1158/0008-5472.CAN-08-0380', 'article-title': 'A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy', 'volume': '68', 'author': 'Lee-Hoeflich', 'year': '2008', 'journal-title': 'Cancer Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib27', 'doi-asserted-by': 'crossref', 'first-page': '1452', 'DOI': '10.1158/1078-0432.CCR-08-1080', 'article-title': 'Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer', 'volume': '15', 'author': 'Lin', 'year': '2009', 'journal-title': 'Clin.Cancer Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib28', 'doi-asserted-by': 'crossref', 'first-page': '405', 'DOI': '10.1007/s10549-013-2754-0', 'article-title': 'A phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases', 'volume': '142', 'author': 'Lin', 'year': '2013', 'journal-title': 'Breast Cancer Res. Treat.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib29', 'doi-asserted-by': 'crossref', 'first-page': '3523', 'DOI': '10.1002/jnr.21364', 'article-title': 'Activation of epidermal growth factor receptors in astrocytes: from development to neural injury', 'volume': '85', 'author': 'Liu', 'year': '2007', 'journal-title': 'J. Neurosci. Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib30', 'doi-asserted-by': 'crossref', 'first-page': '114', 'DOI': '10.3816/CBC.2003.n.016', 'article-title': 'Increased rate of brain metastases with trastuzumab therapy not associated with impaired survival', 'volume': '4', 'author': 'Lower', 'year': '2003', 'journal-title': 'Clin. Breast Cancer'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib31', 'doi-asserted-by': 'crossref', 'first-page': 'R25', 'DOI': '10.1186/bcr3625', 'article-title': 'A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity', 'volume': '16', 'author': 'McMullin', 'year': '2014', 'journal-title': 'Breast Cancer Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib32', 'doi-asserted-by': 'crossref', 'first-page': '1467', 'DOI': '10.1634/theoncologist.12-12-1467', 'article-title': 'Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer', 'volume': '12', 'author': 'Metro', 'year': '2007', 'journal-title': 'Oncologist'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib33', 'doi-asserted-by': 'crossref', 'first-page': '1978', 'DOI': '10.1093/annonc/mdn654', 'article-title': 'High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer', 'volume': '19', 'author': 'Mir', 'year': '2008', 'journal-title': 'Ann. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib34', 'doi-asserted-by': 'crossref', 'first-page': '275', 'DOI': '10.1007/s00280-008-0737-3', 'article-title': 'Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab', 'volume': '63', 'author': 'Montagna', 'year': '2009', 'journal-title': 'Cancer Chemother. Pharmacol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib35', 'doi-asserted-by': 'crossref', 'first-page': '289', 'DOI': '10.1093/neuonc/nou141', 'article-title': 'Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study', 'volume': '17', 'author': 'Morikawa', 'year': '2015', 'journal-title': 'Neuro. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib36', 'doi-asserted-by': 'crossref', 'first-page': '1837', 'DOI': '10.1002/cncr.25771', 'article-title': 'Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study', 'volume': '117', 'author': 'Musolino', 'year': '2011', 'journal-title': 'Cancer'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib37', 'doi-asserted-by': 'crossref', 'first-page': '1027', 'DOI': '10.1080/02841860701316099', 'article-title': 'Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy', 'volume': '46', 'author': 'Niwińska', 'year': '2007', 'journal-title': 'Acta Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib38', 'doi-asserted-by': 'crossref', 'first-page': '1134', 'DOI': '10.1016/j.ijrobp.2009.06.030', 'article-title': 'The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death', 'volume': '77', 'author': 'Niwińska', 'year': '2010', 'journal-title': 'Int. J. Radiat. Oncol. Biol. Phys.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib39', 'doi-asserted-by': 'crossref', 'first-page': '841', 'DOI': '10.1007/s10549-011-1417-2', 'article-title': 'Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab', 'volume': '127', 'author': 'Oliveira', 'year': '2011', 'journal-title': 'Breast Cancer Res. Treat.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib40', 'doi-asserted-by': 'crossref', 'first-page': '48', 'DOI': '10.1007/s10147-008-0797-8', 'article-title': 'Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer', 'volume': '14', 'author': 'Ono', 'year': '2009', 'journal-title': 'Int. J. Clin. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib41', 'doi-asserted-by': 'crossref', 'first-page': '4190', 'DOI': '10.1158/0008-5472.CAN-06-3316', 'article-title': 'Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain', 'volume': '67', 'author': 'Palmieri', 'year': '2007', 'journal-title': 'Cancer Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib42', 'doi-asserted-by': 'crossref', 'first-page': '2727', 'DOI': '10.1158/1078-0432.CCR-13-2588', 'article-title': 'Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner', 'volume': '20', 'author': 'Palmieri', 'year': '2014', 'journal-title': 'Clin. Cancer Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib43', 'doi-asserted-by': 'crossref', 'first-page': '56', 'DOI': '10.1093/annonc/mdn539', 'article-title': 'Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer', 'volume': '20', 'author': 'Park', 'year': '2009', 'journal-title': 'Ann. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib44', 'doi-asserted-by': 'crossref', 'first-page': '3366', 'DOI': '10.1200/JCO.2011.35.0868', 'article-title': 'Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31', 'volume': '29', 'author': 'Perez', 'year': '2011', 'journal-title': 'J. Clin. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib45', 'doi-asserted-by': 'crossref', 'first-page': '935', 'DOI': '10.1093/annonc/mdl064', 'article-title': 'Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)', 'volume': '17', 'author': 'Pestalozzi', 'year': '2006', 'journal-title': 'Ann. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib46', 'doi-asserted-by': 'crossref', 'first-page': '307', 'DOI': '10.1186/1479-5876-11-307', 'article-title': 'Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients', 'volume': '11', 'author': 'Petricevic', 'year': '2013', 'journal-title': 'J. Transl. Med.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib47', 'doi-asserted-by': 'crossref', 'DOI': '10.1158/0008-5472.SABCS11-P4-17-03', 'article-title': 'Incidence rate of asymptomatic brain metastases in patients with HER2+ metastatic breast cancer screened for EGF111438/CEREBEL Study', 'volume': '71', 'author': 'Pivot', 'year': '2011', 'journal-title': 'Cancer Res.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib64', 'doi-asserted-by': 'crossref', 'first-page': '1564', 'DOI': '10.1200/JCO.2014.57.1794', 'article-title': 'CEREBEL (EGF111438): a Phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer', 'volume': '33', 'author': 'Pivot', 'year': '2015', 'journal-title': 'J. Clin. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib48', 'doi-asserted-by': 'crossref', 'first-page': '778', 'DOI': '10.1016/S1470-2045(06)70864-6', 'article-title': 'Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab', 'volume': '7', 'author': 'Platini', 'year': '2006', 'journal-title': 'Lancet Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib49', 'doi-asserted-by': 'crossref', 'first-page': '362', 'DOI': '10.1016/0888-7543(89)90343-1', 'article-title': 'Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12–21.32', 'volume': '4', 'author': 'Popescu', 'year': '1989', 'journal-title': 'Genomics'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib50', 'doi-asserted-by': 'crossref', 'first-page': '50', 'DOI': '10.1007/s12094-006-0095-8', 'article-title': 'Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies', 'volume': '8', 'author': 'Puente Vázquez', 'year': '2006', 'journal-title': 'Clin. Transl. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib51', 'doi-asserted-by': 'crossref', 'first-page': '2100', 'DOI': '10.1200/JCO.2013.54.0955', 'article-title': 'Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: american society of clinical oncology clinical practice guideline', 'volume': '32', 'author': 'Ramakrishna', 'year': '2014', 'journal-title': 'J. Clin. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib52', 'doi-asserted-by': 'crossref', 'first-page': '888', 'DOI': '10.1016/S1470-2045(06)70917-2', 'article-title': 'Care with intrathecal trastuzumab', 'volume': '7', 'author': 'Siderov', 'year': '2006', 'journal-title': 'Lancet Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib53', 'doi-asserted-by': 'crossref', 'first-page': '1273', 'DOI': '10.1056/NEJMoa0910383', 'article-title': 'Adjuvant trastuzumab in HER2-positive breast cancer', 'volume': '365', 'author': 'Slamon', 'year': '2011', 'journal-title': 'N. Engl. J. Med.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib54', 'doi-asserted-by': 'crossref', 'first-page': '177', 'DOI': '10.1126/science.3798106', 'article-title': 'Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene', 'volume': '235', 'author': 'Slamon', 'year': '1987', 'journal-title': 'Science'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib55', 'doi-asserted-by': 'crossref', 'first-page': '783', 'DOI': '10.1056/NEJM200103153441101', 'article-title': 'Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2', 'volume': '344', 'author': 'Slamon', 'year': '2001', 'journal-title': 'N. Engl. J. Med.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib56', 'doi-asserted-by': 'crossref', 'first-page': '29', 'DOI': '10.1016/S0140-6736(07)60028-2', 'article-title': '2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial', 'volume': '369', 'author': 'Smith', 'year': '2007', 'journal-title': 'Lancet'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib57', 'first-page': '1373', 'article-title': 'Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer', 'volume': '15', 'author': 'Stemmler', 'year': '2006', 'journal-title': 'Oncol. Rep.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib58', 'doi-asserted-by': 'crossref', 'first-page': '23', 'DOI': '10.1097/01.cad.0000236313.50833.ee', 'article-title': 'Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of the blood—brain barrier', 'volume': '18', 'author': 'Stemmler', 'year': '2007', 'journal-title': 'Anticancer Drugs'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib59', 'doi-asserted-by': 'crossref', 'first-page': '1116', 'DOI': '10.1093/annonc/mdu133', 'article-title': 'Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA', 'volume': '25', 'author': 'Swain', 'year': '2014', 'journal-title': 'Ann. Oncol.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib60', 'doi-asserted-by': 'crossref', 'first-page': '2273', 'DOI': '10.1016/j.ejca.2011.06.021', 'article-title': 'Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer', 'volume': '47', 'author': 'von Minckwitz', 'year': '2011', 'journal-title': 'Eur. J. Cancer'}, {'issue': '7', 'key': '10.1016/B978-0-12-803508-5.00016-0_bib61', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/jnci/dju145', 'article-title': 'DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer', 'volume': '106', 'author': 'Woditschka', 'year': '2014', 'journal-title': 'J. Natl. Cancer Inst.'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib62', 'doi-asserted-by': 'crossref', 'first-page': '1075', 'DOI': '10.1038/bjc.2012.346', 'article-title': 'Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival', 'volume': '107', 'author': 'Yap', 'year': '2012', 'journal-title': 'Br. J. Cancer'}, {'key': '10.1016/B978-0-12-803508-5.00016-0_bib63', 'doi-asserted-by': 'crossref', 'first-page': '196', 'DOI': '10.1080/02841860500486630', 'article-title': 'Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab', 'volume': '45', 'author': 'Yau', 'year': '2006', 'journal-title': 'Acta Oncol.'}], 'container-title': ['Brain Metastases from Primary Tumors, Volume 3'], 'language': 'en', 'link': [{'URL': 'https://api.elsevier.com/content/article/PII:B9780128035085000160?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://api.elsevier.com/content/article/PII:B9780128035085000160?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': {'date-parts': [[2019, 1, 15]], 'date-time': '2019-01-15T21:47:01Z', 'timestamp': 1547588821000}, 'score': 28.497337, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/B9780128035085000160'}}, 'issued': {'date-parts': [[2016]]}, 'ISBN': ['9780128035085'], 'references-count': 64, 'URL': 'https://doi.org/10.1016/b978-0-12-803508-5.00016-0', 'published': {'date-parts': [[2016]]}}",2025-09-28T10:27:00.623661
crossref,10.1177/1043454214554008,10.1177/1043454214554008,,,Dexrazoxane,https://doi.org/10.1177/1043454214554008,Wu,,"Anthracyclines are a fundamental part of many childhood cancer therapy regimens; however, the discovery of anthracycline-induced cardiotoxicity has raised concern and led to dose limitation. The cardiotoxicity of anthracyclines has resulted in an increased demand for cardioprotectants. Dexrazoxane is the only cardioprotectant that has proven efficacy in reducing cardiotoxic effects when given prior to the administration of anthracyclines. Currently, it is still considered an “off-label” use due to a paucity of data in the literature on dexrazoxane administration in children. Nevertheless, through evaluation of the available data, dexrazoxane is observed to be safe, tolerable, and efficacious in mitigating the cardiotoxic effects of anthracycline in children, without jeopardizing its antineoplastic activity or increasing the risk of developing secondary malignant neoplasms.","{'indexed': {'date-parts': [[2025, 3, 1]], 'date-time': '2025-03-01T06:13:27Z', 'timestamp': 1740809607654, 'version': '3.38.0'}, 'reference-count': 32, 'publisher': 'SAGE Publications', 'issue': '3', 'license': [{'start': {'date-parts': [[2014, 11, 3]], 'date-time': '2014-11-03T00:00:00Z', 'timestamp': 1414972800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://journals.sagepub.com/page/policies/text-and-data-mining-license'}], 'content-domain': {'domain': ['journals.sagepub.com'], 'crossmark-restriction': True}, 'short-container-title': ['J Pediatr Oncol Nurs'], 'published-print': {'date-parts': [[2015, 5]]}, 'abstract': '<jats:p> Anthracyclines are a fundamental part of many childhood cancer therapy regimens; however, the discovery of anthracycline-induced cardiotoxicity has raised concern and led to dose limitation. The cardiotoxicity of anthracyclines has resulted in an increased demand for cardioprotectants. Dexrazoxane is the only cardioprotectant that has proven efficacy in reducing cardiotoxic effects when given prior to the administration of anthracyclines. Currently, it is still considered an “off-label” use due to a paucity of data in the literature on dexrazoxane administration in children. Nevertheless, through evaluation of the available data, dexrazoxane is observed to be safe, tolerable, and efficacious in mitigating the cardiotoxic effects of anthracycline in children, without jeopardizing its antineoplastic activity or increasing the risk of developing secondary malignant neoplasms. </jats:p>', 'DOI': '10.1177/1043454214554008', 'type': 'journal-article', 'created': {'date-parts': [[2014, 11, 4]], 'date-time': '2014-11-04T07:52:32Z', 'timestamp': 1415087552000}, 'page': '178-184', 'update-policy': 'https://doi.org/10.1177/sage-journals-update-policy', 'source': 'Crossref', 'is-referenced-by-count': 13, 'title': ['Dexrazoxane'], 'prefix': '10.1177', 'volume': '32', 'author': [{'given': 'Vivian', 'family': 'Wu', 'sequence': 'first', 'affiliation': [{'name': 'University of Pennsylvania, Philadelphia, PA, USA'}]}], 'member': '179', 'published-online': {'date-parts': [[2014, 11, 3]]}, 'reference': [{'key': 'bibr1-1043454214554008', 'unstructured': 'About Pharmacology. (2012, October 11). Pharmacology of dexrazoxane. Retrieved from http://www.about-pharmacology.com/?s=Pharmacology+of+Dexr'}, {'key': 'bibr2-1043454214554008', 'unstructured': 'American Cancer Society. (2012, September 20). What are the key statistics for childhood cancer? Retrieved from http://www.cancer.org/cancer/cancerinchildren/detailedguide/cancer-in-children-key-statistics'}, {'key': 'bibr3-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1517/14656566.8.8.1039'}, {'key': 'bibr4-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.2007.12.2481'}, {'key': 'bibr5-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.1994.12.8.1659'}, {'key': 'bibr6-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.3346/jkms.2010.25.9.1336'}, {'key': 'bibr7-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.2165/00003495-200565070-00008'}, {'key': 'bibr8-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00520-005-0858-8'}, {'key': 'bibr9-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.2007.14.9401'}, {'key': 'bibr10-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.2007.12.6888'}, {'key': 'bibr11-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1006/mgme.2000.3043'}, {'key': 'bibr12-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.pharmthera.2011.07.006'}, {'key': 'bibr13-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.1997.15.4.1544'}, {'key': 'bibr14-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.breast.2009.05.004'}, {'key': 'bibr15-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/hrt.2007.136093'}, {'key': 'bibr16-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJM199103213241205'}, {'key': 'bibr17-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.2007.11.8778'}, {'key': 'bibr18-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa035153'}, {'key': 'bibr19-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1161/01.CIR.96.8.2641'}, {'key': 'bibr20-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1470-2045(10)70204-7'}, {'key': 'bibr21-1043454214554008', 'first-page': '1572', 'volume': '355', 'author': 'Mariotto A. B.', 'year': '2009', 'journal-title': 'Cancer Epidemiology, Biomarkers & Prevention'}, {'key': 'bibr22-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1124/pr.56.2.6'}, {'key': 'bibr23-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1182/blood-2006-06-027714'}, {'key': 'bibr24-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/0005-2736(85)90195-6'}, {'key': 'bibr25-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMsa060185'}, {'key': 'bibr26-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2010.923'}, {'key': 'bibr27-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.2002.04.178'}, {'key': 'bibr28-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1634/theoncologist.2010-0162'}, {'key': 'bibr29-1043454214554008', 'first-page': '145', 'volume': '3', 'author': 'Seymour L.', 'year': '1999', 'journal-title': 'Cancer Prevention Control'}, {'key': 'bibr30-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.2005.02.3879'}, {'key': 'bibr31-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/14651858.CD003917.pub3'}, {'key': 'bibr32-1043454214554008', 'doi-asserted-by': 'publisher', 'DOI': '10.1200/JCO.1996.14.2.362'}], 'container-title': ['Journal of Pediatric Oncology Nursing'], 'language': 'en', 'link': [{'URL': 'https://journals.sagepub.com/doi/pdf/10.1177/1043454214554008', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://journals.sagepub.com/doi/full-xml/10.1177/1043454214554008', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, {'URL': 'https://journals.sagepub.com/doi/pdf/10.1177/1043454214554008', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': {'date-parts': [[2025, 3, 1]], 'date-time': '2025-03-01T03:52:38Z', 'timestamp': 1740801158000}, 'score': 28.34936, 'resource': {'primary': {'URL': 'https://journals.sagepub.com/doi/10.1177/1043454214554008'}}, 'subtitle': ['A Cardioprotectant for Pediatric Cancer Patients Receiving Anthracyclines'], 'issued': {'date-parts': [[2014, 11, 3]]}, 'references-count': 32, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2015, 5]]}}, 'alternative-id': ['10.1177/1043454214554008'], 'URL': 'https://doi.org/10.1177/1043454214554008', 'ISSN': ['1043-4542', '1532-8457'], 'issn-type': [{'type': 'print', 'value': '1043-4542'}, {'type': 'electronic', 'value': '1532-8457'}], 'published': {'date-parts': [[2014, 11, 3]]}}",2025-09-28T10:27:00.736227
